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Abstract 
Luminescent lanthanide complexes are important tools for molecular sensing and cellular 
staining due to their unique photophysical properties, including their long luminescence 
lifetimes that permit the use of time-gated measurements. However, a common drawback of 
such complexes is the non-specific binding associated with their low solubility in biological 
media.  
A new class of bright, highly water soluble, and negatively charged sulfonate or carboxylate 
derivatives of substituted aryl–alkynyl triazacyclononane complexes has been synthesised 
and their photophysical properties analysed. In addition, new synthetic methodologies have 
been explored for the introduction of solubilising moieties into the ligand system and for the 
incorporation of a linkage point for conjugation with biomolecules.  
Each complex exhibits extremely high quantum yields (up to 38 % in H2O), large extinction 
coefficients (60,000 M
-1
 cm
-1
) and long luminescence lifetimes (1.1 ms). Introduction of the 
charged solubilising moieties suppresses cellular uptake or adsorption to living cells, making 
them applicable for labelling and performing assays on membrane receptors. 
 
These Eu(III) complexes have been applied to monitor fluorescent ligand binding on cell-
surface proteins (G-protein coupled receptors) with time-resolved fluorescence resonance 
energy transfer (TR-FRET) assays and TR-FRET microscopy. 
In addition, the introduction of a linkage point for conjugation on the macrocyclic ring 
provided complete control of the stereochemistry of the final complex. Direct and selective 
formation of chiral complexes was observed with > 95 % optical purity resulting in an intense 
circularly polarised luminescence signal.  
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1 Introduction 
1.1 Luminescence spectroscopy and microscopy 
Biological imaging refers to many different methods that are used to gain information on 
morphology or structure and to follow biochemical processes in living systems. In the 
medical field, a large range of techniques is routinely used to diagnose and examine disease; 
the most common are magnetic resonance imaging (MRI), computed tomography (CT) and 
nuclear medicine imaging (e.g. PET and SPECT). These techniques can provide high quality 
images of large areas, but have a common limitation: their resolution is typically of the order 
of 0.5 to several millimetres. Fluorescence microscopy has become an essential tool in 
biology and biomedical sciences because of its greater inherent resolution (commonly down 
to 120 nm with a confocal microscope) that permits the visualisation of cells and organelles. 
This technique, combined with fluorescence spectroscopy, has been applied in quantitative 
assays for the determination of analytes in several samples and has also been extensively used 
to assess the spatial distribution of a given target molecule.
1
 Drawbacks of this technique are 
auto-fluorescence and absorption of light by endogenous chromophores present in biological 
media. 
1.1.1 Background 
Luminescence is defined as the spontaneous emission of radiation from an electronically 
excited species.
2
 There are various types of luminescence that are described by their mode of 
excitation: i.e. chemiluminescence is the emission of light as a result of a chemical reaction; 
photoluminescence is the emission of light as a result of absorption of photons and 
incorporates fluorescence and phosphorescence. The Jablonski diagram (Figure 1) 
qualitatively describes the energy levels involved in the excitation/emission process. 
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Figure 1: Jablonski diagram. 
The initial absorption of light by a molecule (10
-15
 s) in its ground singlet state (S0) takes the 
molecule to an excited electronic state (S1). The upper vibrational states undergo radiationless 
decay (internal conversion) by releasing energy to the surroundings (10
-13
 to 10
-11
 s). At this 
stage three different pathways can happen: non-radiative decay, radiative transition 
(fluorescence, 10
-9
 to 10
-7
 s) or intersystem crossing to the triplet excited state (T1). From the 
triplet state, non-radiative or radiative (phosphorescence, 10
-4
 to 10
-1
 s) decay can take place. 
The longer decay time for phosphorescence, compared to fluorescence, is associated with the 
forbidden nature of the triplet to singlet transition. Fluorescence and phosphorescence always 
occur at lower frequencies than the incident radiation due to dissipation of energy in the 
excited state (Stokes’ shift). 
 
Figure 2: A representation of the Stokes’ shift for a typical organic fluorophore. 
1.1.2 Luminescent probes in biological systems 
The majority of cellular processes remain invisible, even when using our brightest laser light 
sources. Further progress will depend on improvements in instrumentation and on the 
development of new bright fluorophores and sensors.
3
  Nowadays, extremely bright labelling 
reagents are available in many different colours. Fluorescent proteins can be incorporated in 
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genetically encoded proteins in living cells and ‘solid state’ quantum dot technology is used 
for multi-parameter labelling.
4
 In addition, emissive metal complexes are available as an 
alternative to purely organic labels. The challenge in this area is the synthesis of new very 
bright probes that are able to enter cells, selectively target specific organelles and respond to 
local changes in physical properties. 
1.1.2.1 Fluorescent dyes 
Fluorescent dyes are emissive organic molecules with large molar extinction coefficients (50-
250 mM
-1
 cm
-1
) and high quantum yields (0.2 to 0.8). The most widely used fluorescent dyes 
are based on the xanthene or cyanine structures. Fluorescein (Figure 1a) was the first 
examples of such a label and it is still used despite certain disadvantages (photobleaching and 
pH sensitivity).
5
 Rhodamines (Figure 1b) are pH insensitive and more photostable, but are 
more difficult to use because of their relatively low water solubility.
6
 The introduction of 
solubilising moieties on the rhodamine structure permitted the development of a new class of 
dyes called Alexa Fluor.
7
  In the early 1990s, new cyanine dye labels (Figure 1c) became 
commercially available and provide significantly brighter fluorescence compared to any other 
fluorophores.
8
 Similar properties, such as high brightness and stability towards 
photobleaching, are reported for the more recently developed BODIPY series of fluorescent 
dyes and stains (Figure 1d).
9
  
 
Figure 3: General structures of most common organic dyes: fluorescein (a), rhodamine (b), a cyanine (c), 
BODIPY (d). 
All of these compounds are available in different reactive versions (i.e. active esters, 
isothiocyanates and sulfonyl chlorides) to allow easy conjugation with the biomolecules. The 
use of different substituents also permits the tuning of the absorption and emission 
wavelengths.  
(a) (b) (c) (d)
H 
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Figure 4: Absorption (left) and emission (right) spectra of five fluorescent dyes.
4
 
Fluorescent dyes have found many applications in biological imaging as pH
10
 and ion
11
 
sensors. Problems with this class of probes are their short lived excited states, small Stokes’ 
shifts and often broad emission spectra. 
1.1.2.2 Fluorescent proteins 
Green fluorescent proteins (GFPs) are spontaneously fluorescent biomolecules isolated from 
marine organisms. They convert the blue chemiluminescence of primary proteins, aequorin or 
luciferase, into green fluorescent light (abs = 395/475 nm, em = 508 nm).
12
 GFPs consist of 
imidazolinone dyes within a β-barrel tertiary structure. Their high quantum yields (0.71 - 
0.85), stability within cells and resistance to quenching mean that these GFPs have been used 
as reporters of gene expression and as fusion tags to monitor protein localization within living 
Hoechst 33342 Fluorescein
XRITC
Cy 5 Cy 7
+ 
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cells.
13
 Most GFPs variants display pH-sensitive absorption; such behaviour has been 
exploited to monitor pH within cell compartments.
14
 
 
Figure 5: Tertiary protein structure of a GFP.
15
 
Nowadays, a wide variety of FPs is available in different colours as new tools for biological 
imaging.
16
 Among all the examples, mCherry (red fluorescent monomer, B = 15.8 mM
-1
 cm
-1
 
at 580 nm in water) is one of the most used FPs, due to its colour and stability to 
photobleaching.
17
 
 
Figure 6: Spectral profiles of common FPs (left) and tertiary structure of mCherry (right).
17
 
One limiting issue with the use of FPs as intracellular probes is their large size (27 kDa) and, 
therefore, they can be quite invasive. 
1.1.2.3 Quantum dots 
Quantum dots (QDs) are roughly spherical inorganic colloidal nanoparticles (diameters 
between 1 and 12 nm) with unique light emitting properties. Upon irradiation of QDs by UV 
light, they produce multicolour, extremely narrow and symmetric emission bands. 
Furthermore light emitted by a specific quantum dot is related directly to its size (the smaller 
the dot the lower the frequency of the light emitted).
18
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Figure 7: Solutions containing different sized CdSe quantum dots.
18
 
The broadband excitation and narrow bandwidth emission make QDs excellent probes for use 
in multiplexed type analyses.
19
 The challenge in this area is to preserve their stability and 
improve their capability of labelling targets; in addition the slight toxicity of these 
nanoparticles can limit their application in living systems.  
Recently, a purely organic alternative to QDs has been reported (Pdots). This new class is 
based on -conjugated semiconducting polymers; Pdots possess similar emission properties 
as Qdots, and in addition excellent photostability and low cytotoxicity.
20
 
1.1.2.4 Emissive metal complexes 
Emissive metal complexes can be divided into two main classes: the first is based on d-block 
metals (e.g. Re(I), Ru(II), Os(II), Rh(I), Ir(III), and Pt(II))
21
 and the second is based on 
luminescent lanthanide(III) ions.
22
  
    
Figure 8: Examples of emissive transition metal complexes. 
These complexes show large Stokes’ shifts (hundreds of nm) and long luminescent lifetimes 
(microseconds to milliseconds range). This allows for their use as probes in time-gated 
measurements,
23
 offering the possibility of eliminating the short-lived background 
fluorescence of the endogenous chromophores (order of nanoseconds), (Figure 9).
24
 
Chapter 1: Introduction 
7 
 
 
Figure 9: Use of metal complexes in time-resolved luminescence microscopy. 
These complexes have been used mainly for cellular staining and oxygen sensing.
25
 In 
general, they exhibit a lack of responsiveness to their surroundings; however, in the last few 
years, many publications have emerged showing the utility of metal complexes as responsive 
probes, able to penetrate the cell membrane and report on changes in the local ionic 
composition.
26
 In particular, the emission spectrum of lanthanide complexes, which presents 
many emission bands, makes these complexes suitable for ratiometric analysis, avoiding the 
problem of monitoring the probe concentration in vivo. 
    
Figure 10: Europium emission spectrum as a function of added citrate concentration (ex = 380 nm).
26
 
1.2 Emissive lanthanide complexes 
Lanthanide ions in aqueous media form trivalent cations with partially filled 4f orbitals, due 
to the balance between ionisation energy and hydration enthalpy.
27
 Most lanthanides have 
electronic excited states which radiatively decay to the ground state: Sm
3+
, Eu
3+
, Tb
3+
 and 
Dy
3+
 emit in the visible region, while Nd
3+
, Ho
3+
, Er
3+
 and Yb
3+
 emit in the near-IR region. 
The two longest lived and most commonly used emissive lanthanide ions are Eu
3+
 and Tb
3+
, 
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with 
5
D0 and 
5
D4 electronic excited states, with an energy of 17200 and 20500 cm
-1
 
respectively.
28
  
1.2.1 Europium(III) emission spectrum 
The lowest energy excited state for Eu(III) is the 
5
D0 level with an energy of 17200 cm
-1
. Due 
to spin-orbit coupling, the ground state manifold (
7
F) is split, causing several bands in the 
emission spectrum (Figure 11). Every band is denoted by its J value. The Eu(III) emission 
spectrum consists of five intense emission bands, arising from transitions from the 
5
D0 
excited state to the 
7
FJ (J = 0, 1, 2, 3, 4) ground state levels. Due to the different nature of the 
f orbitals compared to the d orbitals, the emission spectrum of lanthanides complexes is not as 
strongly affected by the nature of the ligand. However, additional fine splitting can be 
observed depending on the coordination environment. This is due to the loss of degeneracy of 
the J levels associated with crystal field splitting. The form and fine splitting of the Eu
3+
 
spectrum is known to be dependent upon the symmetry at the metal centre. In general, the 
spectrum shows less fine structure when the symmetry of the complex is high.
29
 
 
Figure 11: A typical Europium(III) emission spectrum in a low symmetry complex. 
The form of the Eu
3+
 emission spectrum can be predicted with the following rules: the J = 0 
transition is formally forbidden and sensitive to the symmetry of the complex; the magnetic-
dipole allowed J = 1 transition (around 590 nm) is insensitive to the coordination 
environment and typically consists of two (axially symmetric complexes) or three (low 
symmetry complexes) bands; the electric-dipole allowed J = 2 (around 615 nm) and J = 4 
(around 700 nm) manifolds change their intensity considerably as a function of the ligand 
field.
30
  
Chapter 1: Introduction 
9 
 
1.2.2 Lanthanide ion sensitisation 
Lanthanide f–f transitions are Laporte-forbidden and therefore very weak. This renders direct 
excitation of the lanthanide ion very inefficient and only practicable with high power lasers. 
This problem is usually solved by grafting an antenna or chromophore (aromatic moiety) into 
the ligand complexing the metal ion. This antenna absorbs light and sensitises the lanthanide 
ion that can emit (Figure 12).
31
 
  
Figure 12: Indirect excitation of a lanthanide via an antenna (a). Jablonski diagram showing the main energy 
transfer pathways during sensitization of lanthanide luminescence via the antenna (b). 
The classical interpretation of the process of indirect excitation (Figure 12b) of a lanthanide 
ion involves initial excitation of the antenna from its ground state to its singlet excited state 
(S1). This is followed by intersystem crossing (ISC) to the antenna’s triplet state (T1). Due to 
the presence of the Ln(III) ion, a heavy atom, significant amounts of spin-orbit coupling 
occur which facilitate this spin forbidden process. After this, an internal energy transfer step 
(ET) from the antenna to the excited state of the lanthanide occurs, followed by relaxation to 
the lanthanide ground state with emission of lanthanide luminescence.  
Recently, a different mechanism that takes place via the solvent-relaxed internal charge 
transfer (ICT) excited state has been suggested for ligands that possess an intense ICT 
transition (Figure 13). Significant solvatochromism and a notable temperature dependence 
confirmed this hypothesis, although sensitization via a triplet state can still participate to the 
process, for certain substituted systems.
 32
  
Ln(III) Spacer
Ligand
A
n
te
n
n
a
Energy transfer
ISC
a) b) 
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Figure 13: Jablonski diagram showing the energy transfer pathways during sensitization of lanthanide 
luminescence via the solvent-relaxed internal charge transfer excited state.
33
 
In rare cases, a process of sensitisation from the antenna singlet excited state (S1) to the 
lanthanide excited state (Ln
*
) is also thought to occur.
34
 
The overall emission quantum yield (em) is representative of the efficiency of each of the 
main steps involved in the sensitisation process (Figure 14).  
 
Figure 14: Photophysical processes that occur during sensitised lanthanide luminescence.
35
 
Three main processes are involved in the classical mechanism of sensitisation. The formation 
of the intermediate triplet state is determined by the feasibility of the inter-system crossing 
process (ηISC). The next step, which involves the energy transfer from the antenna’s triplet 
state to the lanthanide, is maximised when there is a short distance between the chromophore 
and the lanthanide ion (ET follows an r
-6
 dependence, ηET). For intramolecular energy 
transfer to occur, the triplet excited state of the antenna must be higher in energy than the 
Chapter 1: Introduction 
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excited state of the lanthanide by at least 1700 cm
-1
 to avoid back energy transfer. Finally, the 
intrinsic emissive quantum yield of the lanthanide ion needs to be considered (Ln).  
𝜱𝒕𝒐𝒕 = 𝜱𝑳𝒏𝜼𝑰𝑺𝑪𝜼𝑬𝑻  [1] 
Different types of quenching can occur for each of these steps: radiative decay (fluorescence) 
or quenching by electron transfer can deactivate the sensitiser’s singlet excited state. 
Phosphorescence or quenching by molecular oxygen competes with energy transfer to the 
Ln
3+
 ion in deactivating the chromophore’s triplet state. Finally, the main quenching process 
that deactivates the lanthanide excited state, involves vibrational energy transfer to solvent 
molecules or ligand oscillators. The excited lanthanide energy level approximately 
corresponds in energy to higher energy vibrations of an OH or NH oscillator.
36
 Therefore, the 
highest emission quantum yields are found for complexes that do not possess any coordinated 
water molecules and are not bound to NH donors. 
1.2.3 Chromophores for europium sensitisation 
The antenna for europium sensitisation should have the following properties: a high molar 
extinction coefficient, an excitation wavelength above 320 nm to avoid the excitation of 
common biomolecules (protein and nucleic acids), a relatively low singlet excited state 
energy with a small S1-T1 energy gap to maximize the intersystem crossing efficiency and a 
triplet state energy of around 20000 cm
-1
. This is higher than the 
5
D0 lanthanide excited state 
at 17200 cm
-1 
to avoid back energy transfer, but is not too high in order to maximise the rate 
of energy transfer. In addition, the distance between the lanthanide ion and the chromophore 
should be small. 
A large variety of ligands bearing various highly conjugated moieties has been used as 
lanthanide sensitisers. A list of some of the more important sensitisers with their 
spectroscopic characteristics is presented (Table 1). These chormophores can be part of the 
actual chelating ligand (Figure 15) or be covalently attached to a chelate such as DO3A or  
9-N3 (Figure 16). 
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Figure 15: Examples of chelating antenna ligands.
37-38-39-40 
 
 
Figure 16: Examples of lanthanide complexes bearing a pendant antenna.
41-42-44
 
 
1.1
1.2a  R =H
1.2b  R = tBu
1.3a 1.3b
1.3c
[Ln1.4] [Ln1.5a]
[Ln1.5b] [Ln1.6]
[Ln·1.4] [Ln·1.5a](H2O)
[Ln·1.5 ](H2O) [L ·1.6]
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Table 1: Summary of the photophysical properties of selected chromophores.
a
 All values were measured at 
295 K in H2O except [Eu·(1.2a)3]
3+
 and [Eu·(1.2b)3]
3+
 which were measured in CH3CN and [Eu·1.6] 
which was measured in MeOH. 
Complex max / nm  / mM
-1
 cm
-1
 em / % 
[Eu·1.1]
 3+
 303 18 2 
[Eu·(1.2a)3]
3+
 305 9 3 
[Eu·(1.2b)3]
3+
  305 8 10 
[Eu·1.3c]
-
 345 18 21 
[Eu·1.4] 340 4 18 
[Eu·1.5a] 330 7 7 
[Eu·1.5b] 375 5 2 
[Eu·1.6] (X=OMe, R=Ph) 340 58 52 
a
 Errors on max,  and em are ± 10%. 
The tris(bipyridine) cryptate [Eu·1.1]
3+
 was reported by Lehn and Mathis in 1987.
37
 It has an 
excitation wavelength at 303 nm with a molar extinction coefficient of 18000 M
-1
 cm
-1
. 
Because of its broad absorption spectrum, excitation at 337 nm is possible. The quantum 
yield in water is very low (2 %) due to the presence of two water molecules in the inner 
coordination sphere, which are involved in the quenching of the Eu(III) excited state. This 
problem can be avoided by using this complex in the presence of a large molar excess (0.4 
M) of F
-
 ions, which replace the two coordinated water molecules (em = 10 %). 
Another ligand that coordinates the metal directly with the chromophore is the terpyridine 
ligand 1.2a which forms complexes of the type [Ln·(1.2a)3]
3+
. This avoids the presence of 
water in the inner coordination sphere leading to better quantum yields. Introducing alkyl 
substituents in the para position of the rings ([Ln·(1.2b)3]
3+
) further improves the emission 
quantum yield (up to 10 %).
38
 Although these systems displayed higher quantum yields, their 
low water solubility limits their utility. 
In 2003, the group of K.N. Raymond introduced the 2-hydroxyisophthalamide 'IAM' 1.3a and 
1-hydroxypyridin-2-one '1,2-HOPO' 1.3b based ligands.
39
 They act as strongly chelating 
ligands and also function as antennae. The R group can be modified to control both the 
denticity of the ligand and the geometry at the metal centre. One example is the 1-
hydroxypyridin-2-one '1,2-HOPO' based ligand 1.3c which is very effective in chelating 
Eu(III) ions and gives rise to quantum yields of around 21 %.
40
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 Complexes based on DO3A, bearing a sensitiser arm, have found many applications in 
fluorescence microscopy. One example is the tetraazatriphenylene-based DO3A complex 
[Ln·1.4].
41
 The chromophore binds directly to the metal centre leading to a quantum yield of 
18 %, with excitation at 355 nm.  
Other chromophores, which are exploited to bind directly to the metal centre in DO3A-based 
complexes, include tricyclic heterocyclic aromatics, such as an azaxanthone [Ln·1.5a]
 
and an 
azathiaxanthone [Ln·1.5b].
42
 Excitation of the heterocyclic chromophore in the range 330 to 
382 nm leads to low background fluorescence; moreover, a triplet state energy of around 
25400 cm
-1
 makes azaxanthones very good candidates for europium sensitization. One 
problem with this class of chromophores is that their molar extinction coefficients are not 
very high (around 5000 M
–1
 cm
–1
). 
In 2011, the use of three p-substituted pyridyl-alkynyl-aryl moieties (= 20000 M-1 cm-1 
each)
43
 combined with the shielding of the Eu(III) ion using nonadentate ligands based on 
triazacyclononane was reported ([Eu·1.6]).
44
 Overall extinction coefficients of about 60000 
M
-1
 cm
-1
 and high quantum yields (up to 50 %) make these complexes the brightest 
luminescent europium(III) complexes available. 
1.3 Fluorescence Resonance Energy Transfer (FRET) 
1.3.1 Principles of FRET 
Fluorescence Resonance Energy Transfer (FRET) is a process in which the excited-state 
energy is transferred from an excited donor (D) to an acceptor (A).
45
 This process does not 
involve photon emission, but requires an interaction between the transition dipoles of the 
donor and the acceptor. The donor absorbs and emits light; when the acceptor comes in 
proximity to the donor, the energy is transferred to the acceptor that emits and the emission of 
the donor is quenched.  
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Figure 17: Cartoon explaining the principle of FRET. 
A necessary condition required for this process to occur is an overlap between the emission 
spectrum of the donor and the absorption spectrum of the acceptor; the bigger the spectral 
overlap, the more efficient will be the energy transfer process. It is also important that the 
donor’s emission spectrum does not show any overlapping regions with the acceptor’s 
emission spectrum, in order to be able to measure each partner's fluorescence individually. 
 
Figure 18: Condition required for FRET, spectrum overlap is in yellow. 
The rate of energy transfer kT from D to A is strongly dependent on the distance between the 
two partners (r 
-6
) and it is described by the following equation: 
𝒌𝑻 =
𝟏
𝝉𝟎
(
𝑹𝟎
𝒓
)
𝟔
     [2] 
where 0 is the lifetime of the donor in absence of acceptor and R0 is the Förster distance 
(distance at which FRET is 50 % efficient). The distance R0 is constant for a specific D-A 
pair and is given by: 
𝑹𝟎 = (𝑱𝒌
𝟐𝜱𝟎𝜼
−𝟒)
𝟏
𝟔 ∙ (𝟗. 𝟕𝟗 ∙ 𝟏𝟎𝟐)     [3] 
in which J is the spectral overlap integral (in cm
3
 M
-1
), k
2
 is the orientation factor (2/3), 0 is 
the quantum yield of the donor in the absence of transfer, and  is the refractive index of the 
A
D
FRET
A D
D abs
D em
A abs
A em
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medium. The spectral overlap integral, J, can be calculated from the donor's emission 
spectrum and the acceptor's absorption spectrum: 
𝑱(𝝀) =
∫ 𝑭(𝝀)𝝐(𝝀)𝝀𝟒𝒅𝝀
∫ 𝑭(𝝀)𝒅𝝀
      [4] 
F() is the fraction of donor emission at wavelength , and () is the extinction coefficient 
of the acceptor at wavelength , in units of M-1 cm-1. 
1.3.2 Application of FRET in biological systems 
Fluorescence Resonance Energy Transfer occurs at distances comparable with biomolecular 
dimensions (R0 is typically 10 - 100 Å)
 46
 and has a strong distance dependence; these are the 
reasons why FRET is used in biological systems to measure distances between two points in 
macromolecules or to study macromolecular interaction. A summary of the most common 
bio-applications of FRET is given below. 
In the past, FRET has been used as a biological ruler; in fact, by labelling two different sites 
of a protein with a donor and an acceptor, it is possible to calculate the A-D distance by 
measuring the FRET efficiency (Figure 19).
47
 Because of the flexibility of the probe linkers 
and the FRET dependence on the dipole-dipole orientation, the distances can only be 
measured with a significant degree of uncertainty. In addition, this technique cannot give 
reliable results for very short distances (< 10 nm).    
 
Figure 19: Use of fluorescent labels to measure distances between two points on a protein with FRET. 
FRET has also been used to study protein folding; by monitoring the changes in fluorescence 
of the acceptor, it is possible to follow the time-dependence of the folding of a protein 
(Figure 20).
48
   
D
A
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Figure 20: Fluorescence emission spectrum of Trp183 PyP-eSHMT as a function of time after initiation of 
refolding at 4 °C. Trp is used as the acceptor in the energy transfer.
48
 
Energy transfer occurs independently of the constitution of the linker joining the donor and 
the acceptor; it depends only on the D-A distance. This is the reason why FRET has found 
many applications in the study of biomolecular associations. In the following example 
(Figure 21) one strand of DNA was labeled with fluorescein (F1) and the other strand with 
rhodamine (F2). When association occurs, the emission of fluorescein is quenched and the 
rhodamine emission is enhanced.
49
  
 
Figure 21: DNA association observed with labeled oligonucleotides.
49
 
1.3.3 Lanthanide complexes used in FRET 
The extremely long luminescence lifetime and the sharp emission bands of lanthanide 
complexes make them suitable candidates as donors in FRET applications. In fact, the long 
emission lifetime of these donors leads to a slow deactivation of the acceptor’s excited state, 
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resulting in an increased acceptor lifetime; the acceptor can therefore emit light for up to 
hundreds of microseconds. To exploit this property, the Homogeneous Time Resolved 
Fluorescence technology (HTRF) was introduced; HTRF combines standard FRET 
technology with time-resolved measurement of fluorescence (Figure 22).
50
 Introducing a 
time delay (50 to 150 µs) between the system excitation and fluorescence measurement, 
allows the signal to be clear of short-lived background fluorescence.  
 
Figure 22: Schematic representation of HTRF.
50
 
One of the most studied lanthanide donors is the Eu(TBP) cryptate, developed by G. Mathis 
and J.M. Lehn. The Eu
3+
 cryptates are mainly compatible with red acceptors that show an 
emission peak at 665 nm (Figure 23). The first acceptor used in HTRF experiments was 
allophycocyanin XL665, a large heterohexameric protein of 105 kDa.
51
 The second 
generation of acceptors is characterised by cyanine dyes (d2) that are 100 times smaller, 
which avoids steric problems.
52
 As mentioned in Section 1.2.3, Eu(TBP) has to be used in 
the presence on 0.4 M KF to prevent the quenching from two bound water molecules, but 
even with this addition, its quantum yield is not higher than 10 % (B = 0.4 mM
-1
 cm
-1
 at 304 
nm in water). 
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 Figure 23: Eu(TBP) cryptate (left). Donor emission (green) and acceptor emission (red), (right). 
Lumi4-Tb cryptate is a more recent and bright (B = 13.5 mM
-1
 cm
-1
 at 340 nm in water) 
donor developed by S. Petoud and K. Raymond.
53
 Lumi4-Tb is compatible with green 
acceptors like fluorescein or GFP (emission around 520 nm) and it can also be coupled with 
red acceptors (emission at 665nm).
54
  
  
Figure 24: Lumi4-Tb cryptate (left). Donor emission (black), acceptors emission (green and red), (left). 
These two complexes, both available from Cisbio, have been used in a variety of in vitro and 
in vivo assays to probe molecular interaction,
55
 to monitor the concentration changes of 
second messengers after stimulation of membrane receptors
52
 and to determine the membrane 
receptor structure, conformation, and ligand binding.
56
 By monitoring two single wavelengths 
(620 nm for the donor and 665 nm for the acceptor), all these assays give quantitative 
information. It is easy to notice that the band at 620 nm for the two donors presented above 
(band used for energy transfer and detection) is not the biggest in the total emission of the 
complexes. This factor can lower the inherent efficiency of the energy transfer process and 
raise the detection limit for the assay. 
Wavelength (nm) 
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An alternative to these systems is offered by the LANCE technology provided by Perkin 
Elmer, in which the europium chelating agent (general structure based on the complex in 
Figure 25) is optimised for labelling proteins and peptides. These Eu(III) donors can be used 
with small molecules or large protein acceptors.
57
 These complexes are based on the EDTA 
structure with seven coordination sites; for this reason their stability in media is lower than 
for the highly stable nine coordinated donors. These complexes are also susceptible to Mn
2+
 
quenching.
58
 The presence of only one chromophore makes these donors not the brightest 
donor on the market ( = 27000 M-1 cm-1). 
 
Figure 25: General structure of LANCE Eu(III) chelating reagent (Eu-W1024). 
Recently, much interest has grown in the use of lanthanide complexes as donors with 
quantum dots as acceptors.
 59
 The QDs can offer various perspectives such as the possibility 
of very large Förster radii (about twice the value estimated for organic dyes) and multiplex 
analysis.
60
 This technology is best applied for in vitro assays, due to QDs’ slight toxicity. 
1.4 Circularly polarised luminescence 
1.4.1 Linearly and circularly polarised light 
Light can be described with a transverse waves and its polarisation is determined by the 
direction of its electric field.
61
 When the electric field oscillations are confined to a single 
plane we have linearly polarised light (LP).  
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Figure 26: Unpolarised and linearly polarised light. 
When the electric field vector maintains the same magnitude, but changes its orientation 
describing a helix in the direction of propagation, we have circularly polarised light (CP); this 
type of polarisation can be described as the vector sum of vertical and horizontal polarised 
lights that are 90° out of phase. The helix described can be right (R-CP light) or left (L-CP 
light) handed. 
 
Figure 27: Right circularly polarised light (red) as a sum of vertical (blue) and horizontal (green) polarised 
light. 
Linear polarised light can be seen as the sum of right and left CP light. A chiral molecule 
interacts differently with these two components of LP light. The different absorbance of right 
and left CP is the base of circular dichroism (CD). CD spectroscopy has found many 
applications in the studies of chiral macromolecules or complex biological structures, such as 
proteins, due to their high degree of chirality.
62
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- 
Figure 28: Cartoon explaining CD. LP light (blue) becomes elliptically polarised light after interaction with the 
sample (orange box) because of the predominant absorption of R-CP light (red) compared to L-CP light (green). 
1.4.2 Circularly polarised luminescence spectroscopy 
The equivalent in emission of circular dichroism is circularly polarised luminescence 
(CPL).
63
 In CPL spectroscopy the difference in intensity of left (IL) and right (IR) circularly 
polarised components is monitored as a function of wavelength. The degree of CPL is 
quantified by the emission dissymmetry factor gem. 
𝒈𝒆𝒎 =
𝟐(𝑰𝑳−𝑰𝑹)
𝑰𝑳+𝑰𝑹
     [5] 
Although CPL can be measured for organic molecules
64-65
 and transition metal complexes,
66-
67
 the properties of lanthanides complexes make them most commonly used with this 
technique. In fact, lanthanide ions are considered pure spherical emitters avoiding problems 
of anisotropy. In addition, the magnetic-dipole nature of the f-f transitions of lanthanides 
gives rise to large values of |gem| (usually between 0.1 and 0.5 compared to < 0.01 for organic 
molecules).    
1.4.3 Lanthanide complexes in CPL spectroscopy 
The advantageous CPL properties of lanthanide cations have been exploited for the design of 
emissive optical probes in order to get information on the chiral environment.
68
 Two classes 
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of CPL lanthanides probes can be considered depending on the chirality of the functional 
ligand.  
The use of an achiral ligand generally gives rise to a 50 : 50 mixture of interconverting  and 
 enantiomers (Figure 29). The perturbation of the dynamic equilibrium between the two 
interconverting enantiomers in the presence of an added chiral species leads to the activation 
of an observable CPL signal. This can happen with a non-covalent association between the 
complex and the chiral species studied
69
 or with an actual change in the coordination 
environment of the lanthanide ion.
70
  
 
Figure 29: Examples of the use of a achiral ligand, pyridine-2,6-dicarboxylate (DPA), for the formation of a  
50 : 50 mixture of  and  enantiomers.71 
On the contrary, the use of an enantiopure ligand typically provides the presence of a 
dominant stereoisomer in solution. In this case, the interaction between the complex and the 
species of interest results in an altered CPL signal. 
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Figure 30: Changes in the Eu(III) CPL fingerprints upon addition of bicarbonate.
72
 
The synthesis of an enantiopure system is very challenging, often requiring long and tedious 
chiral chromatography purifications. A logical way to proceed is the transmission of the 
chiral information from the ligand to the metal centre. The incorporation of a single C-
substitution into the ligand system to control the final geometry at the metal centre offers a 
promising method for the production of enantiomerically pure systems.
73
 
1.5 Aims of the project 
Although the commercially available complexes described in Section 1.3.3 are excellent for 
fluorescence microscopy and spectroscopy, an improvement regarding their energy transfer 
properties can be achieved by increasing the spectral overlap and the efficiency of energy 
transfer. This will permit the design of novel bioassays that use smaller quantities of material 
and reduced costs.  
A new series of very bright emissive europium complexes was required to be synthesised and 
characterised, in order to provide better and more efficient donors for time resolved FRET 
applications.   
The characteristics required for the design of the Eu(III) complex as a good donor are:  
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 High brightness: the combination of large molar extinction coefficients and high 
quantum yields is essential for the visualisation of  low concentrations of the complex 
in cellular bioassays;   
 Excitation wavelength: the antenna requires an excitation wavelength above 330 nm, 
in order to avoid the excitation of endogenous chormophores and to match well with 
available excitation sources at 337, 355 and 365 nm; 
 Long luminescence lifetime: a luminescence lifetime of at least 1 ms is necessary for 
the use of time gated measurements; 
 Chemical stability: the complex has to be kinetically and thermodynamically stable 
towards dissociation in biological media;  
 Appropriate spectral properties: as the acceptor will be a cyanine dye (red 
acceptor), the emission spectrum should present high emission intensity in the spectral 
region around 600 - 630 nm and low emission in the other parts of the spectrum, 
notably around 650 - 710 nm (emission of the donor);  
 Water solubility: the complex should be soluble in buffered aqueous solution at pH = 
7; 
 Point of conjugation: the complex should present a reactive functional group, such as 
a primary amine or a carboxylic acid that permits easy conjugation with the 
biomolecule chosen for the assay.  
The first five points have, to a considerable extent, been realised by prior work in the period 
2008-11 using complexes with the general structure of [Eu∙1.6] (Section 1.2.3). These 
complexes will be analysed first in order to understand their behaviour as donors in FRET 
experiments. The synthetic work in this thesis focuses on the introduction of a linkage point 
for conjugation with biomolecules and on the improvement of the water solubility of these 
systems, involving the development of new methodology. 
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2 A series of highly emissive europium complexes  
2.1 Introduction 
The Eu(III) complex [Eu·1.6] presented in Section 1.2.3 is the brightest example of a 
europium complex reported in the literature (B = 32 mM
-1
 cm
-1
 at 332 nm in MeOH).
44 
The 
combination of three pyridyl-alkynyl-aryl moieties and the effective shielding of the Eu(III) 
ion using a triazacyclononane ligand provides a big overall extinction coefficient of 60,000 
M
-1
 cm
-1
 and extremely high quantum yields (up to 50 % in MeOH). Many examples have 
been synthesised incorporating different donor groups to complex the metal ion (e.g. 
carboxylate and phosphinate). In addition, a large variety of substituted aryl groups has been 
tested, in order to tune the photophysical properties, in particular max and .
74
   
   
Figure 31: General structure of the series of highly emissive europium complexes (left), typical absorption 
spectrum for these complexes (right). 
The maximum of absorption for these complexes is typically around 330 nm, into the broad 
absorption band. The absorption band extends to 355 nm and even 365 nm (Figure 31) 
permitting the use of various excitation sources.  
Especially for the phosphinate systems, the very effective shielding of the Eu(III) ion 
provides long luminescence lifetimes (typically ≥ 1 ms) and enhanced stability towards 
intramolecular quenching (e.g. by Mn
2+
, urate or citrate). 
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Figure 32: DFT calculated structures for carboxylate (a), P-Me (b) and P-Ph (c) phosphinate systems, showing 
the steric shielding for the phosphinate series (in particular for the P-Ph system).
75
 
a
 
2.2 Photophysical investigation 
The photophysical analysis of three different Eu(III) complexes (Figure 33) was carried out 
in order to understand if these complexes were suitable as donors in standard FRET 
experiments. These complexes differ from each other in the nature of the substituent on the 
pyridine ring; two of them possess phosphinate donors (P-Me and P-Ph) and the third is the 
carboxylate analogue. Each complex presents a slightly distorted C3 symmetry that leads to 
minimal splitting of the J = 1 and J = 2 manifolds in their Eu(III) emission spectra. 
                                                          
a
 The phosphinate complexes exist as a pair of enantiomers (RRR- and SSS-), from now on only one isomer 
will be drawn. A detailed discussion of the stereochemistry of these complexes can be found in Chapter 5.  
a)
b)
c)
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Figure 33: Structure of three Eu(III) complexes bearing different donor substituents. 
The emission spectra were recorded at the same concentration (5 M) in methanol to allow 
for direct comparison. A very intense set of J = 2 transitions was observed around 610 - 620 
nm for each of the three complexes. The spectra revealed that the carboxylate system has the 
largest J = 2/J = 1 intensity ratio by about 10 %. Minor changes in the form of the 
hypersensitive J = 2 manifold were observed, most probably associated with variation of 
oxygen donor polarisability. The spectra for the two phosphinate derivatives did not display 
any significant differences. 
 
Figure 34: Emission spectra of [EuL
1
] (blue), [EuL
2
] (red) and [EuL
3
] (green), (MeOH, 295 K). 
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Overall quantum yields and lifetimes were calculated and showed similar values for each 
complex (Table 2). The crystal structure of [EuL
1
] (Figure 35) revealed that the Eu(III) ion is 
encapsulated by the ligand in a tricapped trigonal prismatic array where the nearest water 
molecules are over 6 Å from the metal ion. The long distance to the nearest quenching OH 
oscillator partly explains the high quantum yields.  
Table 2: Photophysical properties of three Eu(III) complexes.
 
(MeOH, 295 K).
a 
 max / nm  / mM
-1
 cm
-1
 0ms em / % 
[EuL
1
] 332 58.0 1.26 52 
[EuL
2
] 332 58.1 1.18 43 
[EuL
3
] 340 58.0 0.95 48 
a
 Errors on max,  0 and em are ± 10%. 
The Eu(III) emission lifetimes follow the trend P-Ph > P-Me > carboxylate, in accord with 
the tendency of the phosphorus substituents to block the “upper face” of the complex.   
 
Figure 35: Molecular structure of [EuL
1
] showing part of the hydration sphere (120 K) (left), comparison 
between X-ray and DFT calculated structures (right).
44
 
2.3 Energy transfer analysis 
The acceptor chosen for the energy transfer studies is the commercially available cyanine dye 
Dy647-NH2 (Figure 36). This dye was selected because it is the acceptor used for the 
commercial bioassays marketed by Cisbio Bioassays.  
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Figure 36: Structure of the cyanine dye Dy647-NH2 and its absorption (blue) and emission (purple) spectra, 
(H2O, 295 K). 
The emission form of the three Eu(III) complexes described above presents the optimal 
profile required for efficient energy transfer. Indeed, the intense emission at 610-620 nm 
provides good spectral overlap with the acceptor absorption band and the absence of emission 
at 670 nm permits the monitoring of the two species without significant spectral overlap. 
 
Figure 37: Cyanine dye absorbance (blue) and emission (purple) spectra and [EuL
1
] emission spectrum (red), 
(MeOH, 295 K). 
2.3.1 Studies of energy transfer in methanol 
The quenching of these three complexes by the cyanine dye Dy647-NH2 was examined by 
observing changes in Eu(III) lifetime as a function of added acceptor concentration over the 
range 0.3 to 5 M, using 5 M solutions of the Eu(III) complex. 
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In the rapid diffusion limit, energy transfer from a donor to the quenching acceptor obeys 
pseudo-first order kinetics.
76
 
𝟏
𝛕𝟎
= 𝒌𝟎        [6]        
𝟏
𝛕
= 𝒌𝒐𝒃𝒔       [7]      𝒌𝒐𝒃𝒔 = 𝒌𝟎 + 𝒌𝟐[𝑸]    [8] 
𝝉𝟎
𝛕
=
𝒌𝒐𝒃𝒔 
𝒌𝟎
= 𝟏 +
𝒌𝟐
𝒌𝟎
[𝑸]   [9] 
Hence, the slope of a plot of 0/ vs [Q] represents k2/k0, allowing the second order rate 
constant for energy transfer, k2, to be estimated.   
 
Table 3: Quenching studies for [EuL
1
] (blue), [EuL
2
] (red) and [EuL
3
] (green), (Values recorded (± 5%) 
in MeOH, 295 K). 
 gradient 0ms kmM
-1
s
-1
  (±0.05)
[EuL
1
] 0.81 1.26 0.64 
[EuL
2
] 0.67 1.18 0.57 
[EuL
3
] 1.33 0.95 1.40 
The order of the rate constants shows that an enhanced rate of energy transfer from the 
carboxylate derivative occurs compared to the pair of phosphinates, which are more or less 
the same within experimental error. This can be tentatively ascribed, in part, to a slightly 
better spectral overlap integral for the carboxylate system, examining the J = 2 band 
intensity vs acceptor dye absorption band. Another possible difference is the electric dipole 
transition moments for each system: here, the extended conjugation of the carboxylate system 
(C=O is conjugated into the pyridyl chromophore) and associated greater polarisability may 
favour this system over the phosphinates, where the P=O is not in conjugation. Finally, it 
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may simply be a steric effect, where the P-substituents inhibit the approach of the acceptor, 
although this seems less likely, given the long distances over which such energy transfer 
process are believed to occur.  
Following the quenching studies, some calculations were undertaken in order to estimate the 
Förster radius (R0) and the spectral overlap (J) for the three Eu(III) complexes with this 
acceptor (Table 4). 
𝑹𝟎 = (𝑱𝒌
𝟐𝜱𝟎𝜼
−𝟒)
𝟏
𝟔 ∙ (𝟗. 𝟕𝟗 ∙ 𝟏𝟎𝟐)  [3] 
𝑱(𝝀) =
∫ 𝑭(𝝀)𝝐(𝝀)𝝀𝟒𝒅𝝀
∫ 𝑭(𝝀)𝒅𝝀
  [4] 
Table 4: Förster radii calculated for three Eu(III) complexes, (MeOH, 295 K).
a
 
 [EuL1] [EuL2] [EuL3] 
J / M-1cm3 1.016 x 10-12 1.184 x 10-12 1.109 x 10-12 
 0.52 0.43 0.48 
0 / ms 1.26 1.18 0.95 
R0  / nm 6.81 6.77 6.86 
k2 / mM
-1
s
-1
 0.64 0.57 1.40 
a
 The spectral overlap was calculated for 550 <  < 720 nm. The refractive index for MeOH is 1.328, 
compared to 1.333 for H2O. Errors on 0, and em are ± 10%. 
2.3.2 Studies of energy transfer in water  
Due to the extremely low water solubility of [EuL
1
] and the carboxylate analogue [EuL
3
] it 
was possible to carry out the quenching studies in water (50 mM HEPES buffer, 50 mM 
NaCl, pH = 7.4) only for the P-Me derivative [EuL
2
]. 
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Table 5: Quenching studies for [EuL
2
] in different solvents. (Values recorded (± 5%) at 295 K in: 100 
% 50 mM HEPES buffer, 50 mM NaCl, pH = 7.4 (blue); 50% 50 mM HEPES buffer, 50 mM NaCl and  
50 % MeOH (green); 100 % MeOH (red). ex = 332 nm). 
Solvent gradient 0ms kmM
-1
s
-1
  (±0.05)
MeOH 0.62 1.18 0.57 
MeOH : H2O (50:50) 0.67 1.11 0.56 
H2O 1.64 1.03 1.59  
The results showed a small increase in the value of k2 calculated in water compared to that 
measured in MeOH. This result can be ascribed to the increased polarity of water. No 
differences in k2 were observed between 100 % MeOH and MeOH/H2O 50:50. This is 
probably due to specific solvation of the complex by methanol. Indeed, Soper has shown that 
in binary mixtures of water and alcohols, clusters of alcohol molecules occur (or vice versa), 
so that the more hydrophobic solute is undergoing specific solvation by such a cluster.
77
    
In order to understand the FRET mechanism better, and in particular consider the differences 
in behaviour of the carboxylate and phosphinate complexes, additional different complexes 
were analysed in water (50 mM HEPES buffer, 50 mM NaCl, pH = 7.4). Complexes [EuL
2
] 
and [EuL
4
]
3-
 were provided by Dr. Brian McMahon and Dr. Stephen Butler, complexes 
[EuL
5
], [EuL
6
]
-
, [EuL
7
]
+
 and [EuL
9
]
+
 were supplied by Cisbio and [EuL
8
] was synthesised 
(details of the synthesis are given in Chapter 5).
78
 The quenching of these complexes was 
examined using 4 M solutions of the Eu(III) complex in the presence of quencher 
concentrations over the range 0.3 to 2.5 M. 
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Table 6: Quenching studies. (Values recorded (± 5%) in 50 mM HEPES buffer, 50 mM NaCl, pH = 7.4, 295 K). 
   gradient 0 / ms k2 / mM
-1
s
-1
 
[EuL
2
] 3P-Me (3OMe) 1.64 1.03 1.59 
[EuL
4
]
3-
 3P-Me (3OCH2COO
-
) 1.84 1.04 1.77 
[EuL
5
] 3COO
-
 (3PEG) 0.68 0.82 0.84 
[EuL
6
]
-
 3COO
-
 (2SO3
-
, 1NH3
+
) 1.65 0.80 2.06 
[EuL
7
]
+
 3COO
-
 (2PEG, 1NH3
+
) 1.72 0.76 2.26 
[EuL
8
] 2P-Me 1COO
-
 (3OMe) 0.95 0.89 1.07 
[EuL
9
]
+
 1P-Ph 2COO
- 
(2PEG, 1NH3
+
) 2.06 0.84 2.45 
The analysis of the rate constants calculated for these complexes showed that in water there is 
very little difference between the phosphinate and the carboxylate systems. In addition, the 
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hybrid system (carboxylate and phosphinate) did not offer any obvious advantages with 
regard to rate constants. The negative charges on the chromophore helped water solubility; 
moreover, they did not seem to affect energy transfer kinetics. On the contrary, the PEG 
groups on the chromophore helped water solubility to some degree, but also seemed to 
protect the complex from quenching by the acceptor, and hence [EuL
5
] gave rise to the 
slowest rate of energy transfer observed in the series. 
2.3.3 Comparison with commercially available donors 
In order to have a comparison with the commercially available donors, the same quenching 
studies were performed for the donors Eu(TBP) and Lumi4-Tb (Section 1.3.3) in the 
presence of a range of concentrations of the cyanine dye acceptor Dy647-NH2. The structures 
and emission spectra for these two complexes are reported in Figure 38. 
   
 
Figure 38: Structures and emission spectra of Eu(TBP)-NH2 (red) and Lumi4-Tb-NH2 (green), (H2O, 295K). 
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Table 7: Quenching studies for [EuL
4
] (red), Lumi4-Tb-NH2 (green) and Eu(TBP)-NH2 (blue). (Values 
recorded (± 5%) in 50 mM HEPES buffer, 50 mM NaCl, pH = 7.4, 295 K). 
 
max / nm  / M
-1
cm
-1 em / % 
 
/ ms k2 / mM
-1
s
-1 J / M-1cm3 R0  / nm 
[EuTBP-NH2]
5+
 304 3600 2 0.56 0.92 8.5 x 10
-13
 3.8 
[Lumi4-Tb-NH2] 340 26000 52 2.46 0.48 3.3 x 10
-13
 5.6 
[EuL
4
]
3-
 330 60000 22 1.04 1.77 10.0 x 10
-13
 5.9 
The spectral overlap was calculated for 550 <  < 720 nm. The refractive index for H2O is 1.333. To allow for 
comparison, the results for [EuL
4
]
3-
 are reported as an average for all the complexes reported in Table 6. 
The comparison showed a good improvement in terms of energy transfer properties for the 
new series of compounds. Indeed, a faster rate of energy transfer and a larger spectral overlap 
were calculated.  
Although these results describe a diffusional energy transfer process, an estimation of the 
FRET efficiency for the couple donor-acceptor can be made measuring the differences in 
lifetime in the absence (0) and in the presence of one equivalent of acceptor (DA).  
𝑬 = 𝟏 −
𝝉𝑫𝑨
𝝉𝟎
    [10] 
For each of these complexes, extremely high values (higher than 90 %) can be estimated, 
making this process very efficient. 
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2.4 Water solubility determination 
To complete this study, an experiment to quantify the relative hydrophilicity of these 
complexes (log P in water/octanol) was carried out in order to assess the correlation between 
the rate of energy transfer with the lipophilicity of each complex. 
Three equimolar solutions of complex were prepared in MeOH. The solvent was removed 
under reduced pressure and the resulting solid was dissolved and stirred for 24 h in 0.9 mL of 
a mixture of water/octanol (2:1, 1:1, 1:2) giving a total concentration of approximately 2 M 
for each mixture. After equilibration, an emission spectrum for each layer was recorded in 
MeOH (50 L of solution in 1 mL of MeOH). For each mixture, the logP value was 
calculated, according to the following equation: 
𝑳𝒐𝒈𝑷 = 𝑳𝒐𝒈 (
∫ 𝑰
𝟔𝟑𝟓𝒏𝒎
𝟔𝟎𝟓𝒏𝒎 (𝒐𝒄𝒕)
∫ 𝑰
𝟔𝟑𝟓𝒏𝒎
𝟔𝟎𝟓𝒏𝒎 (𝑯𝟐𝑶)
)    [11] 
Final logP values were calculated as the average of three solvent mixtures. 
In addition to the previously reported complexes, new examples were examined in order to 
have a better understanding of the functionalities that play a key role in the hydrophilicity of 
these systems. 
  
Figure 39: New Eu(III) complexes examined. 
Table 8: logP values for a series of Eu(III) complexes. 
 logP 
[EuL
2
] 1.4 ± 0.3 
[EuL
9
]
+
 1.2 ± 0.2 
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[EuL
5
] 1.1 ± 0.2 
[EuL
8
] 1.1 ± 0.2 
[EuL
11
]
-
 0.8 ± 0.2 
[EuL
7
]
+
 0.7 ± 0.2 
[EuL
10
]
-
 0.3 ± 0.1 
[EuL
12
]
6+
 0.3 ± 0.1 
[EuL
6
]
-
 - 1.1 ± 0.2 
[EuL
4
]
3-
 - 2.2 ± 0.4 
Complex [EuL
1
] and [EuL
3
] have a logP > 2 
From these data, it is clear that the introduction of charged moieties close to the chromophore 
(e.g. [EuL
4
]
3-
) increased the water solubility of the system. On the contrary, the PEG groups 
only showed a small effect (i.e. [EuL
5
]). Unfortunately, these results did not show any 
particular correlation with the rate of energy transfer. 
2.5 Conclusions 
The photophysical analysis of a series of very bright Eu(III) complexes, based on the 9-N3 
ring substituted with three pyridyl-alkynyl-aryl chromophores, showed very promising 
properties. For example, the complexes possess a very intense set of J = 2 transitions (610 - 
620 nm), high quantum yields (> 20 % in water) and long lifetimes (1.0 ms). These features 
are of fundamental importance for the use of these complexes as donors in FRET based 
experiments.  
The quenching of these complexes by the cyanine dye acceptor, Dy647-NH2, revealed an 
improvement in terms of FRET properties; faster rates of energy transfer and bigger spectral 
overlaps were measured, compared to the commercially available donors Eu(TBP) and 
Lumi4-Tb.  
These results provide the starting point for the design of a new series of compounds as very 
efficient donors for FRET experiments.  
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3 A new series of C-substituted europium complexes 
3.1 Introduction 
As discussed in Section 1.5, a linkage point for conjugation with the biomolecule is of 
fundamental importance for the use of these complexes in bioassays. Maintaining the general 
structure of the complexes described in Chapter 2, the introduction of an aliphatic chain on 
the azamacrocycle, terminally substituted with a primary amine, was studied. This approach 
avoids the introduction of different antennae substituents on the macrocyclic ring, as 
asymmetry in the aryl–alkynyl antennae complicates the synthesis. 
 
Figure 40: General structure of the new C-substituted series of complexes. 
Due to the better water solubility and good stability towards quenching, the P-Me 
phosphinate donor was chosen for the general structure. In addition, the introduction of 
solubilising moieties at the end of the aryl–alkynyl antennae was considered, to increase 
water solubility even further. 
3.2 A model C-substituted complex 
The synthesis of a model C-substituted 9-N3 derivative, which allows for linkage via the C-
substituent, was examined initially, in order to assess the effect of substitution on the 
europium emission spectral form (specifically the J = 2/J = 1 intensity ratio).  
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Figure 41: Structure of the model C-substituted 9-N3 derivative. 
The p-Br substituent on the pyridyl ring allows for the synthesis of an extended chromophore 
by Sonogashira coupling.
79
 
3.2.1 Synthetic aspects 
The following methodology for the synthesis of the C-substituted azamacrocycle is based on 
a procedure reported by Parker et al.,
80
 that has subsequently been scaled-up to 2 g for GMP 
(Celltech). Some modifications to improve yield and chemoselectivity of certain steps will be 
discussed in detail. 
The synthesis started with the reaction of the ethyl ester of lysine 1 with neat ethylenediamine 
to form the monoamide, which was reduced using the BH3-THF complex to give the 
tetraamine 2, isolated as the hydrochloride salt in quantitative yield.   
Protection of three nitrogens with Cu
2+
(aq) permitted the selective acylation of the remote 
amino group with benzoyl chloride (in the presence of KOH). Treatment of the copper 
complex with H2S permitted isolation of the free benzamide 3 in a 15 % yield. In order to 
improve the yield of the second step, which had disappointingly low yields on multi-gram 
scales, two alternative reactions were investigated. The replacement of benzoyl chloride with 
the corresponding NHS active ester permitted the avoidance of pH variation during the 
reaction. Unfortunately, this method did not show a great yield improvement (isolated yield 
of 3  < 20 % vs < 15 %). The treatment of 2 (as the free amine) with Mo(CO)6 was found to 
be a better strategy for this selective reaction. Mo(CO)6 formed an octahedral complex with 
the three amines close to each other, leaving the remote NH2 free to react with the active ester 
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of benzoic acid.
81
 This route gave a better yield of 3 (50 %) and it was successfully scaled up 
to 1 g. 
 
Scheme 1: Synthesis and yield optimisation of the C-substituted azamacrocycle, 6. 
Tosylation with TsCl in DCM in the presence of Et3N gave the intermediate 4a, which was 
used for condensation with ethylene glycolditosylate in DMF using Cs2CO3 as base, to afford 
the 9-membered macrocycle 5a in a reasonable yield (66 %). 
Deprotection of compound 5a was attempted with concentrated H2SO4 but the product 6b 
was isolated only in a very poor yield (< 10 %). Another strategy that could lead directly to 
compound 6a was the treatment with SmI2 in presence of H2O and pyrrolidine.
82
 Mass 
spectral analysis of the product mixture showed complete deprotection of the 9-N3 ring, but 
the product could not be easily separated from the pyrrolidine that is required in large excess 
(18 eq). The use of p-methoxybenzenesulfonyl chloride is described as an alternative to tosyl 
chloride; in principle it should be removed under milder acidic conditions, e.g. with HBr in 
AcOH in the presence of PhOH (80 °C).
81
 Mass spectral and 
1
H-NMR analysis showed 
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partial detosylation, but the addition of further HBr did not push the reaction to completion. 
The best way to cleave the tosyl group involved reduction with lithium in liquid ammonia 
that gave compound 6c as the major product (MS showed the presence of compound 6a in 
trace amounts). Treatment with 6 N HCl hydrolysed the amide bond and gave the desired 
compound 6a as the tetrachloride salt. For the model complex, compound 6c, containing 
traces of 6a, was taken on without further purification and used for the subsequent alkylation 
step. 
The synthesis of the pyridine platform 15 is a well-established procedure in the Durham 
group, involving 9 steps.
44
 
 
Scheme 2: Synthesis of the P-Me phosphinate pyridine platform.
 44
 
2-Bromo-6-methyl pyridine 7 was treated with mCPBA in CHCl3 to give the N-oxide 8. 
Nitration with HNO3/H2SO4, followed by deoxygenation with PBr3, gave the 2-bromo-4-
nitro-6-methyl pyridine 10 in high yield. Coupling between intermediate 10 and ethyl 
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methylphosphinate in degassed toluene with Et3N using 
Cl2Pd[bis(diphenylphosphino)ferrocene] as a catalyst was successful (67 % yield). 
Bromination with acetyl bromide followed by re-esterification of the phosphinic acid with 
HC(OEt)3 allowed for the isolation of intermediate 12 in 77 % yield. Compound 12 was 
treated with mCPBA in CH3CN to give N-oxide 13 in 79 % yield. Boekelheide rearrangement 
with (CF3CO)2O and subsequent hydrolysis in EtOH / H2O gave the intermediate 14 in 80 % 
yield. Mesylation under standard conditions gave compound 15 that was used directly for 
alkylation of the 9-N3 derivative 6c. 
 
Scheme 3: Synthesis of the complex [EuL
13
]. 
The crude reaction material, from the alkylation of 6c, was purified by HPLC to give 
compound 16, which was hydrolysed with 0.1 M NaOH in CD3OD/D2O (3 : 1). Completion 
of hydrolysis was confirmed by 
31
P-NMR. After pH adjustment, the material was reacted 
with Eu(AcO)3 to prepare the Eu(III) complex [EuL
13
]. 
3.2.2 Photophysical analysis 
An emission spectrum of [EuL
13
] was recorded and compared to that recorded for the 
unsubstituted analogue [EuL
13a
].
83
 The two spectra did not show any significant differences, 
confirming that the C-substitution on the ring did not affect the emission spectral form. The 
lifetime of [EuL
13
] was also measured (0 = 1.50 ms in MeOH); this value is comparable 
with that of [EuL
13a
] (0 = 1.56 ms in H2O). 
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Figure 42: Structure of [EuL
13
] and its unsubstituted analogue [EuL
13a
]. 
 
Figure 43: Emission spectra of [EuL
13
] (red) and the unsubstituted analogue [EuL
13a
] (blue), (MeOH, 295 K,  
 ex = 272 nm). 
A detailed investigation of the chiroptical features of this compound will be discussed in 
Chapter 5.  
3.3 A series of C-substituted complexes 
Following the promising results obtained for complex [EuL
13
], the design of a series of C-
substituted europium complexes was undertaken (Figure 44). These complexes bear the 
pyridylalkynylaryl chromophore, which permits excitation in the range 330 - 365 nm. In 
addition, substitution of the p-methoxy functionality on the chromophore with a negatively 
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charged moiety (e.g. carboxylate and sulfonate) was also expected to increase the water 
solubility of the complex. 
 
Figure 44: New series of C-substituted europium complexes. 
3.3.1 Synthetic aspects 
For the new series of compounds an easy cleavable protecting group (i.e. Boc) had to be 
introduced, instead of the cyclohexyl amide present in compound [EuL
13
]. This will permit 
the unmasking of the amine at the end of the synthesis without affecting the integrity of the 
chromophores. After complete hydrolysis of the amide 6c with 6 N HCl, various strategies 
for the selective protection of the tetraamine 6a were considered.  
 
Scheme 4: Selective Boc protection of the remote NH2. 
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The treatment of 6a with one equivalent of di-tert-butyl dicarbonate in the presence of PIPES 
buffer (pH = 6.8)
84
 was unsuccessful, leading to a mixture of mono, di, and tri-protected 
compounds. The use of Boc-imidazole, a reagent that is supposedly less reactive than di-tert-
butyl dicarbonate and selective for primary amines,
85
 unfortunately gave the same mixture of 
products. The attempted treatment of the free amine 6a with Mo(CO)6 was unsuccessful 
because of the very low solubility of the starting material in dibutyl ether. The treatment of 9-
N3 with copper (II) chloride forms a very stable complex.
86
 This property was exploited. The 
copper complex of compound 6a was formed and the subsequent selective reaction of the 
remote free NH2 with di-tert-butyl dicarbonate was successful. Bubbling H2S into an aqueous 
solution of this complex removed the Cu(II) as its insoluble sulphide, and permitted isolation 
of compound 17. 
The pyridylalkynylaryl chromophore 18 was synthesised by Sonoghashira coupling between 
the p-Br pyridyl derivative 14 and ethynyl anisole, using a catalytic amount of Pd(dppf)Cl2. 
Mesylation under standard conditions gave compound 19, which was used for direct 
alkylation of the macrocycle 17. 
 
Scheme 5: Synthesis of the extended pyridylalkynylaryl chromophore 19. 
The alkylation of the 9-membered ring derivative 17 with compound 19 was carried out in 
acetonitrile. A mixture of tri-substituted ligand 20 and the di-substituted analogue 21 was 
obtained, that was separated by column chromatography (Scheme 6). The third alkylation 
reaction, next to the C-substituent, occurred more slowly than in the parent unsubstituted 
system. 
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Scheme 6: Synthesis of the tri-substituted ligand 20 and di-substituted ligand 21. 
Deprotection of the primary amine was achieved with TFA (10 % in DCM) at RT. Hydrolysis 
of the phosphinate esters with aqueous NaOH (0.1 M), followed by reaction with Eu(AcO)3, 
gave the complex [EuL
14
]
+
.  
 
Scheme 7: Synthesis of [EuL
14
]
+
. 
3.3.2 Incorporation of solubilising moieties 
The introduction of negatively charged moieties on the chromophores was expected to 
increase the water solubility of the Eu(III) complex. Both carboxylate and sulfonate 
functionalities were considered. Carboxylic acids enhance the hydrophilicity of a molecule 
(when deprotonated) and are easy to handle, but are also rather reactive functionalities that 
Chapter 3: A new series of C-substituted europium complexes 
 
48 
 
might interfere during the labelling of the biomolecule. On the other hand, sulfonates give 
similar degree of water solubility, but they are not reactive groups and should not affect the 
labelling. They are usually introduced at the end of the synthesis, because of their poor 
solubility in organic solvents that makes them difficult to manipulate. Both strategies were 
pursued. 
A modified version of the extended chromophore was prepared in order to introduce the 
carboxylate moieties.
87
 
 
Scheme 8: Synthesis of the pyridylalkynylaryl chromophore, 24. 
Compound 22a was reacted with methanolic HCl to give the Me-ester 22 in almost 
quantitative yield. Sonogashira coupling with ethynyl-trimethylsilane followed by 
deprotection of the triple bond with Et3N-3HF gave compound 23 in 73% yield. A second 
palladium-catalysed coupling between p-Br pyridyl derivatives 14 and compound 23 gave the 
target chromophore 24.  
The di-substituted ligand 21, obtained from the previously described alkylation (Scheme 6), 
was reacted with the mesyl derivative of compound 24, i.e. 25, to give ligand 26.  
 
Scheme 9: Synthesis of ligand 26. 
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Ligand 26 was treated with aqueous NaOH, followed by reaction with Eu(AcO)3, to give 
complex 27. Coupling with homotaurine in presence of PyBOP and DIPEA, followed by 
BOC deprotection with TFA, allowed for formation of complex [EuL
15
], which was purified 
by reverse phase HPLC. 
 
Scheme 10: Synthesis of [EuL
15
]. 
Although the presence of one negative charge improved slightly the water solubility of the 
complex, it was decided to introduce three negative charges to improve it even further.  
Tri-carboxylate ([EuL
16
]
2-
) and tri-sulfonate ([EuL
17
]
2-
) analogues have been prepared from 
common intermediates. The alkylation of the 9-membered ring derivative 17 with the 
mesylate 25 was carried out in order to obtain ligand 28. In the first case, deprotection of the 
primary amine with TFA in DCM, simultaneous base hydrolysis of the phosphinate and 
carboxylate groups followed by reaction with Eu(OAc)3 yielded the complex [EuL
16
]
2-
.  
 
Scheme 11: Synthesis of [EuL
16
]
2-
. 
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For the synthesis of [EuL
17
]
2-
, ligand 28 was complexed after basic hydrolysis. The coupling 
with homotaurine in the presence of HATU and DIPEA in DMSO was successful and the 
subsequent deprotection of the BOC group with TFA gave the desired compound which was 
purified by reverse phase HPLC in the presence of triethylammonium acetate and isolated as 
its triethylammonium salt. 
 
Scheme 12: Synthesis of [EuL
17
]
2-
. 
In a similar manner, the unsubstituted analogue [EuL
17a
]
3-
 was synthesised from [EuL
4
]
3-
 to 
allow for a comparative analysis of the behaviour in bioassays. 
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Scheme 13: Synthesis of the unsubstituted tri-sulfonated system [EuL
17a
]
3-
. 
3.3.3 Photophysical and FRET studies 
The photophysycal properties of the new series of C-substituted complexes were measured 
and compared to those of the unsubstituted analogues. Even in the presence of the extended 
chromophore, no significant differences between the two systems were observed. 
 
Figure 45: Series of C-substituted complexes and unsubstituted analogues. 
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The absorption and emission profiles are very similar for each of these complexes; an 
example for [EuL
17
]
2-
 is shown in Figure 46. A summary of the photophisycal properties is 
presented in Table 9. 
 
Figure 46: Absorption (blue) and total emission (red) spectra for [EuL
17
]
2-
, (H2O, 295 K, ex = 328 nm). 
Table 9: Summary of the photophysical properties for the new series of C-substituted complexes and 
unsubstituted analogues, (H2O, 295 K). 
  max / nm 0 / ms em / %   / mM
-1cm-1 logP 
[EuL2] 328 1.03 24 58 + 1.4 
[EuL4]3- 330 1.04 28 57 - 2.2 
[EuL17a] 3- 328 1.01 26 57 - 2.2 
[EuL14]+ 328 1.00 22 58 n.d. 
[EuL15] 328 1.08 25 58 n.d. 
[EuL16]2- 330 1.05 26 57 n.d. 
[EuL17]2- 328 1.00 26 57 n.d. 
a
 Errors on max, 0, em and  are ± 10%, errors on logP are ± 20%. 
From the results, it was clear that the introduction of the negative charges into the ligand 
system did not affect the photophysical properties of the complexes. In addition, the negative 
values of logP (- 2.2) proved that the carboxylate and the sulfonate moieties gave high water 
solubility to the complex.  
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[EuL2] [EuL4]3- [EuL17a]3-
Some relative stability tests were carried out for the unsubstituted complexes in order to 
predict the behaviour of these systems in the media used commonly for bioassays, or in 
cellulo.  
Ascorbate and urate are two intracellular antioxidants that are able to quench the sensitiser’s 
triplet excited state.
88
 Luminescence spectra and excited state lifetimes were measured in the 
presence of excess of quencher (10 mM for ascorbate, 5 mM for urate); no quenching was 
observed from either antioxidant. 
 
Figure 47: Ascorbate and urate structures. 
To analyse the possible interactions of these compounds with proteins in the media, emission 
spectra were recorded for the three complexes (4 M in water, pH = 7.4) in the absence and 
in the presence of 0.4 mM HSA (human serum albumin). Albumin was chosen as it is present 
in a cell growth medium, and is the most abundant protein in serum. 
Table 10: Photophysical properties of different Eu(III) complex in the absence (blue) and in the presence 
of 0.4 mM HSA (red), (with added HSA, excitation spectroscopy was used to assess max).  
 
 
 [EuL
2
] [EuL
4
]
3-
 [EuL
17a
]
3-
 
max / nm 328 330 328 
max HSA / nm 333 337 329 
0 / nm 1.03 1.04 1.01 
0 HSA / nm 1.10 1.01 1.12 
a
 Errors on max and 0 are ± 10%. 
 
The addition of HSA to the complex caused a decrease in the total emission intensity (up to 
30 %) without affecting the emission spectral form. The most affected complex was [EuL
2
], 
probably due to its higher lipophilicity promoting a hydrophobic interaction with HSA. Also, 
emission lifetimes were generally increased in the presence of HSA (exception [EuL
4
]
3-
). 
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Importantly, the absorption wavelength shifted to the red slightly in every case. This change 
was observed by recording the excitation spectra (rather than the absorption spectrum) in the 
presence of protein. Controls in the absence of added protein showed that the excitation and 
absorption spectra corresponded. The excitation spectral change implied that there was either 
an interaction between the protein’s aromatic chromophores and the arylalkynylpyridyl 
moiety, or that there was a change in the effective dielectric constant of the ‘local medium’, 
following the non-specific protein-complex interaction that perturbs the energy of the ICT 
transition and modifies the intramolecular energy transfer step. Indeed, the ICT band is 
known to be strongly solvatochromic. A spectral titration, adding different concentrations of 
HSA to the Eu(III) complex, did not show any sign of binding, suggesting that these results 
can be tentatively ascribed to a change of local polarity and viscosity of the medium. 
To substantiate this hypothesis, the same photophysical properties were measured in solvents 
with different polarities (Table 11). A general increase in the emission lifetime was measured 
in different solvents; also the overall quantum yield was affected by the polarity of the 
medium. These results proved that changing the medium polarity had a similar effect to that 
observed following addition of HSA. 
Table 11: Photophysical properties for [EuL
17a
]
3-
 measured in solvents with different polarities.
b
 
[EuL
17a
]
3-
 
a max / nm em / % / ms
H2O 1.00 328 26 1.01 
TFE-OH 0.90 328 24 1.26 
MeOH 0.76 330 37 1.21 
EtOH 0.65 330 36 1.23 
DMF 0.40 328 53 1.22 
NMP 0.36 336 38 1.16 
a
 ET
N
 is Reichardt’s normalised solvent polarity parameter.89 b Errors on max, em and 0 
 are ± 10%. 
The FRET properties of the new sulfonate compound [EuL
17a
]
3-
 were assessed in the 
presence of different concentration of acceptor Dy647-NH2 and compared to the results 
presented in Section 2.3.2. 
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Table 12: Quenching studies for [EuL
2
] (red), [EuL
4
]
3-
 (blue) and [EuL
17a
]
3-
 (green). (Values recorded  
(± 5%) in 50 mM HEPES buffer, 50 mM NaCl, pH = 7.4, 295 K). 
 gradient max / nm em / % 0 / ms k2 / mM
-1
s
-1
 
[EuL
2
] 1.64 328 24 1.03 1.59 
[EuL
4
]
3-
 1.84 330 28 1.04 1.77 
[EuL
17a
]
3-
 1.86 328 26 1.01 1.84 
The three complexes did not show any significant differences in their photophysical 
properties nor in the rates of energy transfer, proving that the peripheral anionic groups are 
not interfering with the energy transfer process. 
3.4 Applications in FRET bioassays 
After solving the problem of water solubility, the behaviour of these complexes in FRET 
bioassays was evaluated using SNAP-tag technology.
90
 This is a general strategy that permits 
the irreversible covalent labelling of a fusion protein in vivo with a suitable ligand (e.g. 
optical probe). SNAP-tag is a 20 kDa engineered protein that can be inserted in the protein of 
interest. Its behaviour is based on a human DNA-repair protein O6-alkylguanine-DNA 
alkyltransferase (hAGT); hAGT transfers irreversibly the alkyl group from its substrate, O6-
alkylguanine-DNA, to one of its cysteine residue (Figure 48a). In the same way, SNAP-tag 
reacts with benzylguanine (BG) derivatives permitting the transfer of the optical probe to the 
fusion protein of interest (Figure 48b). 
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Figure 48: Schematic mechanism of hAGT (a) and SNAP-tag (b) technology.
90
 
For our purposes, the SNAP-tag method was used for the labelling of G protein-coupled 
receptors (GPCRs), which have elevated expression levels when transiently transfected in 
HEK293 cells. The results are presented for the cholecystokinin-2 (CCK2) and dopamine-d2 
receptors (membrane receptors). CCK2 receptors are located primarily in the brain, spinal 
cord and stomach and are involved in neurotransmission and regulation of anxiety, feeding 
and locomotion.
91
 Dopamine-d2 receptors are located in the central nervous system and 
control the neural signalling of behaviour, such as spatial working memory, by modulating 
the production of neurotransmitters.
92
  
The assay provides the labelling of the receptor with the Eu(III) complex (Figure 49). To 
permit this labelling using the SNAP-tag technology, a BG derivative of the Eu(III) complex 
had to be synthesised (Section 3.4.1). This labelling does not interfere with the interaction of 
the substrate with the receptor, and permits the visualisation of the receptor on the cell 
surface. When a substrate, labelled with the cyanine dye FRET acceptor, interacts with the 
receptor, the emission of the Eu(III) is quenched and the FRET signal is activated. 
 
ST ST
a) 
b) 
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Figure 49: Cartoon explaining the processes involved in the bioassay. The reaction of SNAP-tag with the  
BG-labelled Eu(III) complex permits the labelling of the receptor. Upon addition of a substrate for the receptor 
labelled with the organic dye (acceptor), the emission of the Eu(III) complex is quenched and the FRET signal is 
activated. 
3.4.1 Conjugation with the biomolecule 
For the G protein-coupled receptors assay, three BG-labelled complexes were prepared. The 
complexes were directly reacted with the active ester of BG-MB-NH-glu-COOH, giving the 
desired compounds in good yields. 
 
Figure 50: Structure of BG-MB-NH-glu-NHS. 
 
Scheme 14: Synthesis of three BG-labelled Eu(III) complexes. 
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3.4.2 Time resolved FRET assays 
These results were obtained in collaboration with Dr Victoria Sadovnikova and Dr Jurriaan 
Zwier at Cisbio Bioassays. 
The complexes presented in Section 2 were originally developed as stains for various 
intracellular compartments, such as mitochondria, following non-specific cell uptake by 
micropinocytosis.
87
 This behaviour is disadvantageous for GPCRs assays. In fact, in order to 
selectively label the desire GPCRs (membrane receptors), it is important that the BG-
complexes do not show any non-specific interactions with the cells, such as internalisation or 
adsorption to the membrane. 
As the cell membrane consists of phospholipids and is thus considered to be negatively 
charged, the carboxylate and sulfonate moieties on complexes [EuL
16
]
2-
 and [EuL
17
]
2-
 should 
decrease the interaction with the cell membrane, as a result of repulsive Coulombic 
interactions. In addition, the hydrophilic nature of these substituents on the aryl-alkynyl 
structure should prevent non-specific protein binding that can occur via hydrophobic 
interactions of the chromophore. 
The specific binding for the three BG-Eu(III) complexes was measured using a saturation 
binding assay. The time-gated luminescence intensity at 620 nm was monitored on HEK293 
cells expressing the SNAP-tagged receptors and on non-transfected HEK293 cells (control), 
after 1 h incubation with different concentrations of the BG-Eu(III) complex (Figure 52 and 
Figure 53). Unfortunately, significant labelling of non-transfected cells occured with the 
more lipophilic compound [EuL
14
]-glu-MB-BG, probably due to cellular uptake. As 
predicted, better behaviour was observed for the negatively charged complexes [EuL
16
]-glu-
MB-BG and [EuL
17
]-glu-MB-BG; negligible values for non-specific interaction were found, 
permitting the selective labelling of the GPCRs on the cell membrane (Figure 52 and Figure 
53). 
Following these excellent results, some ligand-binding assays were performed using an 
agonist for the receptor, which was labelled with a cyanine dye acceptor. Addition of 
increasing concentrations of the fluorescently labelled agonist to the Eu(III) labelled living 
cells activated the FRET signal at 665 nm (emission of the acceptor). By measuring the time 
resolved (TR) emission intensity at 620 nm (donor) and at 665 nm (acceptor), it was possible 
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to calculate a saturation curve for the binding of the agonist. By non-linear least squares 
iterative fitting of the data to a one-site binding model, the affinity of the red-agonist for the 
receptor, was calculated.  
  
Figure 51: Cartoon explaining the ligand-binding assay. The receptor is labelled with the Eu(III) complex, upon 
addition of fluorescent agonist, the Eu(III) emission is quenched and the FRET signal is activated. 
Eu
Eu
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Figure 52: Saturation curves for labelling of HEK293 cells expressing SNAP-CCK2 and non-transfected HEK293 cells monitoring time-gated luminescence intensity  
( = 620 ± 5 nm, 60 - 460 s) after 1h incubation. 
 
 
 
Figure 53: Saturation curves for labelling of HEK293 cells expressing SNAP-d2 and non-transfected HEK293 cells monitoring time-gated luminescence intensity  
( = 620 ± 5 nm, 60 - 460 s) after 1h incubation. 
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The binding of the agonist was shown to be completely reversible, in a dose-dependent way, 
by the addition of excess quantities of an antagonist of the receptor (not labelled with the 
acceptor).  
 
Figure 54: Cartoon explaining the competition-binding assay. The receptor labelled with the Eu(III) complex is 
saturated with the fluorescent agonist (red), upon addition of excess of not labelled antagonist (blue), FRET 
signal disruption occurs and the Eu(III) emission is reactivated. 
In this TR competition binding assay, the disruption of the FRET signal can be monitored as a 
function of the antagonist concentration. At the same time, the full Eu(III) emission intensity 
was re-established. By fitting the dose-response data, the affinity of the antagonist for the 
receptor, can be calculated. This provides a general strategy for high-throughput screenings of 
new drugs, avoiding the problem of labelling the compound to be tested.    
An example of the TR-FRET ligand-binding assay and the TR-FRET competition binding 
assay is presented for the Eu(III) labelled SNAP-CCK2 receptors on living HEK293 cells.
93
 
Compound [EuL
17
]-glu-MB-BG (200 nM) was used for the labelling of the receptors in this 
example ([EuL
16
]-glu-MB-BG gave similar results). Addition of increasing concentration of 
the agonist CCK(26-33)-red (polypeptide labelled with the red acceptor) resulted in 
activation of FRET signal. The fitting of the data permitted the calculation of the dissociation 
constant of the red agonist (Kd = 8 nM), this value is in agreement with previously reported 
results.
94
 Addition of excess quantities of PD135158 (unlabelled antagonist, Figure 55c) 
resulted in FRET disruption; with these results, the inhibition constant for the antagonist was 
calculated (Ki = 6 nM), also in good agreement with previously reported results.
94 
 
Eu
Eu
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Figure 55: Binding of red-CCK(26-33) to HEK293 cells expressing SNAP-CCK2, labelled with  
[EuL
17
]-glu-MB-BG (200 nM), monitored by following the ratio of the emission intensity at = 665 and 620 
nm x 10000, Kd = 8 nM (a). TR-FRET competition binding assay, monitoring the dose–response curve for the 
displacement of red-CCK(26-33) by CCK2 antagonist PD135158. The ratio of the emission intensity at 
wavelengths  = 665 and 620 nm x 10000 was measured, Ki = 6 nM (b). Structure of the antagonist  
PD135158 (c).  
3.4.3 Microscopy studies 
Due to the high brightness of these complexes, it was also possible to visualise these cell-
surface interactions using confocal microscopy; very small quantities of material were 
required (nM concentration). The Eu(III) labelled SNAP-d2 dopamine receptors on living 
HEK293 cells were visualised on the cell surface (A1), compound [EuL
17
]-glu-MB-BG (200 
nM) was used for the labelling. The FRET channel did not show any signal (A2). When the 
red-acceptor (NAPS-red, a well-known substrate for the d2-dopamine receptor labelled with 
a cyanine dye, Figure 56)
95
 was introduced to the system, the Eu(III) emission was quenched 
(B1) and the FRET signal was activated (B2). Three dimensional z-stacks (pixel 0.120 x 
0.120 x 700 nm) revealed cell surface localisation for both the complex and the acceptor. 
 
Figure 56: Structure of the red-acceptor, NAPS-red. 
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Figure 57: 293 HEK cells expressing SNAP-d2 dopamine surface receptor labelled with Eu(III) complex, 
standard (A), in the presence of FRET acceptor (B). Eu(III) Channel (A1 and B1) exc = 355 nm at 4 mW, 
detector 590-650 nm. FRET Channel (A2 and B2) exc = 355 nm at 4 mW, detector 650-690 nm. Acceptor 
Channel (A3 and B3) exc = 633 nm at 2 mW, detector 650-690 nm.   
Following these promising results, the visualisation of these interactions with time-resolved 
FRET microscopy was also pursued. This technique has been reported only recently for 
lanthanide based systems, 
87-96
 primarily using long lived Tb(III) donor complexes.
97
  
Using a delay of 100 s and a gate time of 2 ms, time resolved (TR) images were recorded, 
showing the Eu(III) labelled receptors on the cell surface (d2-dopamine receptors in Figure 
58A1, CCK2 receptors in Figure 59A1). Upon addition of the red agonist, TR-FRET images 
were recorded at  = 670 ± 20 nm showing a high signal in the FRET channel (B2). A 
decrease in the intensity of the Eu(III) channel was also observed (B1). 
A1 A2 A3
A1 A2 A3
B1 B2 B3
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Figure 58: 293 HEK cells expressing SNAP-d2 dopamine surface receptor labelled with the Eu(III) complex, 
standard (A), in the presence of FRET acceptor (B). TR-Eu(III) Channel (A1 and B1)  = 615 ± 10 nm (exc = 
337 nm, 30 Hz, delay = 100 s, gate = 2000 s). TR-FRET Channel (A2 and B2)  = 670 ± 20 nm (exc = 337 
nm, 30 Hz, delay = 100 s, gate = 2000 s).   
 
Figure 59: 293 HEK cells expressing SNAP-CCK2 surface receptor labelled with Eu(III) complex, standard (A), 
in the presence of FRET acceptor (B). TR-Eu(III) Channel (A1 and B1)  = 615 ± 10 nm (exc = 337 nm, 30 Hz, 
delay = 100 s, gate = 2000 s). TR-FRET Channel (A2 and B2)  = 670 ± 20 nm (exc = 337 nm, 30 Hz, delay = 
100 s, gate = 2000 s).   
A1 A2
B1 B2
A1 A2
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3.5 Conclusions 
A new series of bright, kinetically stable and highly water soluble Eu(III) complexes was 
developed. For this purpose, the synthesis of a C-substituted macrocycle core was optimised, 
permitting the production of complexes with a linkage point for conjugation. The C-
substitution on the ring did not affect the emissive properties and created a useful intermediate 
that can be easily functionalised for a variety of applications. 
These complexes were designed to permit excitation with lasers at 337, 355 or 365 nm for in 
vivo FRET experiments. The introduction of carboxylate or sulfonate functionalities onto the 
antenna avoided the non-specific labelling of living HEK cells, permitting the selective 
targeting of membrane receptors. 
TR-FRET binding assays were performed on two GPCRs (d2-dopamine and CCK2) in living 
cells with promising results for the use of this technology in high-throughput screening 
assays. Due to the high brightness of these Eu(III) complexes, the visualisation of these 
systems was possible with confocal and TR-FRET microscopy, using only small quantities of 
material (nM concentrations).  
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4 New hydrophilic sulfonated systems 
4.1 Introduction 
The P-Me phosphinate C-substituted systems described in the previous chapter exhibited 
very good behaviour in the in vivo bioassay. The introduction of negatively charged 
functionalities provided high water solubility to the molecule and suppressed the non-
specific labelling of living cells.  
Notwithstanding the high brightness of the P-Me system (B = 14 mM
-1
 cm
-1
 at 332 nm in 
water), some modifications to improve the quantum yield are possible. The P-Ph 
phosphinate analogue, described in Section 2.2, presented a higher quantum yield (by about 
10 % in MeOH) and longer lifetime (by about 10 %). The main issue with this complex was 
the lack of water solubility. 
 
Table 13: Photophysical properties of two phosphinate Eu(III) complexes, (MeOH,  295 K). The values in 
parenthesis for [EuL
2
] are measured in H2O.
 a
 
 max / nm  / mM
-1
 cm
-1
 0ms em / % 
[EuL
1
] 332 58.0 1.26 52 
[EuL
2
] 332 (328) 58.1 (58.0) 1.18 (1.00) 43 (22) 
a
 Errors on max, 0, and em are ± 10%. 
In this chapter, the introduction of solubilising moieties into the P-Ph system is discussed. 
Chapter 4: New hydrophilic sulfonated systems 
 
67 
 
4.2 Improving the water solubility of the P-Ph system 
Different approaches were considered in order to improve the water solubility of the  
P-Ph phosphinate system. The study of the behaviour of the P-Ph analogues of compounds 
[EuL
16
]
2-
 and [EuL
17
]
2-
 seemed to be the more straightforward option (Figure 60).  
 
Figure 60: Structures of the P-Ph phosphinate analogues. 
The introduction of sulfonate moieties at different position on the ligand was also 
investigated. The sulfonation of the P-Ph aromatic ring was pursued (Figure 61); in addition 
to an enhanced water solubility, this system possesses negative charges close to the Eu(III) 
centre, that could affect the energy transfer properties in a FRET process.  
 
Figure 61: General structures of the P-Ph sulfonate complexes. 
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The last modification considered was the introduction of an aliphatic chain, with a terminal 
sulfonate group, at the 3 position of the aryl group (Figure 62). In fact, the introduction of an 
electron donating group in this position has been established to shift the excitation wavelength 
by about 10 nm to the red.
87
 This makes the excitation more efficient with less energetic 
(higher wavelength) excitation sources (e.g. 355 and 365 nm).  
 
Figure 62: Structure of the P-Ph complex substituted with an aliphatic chain. 
4.2.1 The analogues of the P-Me phosphinate systems 
The P-Ph analogue chromophore 32 was synthesised by Sonoghashira coupling between the 
p-Br pyridyl derivative 31 and compound 23, using Pd(dppf)Cl2 as the catalyst. 
 
Scheme 15: Synthesis of the P-Ph phosphinate chromopohore. 
The synthesis of the two P-Ph analogues followed the same procedure described for the P-
Me systems (Section 3.3.2). The unsubstituted analogues were also synthesised to allow for 
comparison.  
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The alkylation of the 9-membered rings with the mesylate derivative 33 was carried out, using 
standard condition, to obtain the trisubstituted ligands 34 and 35. Deprotection of the primary 
amine with TFA in DCM (only for ligand 34), basic hydrolysis of the phosphinate and 
carboxylate groups followed by complexation yielded [EuL
18
]
2-
 and the unsubstituted 
analogue [EuL
18a
]
3-
.  
 
Scheme 16: Synthesis of [EuL
18
]
2-
 and its usubstituted analogue [EuL
18a
]
3-
. 
For the synthesis of complex [EuL
19
]
2-
, ligand 34 was reacted with Eu(OAc)3 after basic 
hydrolysis. The coupling with homotaurine in the presence of HATU and DIPEA in DMSO 
was successful and the subsequent deprotection of the BOC group with TFA gave the desired 
compound in near quantitative yield. The usubstituted analogue [EuL
19a
]
3-
 was synthesised 
from the coupling reaction between homotaurine and [EuL
18a
]
3-
. 
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Scheme 17: Synthesis of [EuL
19
]
2-
 and its usubstituted analogue [EuL
19a
]
3-
. 
The photophysical properties of the new series of P-Ph phosphinate complexes were 
investigated and compared to the P-Me systems (Table 14). 
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Table 14: Summary of the photophysical properties for the new series of P-Ph C-substituted complexes 
(blue) and unsubstituted analogues compared to the P-Me analogues (red), (H2O, 295 K).
 a
 
  max / nm 0 / ms em / %   / mM
-1cm-1 logP 
[EuL4]3- 330 1.04 28 57 - 2.2 
[EuL17a]3- 328 1.01 26 57 - 2.2 
[EuL18a]3- 330 1.11 38 58 - 1.9 
[EuL19a]3- 328 1.12 32 57 - 2.1 
[EuL16]2- 330 1.05 26 57 n.d. 
[EuL17]2- 328 1.00 26 57 n.d. 
[EuL18]2- 330 1.10 37 58 n.d. 
[EuL19]2- 328 1.11 31 57 n.d. 
a
 Errors on max, 0, em and  are ± 10%, errors on logP are ± 20%. 
As expected, this new series of complexes possess both a higher quantum yield (up to 38 % 
for [EuL
18a
]) and a longer emission lifetime (around 1.1 ms). The logP measurements 
confirmed the good water solubility of the new P-Ph series of complexes (blue), comparable 
with the values measured for the P-Me complexes (red).  
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4.2.2 Introduction of aromatic sulfonates 
The second strategy considered for the enhancement of water solubility of the P-Ph complex 
was aromatic sulfonation. This is a well-known method that has been applied to create water 
soluble dyes and polymers.
98-99
 This series of compounds was designed in order to maintain 
the good properties observed for the P-Ph system (i.e. high quantum yields and long emission 
lifetimes). The sulfonation of this position was not expected to perturb the chromophore 
characteristics significantly, as the phosphorus oxygen bond and the aryl group to which it is 
attached are not strongly conjugated. X-ray structural studies (Figure 35) had earlier 
confirmed that the phosphorus–oxygen double bond lies out of the plane of the aryl rings 
(torsion angle = 20°). In addition, the effect of three negative charges close to the europium 
centre may affect the energy transfer properties. 
4.2.2.1 Synthetic investigations 
Classically, the introduction of sulfonate functionalities into aryl rings is undertaken at the 
end of the synthesis. In fact, the poor solubility of these anionic compounds in organic 
solvents makes them difficult to separate and purify. However, aryl sulfonation occurs under 
forcing electrophilic conditions and is generally not suitable for multifunctional compounds. 
For our purpose, the sulfonate moiety had to be introduced at an early stage in the synthesis, 
so the use of different protecting groups was considered. These PGs are typically electron 
poor or sterically hindered sulfonate esters (e.g. neopentyl or halogenated-ethyl esters)
100-101
 
that prevent a nucleophilic substitution reaction on the C-O bond. Deprotection can be 
achieved either using base,
102
 acid
103
 or enzymatic-catalysis,
104
 releasing the sulfonate group 
in a final reaction step. The protecting group also permits the use of conventional purification 
methods (i.e. column chromatography) avoiding the handling of intermediate anionic systems. 
Three PGs, that provide stability to strong acids, nucleophilic substitution and palladium 
catalysed cross coupling, were considered at the outset.  
In the first case, the sulfonate group was masked as a trifluoromethylthio functionality.  
Oxidation with mCPBA converted the thioether into the sulfone analogue that is reported to 
be hydrolysed in the presence of NaOMe.
105
 Test reactions showed high yields for this 
process, so this strategy was examined first for the synthesis of the target ligand (Scheme 18). 
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Scheme 18: Protecting group for sulfonate, first strategy. 
Two other protecting groups, brought to prominence by the work of Miller,
101
 were also 
considered. Trifluoroethyl (TFE) and phenyl (Ph) sulfonate esters as protecting groups for the 
sulfonic acid moiety have been reported to be stable to strong acids and nucleophilic 
substitution; they are cleaved under basic conditions. Positive results for the test reactions 
confirmed the utility of these PGs for the synthesis of the target compound (Scheme 19). 
 
Scheme 19: Protecting groups for sulfonate, second and third strategies. 
4.2.2.2 Application of the new methodologies for the synthesis of new compounds 
4.2.2.2.1 First strategy 
A retrosynthetic analysis (Scheme 21) identified the 2,4,6-trisubstituted pyridine 52, with a 4-
Br group, as the main building block for the production of the extended chromophore 54. The 
pyridine derivative 52 can be further disconnected, foreseeing two subsequent C-P bond-
forming reactions. This led to the identification of 2-bromo-6-methyl pyridine 10 and 1-
bromo-4-(trifluoromethylthio)benzene 46 as starting materials. 
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Scheme 20: Retrosynthetic approach for pyridine intermediates, first strategy. 
The bromo derivative, 46, was converted to the Grignard reagent and reacted with 
diethylchlorophosphite. Hydrolysis to the corresponding phosphinate 48 was achieved with 
one equivalent of 1 M HCl.
106
 Coupling between intermediate 48 and 2-bromo-4-nitro-6-
methyl pyridine in degassed toluene with Et3N using Cl2Pd[bis(diphenylphosphino)ferrocene] 
as a catalyst was successful. Bromination with acetyl bromide followed by re-esterification of 
the phosphinic acid with HC(OEt)3 allowed the isolation of intermediate 50 in 68 % yield. 
Compound 50 was treated with mCPBA in CHCl3 to give the N-oxide 51, with simultaneous 
oxidation of the thioether to the corresponding sulfone (45 % yield). Treatment with 
(CF3CO)2O and subsequent hydrolysis in EtOH / H2O gave the building block 52 in 92 % 
yield. The introduction of the aryl alkynyl moiety by Sonogashira coupling was successful 
(yield = 67 %). Mesylation under standard conditions gave compound 54, which was used for 
the alkylation of the azamacrocyle, 17 to give ligand 55 (Scheme 22). Deprotection of the 
primary amine with TFA in dry DCM allowed for the formation of ligand 56, in a quantitative 
yield. 
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Scheme 21: Synthesis of the new phosphinate donor, first strategy. 
 
Scheme 22: Synthesis of the new phosphinate ligand, first strategy. 
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The unmasking of the sulfonate groups was attempted on ligand 56 and on the complex 
[EuL
21
]
+
. Unfortunately, the isolated product was [EuL
22
]
+
 and not the expected product,  
[EuL
20
]
2-
. Cooling down the reaction to – 20 °C only resulted in hydrolysis of the phosphinate 
esters leaving the trifluoromethylsulfone unreacted. Evidently, cleavage of the C-S bond 
generates a better aryl leaving group under these reaction conditions, than the CF3
-
, despite 
being cleaved as desired in the model system.   
 
Scheme 23: Synthesis of the new phosphinate complex. 
Despite the unsuccessful synthesis of [EuL
20
]
2-
, the complex [EuL
21
]
+
 was isolated and 
analysed by UV-Vis spectroscopy (Figure 63). The absorption spectrum showed a red shift of 
10 nm to 342 nm, compared to the parent system, which is interesting from a spectroscopic 
point of view, moving the excitation wavelength further away from the excitation of 
endogenous chromophores. The emission lifetime was recorded in MeOH: 0 = 1.1 ms. The 
quantum yield was measured in MeOH (em = 48 %). 
 
Figure 63: Absorption (left) and emission (right) spectra of [EuL
21
]
+
, (MeOH, 295 K, ex = 342 nm). 
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4.2.2.2.2 Second strategy 
The use of TFE and Ph sulfonate esters as PGs, that require milder cleavage conditions, was 
undertaken in order to achieve the target compound. The same Grignard strategy described for 
compound 46 (Scheme 24) was attempted in order to synthesise compound 57 and 58; 
unfortunately, for both esters, the desired compound was isolated in poor yield (< 10 %), with 
a considerable amount of unreacted starting material being recovered.  
 
Scheme 24: Synthesis of the new phosphinate donor, Grignard strategy. 
Lithiation was also tried (Scheme 25), but the bromo compounds 43 and 44 were found to be 
very stable towards BuLi and, once lithiated, completely unreactive towards the chloro- 
phosphine. 
 
Scheme 25: Synthesis of the new phosphinate donor, litiation strategy. 
In order to form the P-C bond, a palladium cross-coupling reaction using anilinium 
hypophosphite as a source of phosphorous was investigated (Scheme 26).
107-108 
The use of a 
bidentate ligand for Pd(II) (i.e. dppf) is important to inhibit the competing reaction to give the 
di-aryl substituted phosphinate ester. Aminopropyltriethoxysilane (1 eq) serves as a base for 
the Pd(II) coupling and enables the in situ esterification of the phosphinic acid.
109 
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Scheme 26: Synthesis of the new phosphinate donor, palladium catalysed strategy. 
The cross-coupling reaction proceeded in 70 % yield for the TFE ester, but failed with the Ph 
ester, probably due to competitive insertion into the O–Ph bond. 
Following the positive result for the TFE protected compound, the synthesis of the extended 
chromophore was pursued (Scheme 27);
110
 both meta and para sulfonated aryl derivative were 
considered. The di-esters 57 and 61 were used in a second coupling reactions with 2-bromo-4-
nitro-6-methyl pyridine in degassed toluene using Cl2Pd[bis(diphenylphosphino)ferrocene] as 
the catalyst to give the phosphinate esters 62 and 63. Bromination with neat acetyl bromide 
followed by re-esterification of the phosphinic acid group with HC(OEt)3 allowed the 
isolation of intermediates 64 and 65 in 81 and 77 % yield respectively. Treatment of the 4-
bromo-pyridyl esters with mCPBA in CHCl3 gave the corresponding N-oxides 66 and 67. 
Activation of the proximate methyl group occurred following treatment with (CF3CO)2O, in a 
Boekelheide rearrangement; subsequent hydrolysis of the trifluoroacetate esters in situ, using 
wet ethanol gave the intermediates 68 and 69. The aryl-alkynyl moiety was introduced by a 
Sonogashira coupling; four chromophores were prepared, two of them with a simple 4-OMe 
aryl group (70 and 71) and two bearing a methyl group in the meta position of the aryl group 
(72 and 73). This substitution has been reported to shift the absorption wavelength of the 
conjugated chromophore by 7–10 nm to the red.87 
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Scheme 27: Synthesis of the new P-Ph-SO3
-
 chromophores. 
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Trialkylation of 1,4,7-triazacyclononane (9-N3) with the appropriate mesylate afforded the 
fully protected neutral ligands. Treatment with aqueous base (NaOH in water/methanol, pH = 
12) hydrolysed the phosphinate and the sulfonate esters. In the latter case, hydrolysis of the 
sulfonate occurred at a similar rate to the phosphinate cleavage reaction and was conveniently 
monitored by observing formation of trifluoroethanol by 
19
F-NMR spectroscopy. 
Complexation of the ligand in aqueous methanol at pH 6 gave the Eu(III) complexes which 
were purified by reverse phase HPLC in the presence of triethylammonium acetate and 
isolated as their triethylammonium salts. Ion-pair adducts of the ammonium salts were 
identified by ES-MS to confirm the constitution of the isolated salt. 
 
Scheme 28: Synthesis of the P-Ph-SO3
-
 complexes. 
Two C-substituted analogues were also prepared via alkylation of the Boc-protected amine 17 
(Scheme 29). The Boc group was removed with TFA at room temperature, prior to base 
hydrolysis and europium complexation. 
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Scheme 29: Synthesis of the C-substituted P-Ph-SO3
-
 complexes. 
The low yields for the last step are due to hydration of the triple bond in the presence of acid 
(TFA); lowering the temperature of the reaction (4 °C) and dry solvents did not change the 
yield. This problem was not observed (or to a lesser extent) with the previously described 
series of complexes and was found to be prominent in the presence of more electron rich 
chromophores (e.g. chromophores 72 and 73). 
Comparison of the photophysical properties of the new P-Ph-SO3
-
 complexes (Table 15) 
showed that they possess similar optical properties (λ, ε, τ, ϕ) to each other and to the parent 
phenylphosphinate complex ([EuL
1
], Chapter 2). This is consistent with the absence of 
perturbation of the sensitiser excited state energies or the coordination environment around 
the Eu(III) centre by the sulfonate negative charge. 
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Table 15: Summary of the photophysical properties for the new series of P-Ph-SO3
-
, (H2O, 295 K).
a
 
  max / nm 0 / ms em / %   / mM
-1cm-1 logP 
[EuL20a]3- 332 1.11 31 58 - 0.7 
[EuL23a]3- 332 1.10 29 58 - 2.2 
[EuL24a]3- 340 1.09 32 58 - 0.1 
[EuL25a]3- 340 1.12 33 58 - 1.4 
[EuL20]2- 332 1.10 30 58 n.d. 
[EuL23]2- 332 1.09 28 58 n.d. 
a
 Errors on max, 0, em and  are ± 10%, errors on logP are ± 20%. 
In each case, the Eu(III) complexes presented good water solubility. The logP measurements 
showed that the introduction of the methyl group in the three phenyl rings led to an increased 
lipophilicity, and that the meta-sulfonated complex [EuL23a], rather surprisingly, had a higher 
negative logP value than the para-substituted isomer. High quantum yields (up to 33 %) and 
long emission lifetimes were registered (around 1.1 ms) for the entire series and a red shift of 
8 nm in the maximum of absorption was observed for the methyl substituted complexes, 
([EuL24a]3- and [EuL25a]3-). 
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4.2.3 Introduction of an aliphatic sulfonate substitutent 
The introduction of an aliphatic chain in the meta position of the aryl group was considered in 
order to get a red shift for the maximum absorption wavelength.
87
 To give water solubility to 
the system, the chain was designed to terminate with a sulfonate group. The length of the 
aliphatic chain (two carbons) was chosen in order to generate an overall electron releasing 
substituent onto the aryl group, notwhistanding the presence of the electron withdrawing 
sulfonate moiety on the chain.  
4.2.3.1 Synthetic investigations 
A retrosynthetic analysis (Scheme 30) identified the 2,4,6-trisubstituted pyridine, 31, and the 
trifunctionalised aryl-alkyne derivative, 89, as the main building blocks for the synthesis of 
the extended chromophore, 90. Compound 89 can be accessed through a second cross-
coupling reaction between compound 84 and ethynyl-trimethylsilane. 
 
Scheme 30: Retrosynthetic analysis of compound 90. 
The sodium salt of compound 84, provided by Cisbio, was chosen as starting material for the 
Sonogashira cross coupling with ethynyl-trimethyl silane to form compound 85 (Scheme 31). 
The functionalisation of the iodo-sulfonated compound proved to be difficult, due to the lack 
of solubility of the sodium salt in the organic medium required for the Pd(II) catalysed 
reaction.  
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Scheme 31: First attempt at functionalisation of compound 85. 
Different strategies to convert the sodium sulfonate moiety into the protected TFE ester were 
attempted, in order to gain sufficient solubility in organic solvents. Direct esterification and 
conversion into the sulfonyl chloride analogues were considered, but failed due to the lack of 
solubility of compound 84. 
 
Table 16: Attempts to functionalise compound 84.   
 Reagents Solvent T (°C) R 
1 POCl3  neat 120 Cl 
2
111
 Cyanuric-Cl / Et3N acetone 60 Cl 
3
112
 HC(OCH2CF3) neat 140 OCH2CF3 
4
113
 HC(OCH2CF3) / TBAI neat 140 OCH2CF3 
 
Strong cation exchange resin (DOWEX 50W X 4-100) was used in order to convert the 
sodium salt 84 into the free sulfonic acid (Table 17, entries 1-3) or into the more lipophilic 
pyridinium salt (Table 17, entries 4-6). Although these compounds presented enhanced 
solubility in the organic solvent, the esterification of the sulfonate remained problematic, due 
to the low electrophilicity of this functionality. The use of sulfonates as nucleophiles in a 
Mitsunobu-like reaction has been described for the formation of tosylates (Table 17, entry 3 
and 6), but failed for this substrate. 
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Table 17: Conversion of sulfonate 84 into more soluble derivatives and further attempted functionalisations. 
 X Reagents Solvent T (°C) R 
1 H POCl3  neat 80 Cl 
2
111
 H Cyanuric-Cl / Et3N acetone 60 Cl 
3
114
 H Ph3P / DIAD / Et3N / 
CF3CH2OH 
toluene 70 OCH2CF3 
4
112
 PyH HC(OCH2CF3) DCM 60 OCH2CF3 
5
115
 PyH Ph3PO / (CF3SO2)2O 
/ Et3N / CF3CH2OH 
DCM 40 OCH2CF3 
6
114
 PyH Ph3P / DIAD / 
CF3CH2OH 
toluene 70 OCH2CF3 
 
A different strategy was attempted in order to introduce the sulfonate ester directly from the 
corresponding bromo-derivative (Scheme 32).
116
 The treatment of the bromo-derivative 86 
with thiourea gave compound 87 in good yield. The subsequent treatment of the crude 
bromide salt, 87, with bleach in the presence of acid, followed by trifluoroethanol, gave 
compound 88 in a “one-pot”, two step reaction sequence. This new synthetic approach 
established a quick method to synthesise a compound soluble in most organic solvents that 
was easy to handle. Compound 88 was reacted with TMS-acetylene under standard 
Sonogashira conditions. The alkyne derivative 89 was isolated in good yield, after cleavage of 
the TMS group with triethylammonium hydrofluoride. 
 
Scheme 32: Synthesis of the sulfonate protected alkynyl derivative 89. 
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4.2.3.2 Application of the new methodology 
The synthesis of the extended chromophore, 90, was achieved with a Sonogashira cross-
coupling reaction between the bromo-substituted pyridine platform, 31, and the TFE-
protected alkyne derivative, 89.  
 
Scheme 33: Successful synthesis of the extended chromophore, 90. 
Alkylation of the 9-N3 with the mesylate derivative, 91, afforded the fully protected ligand 92. 
Hydrolysis of the six esters with acqueous NaOH was slow and required forcing conditions 
(pH = 13, 60 °C, 48 h); reaction completion was confirmed by 
31
P and 
19
F NMR. Surprisingly, 
the addition of Eu(AcO)3 at pH 7 did not show any sign of complexation. This behaviour can 
be tentatively linked to the presence of the negative charges of the sulfonate somehow 
preventing the complexeation.     
 
Scheme 34: Attempted complexation of ligand 92. 
In order to avoid the problems with complexation, the hydrolysis of the phosphinate esters 
was performed with milder conditions, in the presence of KOH (pH = 11, 60 °C, 3 h) leaving 
the sulfonate protecting group intact. Complexation with Eu(OAc)3 gave compound 93, that 
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was further deprotected with KOH (pH = 14, 60 °C, 48 h). Possibly, the strong deprotecting 
conditions caused partial decomplexation, therefore the pH was adjusted to 7 and further 
Eu(OAc)3 was added to the reaction that was heated up for another 16 h giving the complex 
[EuL
26a
]
3-
. 
 
Scheme 35: Synthesis of complex [EuL26a]3-. 
The complex [EuL
26a
] possessed a quantum yield of 27 % and a lifetime of 1.15 ms in water. 
The absorption maximum shifted to the red (max = 336 nm), but not by as much as had been 
expected. The logP measurements (logP = + 0.5) indicate that this complex is much more 
lipophilic than the other sulfonate examples. Due to these results the C-substituted analogue 
was not synthesised. 
4.3 Photophysical characterisation and FRET studies 
The photophysical properties for this new series of hydrophilic complexes have been reported 
previously in the chapter (Section 4.2.1, 4.2.2.2.2 and 4.2.3.2). Here, some data are analysed 
to allow for comparison. 
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Table 18: Summary of the photphysical properties for the four series of Eu(III) complexes, (H2O, 295 K).
a
 
 max / nm em / % / ms logP 
[EuL
2
] 328 24 1.03 + 1.4 
[EuL
4
]
3-
 330 28 1.04 - 2.2 
[EuL
17a
]
3-
 328 26 1.01 - 2.2 
[EuL
18a
]
3-
 330 38 1.11 - 1.9 
[EuL
19a
]
3-
 328 32 1.12 - 2.1 
[EuL
20a
]
3-
 332 31 1.11 - 0.7 
[EuL
23a
]
3-
 332 29 1.10 - 2.2 
[EuL
24a
]
3-
 340 32 1.09 - 0.1 
[EuL
25a
]
3-
 340 33 1.12 - 1.4 
[EuL
26a
]
3-
 336 27 1.15 + 0.5 
a
 Errors on max, 0 and em and are ± 10%, errors on logP are ± 20%. 
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The presence of the phenyl ring led to higher quantum yields (above 30 %) and longer 
luminescence lifetime (1.1 ms) compared to the P-Me analogues (red). The introduction of 
sulfonate groups in different positions of the ligand provides good water solubility with 
negative values of logP for all the complexes, except for [EuL
26a
]
3-
. 
The high quantum yields observed resulted in enhanced brightness for these compounds (B = 
20 mM
-1
 cm
-1
 at 332 nm in water). An experiment to calculate the limit of detection on a 
PHERAstar FS plate reader was set up. The emission intensity from eight solutions of 
[EuL
20a
]
3-
 at different dilutions (50 mM HEPES buffer, pH = 7, 0.1 % BSA) was plotted as a 
function of the complex concentration. The emission from the buffer (I0) was measured for six 
solutions and the standard deviation (σ) calculated. A value of (I0 + 3σ) is considered to lie 
above the instrument noise. The detection limit was calculated to be 0.1 pM, ten times lower 
than for the commercial probe Lumi4-Tb, under the same conditions.  
(𝑰𝟎 + 𝟑𝝈) = 𝒂[𝑬𝒖𝑳
𝟐𝟎𝒂] + 𝑰𝟎   [12] 
  
Figure 64: Calculation of the detection limit for compound [EuL
20a
]
3-
 using a PHERAstar FS plate reader,  
ex = 337 nm, em = 620 nm (left). Values on a logarithmic scale (right). 
The stability of these complexes in the presence of endogenous quenchers was studied and 
compared to the results obtained for the P-Me series (Section 3.3.3) Luminescence spectra and 
excited state lifetimes were measured in the presence of excess ascorbate or urate (10 mM for 
ascorbate, 5 mM for urate); similarly to the P-Me series; no quenching was observed by either 
antioxidant. 
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Emission spectra were recorded for the complexes (4 M in water, pH = 7.4) in the absence 
and in the presence of 0.4 mM HSA, to analyse any possible interactions with protein in the 
medium caused by the addition of the phenyl rings. 
 
Table 19: Photophysical properties of different Eu(III) complexes in the absence (blue) and in the 
presence of 0.4 mM HSA (red), (with added HSA, excitation spectroscopy used to assess max).
a
 
 
max / nm max HSA/ nm 0 / ms 0 HSA / ms logP 
[EuL
2
] 328 333 1.03 1.10 + 1.4 
[EuL
4
]
3-
 330 337 1.04 1.01 - 2.2 
[EuL
17a
]
3-
 328 329 1.01 1.12 - 2.2 
[EuL
18a
]
3-
 330 338 1.11 1.20 - 1.9 
[EuL
19a
]
3-
 328 331 1.12 1.23 - 2.1 
[EuL
20a
]
3-
 332 341 1.11 1.16 - 0.7 
[EuL
23a
]
3-
 332 339 1.10 1.17 - 2.2 
[EuL
24a
]
3-
 340 345 1.09 1.16 - 0.1 
[EuL
25a
]
3-
 340 346 1.12 1.15 - 1.4 
[EuL
26a
]
3-
 336 340 1.15 1.18 + 0.5 
a
 Errors on max, and 0 are ± 10%, errors on logP are ± 20%. 
Unlike the P-Me series that reported a decreased emission intensity (Section 3.3.3), the 
addition of HSA to the P-Ph complexes caused a variation (enhanced or decreased intensity 
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depending on the chromophore) of the total emission intensity; in every case the emission 
spectral form remained unchanged. Increased emission lifetimes and an absorption 
wavelength that had shifted slightly to the red were also noticed (e.g. 0 increased from 1.12 
to 1.23 ms for [EuL
19a
]
3-
 and max shifted from 332 to 341 nm for [EuL
20a
]
3-
). 
A spectral titration adding different concentrations of HSA to the europium complex did not 
show any sign of binding, in agreement with the results for the P-Me systems; such behaviour  
supported the hypothesis that there is a change in the effective dielectric constant of the ‘local 
medium’, following the non-specific protein-complex interaction. This interaction is 
perturbing the energy of the ICT transition. The measurement of the photophysical properties 
for two representative complexes in solvents with different polarities (Table 20) supported 
this idea. For example, [EuL
19a
]
3-
 reported a shift of 6 nm in themax going from water to the 
less polar NMP. Similarly, a red-shift of 4 nm was observed for [EuL
20a
]
3-
 going form water 
to alcohols. Although it is difficult to identify a trend for the changes, also the quantum yields 
and the emission lifetimes for the two complexes are strongly affected by the nature of the 
solvent system.   
Table 20: Photophysical properties for [EuL
19a
]
3-
 and [EuL
20a
]
3-
 measured in solvents with different polarities.
a 
[EuL
19a
]
3-
 
 max / nm em / % / ms
H2O 1.00 328 32 1.12 
TFE-OH 0.90 330 36 1.34 
MeOH 0.76 332 43 1.27 
EtOH 0.65 332 39 1.25 
DMF 0.40 328 57 1.28 
NMP 0.36 334 39 1.18 
[EuL
20a
]
3-
 
 max / nm em / % / ms
H2O 1.00 332 31 1.11 
TFE-OH 0.90 336 37 1.31 
MeOH 0.76 336 56 1.23 
EtOH 0.65 336 49 1.26 
DMF 0.40 328 46 1.26 
NMP 0.36 336 41 1.18 
a
 ET
N
 is Reichardt’s normalised solvent polarity parameter.89 b Errors on max, em and 0 are ± 10%. 
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The quenching of the P-Ph complexes with the cyanine dye Dy647-NH2 was analysed and 
compared with the previously synthesised complexes, as described in Chapter 2 and in 
Section 3.3.3.  
 
Table 21: Quenching studies. (Values recorded (± 5 %) in 50 mM HEPES buffer, 50 mM NaCl, pH = 7.4, 295 K). 
 gradient 0 / ms k2 / mM
-1
s
-1
 
[EuL
2
] 1.74 1.03 1.71 
[EuL
4
]
3-
 1.84 1.04 1.77 
[EuL
17a
]
3-
 1.86 1.01 1.84 
[EuL
18a
]
3-
 2.28 1.11 2.06 
[EuL
19a
]
3-
 2.70 1.12 2.40 
[EuL
20a
]
3-
 3.74 1.11 3.37 
[EuL
23a
]
3-
 4.78 1.10 4.35 
[EuL
24a
]
3-
 2.87 1.09 2.63 
[EuL
25a
]
3-
 3.02 1.12 2.70 
[EuL
26a
]
3-
 3.12 1.15 2.71 
 
0
2
4
6
8
10
12
14
16
18
20
0 0.5 1 1.5 2 2.5 3 3.5
 


Wavelength / nm 
[EuL2]
[EuL4]
[EuL17a]
[EuL18a]
[EuL19a]
[EuL20a]
[EuL23a]
[EuL24a]
[EuL25a]
[EuL26a]
[EuL2]
[EuL4]3-
[EuL17a]3-
[EuL18a]3-
[EuL19a]3-
[EuL20a]3-
[EuL23a]3-
[EuL24a]3-
[EuL25a]3-
[EuL26a]3-
Chapter 4: New hydrophilic sulfonated systems 
 
93 
 
The P-Ph series and, in particular, the P-Ph-SO3
-
 series (black) showed an enhanced rate 
constant for energy transfer compared to the previously analysed P-Me complexes (red), 
highlighting the importance of the phenyl ring in the energy transfer process. It is difficult to 
understand why this should occur, as the presence of aryl  orbitals should not promote the 
overlap of the donor and acceptor wavefunctions in the energy transfer process. 
The development of the C-substituted analogues of these complexes for use in FRET assays is 
under investigation at Cisbio. Preliminary microscopy studies and ICP analysis showed the 
lack of internalisation of these compounds in non-transfected 293 HEK cells after a 3 h 
incubation, predicting low values for non-specific binding. 
4.4 Application in a new FRET based assay 
The lack of cellular internalisation of these compounds suggested the use of these Eu(III) 
complexes in a new FRET based assay. The compound in Figure 65, synthesised by Dr Neil 
Sim, is being investigated as a near-IR emitting acousto-optical probe for NMDA-2B 
receptors on astrocytes.
117
 These receptors, found on the surface of neurons (e.g. astrocytes), 
represent a family of ionotropic glutamate receptor and play a key role in neurotransmission, 
memory and learning.
118
 Mis-regulation of NMDA receptors can be the cause of different 
central nervous system disorders, such as epilepsy, Parkinson’s and Alzheimer’s diseases.119 
The dye conjugated NS155 binds to the glutamate receptors on the cell surface via the 
diamine moiety, which is an established antagonist for these receptors (ifendopril).
120
 
However, it proved challenging to visualise the dye on the cell-surface. Direct excitation of 
NS155 has to be performed with a 785 nm laser that requires a long pass filter (> 800 nm) for 
detection of the weak fluorescence. A common linear CCD detector loses sensitivity at such 
wavelengths (> 800 nm), resulting in a very weak signal. 
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Figure 65: Structure of the IR emitting acousto-optical probe NS155 (left), Absorption (blue) and emission 
(red) spectra of NS155 (right), (H2O, 295 K). 
The Eu(III) complexes described before, although designed to maximise the energy transfer 
properties with a different cyanine dye acceptor (Dy-647-NH2, Section 4.3), presented a 
reasonable degree of spectral overlap with this IR emitting dye (notably in the J = 4 
transition, Figure 66). They can hence be used as donors for the excitation of NS155, via the 
FRET mechanism.  
A study of the energy transfer process was therefore performed in vitro to confirm this 
possibility. The changes in the [EuL
20a
]
3-
 emission lifetime were monitored as a function of 
added dye concentration. An efficiency of 65 % was found for this donor-acceptor couple. 
This is, as expected, lower than the efficiency calculated for the Dy-647-NH2 acceptor (93 
%), due to the smaller spectral overlap (Table 22). The spectral overlap, J, is only twice as 
small as for Dy-647-NH2, and the second order rate constant is ten times less. Nevertheless, 
these data suggested the possibility of using [EuL
20a
]
3-
 as donor for the excitation of NS155. 
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Figure 66:  NS155 dye absorption (green) and [EuL
20a
]
3-
 emission (red) spectra, (H2O, 295 K). 
 
 
Table 22: Quenching studies for [EuL
20a
]
3-
 with NS155 dye (green) and with Dy-647-NH2 (red) as acceptor. 
(Values recorded (± 5%) at 295 K in 50 mM HEPES buffer, 50 mM NaCl, pH = 7.4; ex= 332 nm). 
 gradient 0 / ms k2 / mM
-1
s
-1
 J / M
-1
cm
3
 R0 / nm E / % 
NS155 0.39 1.11 0.35 5.3 x 10
-13
 5.6 65 
Dy-647-NH2 3.74 1.11 3.37 10.2 x 10
-13
 6.3 93 
The differentiated NSC-34 astrocytes cells, labelled with compound NS155 (10 M solution), 
were incubated with [EuL
20a
]
3-
 (20 M solution) for 10 min. The Eu(III) complex itself was 
found not to internalise in the cell; as revealed by examination with confocal microscopy, it 
remained in the incubation media. By exciting [EuL
20a
]
3-
 in the medium using a UV LED at 
365 nm, following the energy transfer process, it was possible to visualise the emission from 
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NS155 on the cell surface. The excitation with a 365 nm UV LED allowed the use of a 780 
nm long pass filter; the visualisation of NS155, selectively at the cell surface, was hence 
possible due to the higher sensitivity of the linear CCD detector at such wavelengths (780 <  
< 800 nm), (Figure 67).  
 
Figure 67: Confocal microscopy image of differentiated NSC-34 astrocytes cells expressing NMDA-2B 
surface receptors labelled with NS155 and [EuL
20a
]
3-
 in the incubation medium. FRET Channel: ex = 365 nm, 
detector > 780 nm. 
The binding of NS155 on the receptor was shown to be reversible, by following emission 
changes by microscopy after the addition of five successive aliquots (Vtot = 500 L) of a 
glutamate-rich (1 mM) culture medium. A ten-fold drop in fluorescence intensity, compared 
to the original cell staining experiment, was observed after treatment of the cells with fresh 
buffer containing 20 M of the [EuL20a]3- (Figure 68B). Furthermore, prior incubation of 
differentiated NSC-34 cells with glutamate-rich (1 mM) solution to block the NMDA 
receptors, the subsequent treatment with both components, NS155 and [EuL
20a
]
3-
, led to a re-
establishment of the original fluorescent intensity (Figure 68C). 
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Figure 68: Live cell fluorescence microscopy images (ex/em = 365/780 nm) of differentiated NSC-34 cells 
labelled with NS155 (10 M, 30 minutes) and  [EuL20a]3- in the incubation media (A); As image (A) but with a 
post glutamate (1 mM) wash (B); Cells first treated with a glutamate (1 mM) rich culture media to block the 
receptors, washed and then re-incubated with both NS155 (10 M, 30 minutes) and [EuL20a]3- (20 M) (C). 
4.5 Conclusions 
New series of highly water soluble sulfonated Eu(III) complexes were developed. The 
introduction of a P-Ph phosphinate made these complexes amongst the brightest Eu(III) 
complexes in aqueous solution (B = 20 mM
-1
 cm
-1
 at 332 nm in water). The presence of the 
phenyl ring also improved the Eu(III) emission lifetime by about 10 % compared to the 
methyl analogue. In terms of FRET properties, the P-Ph systems gave rise to faster rates of 
energy transfer to the cyanine dye donor; this enhancement was most well-defined for the P-
Ph-SO3
-
 series. 
To achieve these multifunctional sulfonated ligands, the application of some new synthetic 
methodology was developed. The utility of TFE sulfonate as a protecting group was 
emphasised in more complex examples that those previously reported in the literature. The 
stability of this PG towards some vigorous reaction conditions was proven, including 
treatment with an acyl bromide, mCPBA oxidation, acid-catalysed trans-esterification and 
palladium catalysed coupling reactions. The production of aliphatic sulfonates was achieved 
in a “one-pot” reaction, resulting in the introduction of a TFE protected sulfonic acid from a 
bromoalkane precursor. Moreover, the release of the trifluoroethyl ester under basic 
conditions, in the final deprotection step, permitted standard normal phase chromatography 
separations and purifications of the intermediate up to that point. 
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The introduction of sulfonate functionalities suppressed the non-specific binding of the 
Eu(III) complexes to hydrophobic pockets in proteins, interactions with the cell membranes 
and inhibited complex internalisation within the cell. These features make these anionic 
complexes ideal for surface receptor visualisation and related bioassays. The development of 
new TR-FRET binding assays on GPCRs using these systems is in progress at Cisbio. 
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5 Structural and chiroptical characterisation  
5.1 Introduction 
The relatively large values of |gem| (between 0.1 and 0.5) for lanthanide ions make them 
suitable for the design of emissive CPL probes, in order to get information on the chiral 
environment. Two classes of CPL lanthanides probes exist, depending on the chirality of the 
functional ligand (Section 1.4.3). An achiral ligand usually gives rise to a 50 : 50 mixture of 
interconverting  and  enantiomers, whereas an enantiopure ligand typically give rise to a 
dominant stereoisomer in solution.  
In this chapter, the stereochemical aspects of chiral triazacyclononane (9-N3) based 
complexes are examined. 
5.2 The C3 symmetric systems 
Complexes based on triazacyclononane (Figure 69) have been studied for NMR 
applications
121
 and have also been used in binding studies of radioisotopes.
122
 These 
complexes present C3 symmetry with a distorted octahedral coordination at the metal centre.  
 
Figure 69: 1,4,7-triazacyclononane-N,N’,N’’ triacetic acid (NOTA). 
Four possible stereoisomers can be considered that arise from carboxylate arm rotation and 
ring inversion of the azamacrocycle. The first chiral element to consider is the N-C-C-O 
torsional angle of the carboxylate arm, which can be positive or negative. It is described with 
the symbols  (+ sign, clockwise) and  (- sign anticlockwise) (Figure 70a). The second 
element is the N-C-C-N torsional angle of the ethylene group on the macrocyclic ring. It is 
depicted with the symbols  (+ sign, clockwise) and  (- sign, anticlockwise) (Figure 70b). 
The combination of these two elements of chirality gives rise to two pairs of enantiomers 
(and). The exchange between  and  isomers is possible via 
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cooperative arm rotation, whereas the synchronous ring inversion permits the exchange 
between () and () isomers.  
 
Figure 70: Stereochemistry resulting from the carboxylate arm rotation (a) and from ring inversion (b) of a 
NOTA complex. Newman projections of the C-C bond of the acetate arm (top-a) and of the C-C bond of the 
macrocyclic ring (top-b).   
Two examples of substituted pyridyl derivatives of the 9-N3 system (Figure 71) have been 
reported that provide 9 coordination sites to accommodate Ln
3+
 ions
123-83
. These complexes 
possess a tricapped trigonal prismatic coordination geometry. In theory, four stereoisomers 
are possible for these complexes. Crystal structure analysis revealed the presence of only the 
 and  enantiomeric pair. It was found that in solution the ring inversion does not 
occur at a measurable rate at room temperature for these systems. In addition, the  
interconversion process has a high activation energy and is likely to be increased further with 
the introduction of more sterically demanding substituents, instead of the carboxylate arms 
(e.g. a phosphinate).
68
 Due to the high energy barrier to racemisation, the two enantiomers can 
be separated by chiral HPLC. 
 
M
a) b)
N N
 
OO
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Figure 71: Two examples of 1,4,7-triazacyclononane substituted ligands.
83-123
 
 
Figure 72: The four possible stereoisomers of the Eu(III) pyridyl 9-N3 derivative. Only the  and 
enantiomers are observed. 
In the phosphinate series (Figure 71), metal coordination allows the P centre to become 
stereogenic; once the first phosphinate oxygen has bound to the metal centre, assuming an R 
or S configuration, the other two also tend to adopt the same configuration.
124
 In addition, for 
an R configuration at P, the ring NCCN and substituent NCCNpy torsion angles are consistent 
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with a  ring conformation and  configuration. Hence, the complex exists as a racemic 
mixture of two enantiomers (RRR)-() and (SSS)-(). 
Upon chiral resolution, the CPL spectra of the two enantiomers can be recorded (Figure 73). 
        
Figure 73: CPL spectra for the Eu(III) complexes of the (RRR)- (red) and (SSS)- (blue) 
enantiomers, (H2O, 295 K).
83
 
5.3 The hybrid system 
The hybrid system, [EuL
8
], described in Chapter 2, bearing two phosphinate and one 
carboxylate donors, has been prepared and its stereochemical features were analysed. 
The 9-N3 mono Boc 93, was alkylated with the mesylate derivative of the P-Me phosphinate 
chromophore, 19. After Boc deprotection with TFA, compound 95 was reacted with the 
carboxylate derivative 96. Hydrolysis followed by complexation yielded the hybrid complex, 
[EuL
8
]. 
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Scheme 36: Synthesis of the hybrid complex [EuL
8
]. 
An emission spectrum was recorded (Figure 74) and emission lifetimes were measured (0 = 
1.12 ms in MeOH and 0 = 0.89 ms in H2O). The splitting of the J = 2 band and the lifetime 
values fall in between those for the tris-carboxylate [EuL
3
] and the tris-phosphinate analogues 
[EuL
2
], as expected (Section 2.3.1). 
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Figure 74: Emission spectrum for [EuL8], (MeOH, 295 K, ex = 332 nm). 
The complex was characterised by 
31
P-NMR spectroscopy and HPLC (Figure 75 and Figure 
76). Due to the asymmetric nature of the complex, the 
31
P-NMR spectrum revealed two 
signals, one for each phosphorus in the molecule.  
 
Figure 75: 
31
P NMR spectrum of complex [EuL
8
], (CD3OD, 14.1 T, 295 K). 
Chiral HPLC analysis confirmed that the complex is present as a 50:50 mixture of two 
enantiomers (RR and SS at P). Presumably, the two isomers are RR- and SS-.  
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Figure 76: HPLC analysis of [EuL
8
]. Method C, tR = 11.0 (top). CHIRALPAK-IC 250 x 4.6 mm 5 μM column, 
100 % MeOH (bottom). 
5.4 The C-substituted 9-N3 systems 
The synthesis of an enantiopure system is very challenging, often requiring long and tedious 
chiral chromatography purifications. The incorporation of a single C-substituent into the 
ligand system has been recently described as a possibility to control the final geometry at the 
metal centre.
73 The introduction of a stereocentre on the macrocyclic ring has been reported to 
induce the preferential formation of one stereoisomer (upon Cu(II) complexation) in a 9 to 1 
ratio. 
 
Figure 77: Structure of the C-substituted 9-N3 ligand which induced the preferential formation of one 
stereoisomer upon Cu(II) complexation.
73
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In the same way, the C-substitution on the 9-N3 in complex [EuL
13
] (Section 3.2) was 
expected to induce the formation of one isomeric species preferentially.  
 
Figure 78: Structure of [EuL
13
] and the unsubstituted analogue [EuL
13a
]. 
The NMR profile for the C-substituted complex [EuL
13
] was compared to that for the 
unsubstituted analogue [EuL
13a
]. The relatively simple pattern of the 
1
H-NMR and 
31
P-NMR 
spectra suggested the presence of one major stereoisomer in each case (Figure 79c and d). 
The non-equivalence of the P atoms in the substituted phosphinate complex [EuL
13
] is 
revealed by the presence of three resonances in the 
31
P NMR spectrum (Figure 79d).  
 
Figure 79: NMR characterization of [EuL
13a
] (top) and [EuL
13
] (bottom), (CD3OD, 295 K, 9.4 T). 
Chemical Shift / ppm
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The presence of a major stereoisomer was further investigated using HPLC. The complex 
[EuL
13a
] exists as 50 : 50 mixture of enantiomers that can be separated by chiral HPLC 
(Figure 80). For the C-substituted complex, chiral HPLC under the same conditions verified 
the preferential formation of one stereoisomer in 80 % diastereomeric excess (Figure 81).
125
 
 
 
Figure 80: Chiral HPLC trace for [EuL
13a
]: racemate (top),  enantiomer (middle),  enantiomer (bottom). 
(CHIRALPAK-ID 4.0 mm × 250 mm, MeOH, 1 mL/min, λ = 268 nm, 290 K). 
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Figure 81: Chiral HPLC trace for [EuL
13
], (CHIRALPAK-ID 4.0 mm × 250 mm, MeOH, 1 mL/min, λ = 268 
nm, 290 K). 
Further studies on this system with different C-substituents revealed that the formation of the 
minor stereoisomer could be traced back to racemisation during the first step of the synthesis 
of the macrocycle (Scheme 37). Racemisation could be avoided by lowering the temperature 
of the reaction between the amino-acid ester and ethylenediamine (100 °C) and by carrying 
out the subsequent distillation to remove excess ethylenediamine at lower pressure and 
temperature. The degree of racemisation was calculated by adding the chiral solvating agent 
R-O-acetyl mandelic acid (1.2 eq) to samples of (2S)-N-(2-aminoethyl)-(2,6-
diaminohexanamide) dissolved in CDCl3.
126
 The amide peak shifted to higher frequency and 
split. Examination of the integral ratios revealed that the enantiomeric purity was  > 90 %, 
under this conditions.  
 
Scheme 37: Possible racemisation occurring during the first step of the synthesis. 
The CPL spectrum of [EuL
13
] was recorded (Figure 83) and compared to the CPL spectra 
recorded for the two enantiomers of the parent derivative, [EuL
13a
] (Figure 82). These 
complexes had been resolved earlier in Durham by Dr Nick Evans and had allowed the 
assignment of the absolute configuration. In this case, for [EuL
13
] the major stereoisomer is 
assigned as S(Lys)-RRR-(). 
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Figure 82: Circularly polarised luminescence spectra of the -enantiomer of [EuL13a] (left) and the -
enantiomer (right), (H2O, ex = 268 nm, 295 K). 
 
  
Figure 83: Circularly polarised luminescence spectrum (left) of [EuL
13
], (H2O, ex = 268 nm, 295 K). Emission 
dissymmetry factor for [EuL
13
] as a function of wavelength (right). 
Large values of emission dissymmetry factors, gem, were found especially in the J = 1 region 
(Table 23).  
𝒈𝒆𝒎 =
𝟐(𝑰𝑳−𝑰𝑹)
𝑰𝑳+𝑰𝑹
  [13] 
Table 23: Emission dissymmetry factors, gem, for [EuL
13
] and for the -enantiomer of [EuL13a]. 
[EuL
13
]    S(Lys)-RRR- 
nm 591 595 655 691 708 
gem 0.08 -0.07 0.06 0.02 0.05 
gem  [EuL
13a
]  () 0.10 -0.07 0.07 0.03 0.06 
 
Chapter 5: Structural and chiroptical characterisation 
 
110 
 
The diastereomeric excess of [EuL
13
] can also be estimated by comparing gem values for the 
same transitions, as the gem value scales directly with the percentage of diastereomeric purity. 
The value for the transition at 591 nm (0.08 compared to 0.10 for the enantiopure complex) 
confirmed an optical purity of 80 %. 
Rationalisation of the induced stereoselectivity was provided by consideration of the X-ray 
structure of the SSS--() enantiomer of [EuL13a] (Figure 84).125 The pro-R ring protons 
(red) sit in a pseudo-equatorial position that is directed away from the steric bulk of the 
pyridyl arms; a C-substitution in this position will be more favourable due to less steric 
hindrance. In the same way, the chirality induced by the stereocentre of lysine (S) will be 
RRR--(), consistent with a less hindered complex, and in agreement with the 
configuration obtained for [EuL
13
]. 
 
Figure 84: X-ray structure of -[EuL13a] (a), part of the crystal structure illustrating the pseudo-equatorial 
positions of the pro-R hydrogens (red) on the 9-N3 ring (b), structure of -[EuL
13a
] (c).
125
 
5.4.1 The C-substituted systems bearing the alkynyl chromophore 
The chiroptical properties for the complexes bearing the extended chromophore were 
analysed. The complex [EuL
27
] was synthesised using a Sonogashira cross coupling reaction 
from the 80 % diastereomerically pure precursor, [EuL
13
], by Dr Stephen Butler.
79
 The two 
stereoisomers were separated and their CPL spectra recorded. 
R
R
a) b) c) 
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Scheme 38: Retrosynthetic approach for the synthesis of [EuL
27
]. 
 
Figure 85: Circularly polarised luminescence spectra of S-RRR-Λ-[EuL27] (black) and S-SSS--[EuL27] (red), 
(MeOH, ex = 355 nm, 295 K). 
Due to the brightness of this complex (B = 30 mM
-1
 cm
-1
 at 355 nm in MeOH) and the |gem| 
values in the range from 0.1 to 0.3 (Table 24), this complex gave the strongest CPL signal yet 
observed for any lanthanide complex in solution, allowing the spectrum to be acquired with 
good signal intensity over a period of 20 minutes, using a 3 μM solution of the complex. 
Table 24: Emission dissymmetry factors, gem, for the diastereopure -[EuL
27
]. 
[EuL
27
]    S(Lys)-RRR- 
nm 598 655 708 
gem -0.11 0.17 0.30 
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The CPL spectrum was recorded for different complexes bearing the akynyl-based 
chromophore; strong CPL signals were observed in each case (Figure 87). 
 
Figure 86: Structures of the complexes analysed using CPL spectroscopy. 
 
Figure 87: Circularly polarised emission spectrum of S-RRR-Λ-[EuL20]2-, (H2O, ex = 332 nm, 295 K). 
The chiral HPLC analysis of these charged complexes was found not to be amenable using the 
standard conditions as for the neutral analogue [EuL
27
] (aqueous methanol gradients).  
However, the enantiomeric purity of the three complexes was estimated by comparing gem 
values for the same transitions (Table 25). Similar values of gem were found for the 
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diastereomerically pure complex [EuL
27
] and the three complexes analysed. Given that the 
experimental error associated with measurement of gem is (± 10 %), it seemed reasonable to 
assume that the values refer to samples with a diastereomeric excess of > 90 %. 
Table 25: Emission dissymmetry factors, gem, for the akynyl complexes (H2O, ex = 332 nm, 295 K). 
 598 nm 655 nm 708 nm 
gem
 a
    [EuL
27
]   -0.11 0.17 0.30 
gem      [EuL
14
] -0.10 0.16 0.25 
gem      [EuL
15
] -0.10 0.22 0.27 
gem      [EuL
20
] -0.10 0.18 0.25 
a
 values recorded in MeOH.  
5.5 Conclusions 
Pyridyl derivatives of 9-N3 complexes exist as a pair of enantiomers that can be separated at 
room temperature with chiral HPLC, due to the high energy of racemisation.  
The mono substitution at a carbon atom on the macrocyclic ring provided complete control of 
the stereochemistry of the final complex. Direct and selective formation of chiral complexes 
was observed with > 90 % optical purity. Due to the high brightness of these compounds, an 
intense CPL signal could be recorded during a short period of time (20 min). Such behaviour 
can be exploited for the preparation of bright and enantiopure emissive complexes that have 
the potential to form the basis of responsive chiral probes for CPL spectroscopy and 
microscopy. 
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6 Conclusions and future work 
6.1 General conclusions  
The Eu(III) complexes based on the triazacyclononane ligand tri-substituted with different 
examples of pyridyl-alkynyl-aryl moieties are the brightest examples of europium complexes 
reported in the literature (B = 30 mM
-1
 cm
-1
 at 332 nm in MeOH). Their photophysical 
properties are very well suited to fluorescence microscopy studies: a broad absorption band 
with a maximum typically around 330 - 340 nm, a long luminescence lifetime, and good 
stability in a biological medium. 
   
Figure 88: General structure of a series of highly emissive europium complexes (left), (X = C or P-R”). 
Absorption (blue) and emission (red) spectra for these Eu(III) complexes (right). 
The complexes possess a very intense set of J = 2 transitions (610 - 620 nm) that is of 
fundamental importance for the use of these complexes as donors in FRET based 
experiments. This particularly favourable emission spectral form resulted in improved 
properties, compared to earlier Eu(III) cryptates, when these complexes are used as donors in 
energy transfer studies with the cyanine dye acceptor Dy647-NH2. Faster rates of energy 
transfer and bigger spectral overlaps were measured, compared to the commercially available 
donors, Eu(TBP) and Lumi4-Tb.  
Taking the structure of these complexes as starting point, the synthetic work focused on the 
introduction of a linkage point for conjugation with biomolecules and on the improvement of 
the water solubility of these systems. The introduction of a linkage point was achieved with 
an aliphatic chain on the azamacrocycle, terminally substituted with a primary amine. The 
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synthesis of a C-substituted macrocyclic core was optimised; the C-substitution on the ring 
did not affect the emissive properties and created a useful intermediate that can be easily 
functionalised for a variety of applications. The introduction of negatively charged moieties 
(e.g. carboxylate and sulfonate) onto the antenna made these complexes fully water soluble 
(logP = -2.2) and did not affect the energy transfer properties of the original neutral complex.  
This first generation of P-Me phophinate C-substituted complexes was evaluated for FRET 
experiments in cellulo. The introduction of carboxylate or sulfonate functionalities into the 
ligand system, in addition to the enhanced water solubility, inhibits the non-specific 
internalisation of these complexes in living cells. The selective targeting of G-protein coupled 
membrane receptors of living HEK cells was therefore possible, due to the low non-specific 
interactions of these complexes. The TR-FRET binding assays were performed on two 
GPCRs (dopamine-d2 and cholecystokinin-2 receptors) in living cells with promising results 
for the use of this technology in high-throughput screening assays. In addition, the 
visualisation of these systems with confocal and TR-FRET microscopy was possible and 
required very small quantities of material (nM concentrations), due to the high brightness of 
these complexes.  
 
Figure 89: General structures of first (left) and second (right) generation of C-substituted Eu(III) complexes. 
A second generation of highly water soluble sulfonated Eu(III) complexes was designed and 
synthesised. The introduction of the P-Ph phosphinates made these complexes amongst the 
brightest Eu(III) complexes in aqueous solution (typically B = 20 mM
-1
 cm
-1
 at 332 nm in 
water). The high quantum yields allowed the calculation of a low limit of detection, ten times 
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lower than for the Lumi4-Tb under the same conditions. The Eu(III) emission lifetime 
increased by about 10 % compared to the first generation P-Me analogues, as a consequence 
of the presence of the phenyl ring. Faster rate of energy transfer to the cyanine dye donor 
were also observed; this enhancement was most well-defined for the P-Ph-SO3
-
 series. The 
presence of the sulfonate moieties was sufficient to achieve a high degree of water solubility, 
even in the presence of the lipophilic phenyl rings. Suppression of non-specific binding to 
hydrophobic pockets in proteins, interactions with the cell membranes and inhibition of 
internalisation within the cell were also observed for those complexes. This behaviour was 
exploited for the visualisation of a near-IR emitting acousto-optical probe on the NDMA-2B 
surface receptors on astrocytes.  
To achieve these multifunctional sulfonated ligands, new synthetic methodologies were 
applied. Different sulfonate protecting groups were considered and the utility of a 
trifluoroethylsulfonate group was emphasised, in more complex examples that those 
previously reported in the literature. These TFE-sulfonates were proved to be stable towards 
vigorous reaction conditions, including treatment with an acyl bromide, mCPBA oxidation, 
acid-catalysed trans-esterification and palladium catalysed coupling reactions. Moreover, the 
release of the trifluoroethyl ester under basic conditions, in the final deprotection step, 
permitted easy handling and purification of the intermediates up to that point. Aliphatic 
sulfonates were synthesised in a “one-pot” reaction, resulting in the introduction of a TFE 
protected sulfonic acid from a bromo alkane precursor.  
The utility of these C-substituted complexes was evaluated also as potential chiral CPL 
emitting probes. In fact, the monosubstitution at a carbon atom on the macrocyclic ring 
provided complete control of the stereochemistry of the final complex. This synthesis led to 
the direct and selective formation of chiral complexes with > 90 % enantiomeric purity. An 
intense CPL signal was recorded for these complexes during a short period of time (20 min) 
resulting in the strongest CPL signal yet observed for any lanthanide complex in solution. 
6.2 Future work 
The second generation of P-Ph phosphinate complexes is under evaluation in in vivo TR-
FRET assays. The benzyl-guanine labelled complexes have been prepared and they will be 
used for GPCRs binding assays.  
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The preparation of the NHS active ester of these complexes is also under investigation 
(Figure 90).  These reactive compounds will be used for the direct labelling of antibodies, 
which will be used for a variety of immunoassays (currently under investigation at Cisbio 
Bioassays).
127
 
 
Figure 90: NHS active ester of the a general Eu(III) complex. 
Many examples of these Eu(III) complexes have been prepared and evaluated in various 
biological assays. Two patents, which describe the preparation of all these different 
complexes, are available.
74-78
 The sulfonate complex [EuL
19
] seems to report the best results 
for the in vivo TR-FRET assays, due to the high water solubility and the suppression of the 
non-specific binding. A systematic analysis of the different examples of complexes in 
different HTRF bioassays will permit the selection of one (or more) target complexes for the 
commercialization of these systems. The technology evaluated for the GPCRs assay is 
showing promising results and can be further developed to provide access to general high-
throughput screening assays.  
The low non-specific interactions of these complexes will be also of great advantage to the 
development of novel bioassays, where specific biological interactions are studied. The easy 
and accessible conjugation of these complexes with biologically relevant molecules may 
permit the targeting of different receptors on the cell surface. For example, the conjugation 
of these complexes with folic acid might be a feasible method to target cancer cells, where 
folate receptors are overexpressed.
128
 Internalisation of the folate-conjugated complex might 
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occur upon interaction with the receptor. Another possibility will be the conjugations of 
these complexes with known small organic molecules to selective target the dopamine 
receptors, overexpressed on the surface of cancer stem cells.
129
 
 
Figure 91: Targeting of a receptor with a specific vector. 
Having suppressed the internalisation of these complexes through the micropinocytosis 
mechanism,
87
 it will might be also possible to attach these complexes to specific targeting 
sequences, which use different internalisation pathways (e.g. cell penetrating peptides),
130
 to 
send the complexes to specific organelles or to the nucleus. 
Towards the use of lanthanide complexes as stains for fluorescence microscopy, some 
assessments can be made regarding the use of different excitation sources. The use of less 
powerful (red shifted) excitation wavelengths results in low phototoxicity and reduced 
background fluorescence from the endogenous chromophores.
131
 Due to the high brightness 
of these complexes, the use of pulsed excitation at 365 nm is possible; in addition, the use of 
a phase-modulation method to improve the intrinsic resolution (130 nm for ex = 365 nm) 
has allowed microscopic resolution of 65 nm to be achieved.
87 By introducing different 
electron-donating moieties on the aryl ring, the development of chromophores whose 
electronic absorption bands are bathochromically shifted is possible, due to the perturbation 
of the ICT band for the sensitisation of the Eu(III). This change also has an effect on the 
quantum yield of the complex; in fact, the perturbation of the ICT band can cause back 
energy transfer resulting in a decrease in the emission quantum yield. A good balance was 
achieved with the tri-methoxy derivative [EuL
27
] (ex = 355 nm, em = 55 % in MeOH). 
Receptor
Subst.
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These bright complexes have also been used as responsive probes for the monitoring of the 
local changes in the anion concentration.
132
 Five bis-substituted systems (P-Me or P-Ph 
phosphinate donors) were studied and reported changes in the emission spectra upon 
displacement of the bound water molecule with different oxy-anions (logKa = 3). Following 
the synthetic methodology developed for the production of the P-Ph-SO3
-
 system, different R’ 
substituents can be introduced in order to have stronger binding affinity or increased binding 
selectivity (e.g. hydrogen bond donors that increase the overall electrostatic interactions and 
lead to some directionality in the binding).
133 
 
Figure 92: Bis-substituted Eu(III) complex that binds anions. 
 
Figure 93: Cartoon explaining the mechanism of anion binding stabilisation. 
The application of these complexes as chiral probes for CPL spectroscopy and microscopy is 
also a possibility. The stereoselectivity of the synthesis allowed for the formation of chiral 
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complexes with > 90 % optical purity that reported a very intense CPL emission. New 
examples of enantiomerically pure probes that report changes in their chiral environment can 
be envisaged.  
 
Figure 94: Bis-substituted enantiopure Eu(III) complex. 
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7 Experimental 
7.1 General experimental 
7.1.1 General procedures 
All reagents were used as received from their respective suppliers. Solvents were laboratory 
grade and were dried over appropriate drying agents when necessary. Air sensitive reactions 
were carried out under an atmosphere of argon using Schlenk-line techniques.  
Isolated yields for the Eu(III) complexes are based on the measured absorbance as the isolated 
amount of material was small and the extinction coefficients are particularly high and were 
assumed to be the same for the precursor ligand and the complex. Such behaviour has been 
observed previously for related series of complexes with strong ICT bands, ( = 60000 M-1 
cm
-1
 in MeOH). The structure reported for the Eu(III) complexes represents the species 
present in water at neutral pH, although most complexes were isolated as a salt (details in the 
synthetic procedure). 
Thin-layer chromatography was carried out on silica plates (Merck 5554) and visualised 
under UV irradiation (254/365 nm). Preparative column chromatography was carried out 
using silica (Merck Silica Gel 60, 230 – 400 mesh).  
Electrospray mass spectra were obtained on a TQD mass spectrometer equipped with an 
Acquity UPLC, an electrospray ion source and an Acquity photodiode array detector (Waters 
Ltd, UK). Methanol was used as the carrier solvent. For LC-MS analyses a 2.1 x 50 mm 1.7 
micron Acquity UPLC BEH C18 column was used.  
Accurate masses were recorded on a QTOF Premier mass spectrometer equipped with an 
Acquity UPLC, a lock-mass electrospray ion source and an Acquity photodiode array detector 
(Waters Ltd, UK). Methanol was used as the carrier solvent.  
1
H, 
19
F, 
31
P and 
13
C NMR spectra were obtained at 295 K on Varian spectrometers operating 
at 4.7, 9.4, 11.7, 14.1, 16.5 Tesla, specifically on a Mercury 200 (
1
H at 200.06 MHz, 
19
F at 
188.24 MHz, 
31
P at 80.99 MHz, 
13
C at 50.30 MHz), a Mercury 400 spectrometer (
1
H at 
399.97 MHz, 
19
F at 376.33 MHz, 
31
P at 161.91 MHz, 
13
C at 100.61 MHz), a Varian Inova-500 
spectrometer (
1
H at 499.78 MHz, 
19
F at 470.32 MHz, 
31
P at 202.34 MHz, 
13
C at 155.69 MHz), 
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a Varian VNMRS-600 spectrometer (
1
H at 599.94 MHz, 
19
F at 564.51 MHz, 
31
P at 242.86 
MHz, 
13
C at 150.86 MHz) and a Varian VNMRS-700 spectrometer (
1
H at 700.00 MHz, 
19
F at 
658.66 MHz, 
31
P at 283.37 MHz, 
13
C at 175.95 MHz). Commercially available deuterated 
solvents were used. All chemical shifts are given in ppm with coupling constants in Hz. 
Melting points were recorded using a Sanyo Gallenkamp Melting Point Apparatus and are 
uncorrected. 
7.1.2 HPLC analysis 
HPLC analysis and purifications was performed at 295 K with three different set-ups: 
o Waters Mass Directed Auto Preparation (MDAP) system: Waters 575 pump, Waters 
"System Fluidics Organizer", Waters 2545 "Binary Gradient Module", Waters 2767 
"Sample Manager", Waters Fraction Collector III, Waters 2998 Photodiode Array 
Detector and Waters 3100 Mass Detector. 
o Perkin Elmer system: Perkin Elmer Series 200 pump, Perkin Elmer Series 200 auto-
sampler, Perkin Elmer Series 200 UV/Vis detector and Perkin Elmer Series 200 
fluorescence detector.  
o Shimadzu system: Degassing Unit (DGU-20A5R), a Prominence Preparative Liquid 
Chromatograph (LC-20AP), a Prominence UV/Vis Detector (SPD-20A) and a 
Communications Bus Module (CBM-20A).  
Various chromatographic systems were employed for analytical and preparative HPLC: 
 Method A: (XBridge C18 OBD, 19 x 100 mm, i.d. 5 μm) flow rate of 17 mL / min with 
H2O (0.1% formic acid) – 10 % MeOH (0.1% formic acid) as eluents [linear gradient to 
100 % MeOH (0.1% formic acid) (15 min)]. 
 Method B: (XBridge C18 OBD, 4.6 x 100 mm, i.d. 5 μm) flow rate of 1 mL / min with 
H2O (0.1% formic acid) – 10 % MeOH (0.1% formic acid) as eluents [linear gradient to 
100 % MeOH (0.1% formic acid) (15 min)]. 
 Method C: (XBridge C18 OBD, 4.6 x 100 mm, i.d. 5 μm) flow rate of 1 mL / min with 
H2O (0.1% formic acid) – 30 % MeOH (0.1% formic acid) as eluents [linear gradient to 
100 % MeOH (0.1% formic acid) (10 min), isocratic 100 % MeOH (0.1% formic acid) (5 
min)]. 
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 Method D: (XBridge C18 OBD 10 x 100 mm, i.d. 3.5 μM) flow rate of 4.4 mL / min with 
H2O (0.05 M ammonium bicarbonate) – 30 % MeOH as eluents [linear gradient to 100 % 
MeOH (15 min)]. 
 Method E: (XBridge C18 OBD 10 x 100 mm, i.d. 3.5 μM) flow rate of 4.4 mL / min with 
H2O (0.1% formic acid) – 40 % MeOH (0.1% formic acid) as eluents [linear gradient to 
100 % MeOH (0.1% formic acid) (15 min)]. 
 Method F: (XBridge C18 OBD, 19 x 100 mm, i.d. 5 μm) flow rate of 20 mL / min with 
H2O (0.1% formic acid) – 30 % MeOH (0.1% formic acid) as eluents [linear gradient to 
100 % MeOH (0.1% formic acid) (20 min)]. 
 Method G: (XBridge C18 OBD, 19 x 100 mm, i.d. 5 μm) flow rate of 20 mL / min with 
H2O (25 mM triethylammonium acetate buffer, pH = 7) – 2 % CH3CN as eluents [linear 
gradient to 40 % CH3CN (20 min)]. 
 Method H: (XBridge C18 OBD, 19 x 100 mm, i.d. 5 μm) flow rate of 20 mL / min with 
H2O (0.1% formic acid) – 10 % CH3CN (0.1% formic acid) as eluents [linear gradient to 
60 % CH3CN (0.1% formic acid) (19 min)].  
 Method I: (XBridge C18 OBD, 4.6 x 100 mm, i.d. 5 μm) flow rate of 1 mL / min with 
H2O (0.1% formic acid) – 30 % MeOH (0.1% formic acid) as eluents [linear gradient to 
100 % MeOH (0.1% formic acid) (15 min), isocratic 100 % MeOH (0.1% formic acid) (5 
min)]. 
 Method J: (XBridge C18 column, 19 x 100 mm, i.d. 5 μm) flow rate of 17 mL / min with 
H2O (0.1 % formic acid) – 30 % MeOH (0.1 % formic acid) as eluents (3 min) [linear 
gradient to 100 % MeOH (15 min)]. 
 Method K: (XBridge C18 column, 19 x 100 mm, i.d. 5 μm) flow rate of 17 mL / min with 
H2O (25 mM triethylammonium acetate buffer, pH = 7) – 2 % CH3CN) as eluents (3 min) 
[linear gradient to 40 % MeOH (15 min), linear gradient to 100 % MeOH (3 min)]. 
 Method L: (XBridge C18 column, 4.6 x 100 mm, i.d. 5 μm) flow rate of 2 mL / min with 
H2O (25 mM triethylammonium acetate buffer, pH = 7) – 2 % CH3CN) as eluents (3 min) 
[linear gradient to 40 % MeOH (15 min), linear gradient to 100 % MeOH (3 min)]. 
 Method M: Performed on the QTOF Premier mass spectrometer described above. Solvent 
system H2O (25 mM triethylammonium acetate buffer, pH = 7) – 2 % CH3CN as eluents 
[linear gradient to 40 % CH3CN (6 min), linear gradient to 100 % CH3CN (4 min), 
isocratic 100 % MeOH (2 min)]. 
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 Method N: Performed on the TQD mass spectrometer described above. Solvent system 
H2O + 0.1% formic acid – 5 % MeOH [linear gradient to 95 % MeOH (0.1% formic acid) 
(5 min)]. 
Chiral HPLC was performed on the Perkin Elmer system described above using analytical 
CHIRALPAK-IC 250 x 4.6 mm 5 μM or CHIRALPAK-ID 250 x 4.6 mm 5 μM chiral 
columns with an isocratic solvent system of MeOH. 
7.1.3 Optical techniques 
UV/Vis absorbance spectra were recorded on a Perkin Elmer Lambda 900 UV/Vis/NIR 
spectrometer. Emission spectra were recorded on a ISA Jobin-Yvon Spex Fluorolog-3 
luminescence spectrometer. Lifetime measurements were carried out using a Perkin Elmer 
LS55 spectrometer using FL Winlab software. Quantum yields were calculated by 
comparison with two standards, as reported in literature.
44
 
CPL was measured with a home-built (modular) spectrometer. The excitation source was a 
broad band (200 – 1000 nm) laser-driven light source EQ 99 (Elliot Scientific). The excitation 
wavelength was selected by feeding the broadband light into an Acton SP-2155 
monochromator (Princeton Instruments); the collimated light was focused into the sample cell 
(1 cm quartz cuvette). Sample PL emission was collected perpendicular to the excitation 
direction with a lens (f = 150 mm). The emission was fed through a photoelastic modulator 
(PEM) (Hinds Series II/FS42AA) and through a linear sheet polariser (Comar). The light was 
then focused into a second scanning monochromator (Acton SP-2155) and subsequently on to 
a photomultiplier tube (PMT) (Hamamatsu H10723 series). The detection of the CPL signal 
was achieved using the field modulation lock-in technique. The electronic signal from the 
PMT was fed into a lock-in amplifier (Hinds Instruments Signaloc Model 2100). The 
reference signal for the lock-in detection was provided by the PEM control unit. The 
monchromators, PEM control unit and lock-in amplifier were interfaced to a desktop PC and 
controlled by a Labview code. The lock-in amplifier provided two signals, an AC signal 
corresponding to (IL- IR) and a DC signal corresponding to (IL + IR) after background 
subtraction. The emission dissymmetry factor was therefore readily obtained from the 
experimental data, as 2 AC/DC. 
Spectral calibration of the scanning monochromator was performed using a Hg-Ar calibration 
lamp (Ocean Optics). A correction factor for the wavelength dependence of the detection 
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system was constructed using a calibrated lamp (Ocean Optics). The measured raw data was 
subsequently corrected using this correction factor. The validation of the CPL detection 
systems was achieved using light emitting diodes (LEDs) at various emission wavelengths. 
The LED was mounted in the sample holder and the light from the LED was fed through a 
broad band polarising filter and l/4 wave plate (Ocean Optics) to generate circularly polarised 
light. Prior to all measurements, the /4 plate and a LED were used to set the phase of the 
lock-in amplifier correctly. The emission spectra were recorded with 0.5 nm step size and the 
slits of the detection monochromator were set to a slit width corresponding to a spectral 
resolution of 0.25 nm. CPL spectra (as well as total emission spectra) were obtained through 
an averaging procedure of several scans. The CPL spectra have been smoothed using 
Savitzky-Golay smoothing (polynomial order 5, window size 9 with reflection at the 
boundaries) to enhance visual appearance; all calculations were carried out using raw spectral 
data. Analysis of smoothed vs raw data was used to help to estimate the uncertainty in the 
stated gem factors, which was typically ± 10%.  
7.1.4 Cellular studies and microscopy 
The Tag-lite labelling medium (LABMED), the SNAP-CCK2 plasmid for transient 
transfection of CCK2 receptors (PSNAP-CCK2), the SNAP-Dopamine D2 plasmid for 
transient transfection of dopamine-d2 receptors (PSNAPD2), the red-fluorescent red-
CCK(26-33) agonist (L0013RED) and the red-NAPS antagonist (L002RED) were obtained 
from Cisbio Bioassays. The CCK2 receptor antagonist PD135158 was purchased from 
Tocris. CCK(26-33) was obtained from Almac (Craigavon, UK). The 96-well plates were 
purchased from Greiner Bio-One (ref. 655086, Monroe, NC). 
HEK293 wild-type cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
glutaMAX (1966-021; Invitrogen, Carlsbad, CA) supplemented with fetal bovine serum (10 
%), non-essential amino acids (1 %), penicillin/streptomycin (1 %), and HEPES (2 mM). 
Transient transfection was performed in 96-well plates using 100,000 cells per well 
according to a previously described procedure.
96
 Prior to cell seeding, the wells of the plates 
were pre-coated with poly-L-ornithine (50 L) for 30 min at 37 °C. The transfection mixture 
(per individual well) was prepared by adding the SNAP-tag-CCK2 plasmid (100 ng) to 
optiMEM medium (49 L), and Lipofectamine 2000 (0.8 L; Invitrogen) and incubating for 
20 min at room temperature prior to the addition to the plates. Subsequently, HEK293 cells 
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(100 L) at a density of 106 cell mL-1 were distributed in each well of the plates. The plates 
were incubated overnight at 37 °C under 5% CO2. 
For the labelling of SNAP-CCK2-expressed HEK293 cells, with the Eu(III) complexes, a 
previously described procedure was used.
96
 A concentration series ranging from 0–500 nM 
was prepared in Tag-lite labelling medium. After incubation, the transfection mixture was 
removed from 96-well plates, and cells were treated with the prepared solutions (50 mL) and 
incubated for 1 h at 37 °C under 5% CO2. The residual compounds were removed by 
washing each well four times with Tag-lite labelling medium (100 mL). 
The affinity of red-CCK(26-33) for the CCK2 receptors was determined by incubating 
labelled cells with increasing concentrations of the fluorescent ligand. The non-specific 
signal for each ligand concentration was determined by adding an excess of the 
corresponding unlabelled CCK(26-33) compound (10 M). The unlabelled CCK(26-33) 
compound (20 L) was added to plates containing labelled cells with Tag-lite labelling 
medium (100 L), followed by the addition of the fluorescent red- CCK(26-33) agonist (20 
L). Plates were incubated at room temperature for 2 h before signal detection.  
In competitive binding experiments, a fixed concentration of the fluorescent red-CCK(26-
33) agonist (10 nM) was used in the presence of increasing concentrations of antagonist 
PD135158. PD135158 (20 L) was added to plates containing labelled cells with Tag-lite 
labelling medium (100 L), followed by the addition of the fluorescent red-CCK(26-33) 
agonist (10 L). Plates were incubated at room temperature for 4 h before signal detection. 
Signal detection was performed on PHERAstar FS plate reader (BMG LABTECH, 
Champigny-sur-Marne, France) at  = 620 nm and  = 665 nm (in TR mode: delay = 60 s; 
gate = 400 s) upon  = 337 nm laser excitation. Recorded data were analysed using 
GraphPad Prism (GraphPad Software, Inc., San Diego, CA). Specific binding was 
determined by subtracting the non-specific signal from the total signal. Kd values of the 
fluorescent ligand were obtained from the saturation curve of the specific binding. Ki values 
were calculated from competition assay experiments according to the Cheng and Prusoff 
equation.
134
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A Lab-Tek 8 chamber slide system was pre-coated with poly-L-ornithine (200 L) and 
incubated for 30 minutes at 37 °C. The slide was washed with PBS (200 L) and HEK293 
cells were plated at a density of 5 x 10
4
 cells per well (c/w) and incubated overnight at 37 °C 
under 5% CO2. The following day, transfection was performed with optiMEM medium (100 
L), Lipofectamine 2000 (0.8 L), and SNAP-CCK2 plasmid (1.2 g per well). The Lab-
Tek slide was further incubated for 2 days at 37 °C under 5% CO2. After removal of the 
medium, SNAP-CCK2 receptors were labelled with the Eu(III) complex (200 nM) for 1 h at 
37 °C and washed twice with Tag-lite medium. The fluorescent red-CCK(26-33) ligand (10 
nM) was added for the FRET signal detection. Hoechst 33342 (2 mg mL
-1
 per well) was 
added and after 20 min incubation at room temperature and washing twice with Tag-lite 
medium, the Lab-Tek slide was observed with a Zeiss oil immersion objective (40 x 
magnification, 1.3 F-Fluar) on the Zeiss Axiovert 200M TR-FRET inverted microscope 
equipped with a pulsed nitrogen laser ( = 337 nm, 30 Hz) and a cooled intensified CCD 
camera PI Max 1024X1024 GenIII. For the luminescence images, a  = 615 ± 10 nm band-
pass filter was used with delay = 100 s, gate = 2000 s, and at 60 gates per exposure. TR-
FRET images were collected with a  = 670 ± 20 nm band-pass filter using the same 
procedure. The recorded data were analysed using ImageJ software. 
For the d2-dopamine receptors, the same procedure described for CCK2 receptors was used. 
Confocal microscopy images were obtained using a Leica SP5 II microscope. In order to 
achieve excitation with maximal probe emission, the microscope was coupled by an optical 
fibre to a Coherent 355nm CW (Nd:YAG) laser, operating at 12mW power. The microscope 
was equipped with a triple channel imaging detector, comprising two conventional PMT 
systems and a HyD hybrid avalanche photodiode detector. The latter part of the detection 
system, when operated in the BrightRed mode, is capable of improving imaging sensitivity 
above 550 nm by 25%, reducing signal to noise by a factor of 5. The pinhole was always 
determined by the Airy disc size, calculated from the objective in use, using the lowest 
excitation wavelength. Scanning speed was adjusted to 100 Hz in a unidirectional mode, to 
ensure both sufficient light exposure and time to collect the emitted light from the lanthanide 
based optical probes. Spectral imaging on this Leica system is possible with the xyλ-scan 
function, using the smallest allowed spectral band-pass (5 nm) and step-size (3 nm) settings. 
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NSC-34 cells were cultured in a 1:1 mixture of Dulbecco’s modified Eagle’s (DMEM) and 
F12 medium supplemented with fetal bovine serum (FBS, 10% v/v), non essential amino 
acids (0.5%) and Penicillin/Streptomycin (0.1%). At approximately 90% confluence after 3 
healthy passages, cells were sub-cultured into a different growth medium, which contained a 
mixture of DMEM/Ham’s F12 (1:1), FBS (1%), non-essential amino acids (1%) and 
Penicillin/Streptomycin (0.1%). Cells were allowed to proliferate over a period of several 
days to allow for the growth of functional NMDA receptors. 
Cell Microscopy and spectral imaging of NS155 in cells was achieved using a custom built 
microscope (modified Zeiss Axiovert 200M), using a Zeiss APOCHROMAT 63x/1.40 NA 
objective combined with a low voltage 365 nm pulsed UV LED focused, collimated 
excitation source (1.2W). For rapid spectral acquisition the microscope was equipped at the 
X1 port with a Peltier cooled 2D-CCD detector (Ocean Optics) used in an inverse 100 Hz 
time gated sequence. Probe lifetimes were measured on the same microscope platform using 
a novel cooled PMT detector (Hamamatsu H7155) interchangeable on the X1 port. Both the 
control and detection algorithm were written in LabView2011.  
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7.2 Synthetic procedures 
(2S)-N-(2-aminoethyl)-(2,6-diaminohexanamide), 1a 
 
(2S)-Lysine ethyl ester hydrochloride, 1 (5.0 g, 20 mmol) was added in small portions over 1 
h to ethylenediamine (50 mL) at 80 °C, under argon, with continuous stirring. The reaction 
was heated to 120 °C for 3 h, after which time, the ethylenediamine was removed by 
distillation under reduced pressure. The orange oil was taken into aqueous sodium hydroxide 
(4 M, 10 mL), the solvent was evaporated and the residue was dissolved in MeOH (20 mL). 
The solution was filtered and the filtrate was added to DCM (50 mL) and passed down a pad 
of Celite. The combined filtrates were evaporated to give a yellow oil (3.2 g, 85 %); H 
(CDCl3) 7.57 (1H, br, NH), 3.35-3.32 (1H, m, H
2
), 3.28 (2H, q, 
3
JH-H 6 Hz, H
7
), 2.80 (2H, t, 
3
JH-H 6 Hz, H
8
), 2.68 (2H, t, 
3
JH-H 6 Hz, H
6
), 1.85 (2H, m, H
3
), 1.46-1.30 (10H, m, NH2 and 
H
4-5
); C (CDCl3) 188.6 (CO), 55.2 (C
2
), 41.9, 41.7, 41.5 (C
6-7-8
), 35.0, 33.5, 23.2 (C
3-4-5
), 
NMR data are in good agreement with those previously reported;
80
 m/z (ESI) 211.3 
[M + Na]
+
. 
Racemisation may occur in this step, but it can be suppressed by lowering the temperature of 
the reaction between the amino-acid ester and ethylenediamine (100 °C) and the bath 
temperature in the subsequent distillation. The degree of racemization was calculated by 
adding the chiral solvating agent R-O-acetyl mandelic acid (1.2 eq) to samples of (2S)-N-(2-
aminoethyl)-(2,6-diaminohexanamide) dissolved in CDCl3.
126
 The amide peak shifted to 
higher frequencies and split (H(major) = 8.09 ppm, H(minor) = 8.32 ppm, CDCl3, 295 K). From 
the integral ratios, an enantiomeric purity of  > 90 % was established.  
(5S)-1,5,9-Triamino-3-azanonane, 2 
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(2S)-N-(2-Aminoethyl)-(2,6-diaminohexanamide) 1a, (3.2 g, 17 mmol) was boiled under 
reflux (70  °C) in BH3-THF (100 mL, 100 mmol) for 24 h. The reaction was quenched with 
methanol (100 mL) at 0 °C and the solvents were evaporated. Reaction completion was 
confirmed by IR which revealed disappearance of the amide carbonyl group. The resulting 
white solid was boiled under reflux overnight in HCl (2 M, 50 mL). Evaporation of the 
solvent, followed by treatment of the residue with MeOH (50 mL) followed by evaporation 
(three times), gave the tetra-hydrochloride salt as a white solid (5.5 g, quantitative yield); H 
(D2O) 3.64-3.58 (1H, m, H
2
), 3.38-3.30 (6H, m, H
1-7-8
), 2.93 (2H, t, 
3
JH-H 8 Hz, H
6
), 1.73-1.38 
(6H, m, H
3-4-5
); C (D2O) 49.3, 48.6, 45.3, 39.2, 35.5 (C
1-2-6-7-8
), 30.0, 26.5, 21.5 (C
3-4-5
), NMR 
data were in good agreement with those previously reported;
80
 m/z (ESI) 175.2 [M + H]
+
. 
(5S)-N-(5,9-Diamino-7-azanonyl)benzamide, 3 
 
First procedure: 
The tetra-hydrochloride salt of (5S)-1,5,9-triamino-3-azanonane, 2 (1.0 g, 3.1 mmol) was 
dissolved in water (15 mL) and converted into the free tetra-amine by addition of aqueous 
potassium hydroxide solution (to pH = 7). Addition of basic copper carbonate 
Cu(CO3)Cu(OH)2 (0.4 g, 1.8 mmol) to the stirred solution gave an intense blue colour. The 
mixture was heated to 50 °C for 30 min. Benzoyl chloride (470 L, 4.1 mmol) was added 
over 1 h to the cooled solution (0 °C), and the pH was maintained between 8 and 9 by 
periodic addition of small KOH pellets. The reaction was allowed to warm to RT and stirring 
was continued for 1 h. The solution was filtered and the filtrate was treated with H2S over 5 
min. After filtration of the dark solid, the solution was pale yellow. The filtrate was washed 
with DCM and the aqueous layer was reduced to half the initial volume. The pH was 
increased up to 11 and the solution was extracted repeatedly with DCM. The organic layer 
was concentrated to give a colourless oil (130 mg, 15 %).  
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Second procedure: 
The tetra-hydrochloride salt of (5S)-1,5,9-triamino-3-azanonane, 2 (1.0 g, 3.1 mmol) was 
dissolved in water (20 mL) and converted into the free tetra-amine by addition of potassium 
hydroxide (to pH = 7). Addition of copper carbonate Cu(CO3)Cu(OH)2 (0.4 mg, 1.8 mmol) to 
the stirred solution gave an intense blue colour. The mixture was heated to 50 °C for 30 min. 
The solution was cooled to RT, the pH was adjusted to 9 with KOH pellets and the benzoic 
acid NHS active ester (0.9 g, 4.0 mmol) was added. The reaction was heated to 40 °C with 
efficient stirring for 2 h, the solution was filtered and the filtrate treated with H2S over 5 min. 
After filtration of the dark solid, the solution was pale yellow. The filtrate was washed with 
DCM and the aqueous layer was reduced to half the initial volume. The pH was increased up 
to 11 and the solution was extracted repeatedly with DCM. The organic layer was 
concentrated to give a colourless oil (170 mg, 20 %). 
Third procedure: 
The tetra-hydrochloride salt of (5S)-1,5,9-triamino-3-azanonane, 2 was converted into the free 
tetra-amine (1.0 g, 5.7 mmol) by anion exchange chromatography using DOWEX 1x2-200 
resin. The free amine was dried under reduced pressure and then dissolved in anhydrous 
dibutyl ether (60 mL) and the solution degassed using a freeze-pump-thaw cycles. Mo(CO)6 
(1.5 g, 5.7 mmol) was added and the solution was heated to 140 °C for 2 h in which a yellow 
precipitate formed. After cooling to RT, the solvent was removed with a syringe and dry DMF 
(40 mL) previously degassed with freeze-thaw cycles was added. 2,5-dioxopyrrolidin-1-yl 
benzoate  (1.6 g, 7.3 mmol) was added quickly and the solution was stirred at RT for 1 h. The 
reaction was monitored by observing the disappearance of the active ester by TLC (Rf = 0.34 
silica, Hex: EtOAc 1 : 1). The solvent was removed and the brown residue was taken up in 
dilute HCl (10 %, 12 mL) and stirred in air at RT for 18 h. The solution was centrifuged and 
the red solution was decanted and washed with DCM (2 x 30 mL). The pH was raised to 7 
and the solution was washed with DCM (2 x 30 mL). The pH was raised to 12 and the 
solution was extracted repeatedly with DCM. The solvent was removed to give a colourless 
oil (870 mg, 52 %). 
H (CDCl3) 7.80-7.77 (2H, m, ArH), 7.51-7.43 (3H, m, ArH), 6.33 (1H, br, CONH), 2.82 (2H, 
t,
 3
JH-H 4 Hz H
1
), 2.72-2.66 (6H, m, H
6-8-9
), 2.41 (1H, m, H
5
), 1.67-1.53 (11H, m, NH2 and H
2-
3-4
); C (CDCl3) 166.6 (CO), 133.8, 130.3, 127.5, 125.9 (Ar), 55.6 (C
5
), 51.6, 50.0, 40.8 (C
6-8-
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9
), 38.7 (C
1
), 28.7, 23.7, 22.5 (C
2-3-4
), NMR data were in good agreement with those 
previously reported;
80
 m/z (ESI) 279.4 [M + H]
+
. 
2,5-Dioxopyrrolidin-1-yl benzoate 
 
Triethylamine (5.7 mL, 41 mmol) was added to a solution of benzoic acid (5.0 g, 41 mmol) in 
dry DCM (70 mL) under argon. EDC (7.8 g, 41 mmol) was added and a white solid 
precipitated. After 10 min of vigorous stirring, N-hydroxysuccinimide (4.7 g, 41 mmol) was 
added and the solution became colourless. After stirring for 4 h at RT, the solution was 
washed with water, dried over MgSO4, filtered and evaporated. The white solid was purified 
by crystallization from diethyl ether to give a white solid (5.2 g, 60 %); m.p. 138 – 140 °C 
[lit.
135
 137 – 138 °C]; H (CDCl3) 8.16 (2H, d, 
3
JH-H 4 Hz, o-H), 7.71 (1H, dd, 
3
JH-H 4 Hz, 
3
JH-
H 2 Hz, p-H), 7.54 (2H, dd, 
3
JH-H 4 Hz, 
3
JH-H 2 Hz, m-H), 2.93 (4H, s, 2CH2); Rf = 0.26 (silica, 
Hex : EtOAc 1 : 1). 
(5S)-N-(5,9-Bis-p-toluenesulphonamido-7-p-toluenesulphonyl-7-azanonyl)benzamide, 4a 
 
A solution of tosyl chloride (1.6 g, 8.4 mmol) in DCM (20 mL) was added dropwise to a 
solution of (5S)-N-(5,9-diamino-7-azanonyl)benzamide, 3 (660 mg, 2.4 mmol) and Et3N (1.5 
mL, 10.8 mmol) in DCM (20 mL) with stirring over a period of 1 h. The reaction mixture was 
stirred at RT overnight, after which time, the mixture was washed with water (2 x 20 mL). 
The water layer was extracted with EtOAc and the combined organic layers were 
concentrated. DCM (30 mL) was added to the brown oil and a white precipitate formed. The 
solid was isolated and the filtrate was concentrated and purified by column chromatography 
(silica, DCM : EtOAc 100 : 0 to 70 : 30) to give a white solid (800 mg, 46 %); m.p. 148 – 150 
°C [lit.
80
 149 – 151 °C]; H (CDCl3) 7.86 (2H, d, 
3
JH-H 8 Hz,  ArH), 7.78 (3H, m, ArH), 7.70 
(2H, d, 
3
JH-H 8 Hz,  ArH), 7.53 (1H, m, ArH), 7.44 (2H, m, ArH), 7.02-6.99 (5H, m, ArH), 
6.90 (2H, m, ArH), 6.48 (1H, br, CONH), 5.30-5.26 (2H, m, NHTs), 3.35-3.04 (9H, m, H
1-5-6-
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8-9
), 2.73 (6H, s, CH3), 2.25 (3H, s, CH3), 1.71(1H, m, H
4
), 1.50-1.35 (3H, m, H
2-4
), 1.02-0.98 
(2H, m, H
3
); C (CDCl3) 166.8 (CO), 143.2, 142.6, 136.1, 135.8, 133.3, 130.4, 129.0, 128.8, 
128.7, 127.5, 126.4, 126.3, 126.1 (Ar), 55.0 (C
5
), 52.4, 51.6, 50.1 (C
6-8-9
), 41.7 (C
1
), 38.0, 
30.1, 27.7 (C
2-3-4
), 20.5 (CH3), 5 signals obscured or overlapping; m/z (ESI) 763.4 [M + Na]
+
; 
Rf = 0.16 (silica, DCM : EtOAc 9 : 1). 
(S)-N-(6-(4-Methoxy-N-(2-(4-methoxyphenylsulfonamido)ethyl)phenylsulfonamido)-5-
(4-methoxyphenylsulfonamido)hexyl)benzamide, 4b 
 
A solution of p-methoxybenzenesulfonyl chloride (1.2 g, 5.7 mmol) in DCM (15 mL) was 
added dropwise to a solution of (5S)-N-(5,9-diamino-7-azanonyl)benzamide, 3 (440 mg, 1.6 
mmol) and Et3N (1.0 mL, 7.3 mmol) in DCM (35 mL) with stirring over a period of 1 h. The 
reaction mixture was stirred at RT overnight, after which time, it was washed with water, 
dried over MgSO4, filtered and evaporated. The brown residue was purified by column 
chromatography (silica, DCM: EtOAc 100 : 0 to 70 : 30) to give a white solid (470 mg, 38 
%); m.p. 145 – 148 °C; anal. calc. for C36H44N4O10S3: C, 54.81; H, 5.62; N, 7.10 %; found: C, 
54.90; H, 5.55; N, 7.13 %; H (CDCl3) 7.76 (2H, d, 
3
JH-H 8 Hz,  ArH), 7.65 (3H, m, ArH), 
7.54 (2H, d, 
3
JH-H 8 Hz, ArH), 7.40 (1H, m, ArH), 7.35 (2H, m, ArH), 7.26-7.19 (5H, m, 
ArH), 7.13-7.11 (2H, m, ArH), 6.40 (1H, br, CONH), 5.22-5.18 (2H, m, NHTs’), 3.90 (6H, s, 
CH3), 3.79 (3H, s, CH3), 3.35-3.04 (9H, m, H
1-5-6-8-9
), 1.71(1H, m, H
4
), 1.50-1.35 (3H, m, H
4-
2
), 1.02-0.98 (2H, m, H
3
); C (CDCl3) 166.8 (CO), 143.2, 142.6, 136.1, 135.8, 133.3, 130.4, 
129.0, 128.8, 128.7, 127.5, 126.4, 126.3, 126.1 (Ar), 55.0 (C
5
), 52.4, 51.6, 50.1 (C
6-8-9
), 41.7 
(C
1
), 38.0 (CH3), 30.1, 28.7 21.9 (C
2-3-4
), 5 signals obscured or overlapping; m/z (ESI) 811.8 
[M + Na]
+
; Rf = 0.21 (silica, DCM : EtOAc 8 : 2). 
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 (S)-2-(4-Benzamidobutyl)-1,4,7-tris(p-toluenesulphonyl)-1,4,7-triazacyclononane, 5a 
 
Caesium carbonate (1.0 g, 3.3 mmol) was added to a solution of the tritosylamide, 4a (750 
mg, 1 mmol), in anhydrous DMF (45 mL) under argon. A solution of ethylene glycol 
bis(toluene-p-sulphonate) (412 mg, 1.1 mmol) in anhydrous DMF (20 mL) was added 
dropwise over a period of 2 h, with efficient stirring. After stirring for 16 h, the temperature 
was raised to 65 °C for 5 h. The solvent was removed under reduced pressure and the residue 
was dissolved in chloroform (50 mL) and washed with water. The organic layer was dried 
over MgSO4, filtered and evaporated. The yellow oil was purified by column chromatography 
(silica, DCM: EtOAc 100 : 0 to 80 : 20) to give a white solid (495 mg, 66 %); m.p. 107 – 109 
°C [lit.
80
 106 – 108 °C]; H (CDCl3) 7.84-7.82 (2H, d, 
3
JH-H 8 Hz,  ArH), 7.75 (2H, m, ArH), 
7.63 (2H, m, ArH), 7.61 (2H, m, ArH), 7.39-7.27 (9H, m, ArH), 6.59 (1H, br, CONH), 3.61-
3.10 (13H, m, H
2-3-5-6-8-9-13
), 2.45-2.39 (9H, m, CH3), 1.54-1.24 (6H, m, H
10-11-12
); C (CDCl3) 
166.5 (CO), 143.2, 143.1, 142.9, 133.6, 113.4, 133.2, 130.3, 129.0, 128.9, 128.8, 127.5, 
127.0, 126.7, 126.6, 126.5, 126.3, 126.0 (Ar), 59.4 (C
2
), 52.7, 51.6, 49.7, 45.3 (C
3-5-6-8-9
), 38.7 
(C
13
), 38.5, 28.0, 23.0, (C
10-11-12
), 20.5 (CH3), 2 signals obscured or overlapping; m/z (ESI) 
789.4 [M + Na]
+
; Rf = 0.47 (silica, DCM : EtOAc 8 : 2). 
(S)-N-(4-(1,4,7-Tris(4-methoxyphenylsulfonyl)-1,4,7-triazacyclononan-2-
yl)butyl)benzamide, 5b 
 
Caesium carbonate (140 mg, 0.43 mmol) was added to a solution of the tritosylamide, 4b (100 
mg, 0.13 mmol), in anhydrous DMF (10 mL) under argon. A solution of ethylene glycol 
bis(toluene-p-sulphonate) (61 mg, 0.17 mmol) in anhydrous DMF (10 mL) was added 
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dropwise over a period of 2 h, with efficient stirring. After stirring overnight RT, the 
temperature of the mixture was raised to 65 °C for 5 h. The solvent was removed under 
reduced pressure and the residue was dissolved in chloroform (25 mL) and washed with 
water. The organic layer was dried over MgSO4, filtered and evaporated. The yellow oil was 
purified by column chromatography (silica, DCM: EtOAc 100 : 0 to 80 : 20) to give the a 
white solid (67 mg, 63 %); m.p. 104 – 106 °C; anal. calc. for C38H46N4O10S3: C, 56.00; H, 
5.69; N, 6.87 %; found: C, 56.50; H, 5.78; N, 6.82 %; H (CDCl3) 7.85-7.82 (2H, d, 
3
JH-H 8 
Hz,  ArH), 7.76 (2H, m, ArH), 7.68 (2H, m, ArH), 7.44 (2H, m, ArH), 7.01-6.98 (9H, m, 
ArH), 6.43 (1H, br, CONH), 3.90-3.87 (9H, m, CH3), 3.61-3.10 (13H, m, H
2-3-5-6-8-9-13
), 1.54-
1.24 (6H, m, H
10-11-12
); C (CDCl3) 166.5 (CO), 143.2, 143.1, 142.9, 133.6, 113.4, 133.2, 
130.3, 129.0, 128.9, 128.8, 127.5, 127.0, 126.7, 126.6, 126.5, 126.3, 126.0 (Ar), 59.4 (C
2
), 
52.7, 51.6, 49.7, 45.3 (C
3-5-6-8-9
), 38.7 (C
13
), 38.5 (CH3), 28.0, 23.0, 20.5 (C
10-11-12
), 2 signals 
obscured or overlapping; m/z (ESI) 837.8 [M + Na]
+
; Rf = 0.34 (silica, DCM : EtOAc 9 : 1). 
 (S)-N-(4-(1,4,7-Triazacyclononan-2-yl)butyl)cyclohexanecarboxamide, 6c 
 
Ammonia (40 mL) was condensed into a solution of the tritosylamide, 5a (450 mg, 0.55 
mmol) in a mixture of dry THF (20 mL) and dry EtOH (1.5 mL) whilst stirring under argon at 
-78 °C. Lithium (350 mg, excess) was added in small portions to the solution and a strong 
blue colour developed. The solution was slowly warmed to RT overnight; during this period 
the solution turned colourless and the ammonia gas was allowed to evaporate through an anti-
suck back apparatus. Water (20 mL) was added slowly to the solution and the solvent was 
removed. The residue was dissolved in HCl (18 mL, 2 M) and washed with ether. The 
aqueous layer was concentrated, and the residue was dissolved in aqueous KOH solution (15 
mL, 6 M) and extracted with DCM (3 x 20 mL). The organic layer was concentrated to give a 
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yellow oil (100 mg). The presence of the ligand 6c was confirmed by MS, which also 
revealed the presence of compound 6a. Completion of reaction was confirmed by 
1
H-NMR, 
observing the disappearance of the aromatic signals and by 
13
C-NMR observing the 
appearance of the cyclohexyl peak at 24 and 28 ppm.  The product was taken on without 
further purification and used for the alkylation step; m/z (HRMS
+
) 311.2801 [M + H]
+
 
(C17H35N4O requires 311.2811)
 
for 6c and 201.2068 [M + H]
+
 (C10H25N4 requires 201.2079)
 
for 6a. 
(S)-4-(1,4,7-Triazacyclononan-2-yl)butan-1-amine, 6a 
 
2-(4-Cyclohexylamidobutyl)-1,4,7-triazacyclononane, 6c (65 mg, 0,21 mmol) was dissolved 
in HCl (6 M, 3 mL) and stirred at 100 °C for 72 h. After completion the reaction was diluted 
with H2O (3 mL) and washed with diethyl ether (3 x 10 mL). The aqueous layer was 
concentrated to give the tetrahydrochloride salt (100 mg, quantitative yield). H (D2O): 3.42-
3.13 (10H, m, H
3-5-6-9-9
), 3.96-2.87 (3H, m, H
2-13
), 1.64-1.37 (6H, m, H
10-11-12
);  C (D2O): 53.3 
(C
2
), 46.1, 43.2, 41.8, 39.2, 39.1, 39.0 (C
3-5-6-8-9-13
), 30.6, 26.5, 22.1, (C
10-11-12
); m/z (HRMS
+
) 
201.2068 [M + H]
+
 (C10H25N4 requires 201.2079). 
2-Bromo-6-methylpyridine-1-oxide, 8 
 
2-Bromo-6-methylpyridine, 7 (10.0 g, 0.58 mol) was dissolved in CHCl3 (150 mL). mCPBA 
(20.1 g, 1.16 mol) was added and the solution was stirred at 65 °C under argon for 18 h. The 
volume of the solution was reduced to 75 mL by removal of the solvent under reduced 
pressure. The solution was cooled to 0 °C overnight causing precipitation of 3-chlorobenzoic 
acid, which was removed by filtration. From the remaining filtrate, the solvent was removed 
under reduced pressure to give a yellow oil, which was dissolved in aqueous NaOH solution 
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(1 M, 50 mL) and extracted with DCM (3 × 50 mL). The organic extracts were combined, 
dried over MgSO4, filtered and the solvent removed under reduced pressure to give a yellow 
solid (6.0 g, 55 %); m.p. 54 – 57 °C [lit.78 48 – 55 °C];b H (CDCl3) 7.55 (1H, dd, 
3
JH-H 8 Hz, 
4
JH-H 1.5 Hz, H
3
), 7.23 (1H, dd, 
3
JH-H 8 Hz, 
4
JH-H 1.5 Hz, H
5
), 7.01 (1H, t, 
3
JH-H 8 Hz, H
4
), 
2.57 (3H, s, H
7
);C (CDCl3) 151.2 (s, C
2
), 133.5 (s, C
6
), 128.7 (s, C
3
),125.3 (s, C
5
), 125.2 (s, 
C
4
), 19.3 (s, C
7
); m/z (HRMS
+
) 187.9698 [M + H]
+
 (C6H7NO
79
Br requires 187.9711); Rf = 
0.16 (silica, DCM : 2 % MeOH). 
2-Bromo-6-methyl-4-nitropyridine-1-oxide, 9 
 
2-Bromo-6-methylpyridine-1-oxide, 8 (15.0 g, 80.0 mmol) was dissolved in concentrated 
H2SO4 (98%, 23 mL). The solution was stirred at 0 °C and HNO3 (70 %, 26 mL, 0.38 mol) 
was added dropwise. The mixture was heated to 100 °C for 16 h. The yellow solution was 
dropped onto stirred ice (150 g) causing a pale yellow solid to precipitate. After 1 h the 
precipitate was filtered and dried under high vacuum to afford a pale yellow solid (12.0 g, 65 
%); m.p. 138 – 139 °C [lit.78 137 – 138 °C];c H (CDCl3) 8.40 (1H, d, 
4
JH-H 3 Hz, H
3
), 8.09 
(1H, d, 
4
JH-H 3 Hz, H
5
), 2.62 (3H, s, H
7
); C (CDCl3) 151.8 (s, C
4
), 140.7 (s, C
2
), 134.0 (s, C
6
), 
122.8 (s, C
3
), 118.9 (s, C
5
), 19.6 (s, C
7
); m/z (HRMS
+
) 232.9564 [M + H]
+
 (C6H6N2O3
79
Br 
requires 232.9556); Rf = 0.53 (silica, DCM : 2% MeOH). 
2-Bromo-6-methyl-4-nitropyridine, 10 
 
2-Bromo-6-methyl-4-nitropyridine-1-oxide, 9 (2.0 g, 8.6 mmol) was dissolved in CHCl3 (50 
mL) and PBr3 (2.4 mL, 25.8 mmol) was added dropwise. The mixture was stirred at 60 °C 
under argon for 48 h. The solvent was removed under reduced pressure to give a yellow oil. 
Aqueous NaOH solution (2 M, 100 mL) was added cautiously and the solution was extracted 
with DCM (3 × 100 mL). The organic extracts were combined, dried over MgSO4 and the 
                                                          
b
 This compound is commercially available, http://www.acespharma.com 
c
 This compound is commercially available, http://www.acccorporation.com 
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solvent removed under reduced pressure to give a yellow oil, which was purified by column 
chromatography on silica (DCM) to yield a pale yellow oil (1.6 g, 78 %);  H (CDCl3) 8.02 
(1H, d, 
4
JH-H 3 Hz, H
3
), 7.83 (1H, d, 
4
JH-H 3 Hz, H
5
), 2.70 (3H, s, H
7
); C (CDCl3) 162.9 (s, 
C
4
), 154.9 (s, C
2
), 142.4 (s, C
6
), 118.4 (s, C
3
), 115.0 (s, C
5
), 24.6 (s, C
7
); m/z (HRMS
+
) 
216.9621 [M + H]
+
 (C6H6N2O2
79
Br requires 216.9613); Rf = 0.75 (silica, DCM : 2 % MeOH). 
Ethyl (6-methyl-4-nitropyridin-2-yl)(methyl)phosphinate, 11  
 
Neat ethyl methylphosphinate (570 mg, 3.67 mmol), containing one equivalent of ethanol, 
was added to degassed (freeze-thaw cycle) toluene (10 mL), followed by 
2-bromo-6-methyl-4-nitropyridine, 10 (660 mg, 3.06 mmol) and freshly distilled 
triethylamine (1.49 mL, 10.70 mmol). Argon was bubbled through the yellow solution for 
30 min, then PdCl2(dppf)·DCM (50 mg, 0.061 mmol) was added, and the mixture stirred at 
125 °C for 16 h under argon, during which time the mixture turned black. The solvent was 
removed under reduced pressure, with purification of the resulting black oil by column 
chromatography (silica, EtOAc : Hex 1:1 to 3:1) giving an off-white oil (510 mg, 67 %); H 
(CDCl3) 8.54-8.56 (1H, m, H
3
), 7.96-8.01 (1H, m, H
5
), 3.68-4.44 (2H, m, H
9
), 2.79 (3H, s, 
H
7
), 1.83 (3H, d, 
2
JH-P 15 Hz, H
8
), 1.31 (3H, t, 
3
JH-H 7 Hz, H
10
); C (CDCl3) 163.2 (d, 
3
JC-P 
21 Hz, C
4
), 158.1 (d, 
1
JC-P 157 Hz, C
2
), 154.3 (d, 
3
JC-P 157 Hz, C
6
), 117.9 (d, 
4
JC-P 3 Hz, C
5
), 
117.2 (d, 
2
JC-P 23 Hz, C
3
), 61.6 (d, 
3
JC-P 7 Hz, C
9
), 24.9 (s, C
7
), 16.6 (d, 
4
JC-P 6 Hz, C
10
), 13.5 
(d, 
1
JC-P 105 Hz, C
8
); P (CDCl3) + 37.2; m/z (HRMS
+
) 267.0527 [M + Na]
+
 (C9H13N2O4PNa 
requires 267.0511); Rf = 0.14 (silica, EtOAc : Hex 1 : 3). 
Ethyl methylphosphinate 
 
Neat diethyl methylphosphonite (2.0 g, 14.7 mmol) was stirred under argon at RT and H2O 
(264 μL, 14.7 mmol) was added. The mixture was stirred for 18 h. 1H- and 31P-NMR were 
used to confirm formation of the product, which was used in situ without further purification. 
The reaction mixture also contains one equivalent of ethanol as a by-product (100 % 
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conversion by 
1
H-NMR); H (CDCl3) 7.22 (1H, dq, 
1
JH-P 536, 
2
JH-H 2 Hz, H
1
), 4.11 (2H, dqd,
 
2
JH-H 36 Hz 
3
JH-H 7 Hz 
3
JH-P 4 Hz, H
2
), 1.54 (3H, dd, 
2
JH-P 15 Hz 
3
JH-H 2 Hz, H
4
), 1.23 (3H, 
3
JH-H 7 Hz, H
3
); P (CDCl3)  +34.5;C (CDCl3) 62.3 (d, 
2
JC-P 7 Hz, C
2
), 16.1 (s, C
3
), 14.9 (d, 
1
JC-P 95 Hz, C
4
); m/z (HRMS+) 109.0414 [M + H]
+ 
(C3H10O2P requires 109.0418). 
 (4-Bromo-6-methylpyridin-2-yl)(methyl)phosphinic acid, 11a 
 
Ethyl (6-methyl-4-nitropyridin-2-yl)(methyl)phosphinate, 11 (750 mg, 3.07 mmol) was 
dissolved in acetyl bromide (6.8 mL, 92 mmol) and the mixture stirred at 70 °C for 16 h under 
argon. A pale brown precipitate formed. Both precipitate and solution were dropped 
cautiously into MeOH (30 mL) stirred at 0 °C. The solvent was removed under reduced 
pressure to yield a pale brown solid. The material, containing minor impurities, was used in 
the next step without further purification, assuming quantitative conversion to the bromo-
phosphinic acid; H (CD3OD) 8.25-8.28 (1H, m, H
3
), 8.17-8.18 (1H, m, H
5
), 2.76 (3H, s, H
7
), 
1.80 (3H, d, 
2
JH-P 16 Hz, H
8
); P (CD3OD) + 28.6; m/z (HRMS
+
) 249.9627 [M + H]
+
 
(C7H10NO2
79
BrP requires 249.9627); Rf = 0.01 (silica, DCM : MeOH 95 : 5). 
Ethyl (4-bromo-6-methylpyridin-2-yl)(methyl)phosphinate, 12 
 
Crude (4-bromo-6-methylnitropyridin-2-yl)(methyl)phosphinic acid, 11a (768 mg, 3.07 
mmol) was added to HC(OCH2CH3)3 (25 mL) and the mixture stirred at 140 °C for 72 h 
under argon. The solvent was removed under reduced pressure and the resulting residue was 
purified by column chromatography (silica, DCM :  MeOH 1 to 2 %) to yield a yellow oil 
(660 mg, 77 % over two steps); H (CDCl3) 8.04 (1H, dd 
3
JH-P 6 Hz 
4
JH-H 2 Hz, H
3
), 7.46 (1H, 
app s, H
5
), 3.82-4.16 (2H, m, H
9
), 2.59 (3H, s, H
7
), 1.77 (3H, d, 
2
JH-P 15 Hz, H
8
), 1.28 (3H, t, 
3
JH-H 7 Hz, H
10
); C (CDCl3) 161.1 (d, 
3
JC-P 21 Hz, C
4
), 155.4 (d, 
1
JC-P 156 Hz, C
2
), 133.6 (d, 
3
JC-P 14 Hz, C
6
), 128.9 (d, 
4
JC-P 3 Hz, C
5
), 128.2 (d, 
2
JC-P 22 Hz, C
3
), 61.3 (d, 
3
JC-P 6 Hz, C
9
), 
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24.4 (s, C
7
), 16.5 (d, 
4
JC-P 6 Hz, C
10
), 13.6 (d, 
1
JC-P 104 Hz, C
8
); P (CDCl3) + 38.0; m/z 
(HRMS
+
) 277.9973 [M + H]
+
 (C9H14NO2
79
BrP requires 277.9946); Rf = 0.33 (silica, 
DCM :  MeOH 95 : 5). 
Ethyl (4-bromo-6-methylpyridin-1-oxide-2-yl)(methyl)phosphinate, 13 
 
Ethyl (4-bromo-6-methylpyridin-2-yl)(methyl)phosphinate, 12 (250 mg, 1.10 mmol) was 
dissolved in CH3CN (5 mL). 3-Chloroperbenzoic acid (378 mg, 2.19 mmol) was added and 
the solution stirred at 65 °C for 16 h. The solvent was then removed under reduced pressure, 
with the resulting material being re-dissolved in DCM (10 mL), and washed with aqueous 
NaHCO3 (0.5 M, 10 mL). The aqueous layer was re-extracted with DCM (3 × 10 mL), the 
organic extracts combined, dried over MgSO4, and the solvent removed under reduced 
pressure, with purification of the resulting yellow oil by column chromatography (silica, 
DCM : MeOH 0 to 3 %) giving a colourless oil (256 mg, 79 %); H (CDCl3) 8.04 (1H, dd 
3
JH-
P 8 Hz 
4
JH-H 3 Hz, H
3
), 7.54 (1H, dd 
4
JH-H 3 Hz, H
5
), 3.89-4.22 (2H, m, H
9
), 2.48 (3H, s, H
7
), 
1.97 (3H, d, 
2
JH-P 17 Hz, H
8
), 1.31 (3H, t, 
3
JH-H 7 Hz, H
10
); C (CDCl3) 151.1 (d, 
3
JC-P 4 Hz, 
C
4
), 143.8 (d, 
1
JC-P 136 Hz, C
2
), 133.4 (d, 
3
JC-P 11 Hz, C
6
), 132.3 (d, 
4
JC-P 2 Hz, C
5
), 118.0 (d, 
2
JC-P 12 Hz, C
3
), 62.1 (d, 
3
JC-P 7 Hz, C
9
), 17.5 (s, C
7
), 16.6 (d, 
4
JC-P 6 Hz, C
10
), 14.5 (d, 
1
JC-P 
111 Hz, C
8
); P (CDCl3) + 32.2; m/z (HRMS
+
) 293.9909 [M + H]
+
 (C9H14NO3
79
BrP requires 
293.9895); Rf = 0.27 (silica, DCM : MeOH 95 : 5). 
Ethyl (4-bromo-6-hydroxymethylpyridin-2-yl)(methyl)phosphinate, 14 
  
Trifluoroacetic anhydride (5 mL) was added to a solution of ethyl (4-bromo-6-methylpyridin-
1-oxide-2-yl)(methyl)phosphinate, 13 (557 mg, 2.00 mmol) in dry CH3CN (15 mL). The 
reaction mixture was heated to 60 °C for 3 h under argon. The solvent was removed under 
reduced pressure and the resulting oil was dissolved in EtOH (15 mL) and H2O (15 mL) and 
stirred for 16 h. After this time, the solution was concentrated (ca. 10 mL) and extracted with 
Chapter 7: Experimental 
 
141 
 
DCM (3 × 30 mL). The organic extracts were combined, dried over MgSO4, and the solvent 
removed under reduced pressure, with purification of the resulting oil by column 
chromatography (silica, DCM :  MeOH 1 to 3 %) giving a golden oil (470 mg, 80 %); H 
(CDCl3) 8.13 (1H, dd 
3
JH-P 6 Hz 
4
JH-H 1.8 Hz, H
3
), 7.63 (1H, app s, H
5
), 4.80 (2H, s, H
7
), 
3.70-4.20 (2H, m, H
9
), 3.26 (1H, br s, OH), 1.76 (3H, d, 
2
JH-P 15 Hz, H
8
), 1.27 (3H, t, 
3
JH-H 
7 Hz, H
10
); C (CDCl3) 162.8 (d, 
3
JC-P 20 Hz, C
4
), 154.8 (d, 
1
JC-P 154 Hz, C
2
), 134.5 (d, 
3
JC-P 
13 Hz, C
6
), 129.5 (d, 
2
JC-P 22 Hz, C
3
), 126.3 (d, 
4
JC-P 3 Hz, C
5
), 64.2 (s, C
7
), 61.5 (d, 
3
JC-P 
6 Hz, C
9
), 16.5 (d, 
4
JC-P 6 Hz, C
10
), 13.6 (d, 
1
JC-P 105 Hz, C
8
); P (CDCl3) + 38.0; m/z 
(HRMS
+
) 315.9729 [M + Na]
+
 (C9H13NO3
79
BrPNa requires 315.9714); Rf = 0.24 (silica, 
DCM :  MeOH 95 : 5). 
(4-Bromo-6-(ethoxy(methyl)phosphoryl)pyridin-2-yl)methyl methanesulfonate, 15 
 
Ethyl (4-bromo-6-hydroxymethylpyridin-2-yl)(methyl)phosphinate, 14 (330 mg, 1.12 mmol) 
was dissolved in dry THF (15 mL) under argon. Et3N (250 L, 3.37 mmol) was added and the 
solution was cooled to 0 °C. Methanesulfonyl chloride (130 L, 1.68 mmol) was added and 
the stirring was continued for 15 min, the progress of the reaction being monitored by TLC 
(silica, DCM : 3 % MeOH, Rf(product) = 0.50, Rf(reactant) = 0.24). The solvent was removed 
and the resulting oil was dissolved in DCM (20 mL) and washed with brine. The aqueous 
layers were extracted with DCM; the organic layers were combined, reduced in volume (20 
mL), washed with brine, dried over MgSO4, and the solvent removed under reduced pressure 
giving a pale yellow solid (320 mg, 75 %); the material was used without purification for the 
next step; H (CDCl3) 8.14 (1H, dd 
3
JH-P 6 Hz 
4
JH-H 2 Hz, H
3
), 7.72 (1H, app s, H
5
), 5.29 (2H, 
s, H
7
), 3.78-4.10 (2H, m, H
9
), 3.09 (3H, br s, H
11
), 1.71 (3H, d, 
2
JH-P 15 Hz, H
8
), 1.22 (3H, t, 
3
JH-H 7 Hz, H
10
); Rf = 0.50 (silica, DCM : 3 % MeOH). 
 
 
 
Chapter 7: Experimental 
 
142 
 
Triethyl 6,6',6''-((S)-2-(4-(cyclohexanecarboxamido)butyl)-1,4,7-triazacyclononane-
1,4,7-triyl)tris(methylene)tris(4-bromopyridine-6,2-diyl)tris(methylphosphinate), 16 
 
(S)-N-(4-(1,4,7-Triazacyclononan-2-yl)butyl)cyclohexanecarboxamide 6c (75 mg, 0.24 
mmol), containing traces of (S)-4-(1,4,7-triazonan-2-yl)butan-1-amine 6a, was added to a 
solution of (4-bromo-6-(ethoxy(methyl)phosphoryl)pyridin-2-yl)methyl methanesulfonate 
(320 mg, 0.86 mmol) and K2CO3 (198 mg, 1.47 mmol) in dry CH3CN (15 mL) and stirred 
under argon at 65 °C. After 6 h the solution was allowed to cool to RT and filtered. The 
filtrate was concentrated and purified by HPLC (Method A, tR = 8.5 min) to give a yellow oil 
(65 mg, 25 %); H (CDCl3) 8.20-7.82 (6H, m,  Py), 6.45 (1H, br, CONH), 4.17-3.87 (12H, m, 
POCH2 and H
17-17’-17’’
), 3.23-2.59 (13H, m, H
2-3-5-6-8-9-13
), 1.82-1.76 (9H, m, PCH3), 1.76-1.26 
(26H, m, CH3(Et) and H
10-11-12-14-15-16-17
); P (CDCl3) + 37.76; m/z (HRMS
+
) 1138.191 
[M + H]
+
 (C44H68
79
Br3N7O7P3 requires 1138.193).  
Europium (III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(cyclohexanecarboxamido)butyl)-
1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-bromopyridine-6,2-
diyl)tris(methylphosphinate), [EuL
13
] 
 
Triethyl 6,6',6''-((S)-2-(4-(cyclohexanecarboxamido)butyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-bromopyridine-6,2-diyl)tris(methylphosphinate), 16 (10.0 mg, 8.8 
mol) was dissolved in CD3OD (3 mL) and a solution of NaOH in D2O (0.1 M, 1 mL) was 
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added. The mixture was heated to 90 °C under argon and monitored with 
31
P-NMR 
[P(reactant) = 38.8, (P(product) = 25.9]. After 5 h the solution was cooled to RT and the pH 
was adjusted to 7 with HCl. Eu(AcO)3H2O (3.2 mg, 9.7mol) was added and the mixture 
heated to 65 °C overnight under argon. The solvent was removed under reduced pressure and 
the product purified by column chromatography (silica, DCM : MeOH : NH3 9 : 1: 0.1) giving 
a white solid (3.0 mg, 30 %); P (CD3OD) 43.4, 40.7, 37.5 ; m/z (HRMS
+
) 1203.995 [M + H]
+
 
(C38H53
79
Br3
153
EuN7O7P3 requires 1203.995); Rf = 0.32 (silica, DCM : MeOH : NH3 9 : 1: 
0.1);  MeOH = 1.50 ms; max (MeOH) = 272 nm,  = 8 mM
-1
 cm
-1
.  
 
Method B, tR = 8.8 min 
(S)-tert-Butyl 4-(1,4,7-triazacyclononane-2-yl)butylcarbamate, 17 
 
The tetrahydrochloride salt of (S)-4-(1,4,7-triazacyclononane-2-yl)butan-1-amine, 6a was 
converted into the free tetra-amine (66 mg, 0.33 mmol) by anion exchange chromatography 
using DOWEX 1x2-200 resin (hydroxide form). The free amine was dissolved in MeOH (4 
mL) and CuCl2∙H2O (56 mg, 1.33 mmol) was added, resulting in an intense green mixture. 
The mixture was stirred at RT under argon for 2 h, after which the solvent was removed and 
the green solid was dissolved in H2O (2 mL). A solution of di-tert-butyl-dicarbonate (140 mg, 
0.66 mmol) in dioxane (2 mL) was added and the solution was stirred at RT. After 3 h another 
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00
A
U
0.0
1.0e-2
2.0e-2
3.0e-2
4.0e-2
5.0e-2
6.0e-2
7.0e-2
23April12_MD022 3: Diode Array 
254
Range: 7.707e-2
8.76
8.45
8.27
1.39
0.03
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equivalent of di-tert-butyl-dicarbonate (70 mg) was added and the reaction was stirred for 16 
h. At this time, LC-MS revealed complete consumption of starting material. The blue solution 
was treated with H2S over 5 min and the mixture was centrifuged to remove the dark 
precipitate. The supernatant was washed with DCM and the pH was adjusted to 11 before 
extracting repeatedly with DCM. The organic layer was concentrated to give a colourless oil 
(54 mg, 55 %); H (CDCl3): 6.46 (1H, br, CONH), 3.13 (2H, m, H
13
), 2.89-2.47 (10H, m, H
3-5-
6-8-9
), 2.79 (1H, m, H
2
), 2.35 (3H, br, NH), 1.47 (9H, s, CH3(Boc)), 1.49-1.35 (6H, m, H
10-11-
12
);  C (CDCl3): 156.3 (CO), 79.3 (C(Boc)), 55.2 (C
2
), 49.9, 46.2, 45.3, 44.3, 40.6 (C
3-5-6-8-9
), 
40.3(C
13
), 33.9, 30.4, 23.7, (C
10-11-12
), 28.6 (CH3(Boc)); (HRMS
+
) 301.2603 [M + H]
+
 
(C15H33N4O2 requires 301.2604). Analysis of the enantiomeric purity of this amine by 
1
H- 
NMR using R-O-acetyl mandelic acid (CDCl3, 500 MHz, 295 K) as a chiral solvating 
agent;
126
 the analysis of the shift of the H
2
 proton at 2.84 ppm, (that resolved into two signals 
for a sample that was scalemic) confirmed the enantiomeric purity to be > 98 %. 
Ethyl(6-(hydroxymethyl)-4-[2-(4-methoxyphenyl)ethynyl]pyridin-2-
yl)(methyl)phosphinate, 18 
 
Ethyl (6-(hydroxymethyl)-4-(bromopyridin-2-yl)(methyl)phosphinate, 14 (100 mg, 0.34 
mmol) was dissolved in dry THF (2 mL) and the solution was degassed (freeze-thaw cycle) 
three times. 4-Ethynylanisole (67 mg, 0.51 mmol) and NEt3 (0.2 mL) were added and the 
solution degassed once more. [1,1’-Bis(diphenylphosphino)ferrocene]palladium(II) chloride 
(28 mg, 0.034 mmol) and CuI (13 mg, 0.068 mmol) were added and the solution was 
degassed a further three times. The solution was stirred at 65 °C under argon for 12 h, solvent 
was removed under reduced pressure and the crude material purified by column 
chromatography (silica, DCM : MeOH 0 to 3 %) to give a dark yellow oil (113 mg, 96 %); H 
(CDCl3) 7.95 (1H, bs, H
3
), 7.51 (1H, bs, H
5
), 7.42 (2H, d, 
3
JH-H 9 Hz, H
14
), 6.84 (2H, d, 
3
JH-H 
9 Hz, H
15
), 4.78 (2H, s, H
7
),  4.10 – 4.04 (1H, m, H9), 3.86 – 3.81 (1H, m, H9), 3.78 (3H, s, 
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H
17
), 1.73 (3H, d, 
2
JH-P 15 Hz, H
8
), 1.23 (3H, t, 
3
JH-H 7 Hz, H
10
); C (CDCl3) 161.2 (d,
 3
JC-P 18 
Hz, C
6
),  160.6 (s, C
16
), 153.1 (d, 
1
JC-P 156 Hz, C
2
), 133.6 (s, C
14
), 132.9 (d, 
2
JC-P 12 Hz, C
4
), 
127.7 (d, 
3
JC-P 19 Hz, C
3
), 124.1 (d, 
4
JC-P 4 Hz, C
5
), 114.2 (s, C
15
), 114.0 (s, C
13
), 96.0 (s, C
12
), 
85.3 (s, C
11
), 64.2 (s, C
7
), 61.2 (d, 
2
JC-P 6 Hz, C
9
), 55.3 (s, C
17
), 16.4 (d, 
3
JC-P 6 Hz, C
10
), 13.4 
(d, 
1
JC-P 104 Hz, C
8
); P (CDCl3) +38.6; m/z (HRMS
+
) 346.1228 [M + H]
+
 (C18H21O4NP 
requires 346.1208); Rf = 0.20 (silica, DCM : 10 % MeOH). 
Ethyl(6-(ethyl-methanesulfonate)-4-[2-(4-methoxyphenyl)ethynyl]pyridin-2-
yl)(methyl)phosphinate,19 
 
Ethyl(6-(hydroxymethyl)-4-[2-(4-methoxyphenyl)ethynyl]pyridine-2-yl)(methyl)phosphinate, 
18 (128 mg, 0.37 mmol) was dissolved in anhydrous THF (3 mL) and NEt3 (0.18 mL, 1.3 
mmol) was added. The mixture was stirred at 5 °C and methanesulfonyl chloride (43 μL, 0.56 
mmol) was added. The reaction was monitored by TLC (silica, DCM : 10 % MeOH, 
Rf(product) = 0.65, Rf(reactant) = 0.20) and stopped after 15 min. The solvent was removed 
under reduced pressure and the residue dissolved in DCM (15 mL) and washed with NaCl 
solution (saturated, 10 mL). The aqueous layer was re-extracted with DCM (3 × 10 mL) and 
the organic layers combined, dried over MgSO4 and the solvent removed under reduced 
pressure to leave a colourless oil (128 mg, 81 %); H (CDCl3) 8.11 (1H, dd,
 3
JH-P 6 Hz, 
4
JH-H 
1.5, H
3
), 7.65 (1H, bs, H
5
), 7.52 (2H, d, 
3
JH-H 9 Hz, H
14
), 6.93 (2H, d, 
3
JH-H 9 Hz, H
15
), 5.39 
(2H, s, H
7
), 4.20 – 4.10 (1H, m, H9), 3.95 – 3.88 (1H, m, H9), 3.86 (3H, s, H17), 3.16 (3H, s, 
H
18
) 1.80 (3H, d, 
2
JH-P 15 Hz, H
8
), 1.31 (3H, t, 
3
JH-H 7 Hz, H
10
); m/z (HRMS
+
) 446.0804 [M + 
Na]
+
 (C19H22O6SNPNa requires 446.0803); Rf = 0.65 (silica, DCM : 10 % MeOH). 
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tert-Butyl 4-((S)-1,4,7-tris((6-(ethoxy(methyl)phosphoryl)-4-((4-
methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-triazacyclononan-2-
yl)butylcarbamate, 20 
tert-butyl 4-((S)-4,7-bis((6-(ethoxy(methyl)phosphoryl)-4-((4-
methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-triazacyclononan-2-
yl)butylcarbamate, 21 
 
(S)-tert-Butyl 4-(1,4,7-triazacyclononan-2-yl)butylcarbamate, 16 (21 mg, 0.071 mmol) and 
ethyl(6-(ethyl-methanesulfonate)-4-[2-(4-methoxyphenyl)ethynyl]pyridin-2-
yl)(methyl)phosphinate, 19 (90 mg, 0.21 mmol) were dissolved in anhydrous CH3CN (4 mL) 
and K2CO3 (30 mg, 0.21 mmol) was added. The mixture was stirred under argon at 60 °C. 
After 24 h, MS showed the formation of the di-alkylated and tri-alkylated compounds in equal 
amount. The reaction was cooled and the solution decanted from excess potassium salts. The 
solvent was removed under reduced pressure and the crude material purified by column 
chromatography (silica, DCM : MeOH 0 to 20 %) to give tert-butyl 4-((S)-1,4,7-tris((6-
(ethoxy(methyl)phosphoryl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-
triazonan-2-yl)butylcarbamate as a yellow oil (18 mg, 20 %) and tert-butyl 4-((S)-4,7-bis((6-
(ethoxy(methyl)phosphoryl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-
triazonan-2-yl)butylcarbamate as a yellow oil (14 mg, 20 %). 
tert-Butyl-4-((S)-1,4,7-tris((6-(ethoxy(methyl)phosphoryl)-4-((4-
methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-triazacyclononan-2-yl)butylcarbamate, 
20: H (CDCl3) 7.96 (3H, m, H
12
), 7.46 (9H, m H
11
 and H
13
), 6.88 (6H, m, H
14
), 5.04 (1H, br, 
CONH), 4.11-3.84 (12H, m, P-OCH2 and H
10
), 3.80 (9H, m, OMe), 3.09-2.74 (13H, m, H
2-3-5-
6-8-9-18
), 1.77-1.70 (9H, m, P-Me), 1.39 (9H, s, Boc), 1.42-1.23 (7H, H
15-16-17
 and NH), 1.25 
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(9H, m, CH3(Et)); P (CDCl3) +39.2; m/z (HRMS+) 1282.570 [M + H]
+
 (C69H87N7O11P3 
requires 1282.568); Rf = 0.54 (silica, DCM : 20% MeOH). 
tert-Butyl-4-((S)-4,7-bis((6-(ethoxy(methyl)phosphoryl)-4-((4-
methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-triazacyclononan-2-yl)butylcarbamate, 
21: H (CDCl3) 7.87 (2H, m, H
12
), 7.40 (6H, m H
11
 and H
13
), 6.82 (4H, m, H
14
), 5.04 (1H, br, 
CONH), 4.09-3.98 (8H, m, P-OCH2 and H
10
), 3.75 (6H, m, OMe), 3.08-2.60 (13H, m, H
2-3-5-6-
8-9-18
), 1.82-1.69 (6H, m, P-Me), 1.35 (9H, s, Boc), 1.51-1.20 (7H, H
15-16-17
 and NH), 1.22 
(6H, m, CH3(Et)); P (CDCl3) +39.4; m/z (HRMS+) 955.4622 [M + H]
+
 (C51H69N6O8P2 
requires 955.4652); Rf = 0.51 (silica, DCM : 20% MeOH). 
Triethyl-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-
diyl)tris(methylphosphinate), 20a 
 
tert-Butyl-4-((S)-1,4,7-tris((6-(ethoxy(methyl)phosphoryl)-4-((4-
methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-triazacyclononan-2-yl)butylcarbamate, 20 
(12.0 mg, 9.4 mol) was dissolved in dry DCM (0.8 mL). Argon was bubbled for 10 min after 
which time TFA (0.2 mL) was added. The solution was stirred for 15 min and the solvent was 
removed under reduced pressure to give the trifluoroacetate salt as a sticky yellow oil (12.0 
mg, quantitative yield); H (CDCl3) 7.93 (3H, m, H
12
), 7.46 (9H, m H
11
 and H
13
), 6.88 (6H, m, 
H
14
), 4.15-3.84 (12H, m, P-OCH2 and H
10
), 3.76 (9H, m, OMe), 3.00-2.71 (13H, m, H
2-3-5-6-8-
9-18
), 1.80-1.75 (9H, m, P-Me), 1.42-1.23 (7H, H
15-16-17
 and NH), 1.25 (9H, m, CH3(Et)); P 
(CDCl3) +39.7; m/z (HRMS+) 1182.518 [M + H]
+
 (C64H79N7O9P3 requires 1182.515). 
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Europium (III) complexes of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-
6,2-diyl)tris(methylphosphinate), [EuL
14
]
+
 
 
Triethyl 6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-
diyl)tris(methylphosphinate), 20a (25.0 mg, 21 mol) was dissolved in CD3OD (3 mL) and a 
solution of NaOH in D2O (0.1 M, 1 mL) was added. The mixture was heated to 60 °C under 
argon and monitored with 
31
P-NMR [P(reactant) = + 39.7, P(product) = + 27.8]. After 5 h 
the solution was cooled to RT and the pH was adjusted to 7 with HCl. Eu(AcO)3H2O (7.6 mg, 
23mol) was added and the mixture heated to 65 °C overnight under argon. The solvent was 
removed under reduced pressure and the product purified by purified by HPLC (Method A, tR 
= 9.2 min) giving a white solid (8.0 mg, 30 %); P (CD3OD) 43.5, 40.3, 36.6; m/z (HRMS+) 
1246.321 [M]
+
 (C58H64
153
EuN7O9P3 requires 1246.318);  H2O = 1.00 ms; max (H2O) = 328 nm; 
 = 58 mM-1 cm-1. 
 
Method B, tR = 9.5 min 
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00
%
0
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00
A
U
-1.0e+1
0.0
1.0e+1
2.0e+1
1Oct12_MD049 pure 3: Diode Array 
Range: 4.408e+19.50
1.33
0.11 8.88
1Oct12_MD049 pure 1: Scan ES+ 
TIC
1.62e8
8.76
8.13
13.54
9.39 12.03
11.68
11.03
9.86 10.91
12.32
12.52
12.77
14.96
14.23
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Methyl 2-(4-bromophenoxy)acetate, 22  
 
2-(4-Bromophenoxy)acetic acid, 22a (1.0 g, 4.3 mmol) was dissolved in methanolic HCl (3 
M, 3 mL) and stirred at RT for 20 h. The solvent was removed under reduced pressure, the 
resulting oil was dissolved in DCM (15 mL) and sequentially washed with H2O, saturated 
aqueous NaHCO3 and H2O, then dried over MgSO4, filtered and the solvent removed under 
reduced pressure giving a clear oil (1.0 mg, 95 %); H (CDCl3) 7.31 (2H, d, 
3
JH-H 8.5 Hz, H
3
), 
6.78 (2H, d, 
3
JH-H 8.5 Hz, H
2
), 4.55 (2H, s, H
7
), 3.80 (3H, s, Me), NMR data are in good 
agreement with those previously reported;
136
 Rf = 0.65 (silica, EtOAc : Hex 1 : 1).
 
Methyl 2-(4-ethynylphenoxy)acetate, 23  
 
Methyl-(4-bromophenoxy)acetate, 22 (1.20 g, 4.89 mmol) was dissolved in anhydrous THF (2 
mL) and the solution was degassed (freeze-thaw cycle) three times. Ethynyltrimethylsilane 
(0.83 mL, 5.87 mmol) and triethylamine (3.40 mL, 24.5 mmol) were added and the solution 
was degassed (2 freeze-thaw cycles) once more. [1,1-
Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.41 g, 0.489 mmol) and CuI (93 
mg, 0.489 mmol) were added and the resulting brown solution was stirred at 65  °C under 
argon for 24 h. The solvent was removed under reduced pressure and the resulting brown oil 
was purified by column chromatography (silica, Hex : DCM 3 : 1 to 1 : 1) to give methyl 2-
(4-((trimethylsilyl)ethynyl)phenoxy)acetate as a yellow oil (0.76 g, 60 %); Rf = 0.47 (silica, 
Hex : EtOAc 4 : 1). This material (140 mg, 0.54 mmol) was dissolved in anhydrous THF (2 
mL) and triethylamine trihydrofluoride (0.870 mL, 5.35 mmol) was added. The mixture was 
stirred at 35 °C under argon for 24 h. The solvent was removed under reduced pressure to 
give a yellow oil which was subjected to column chromatography (silica, Hex : DCM 3 : 1), 
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giving a colourless oil (89 mg, 87 %); H (CDCl3) 7.43 (2H, d, 
3
JH-H 9 Hz, H
4
), 6.85 (2H, d, 
3
JH-H 9 Hz, H
5
), 4.64 (2H, s, H
7
), 3.80 (3H, s, H
9
), 3.00 (1H, s, H
1
); C (CDCl3) 169.1 (s, C
8
), 
158.2 (s, C
6
), 133.8 (s, C
4
), 115.6 (s, C
3
), 114.7 (s, C
5
), 83.4 (s, C
2
), 76.3 (s, C
1
), 65.3 (s, C
7
), 
52.5 (s, C
9
); MS (ESI) m/z 189 [M-H]
-
;
d
 Rf = 0.39 (silica, Hex : EtOAc 4 : 1). 
Methyl 2-(4-((2-(ethoxy(methyl)phosphoryl)-6-(hydroxymethyl)pyridin-4-
yl)ethynyl)phenoxy)acetate, 24 
 
To a stirred degassed solution of ethyl (6-(hydroxymethyl)-4-(bromopyridin-2-
yl)(methyl)phosphinate, 14 (103 mg, 0.351 mmol) in anhydrous THF (1 mL) was added 
methyl 2-(4-ethynylphenoxy)acetate, 23 (80 mg, 0.421 mmol) and triethylamine (0.245 mL, 
1.75 mmol), and the solution was degassed (freeze-thaw cycle) three times. [1,1-
Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (30 mg, 0.035 mmol) and CuI (7 mg, 
0.035 mmol) were added and the resulting brown solution was stirred at 65 °C under argon 
for 18 h. The solvent was removed under reduced pressure and the brown residue was purified 
by column chromatography (silica, DCM : MeOH 1 to 3%) to afford a yellow oil (122 mg, 87 
%); H (CDCl3) 7.98 (1H, br s, H
3
), 7.50 (1H, br s, H
5
), 7.45 (2H, d, 
3
JH-H 9 Hz, H
14
), 6.88 
(2H, d, 
3
JH-H 9 Hz, H
15
), 4.80 (2H, s, H
7
), 4.65 (2H, s, H
17
), 4.09 (1H, m, H
9
), 3.99 (1H, br s, 
CH2OH), 3.86 (1H, m, H
9
), 3.79 (3H, s, H
19
), 1.76 (3H, d, 
2
JH-P 15 Hz, H
8
), 1.26 (3H, t, 
3
JH-H 
7 Hz, H
10
); C (CDCl3) 168.9 (s, C
18
), 161.0 (d,
 3
JC-P 19 Hz, C
6
), 158.8 (s, C
16
), 153.3 (d, 
1
JC-P 
155 Hz, C
2
), 133.8 (s, C
14
), 132.9 (d, 
3
JC-P 12 Hz, C
4
), 128.1 (d, 
2
JC-P 22 Hz, C
3
), 124.2 (s, C
5
), 
115.1 (s, C
13
), 115.0 (s, C
15
), 95.7 (s, C
12
), 85.6 (s, C
11
), 65.2 (s, C
17
), 64.3 (s, C
7
), 61.3 (d, 
2
JC-
P 5 Hz, C
9
), 52.5 (s, C
19
), 16.5 (d, 
3
JC-P 4 Hz, C
10
), 13.5 (d, 
1
JC-P 104 Hz, C
8
); P (CDCl3) 
+39.5; m/z (HRMS+) 426.1063 [M + Na]
+
 (C20H22NO6PNa requires 426.1082); Rf = 0.44 
(silica, DCM : 10% MeOH).  
                                                          
d
 HRMS could not be obtained due to low ionisation 
Chapter 7: Experimental 
 
151 
 
Methyl 2-(4-((2-(ethoxy(methyl)phosphoryl)-6-((methylsulfonyloxy)methyl)pyridin-4-
yl)ethynyl)phenoxy)acetate, 25 
 
Methyl 2-(4-((2-(ethoxy(methyl)phosphoryl)-6-(hydroxymethyl)pyridin-4-
yl)ethynyl)phenoxy)acetate, 24 (122 mg, 0.30 mmol) was dissolved in anhydrous THF (3 mL) 
and NEt3 (0.15 mL, 1.0 mmol) was added. The mixture was stirred at 5 °C and 
methanesulfonyl chloride (35 μL, 0.45 mmol) was added. The reaction was monitored by 
TLC (silica; DCM : 10 % MeOH, Rf(product) = 0.70, Rf(reactant) = 0.44) and stopped after 15 
min. The solvent was removed under reduced pressure and the residue dissolved in DCM (15 
mL) and washed with NaCl solution (saturated, 10 mL). The aqueous layer was re-extracted 
with DCM (3 × 10 mL) and the organic layers combined, dried over MgSO4 and the solvent 
removed under reduced pressure to leave a colourless oil (115 mg, 80 %); H (CDCl3) 8.08 
(1H, br s, H
3
), 7.63 (1H, br s, H
5
), 7.48 (2H, d, 
3
JH-H 9 Hz, H
14
), 6.90 (2H, d, 
3
JH-H 9 Hz, H
15
), 
5.35 (2H, s, H
7
), 4.66 (2H, s, H
17
), 4.12 (1H, m, H
9
), 3.87 (1H, m, H
9
), 3.80 (3H, s, H
19
), 3.10 
(3H, s, H
20
), 1.76 (3H, d, 
2
JH-P 15 Hz, H
8
), 1.26 (3H, t, 
3
JH-H 7 Hz, H
10
); P (CDCl3) +38.2; 
m/z (HRMS+) 504.0859 [M + Na]
+
 (C21H24NO8PSNa requires 504.0858); Rf = 0.56 (silica, 
DCM : 10% MeOH). 
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Methyl 2-(4-((2-(((S)-2-(4-(tert-butoxycarbonylamino)butyl)-4,7-bis((6-
(ethoxy(methyl)phosphoryl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-
triazacyclononan-1-yl)methyl)-6-(ethoxy(methyl)phosphoryl)pyridin-4-
yl)ethynyl)phenoxy)acetate, 26 
 
Methyl 2-(4-((2-(ethoxy(methyl)phosphoryl)-6-((methylsulfonyloxy)methyl)pyridin-4-
yl)ethynyl)phenoxy)acetate, 25 (8.0 mg, 17mol)  and tert-butyl 4-((S)-4,7-bis((6-
(ethoxy(methyl)phosphoryl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-
triazacyclononan-2-yl)butylcarbamate, 21 (14.0 mg, 15 mol) were dissolved in anhydrous 
CH3CN (0.7 mL) and K2CO3 (2.0 mg, 17mol) was added. The mixture was stirred under 
argon at 60 °C for 24 h, after which time, the reaction was cooled and the solution decanted 
from excess potassium salts. The solvent was removed under reduced pressure to give a 
yellow oil that was used in the next step without further purification (19.0 mg, 95 %); H 
(CDCl3) 7.92 (3H, m, H
12
), 7.43 (9H, m H
11
 and H
13
), 6.83 (6H, m, H
14
), 5.04 (1H, br, 
CONH), 4.59 (2H, s, H
19
), 4.06-3.77 (12H, m, P-OCH2 and H
10
), 3.75 (9H, m, OMe and 
CO2Me), 3.00-2.55 (13H, m, H
2-3-5-6-8-9-18
), 1.74-1.66 (9H, m, P-Me), 1.33 (9H, s, Boc), 1.35-
1.16 (6H, H
15-16-17
), 1.19 (9H, m, CH3(Et)); P (CDCl3) +41.1; m/z (HRMS+) 1340.573 [M + 
H]
+
 (C71H89N7O13P3 requires 1340.573). 
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Europium (III) complex of 2-(4-((2-(((S)-2-(4-(tert-butoxycarbonylamino)butyl)-4,7-
bis((6-((R)-hydroxy(methyl)phosphoryl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-
yl)methyl)-1,4,7-triazacyclononan-1-yl)methyl)-6-((R)-
hydroxy(methyl)phosphoryl)pyridin-4-yl)ethynyl)phenoxy)acetate, 27 
 
Methyl 2-(4-((2-(((S)-2-(4-(tert-butoxycarbonylamino)butyl)-4,7-bis((6-
(ethoxy(methyl)phosphoryl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-
triazacyclononan-1-yl)methyl)-6-(ethoxy(methyl)phosphoryl)pyridin-4-
yl)ethynyl)phenoxy)acetate, 26 (7.0 mg, 5.2 mol) was dissolved in CD3OD (1.5 mL) and a 
solution of NaOH in D2O (0.1 M, 0.5 mL) was added. The mixture was heated to 60 °C under 
argon and monitored using 
31
P-NMR [P(reactant) = + 39.7, (P(product) = + 27.8]. After 16 h 
the solution was cooled to RT and the pH was adjusted to 7 with HCl. Eu(AcO)3H2O (1.8 mg, 
5.7mol) was added and the mixture heated to 65 °C overnight under argon. The solvent was 
removed under reduced pressure and the product purified by HPLC (Method D, tR = 8.6 min) 
giving the ammonium salt as white solid (2.2 mg, 30 %); m/z (ESI) 1390.4 [MH + H]
+eH2O 
= 1.06 ms; max(H2O) = 328 nm;  = 58 mM
-1
 cm
-1
. 
 
 
 
 
 
                                                          
e
 HRMS could not be obtained due to low ionisation 
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Europium (III) complex of 3-(2-(4-((2-(((S)-2-(4-aminobutyl)-4,7-bis((6-((R)-
hydroxy(methyl)phosphoryl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-
triazacyclononan-1-yl)methyl)-6-((R)-hydroxy(methyl)phosphoryl)pyridin-4-
yl)ethynyl)phenoxy)acetamido)propane-1-sulfonate, [EuL
15
] 
 
The europium(III) complex of 2-(4-((2-(((S)-2-(4-(tert-butoxycarbonylamino)butyl)-4,7-
bis((6-(hydroxy(methyl)phosphoryl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-
1,4,7-triazacyclononan-1-yl)methyl)-6-((hydroxy(methyl)phosphoryl)pyridin-
4yl)ethynyl)phenoxy)acetate, 27 (0.35 mg, 0.25 mol) was dissolved in dry DMF (50 L) and 
10 L of a solution of PyBOP (2.00 mg, 3.75 mol) in dry DMF (100 L) was added.  A 
solution of DIPEA (2.2 L, 13 mol) in DMF (100 L) was prepared and 5 L of that 
solution was added to the reaction.  The mixture was stirred for 5 min under argon after which 
time 10 L of a solution of homotaurine (0.50 mg, 3.75 mol) in H2O (100 L) was added. 
After 16 h, the solvent was removed under reduced pressure giving a white solid (quantitative 
conversion by ESI-MS, m/z 1511 [M]
-
). The white solid was dissolved in dry DCM (95 L) 
under argon at 4 °C and TFA (5 L) was added. The mixture was stirred for 20 min after 
which time the solvent was removed under reduced pressure. The product was purified by 
HPLC (Method E, tR = 8.5 min) giving a white solid (0.30 mg, 85 %); m/z (HRMS-) 1409.311 
[M - H]
-
 (C62H69O13N8
151
EuP3S requires 1409.312); H2O = 1.08 ms; max(H2O) = 328 nm;  = 
58 mM
-1
 cm
-1
. 
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Method B, tR = 5.5 min 
Trimethyl 2,2',2''-(4,4',4''-6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(2-(ethoxy(methyl)phosphoryl)pyridine-
6,4-diyl)tris(ethyne-2,1-diyl)tris(benzene-4,1-diyl)tris(oxy))triacetate, 28 
 
(S)-tert-Butyl 4-(1,4,7-triazacyclononan-2-yl)butylcarbamate, 17 (23 mg, 0.075 mmol) and 
methyl 2-(4-((2-(ethoxy(methyl)phosphoryl)-6-((methylsulfonyloxy)methyl)pyridin-4-
yl)ethynyl)phenoxy)acetate, 25  (105 mg, 0.22 mmol), were dissolved in anhydrous CH3CN 
(4 mL) and K2CO3 (32 mg, 0.23 mmol) was added. The mixture was stirred under argon at 60 
°C for 18 h. The reaction was cooled and the solution decanted from excess potassium salts. 
The solvent was removed under reduced pressure and the crude material purified by column 
chromatography (silica, DCM : MeOH 0 to 20 %) to give a yellow oil (45 mg, 41 %): H 
(CDCl3) 7.99 (3H, m, H
12
), 7.49 (9H, m H
11
 and H
13
), 6.90 (6H, m, H
14
), 5.10 (1H, br, 
CONH), 4.67 (6H, s, H
19
), 4.12-3.86 (12H, m, P-OCH2 and H
10
), 3.82 (9H, m, CO2Me), 3.12-
2.90 (13H, m, H
2-3-5-6-8-9-18
), 1.85-1.70 (9H, m, P-Me), 1.41 (9H, s, Boc), 1.45-1.28 (6H, H
15-
16-17
), 1.27 (9H, m, CH3(Et)); P (CDCl3) +40.4; m/z (HRMS+) 728.7949 [M + 2H]
2+
 
(C75H94N7O17P3 requires 728.7960); Rf = 0.50 (silica; DCM : 20% MeOH). 
Time
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00
AU
-1.0e+1
0.0
1.0e+1
2.0e+1
3.0e+1
4.0e+1
5.0e+1
6.0e+1
24Oct12_MD055 3: Diode Array 
Range: 8.407e+15.50
1.32
1.59
4.12
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Trimethyl 2,2',2''-(4,4',4''-(6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(2-(ethoxy(methyl)phosphoryl)pyridine-6,4-diyl))tris(ethyne-2,1-
diyl)tris(benzene-4,1-diyl))tris(oxy)triacetate, 28a 
 
Trimethyl 2,2',2''-(4,4',4''-6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(2-(ethoxy(methyl)phosphoryl)pyridine-6,4-
diyl)tris(ethyne-2,1-diyl)tris(benzene-4,1-diyl)tris(oxy))triacetate, 28 (30 mg, 20 mol), was 
dissolved in dry DCM (1.8 mL). Argon was bubbled for 10 min after which time TFA (0.2 
mL) was added at 4 °C. The solution was allowed to warm up to RT and stirred for 15 min. 
The solvent was removed under reduced pressure to give the trifluoroacetate salt as a yellow 
oil (27 mg, quantitative yield); H (CDCl3) 7.91 (3H, m, H
12
), 7.51 (9H, m H
11
 and H
13
), 6.92 
(6H, m, H
14
), 4.67 (6H, s, H
19
), 4.16-3.97 (12H, m, P-OCH2 and H
10
), 3.81 (9H, m, CO2Me), 
3.12-2.90 (13H, m, H
2-3-5-6-8-9-18
), 1.89-1.75 (9H, m, P-Me), 1.45-1.32 (8H, H
15-16-17
 and NH2), 
1.29 (9H, m, CH3(Et)); P (CDCl3) +41.2; m/z (HRMS+) 1356.533 [M + H]
+
 (C70H85O15N7P3 
requires 1356.531). 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-(carboxymethoxy)phenyl)ethynyl)pyridine-6,2-
diyl)tris(methylphosphinate), [EuL
16
]
2-
 
 
Trimethyl 2,2',2''-(4,4',4''-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(2-((ethoxy(methyl)phosphoryl)pyridine-6,4-diyl)tris(ethyne-2,1-
diyl)tris(benzene-4,1-diyl))tris(oxy)triacetate, 28a (27 mg, 20 mol) was dissolved in CD3OD 
(3 mL) and a solution of NaOH in D2O (0.1 M, 1.5 mL) was added. The mixture was heated 
to 60 °C under argon and monitored with 
31
P-NMR [P(reactant) = + 41.2, (P(product) = + 
25.6]. After 5 h the solution was cooled to RT and the pH was adjusted to 7 with HCl. 
Eu(AcO)3H2O (7 mg, 21mol) was added and the mixture heated to 65 °C overnight under 
argon. The solvent was removed under reduced pressure and the product purified by HPLC 
(Method F, tR = 9.6 min) giving a white solid (11 mg, 40 %); m/z (ESI) 690.6 [MH2 + 2H]
2+
;
f
 
 H2O = 1.05 ms; max(H2O) = 330 nm;  = 57 mM
-1
 cm
-1
. 
 
 
 
 
                                                          
f
 HRMS could not be obtained due to low ionisation 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
(carboxymethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(methylphosphinate), 29 
 
Trimethyl 2,2',2''-(4,4',4''-6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(2-(ethoxy(methyl)phosphoryl)pyridine-6,4-
diyl)tris(ethyne-2,1-diyl)tris(benzene-4,1-diyl)tris(oxy))triacetate, 28 (10.0 mg, 6.8 mol) was 
dissolved in CD3OD (2 mL) and a solution of NaOH in D2O (0.1 M, 1 mL) was added. The 
mixture was heated to 60 °C under argon and monitored with 
31
P-NMR [P(reactant) = + 40.4, 
(P(product) = + 26.7]. After 5 h the solution was cooled to RT and the pH was adjusted to 7 
with HCl. Eu(AcO)3H2O (1.8 mg, 5.7mol) was added and the mixture heated to 65 °C 
overnight under argon. The solvent was removed under reduced pressure and the product 
purified by HPLC (Method F, tR = 11.8 min) giving a white solid (6.0 mg, 59 %); m/z (ESI) 
740.2 [MH3 + 2H]
2+
;  H2O = 1.05 ms; max(H2O) = 330 nm;  = 57 mM
-1
 cm
-1
. 
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Eu(III) complex of 6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
(2-oxo-2-(3-sulfopropylamino)ethoxy)phenyl)ethynyl)pyridine-6,2-
diyl)tris(methylphosphinate), [EuL
17a
]
3-
 
 
The Eu(III) complex of 6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
(carboxymethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(methylphosphinate), [EuL
4
]
3-
 (0.5 
mg, 0.38 mol) and homotaurine (0.32 mg, 2.3 mol) were dissolved in a mixture of  DMSO 
(0.2 mL) and H2O (20 L). HATU (1.2 mg, 2.3 mol) and DIPEA (0.7 L, 3.8 mol) were 
added to the reaction and the mixture was stirred for 24 h under argon after which time LC-
MS showed complete conversion. The product was purified by HPLC (Method K, tR = 13.0 
min) giving the triethylammonium salt as a white solid (0.4 mg, 67 %); m/z (HRMS-) 
834.6254 [MH]
2-
 (C66H73
153
EuN9O21P3S3 requires 834.6257);  H2O = 1.01 ms; max(H2O) = 328 
nm;  = 57 mM-1 cm-1. 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-(2-oxo-2-(3-
sulfopropylamino)ethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(methylphosphinate), 30 
 
The Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
(carboxymethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(methylphosphinate), 29 (7.1 mg, 4.8 
mol) and homotaurine (4.0 mg, 28.8 mol) were dissolved in dry DMSO (1 mL). HATU 
(5.4 mg, 14.4 mol) and DIPEA (9 L, 48 mol) were added to the reaction and the mixture 
was stirred for 1 h under argon after which time LC-MS showed complete conversion. The 
product was purified by HPLC (Method G, tR = 14.9 min) giving the triethylammonium salt 
as a white solid (6.6 mg, 70 %); m/z (HRMS+) 922.2045 [MH3 + 2H]
2+
 
(C75H94
153
EuN10O23P3S3 requires 922.2039).  H2O = 1.01 ms; max(H2O) = 328 nm;  = 57 mM
-1
 
cm
-1
. 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-(2-oxo-2-(3-
sulfopropylamino)ethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(methylphosphinate), 
[EuL
17
]
2-
 
 
The Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-(2-oxo-2-(3-
sulfopropylamino)ethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(methylphosphinate), 30 (6.6 
mg, 3.6 mol) was dissolved in dry DCM (0.8 mL). TFA (0.2 mL) was added and the mixture 
was stirred at RT for 20 min. The solvent was removed under reduced pressure to give the 
triethylammonium salt as a white solid (6.4 mg, quantitative yield); m/z (HRMS+) 872.1781 
[MH2 + 2H]
2+
 (C70H86
153
EuN10O21P3S3 requires 872.1776);  H2O = 1.00 ms; max (H2O) = 328 
nm;  = 57 mM-1 cm-1.  
 
Method G, tR = 4.5 min 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(4-carboxybutanamido)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-
6,2-diyl)tris(methylphosphinate), [EuL
14
]-glu
-
 
 
The Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-
diyl)tris(methylphosphinate), [EuL
14
]
+
 (0.80 mg, 0.65 mol), was dissolved in dry DMF (400 
L). Glutaric anhydride (0.10 mg, 0.65 mol) and DIPEA (4 L) were added and the reaction 
was stirred at RT for 1 h. The product was purified by HPLC (Method H, tR = 14.2 min) 
giving a white solid (0.54 mg, 61 %); m/z (ESI) 1361.9 [MH + H]
+
. 
Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(5-(2,5-dioxopyrrolidin-1-yloxy)-5-
oxopentanamido)butyl)-1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(methylphosphinate), [EuL
14
]-glu-NHS 
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The Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(4-carboxybutanamido)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-
diyl)tris(methylphosphinate), [EuL
14
]-glu
-
 (0.54 mg, 0.40 mol) was dissolved in dry DMF 
(400 L). TSTU (0.15 mg, 0.48 mol) and DIPEA (4 L) were added and the reaction was 
stirred at RT for 15 min. The product was purified by HPLC (Method H, tR = 15.2 min) giving 
a white solid (0.38 mg, 65 %); m/z (ESI) 1458.3 [M + H]
+
. 
Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(5-(4-(4-((2-Amino-9H-purin-6-
yloxy)methyl)benzylcarbamoyl)benzylamino)-5-oxopentanamido)butyl-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-
6,2-diyl)tris(methylphosphinate), [EuL
14
]-glu-MB-BG 
 
To a solution of the Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(5-(2,5-dioxopyrrolidin-1-
yloxy)-5-oxopentanamido)butyl)-1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-
((4-methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(methylphosphinate), [EuL
14
]-glu-NHS 
(0.20 mg, 140 nmol) in dry DMSO (100 μL) was added BG-MB-NH2 (0.26 mg, 500 nmol) 
and DIPEA (1 μL). The mixture was stirred at room temperature for 1 h. After this period, the 
reaction was completed. The mixture was purified by preparative HPLC (Method H, tR = 11.9 
min) to give a white solid (50 nmol, 37 %). m/z (HRMS+) 874.2626 [M + 2H]
2+
 
(C84H90
153
EuN14O13P3 requires 874.2618). 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(5-(4-(4-((2-Amino-9H-purin-6-
yloxy)methyl)benzylcarbamoyl)benzylamino)-5-oxopentanamido)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
(carboxymethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(methylphosphinate),  
[EuL
16
]-glu-MB-BG 
 
The Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-(carboxymethoxy)phenyl)ethynyl)pyridine-6,2-
diyl)tris(methylphosphinate), [EuL
16
]
2-
 (0.27 mg, 0.20 mol) and BG-MB-glu-NHS (0.12 
mg, 0.20 mol) were dissolved in DMSO (0.7 mL) and DIPEA (2 L) was added. The 
reaction was stirred at RT for 1 h, after which time, more BG-MB-glu-NHS (0.30 mg, 0.50 
mol) was added. After 1 h the same addition BG-MB-glu-NHS (0.30 mg, 0.50 mol) was 
repeated and the reaction was stirred for 1 h after which time LC-MS showed complete 
conversion. The product was purified by HPLC (Method G, tR = 9.3 min) giving a white solid 
(0.30 mg, 80 %); m/z (ESI) 940.4 [MH3 + 2H]
2+
.
g
 
 
 
 
 
                                                          
g
 HRMS could not be obtained due to low ionisation 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(5-(4-(4-((2-Amino-9H-purin-6-
yloxy)methyl)benzylcarbamoyl)benzylamino)-5-oxopentanamido)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-(2-oxo-2-(3-
sulfopropylamino)ethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(methylphosphinate), 
[EuL
17
]-glu-MB-BG 
 
The Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-(2-oxo-2-(3-sulfopropylamino)ethoxy)phenyl)ethynyl)pyridine-
6,2-diyl)tris(methylphosphinate), [EuL
17
]
2-
 (0.90 mg, 0.52 mol) and BG-MB-glu-NHS (0.30 
mg, 0.50 mol) were dissolved in phosphate buffer (0.05 M, pH = 8, 0.7 mL) and DMSO (0.3 
mL). The reaction was stirred overnight after which time LC-MS showed 85 % conversion. 
The product was purified by HPLC (Method H, tR = 7.5 min) giving a white solid (0.99 mg, 
85 %); m/z (HRMS+) 748.1867 [MH3 + 3H]
3+
 (C96H112
153
EuN17O25P3S3 requires 748.1866). 
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Methyl 2-(4-((2-(ethoxy(phenyl)phosphoryl)-6-(hydroxymethyl)pyridin-4-
yl)ethynyl)phenoxy)acetate, 32 
 
To a stirred degassed solution of ethyl (6-(hydroxymethyl)-4-(bromopyridin-2-
yl)(phenyl)phosphinate, 31 (234 mg, 0.650 mmol) in anhydrous THF (2.5 mL) was added 
methyl 2-(4-ethynylphenoxy)acetate, 23 (185 mg, 0.980 mmol) and triethylamine (1.5 mL), 
and the solution was degassed (freeze-thaw cycle) three times. [1,1-
Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (62 mg, 0.065 mmol) and CuI (10 
mg, 0.065 mmol) were added and the resulting brown solution was stirred at 65 °C under 
argon for 18 h. The solvent was removed under reduced pressure and the brown residue was 
purified by column chromatography (silica, DCM : MeOH 1 to 2%) to afford a yellow oil 
(226 mg, 75 %); H (CDCl3) 8.06 (1H, d, 
3
JH-P 6 Hz, H
3
), 7.95 (2H, dd,
 3
JH-P 12 Hz,
 3
JH-H 7.5 
Hz, H
20
), 7.53 (1H, t, 
3
JH-H 7.5 Hz, H
22
), 7.45 (4H, m, H
14-21
), 7.39 (1H, s, H
5
), 6.87 (2H, d, 
3
JH-H 9 Hz, H
15
), 4.75 (2H, s, H
7
), 4.66 (2H, s, H
17
), 4.16 (2H, m, H
9
), 3.80 (3H, s, H
19
), 3.54 
(1H, br, OH), 1.37 (3H, t, 
3
JH-H 7 Hz, H
10
); C (CDCl3) 168.8 (s, C
18
), 161.3 (d,
 3
JC-P 19 Hz, 
C
6
), 158.7 (s, C
16
), 153.3 (d, 
1
JC-P 164 Hz, C
2
), 133.7 (s, C
14
), 132.9 (d, 
3
JC-P 12 Hz, C
4
), 132.8 
(d, 
4
JC-P 3 Hz, C
22
), 132.6 (d, 
4
JC-P 2.5 Hz, C
20
), 129.6 (d, 
1
JC-P 140.5 Hz, C
8
), 128.7 (d, 
2
JC-P 
22 Hz, C
3
), 128.5 (d, 
3
JC-P 13 Hz, C
21
), 125.8 (s, C
13
), 123.9 (s, C
5
), 115.0 (s, C
15
), 95.6 (s, 
C
12
), 85.5 (s, C
11
), 65.1 (s, C
17
), 63.8 (s, C
7
), 61.9 (d, 
2
JC-P 6 Hz, C
9
), 52.4 (C
19
), 16.5 (d, 
3
JC-P 
6 Hz, C
10
); P (CDCl3) +25.4; m/z (HRMS+) 466.1398 [M + H]
+
 (C25H25NO6P requires 
466.1420); Rf = 0.50 (silica; DCM : 3 % MeOH).  
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Methyl 2-(4-((2-(ethoxy(phenyl)phosphoryl)-6-((methylsulfonyloxy)methyl)pyridin-4-
yl)ethynyl)phenoxy)acetate, 33 
 
Methyl 2-(4-((2-(ethoxy(phenyl)phosphoryl)-6-(hydroxymethyl)pyridin-4-
yl)ethynyl)phenoxy)acetate, 32 (120 mg, 0.25 mmol) was dissolved in anhydrous THF (2.5 
mL) and NEt3 (92 L, 0.75 mmol) was added. The mixture was stirred at 5 °C and 
methanesulfonyl chloride (25 μL, 0.38 mmol) was added. The reaction was monitored by 
TLC (silica; DCM : 3 % MeOH, Rf(product) = 0.58, Rf(reactant) = 0.50) and stopped after 15 
min. The solvent was removed under reduced pressure and the residue dissolved in DCM (15 
mL) and washed with NaCl solution (saturated, 10 mL). The aqueous layer was re-extracted 
with DCM (3 × 10 mL) and the organic layers combined, dried over MgSO4 and the solvent 
removed under reduced pressure to leave a colourless oil (130 mg, 93 %); H (CDCl3) 8.13 
(1H, dd, 
3
JH-P 6 Hz, 
4
JH-H 1.5 Hz, H
3
), 7.93 (2H, m, H
20
), 7.56 (1H, m, H
22
), 7.48 (5H, m, H
5-
14-21
), 6.89 (2H, d, 
3
JH-H 9 Hz, H
15
), 5.32 (2H, s, H
7
), 4.67 (2H, s, H
17
), 4.15 (2H, m, H
9
), 3.82 
(3H, s, H
19
), 3.01 (3H, s, Ms), 1.38 (3H, t, 
3
JH-H 7 Hz, H
10
); P (CDCl3) +24.8; m/z (HRMS+) 
544.1188 [M + H]
+
 (C26H27NO8PS requires 544.1195); Rf = 0.58 (silica; DCM : 3 % MeOH). 
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Trimethyl 2,2',2''-(4,4',4''- 6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(2-(ethoxy(phenyl)phosphoryl)pyridine-
6,4-diyl)tris(ethyne-2,1-diyl)tris(benzene-4,1-diyl)tris(oxy))triacetate, 34 
 
(S)-tert-Butyl 4-(1,4,7-triazacyclononan-2-yl)butylcarbamate, 17 (24 mg, 0.08 mmol) and 
methyl 2-(4-((2-(ethoxy(phenyl)phosphoryl)-6-((methylsulfonyloxy)methyl)pyridin-4-
yl)ethynyl)phenoxy)acetate, 33  (130 mg, 0.24 mmol), were dissolved in anhydrous CH3CN 
(4 mL) and K2CO3 (33 mg, 0.24 mmol) was added. KI (0.1 mg) was added to the reaction and 
the mixture was stirred under argon at 60 °C for 3 h. The reaction was cooled and the solution 
decanted from excess potassium salts to give a yellow oil (68 mg, 52 %): H (CDCl3) 8.02 
(9H, m, H
3-20
), 7.53 (18H, m, H
5-14-21-22
), 6.94 (6H, m, H
15
), 5.10 (1H, br, CONH), 4.64 (6H, 
s, H
17
), 4.11 (6H, m, H
9
), 3.96 (6H, s, H
7
), 3.79 (9H, s, CO2Me), 2.82 (14H, br, 9N3 and H
26
), 
1.41 (9H, s, Boc), 1.45-1.28 (6H, H
23-24-25
), 1.39 (9H, m, H
10
); P (CDCl3) +25.3; m/z 
(HRMS+) 1642.627 [M + H]
+
 (C90H98N7O17P3 requires 1642.631). 
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Trimethyl 2,2',2''-(4,4',4''-(6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(2-(ethoxy(phenyl)phosphoryl)pyridine-6,4-diyl))tris(ethyne-2,1-
diyl)tris(benzene-4,1-diyl))tris(oxy)triacetate, 35 
 
Trimethyl 2,2',2''-(4,4',4''-6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(2-(ethoxy(phenyl)phosphoryl)pyridine-6,4-
diyl)tris(ethyne-2,1-diyl)tris(benzene-4,1-diyl)tris(oxy))triacetate, 34 (23 mg, 14 mol), was 
dissolved in dry DCM (1.8 mL). Argon was bubbled for 10 min after which time TFA (0.2 
mL) was added at 4 °C. The solution was allowed to warm up to RT and stirred for 15 min. 
The solvent was removed under reduced pressure to give the trifluoroacetate salt as a yellow 
oil (21 mg, 97 %); H (CDCl3) 8.05 (9H, m, H
3-20
), 7.56 (18H, m, H
5-14-21-22
), 6.99 (6H, m, 
H
15
), 4.67 (6H, s, H
17
), 4.11 (6H, m, H
9
), 3.96 (6H, s, H
7
), 3.81 (9H, s, CO2Me), 2.95 (14H, 
br, 9N3 and H
26
), 1.45-1.28 (8H, H
23-24-25 
and NH2), 1.34 (9H, m, H
10
); P (CDCl3) +26.6; m/z 
(HRMS+) 771.7914 [M + 2H]
2+
 (C85H90N7O15P3 requires 771.7932). 
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Trimethyl 2,2',2''-(4,4',4''-(6,6',6''-(1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(2-(ethoxy(phenyl)phosphoryl)pyridine-6,4-diyl))tris(ethyne-2,1-
diyl)tris(benzene-4,1-diyl))tris(oxy)triacetate, 36 
 
1,4,7-Triazacyclononane trihydrochloride (1.8 mg, 7.6 mol) and methyl 2-(4-((2-
(ethoxy(phenyl)phosphoryl)-6-((methylsulfonyloxy)methyl)pyridin-4-
yl)ethynyl)phenoxy)acetate, 33 (12 mg, 22 mol), were dissolved in anhydrous CH3CN (1 
mL) and K2CO3 (6.3 mg, 44 mol) was added. KI (0.1 mg) was added to the reaction and the 
mixture was stirred under argon at 60 °C for 3 h. The reaction was cooled and the solution 
decanted from excess potassium salts to give a yellow oil (10 mg, 89 %); H (CDCl3) 8.03 
(9H, m, H
3-20
), 7.53 (18H, m, H
5-14-21-22
), 6.92 (6H, d, 
3
JH-H 9 Hz, H
15
), 4.67 (6H, s, H
17
), 4.16 
(6H, m, H
9
), 3.96 (6H, s, H
7
), 3.82 (9H, s, CO2Me), 2.82 (12H, br, 9N3), 1.37 (9H, t, 
3
JH-H 7 
Hz, H
10
); C (CDCl3) 168.9 (s, C
18
), 160.3 (s, C
6
), 158.6 (s, C
16
), 153.3 (d, 
1
JC-P 163 Hz, C
2
), 
133.7 (s, C
14
), 132.9 (s, C
4
), 132.8 (s, C
22
), 132.5 (s, C
20
), 129.2 (d, 
1
JC-P 140.5 Hz, C
8
), 128.9 
(d, 
2
JC-P 16 Hz, C
3
), 128.5 (s, C
21
), 125.4 (s, C
13
), 124.0 (s, C
5
), 115.0 (s, C
15
), 95.6 (s, C
12
), 
85.6 (s, C
11
), 65.1 (s, C
17
), 63.8 (s, C
7
), 61.5 (s, C
9
), 55.4-54.7 (br, 9N3), 52.3 (CO2Me), 16.5 
(ds, C
10
); P (CDCl3) +25.4; m/z (HRMS+) 1471.504 [M + H]
+
 (C81H82N6O15P3 requires 
1471.501). 
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Eu(III) complex of 2,2',2''-(4,4',4''-(6,6',6''-(1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(2-(hydroxy(phenyl)phosphoryl)pyridine-6,4-diyl))tris(ethyne-
2,1-diyl)tris(benzene-4,1-diyl))tris(oxy)triacetate, [EuL
18a
]
3-
 
 
Trimethyl 2,2',2''-(4,4',4''-(6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(2-
(ethoxy(phenyl)phosphoryl)pyridine-6,4-diyl))tris(ethyne-2,1-diyl)tris(benzene-4,1-
diyl))tris(oxy)triacetate, 36 (7.0 mg, 4.8 mol) was dissolved in CD3OD (1 mL) and a 
solution of NaOH in D2O (0.1 M, 0.5 mL) was added. The mixture was heated to 60 °C under 
argon and reaction monitored by 
31
P-NMR [P(reactant) = + 25.4, (P(product) = + 14.9]. 
After 3 h the solution was cooled to RT and the pH was adjusted to 7 with HCl. 
Eu(OAc)3H2O (1.7 mg, 5mol) was added and the mixture heated to 65 °C overnight under 
argon. The solvent was removed under reduced pressure and the product purified by HPLC 
(Method J, tR = 14.4 min) giving a white solid (4.8 mg, 67 %); m/z (HRMS+) 747.1342 [MH3 
+ 2H]
2+
 (C72H60
151
EuN6O15P3 requires 747.1342);  H2O = 1.11 ms; max (H2O) = 330 nm;  = 58 
mM
-1
 cm
-1
. 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-(carboxymethoxy)phenyl)ethynyl)pyridine-6,2-
diyl)tris(phenylphosphinate), [EuL
18
]
2-
 
 
Trimethyl 2,2',2''-(4,4',4''-(6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(2-((ethoxy(phenyl)phosphoryl)pyridine-6,4-diyl)tris(ethyne-2,1-
diyl)tris(benzene-4,1-diyl))tris(oxy)triacetate, 35 (7 mg, 4.5 mol) was dissolved in CD3OD 
(3 mL) and a solution of NaOH in D2O (0.1 M, 1.5 mL) was added. The mixture was heated 
to 60 °C under argon and reaction monitored by 
31
P-NMR [P(reactant) = + 26.6, (P(product) 
= + 16.2]. After 5 h the solution was cooled to RT and the pH was adjusted to 7 with HCl. 
Eu(AcO)3H2O (1.6 mg, 5.0mol) was added and the mixture heated to 65 °C overnight under 
argon. The solvent was removed under reduced pressure and the product purified by HPLC 
(Method J, tR = 13.5 min) giving a white solid (3 mg, 43 %); m/z (HRMS+) 783.6727 [MH2 + 
2H]
2+
 (C76H69
153
EuN7O15P3 requires 783.6724);  H2O = 1.10 ms; max (H2O) = 330 nm;  = 58 
mM
-1
 cm
-1
. 
 
Method N, tR = 2.5 min 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
(carboxymethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(phenylphosphinate), 37 
 
Trimethyl 2,2',2''-(4,4',4''-6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(2-(ethoxy(phenyl)phosphoryl)pyridine-6,4-
diyl)tris(ethyne-2,1-diyl)tris(benzene-4,1-diyl)tris(oxy))triacetate, 34 (16.0 mg, 10 mol) was 
dissolved in CD3OD (2 mL) and a solution of NaOH in D2O (0.1 M, 1 mL) was added. The 
mixture was heated to 60 °C under argon and the reaction monitored by 
31
P-NMR 
[P(reactant) = + 25.3, (P(product) = + 14.9]. After 3 h, the solution was cooled to RT and the 
pH was adjusted to 7 with HCl. Eu(AcO)3H2O (3.6 mg, 10.1mol) was added and the 
mixture heated to 65 °C overnight under argon. The solvent was removed under reduced 
pressure and the product purified by HPLC (Method J, tR = 14.7 min) giving a white solid (8.8 
mg, 53 %); m/z (HRMS+) 1666.388 [MH3 + H]
+
 (C81H77
153
EuN7O17P3 requires 1666.389);  
H2O = 1.12 ms; max (H2O) = 330 nm;  = 58 mM
-1
 cm
-1
.  
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-(2-oxo-2-(3-
sulfopropylamino)ethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(phenylphosphinate), 38 
 
Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
(carboxymethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(phenylphosphinate), 37 (8.8 mg, 5.3 
mol) and homotaurine (4.4 mg, 31.8 mol) were dissolved a mixture of  DMSO (1 mL) and 
H2O (50 L). HATU (12.0 mg, 31.8 mol) and DIPEA (9 L, 53 mol) were added to the 
reaction and the mixture was stirred for 3 h under argon, after which time LC-MS showed 
complete conversion. The product was purified by HPLC (Method K, tR = 17.3 min) giving 
the triethylammonium salt as a white solid (8.1 mg, 76 %); m/z (HRMS-) 1013.211 [MH]
2-
 
(C90H98
153
EuN10O23P3S3 requires 1013.213); H2O = 1.11 ms; max (H2O) = 328 nm;  = 57 mM
-
1
 cm
-1
. 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-(2-oxo-2-(3-
sulfopropylamino)ethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(phenylphosphinate), 
[EuL
19
]
2-
 
 
Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(tert-butoxycarbonylamino)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-(2-oxo-2-(3-
sulfopropylamino)ethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(phenylphosphinate), 38 (21 
mg, 10 mol) was dissolved in dry DCM (1.7 mL). TFA (0.3 mL) was added and the mixture 
was stirred at RT for 20 min. The solvent was removed under reduced pressure and the 
product was purified by HPLC (Method K, tR = 16.4 min) giving the triethylammonium salt as 
a white solid (18 mg, 93 %); m/z (HRMS-) 963.1838 [M]
2-
 (C85H90
153
EuN10O21P3S3 requires 
963.1862);  H2O = 1.11 ms; max (H2O) = 328 nm;  = 57 mM
-1
 cm
-1
.  
 
Method M, tR = 4.5 min 
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Eu(III) complex of 6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
(2-oxo-2-(3-sulfopropylamino)ethoxy)phenyl)ethynyl)pyridine-6,2-
diyl)tris(phenylphosphinate), [EuL
19a
]
3-
 
 
The Eu(III) complex of 2,2',2''-(4,4',4''-(6,6',6''-(1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(2-(hydroxy(phenyl)phosphoryl)pyridine-6,4-diyl))tris(ethyne-2,1-
diyl)tris(benzene-4,1-diyl))tris(oxy)triacetate, [EuL
18a
]
3-
 (3.2 mg, 2.0 mol) and homotaurine 
(1.8 mg, 18 mol) were dissolved in a mixture of  DMSO (1 mL) and H2O (100 L). HATU 
(4.5 mg, 18 mol) and DIPEA (3.5 L, 20 mol) were added to the reaction and the mixture 
was stirred for 3 h under argon, after which time, LC-MS showed complete conversion. The 
product was purified by HPLC (Method K, tR = 17.4 min) giving a the triethylammonium salt 
as a white solid (2.3 mg, 62 %); m/z (HRMS-) 927.6472 [MH]
2-
 (C81H81
153
EuN9O21P3S3 
requires 927.6494);  H2O = 1.12 ms; max (H2O) = 328 nm;  = 57 mM
-1
 cm
-1
. 
 
Method M, tR = 4.7 min 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-(4-carboxybutanamido)butyl)-1,4,7-
triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-(2-oxo-2-(3-
sulfopropylamino)ethoxy)phenyl)ethynyl)pyridine-6,2-diyl)tris(phenylphosphinate), 
[EuL
19
]-glu
4-
 
 
The Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-(2-oxo-2-(3-sulfopropylamino)ethoxy)phenyl)ethynyl)pyridine-
6,2-diyl)tris(phenylphosphinate), [EuL
19
]
2-
 (17.0 mg, 8.8 mol), was dissolved in dry DMF (1 
mL). Glutaric anhydride (1.0 mg, 8.8 mol) and DIPEA (10 L, 52.8 mol) were added and 
the reaction was stirred at RT for 1 h. The product was purified by HPLC (Method K, tR = 
16.5 min) giving the triethylammonium salt as a white solid (16.5 mg, 92 %); m/z (HRMS-) 
1020.202 [M - 2H]
2-
 (C90H96
153
EuN10O24P3S3 requires 1020.202). 
 
Method M, tR = 4.4 min 
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2,2,2-Trifluoroethyl 4-bromobenzenesulfonate, 43 
 
4-Bromobenzenesulfonyl chloride, 42 (3.00 g, 11.7 mmol) was dissolved in DCM (20 mL) 
and trifluoroethanol (840 L, 11.7 mmol) was added. A solution of DABCO (1.50 g, 13.4 
mmol) in DCM (10 mL) was added resulting in precipitate formation. The reaction was stirred 
for 1 h at RT, after which time a solution of aqueous NaOH (1 M, 3 mL) was added. The 
reaction was diluted in EtOAc (100 mL) and washed with 0.5 M NaHCO3, 0.1 M HCl, water 
and brine. The organic layer was dried over MgSO4 and the solvent removed under reduced 
pressure to give a white solid (3.40 g, 91 %); m.p. 105 – 107 °C; anal. calc. for C8H6F3BrO3S: 
C, 30.11; H, 1.90 %; found: C, 30.15; H, 1.88 %; H (CDCl3) 7.77 (4H, m, H
2-3
), 4.40 (2H, q, 
3
JH-F 8 Hz, H
5
); C (CDCl3) 134.1 (C
1
), 133.1 (C
3
), 130.3 (C
4
), 129.7 (C
2
), 122.0 (q, 
1
JC-F 278 
Hz, CF3), 65.0 (q, 
2
JC-F 38 Hz, C
5
);F (CDCl3) -74.2 (t, 
3
JF-H 7 Hz); m/z (HRMS+) 340.9077 
[M + Na]
+
 (C8H6O3S
79
BrF3Na requires 340.9071); Rf = 0.58 (silica, EtOAc : Hex 2 : 8).  
Phenyl 4-bromobenzenesulfonate, 44 
 
4-Bromobenzenesulfonyl chloride, 42 (10.0 g, 39 mmol), was dissolved in DCM (40 mL) and 
phenol (3.7 g, 39 mmol) was added. A solution of DABCO (5.2 g, 46 mmol) in DCM (30 
mL) was added resulting in precipitate formation. The reaction was stirred for 30 min at RT, 
after which time a solution of aqueous NaOH (1 M, 20 mL) was added. The reaction was 
diluted in EtOAc (250 mL) and washed successively with 0.5 M aq. NaHCO3, 0.1 M HCl, 
water and brine. The organic layer was dried over MgSO4 and the solvent removed under 
reduced pressure to give a white solid (11.5 g, 95 %); m.p. 116 – 117 °C [lit.137 116 – 117 
°C]; H (CDCl3) 7.66 (4H, m, H
2-3
), 7.30 (2H, m, H
7
), 7.26 (1H, m, H
8
), 6.99 (2H, m, H
6
); C 
(CDCl3) 149.4 (s, C
5
), 134.4 (s, C
1
), 132.8 (s, C
3
), 129.9 (s, C
2
), 129.8 (s, C
7
), 129.6 (s, C
4
), 
127.3 (s, C
8
), 122.2 (s, C
6
); m/z (ESI) 311.0 [M - H]
-
; Rf = 0.47 (silica, EtOAc : Hex 1 : 9). 
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Ethyl 4-(trifluoromethylthio)phenylphosphinate, 48 
 
 
1-Bromo-4-(trifluoromethylthio)benzene, 46 (5.00 g, 19.5 mmol) was dissolved in dry THF 
(30 mL); 2 mL of this solution was added to magnesium turnings (0.70 g, 0.29 mmol) 
previously activated by heating for 2 h in the oven and 15 min under vacuum. A few drops of 
dibromoethane were added to the mixture and the rest of the solution was added dropwise 
under argon. The mixture was stirred for 1 h, after which time, diethylchlorophosphite (1.7 
mL, 11.7 mmol) was added to the dark solution. The mixture was stirred at RT overnight after 
which time the solvent was removed and hexane (50 mL) was added to the brown oil. The 
reaction was stirred for 10 min and decanted in order to remove the brown solid. This 
procedure was repeated another 3 times. The organic fractions were combined and the solvent 
was removed under reduced pressure giving the aryl phosphonite, 47 as an orange oil (
31
P-
NMR P(product) = 153.7]. The oil was dissolved in EtOH (3 mL) and 1 eq of 1 M HCl was 
added. The solvent was removed under pressure giving an orange oil (1 g, 32 %). The product 
was taken on without further purification and used in the next step; H (CDCl3) 7.61 (1H, d, 
1
JH-P 536 Hz, PH), 7.78-7.40 (4H, m, H
2-3
), 4.16 (2H, m, H
5
), 1.39 (3H, t, 
3
JH-H 7 Hz, H
6
); F 
(CDCl3) -42.0; P (CDCl3)  +22.4; m/z (HRMS+) 271.0161 [M + H]
+
 (C9H11O2F3PS requires 
271.0169). 
Ethyl 6-methyl-4-nitropyridin-2-yl(4-(trifluoromethylthio)phenyl)phosphinate, 49 
 
Ethyl 4-(trifluoromethylthio)phenylphosphinate, 48 (0.70 g, 2.60 mmol) was added to 
degassed toluene (10 mL), followed by 2-bromo-6-methyl-4-nitropyridine, 10 (0.56 g, 2.60 
mmol), and freshly distilled triethylamine (1.2 mL, 9.10 mmol). Argon was bubbled through 
the yellow solution for 30 min, then PdCl2(dppf)·DCM (60 mg, 0.05 mmol) was added, and 
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the mixture stirred at 125 °C for 16 h under argon, during which time the mixture turned 
black. The solvent was removed under reduced pressure, with purification of the resulting 
black oil by column chromatography (silica, EtOAc : Hex 1:1 to 3:1) giving a clear oil 
(0.32 g, 30 %); H (CDCl3) 8.60 (1H, dd, 
3
JH-P 6 Hz, 
4
JH-H 1.5 Hz, H
4
), 8.05 (2H, dd, 
3
JH-P 12 
Hz,
 3
JH-H 8.5 Hz, H
11
), 7.95 (1H, s, H
2
), 7.74 (2H, dd, 
3
JH-H 8.5 Hz, 
4
JH-P 3 Hz, H
12
), 4.31 – 
3.87 (2H, m, H
7
), 2.75 (3H, s, H
9
), 1.40 (3H, t, 
3
JH-H 7 Hz, H
8
); C (CDCl3) 163.3 (d, 
5
JC-P 21 
Hz, C
1
), 157.3 (d, 
1
JC-P 169 Hz, C
5
), 154.1 (d, 
3
JC-P 14 Hz, C
3
), 135.3 (d, 
3
JC-P 14 Hz, C
12
), 
133.4 (d, 
2
JC-P 10 Hz, C
11
), 132.0 (d, 
1
JC-P 140 Hz, C
10
), 130.1 (s, C
13
), 129.2 (q, 
1
JC-F 309 Hz, 
CF3), 117.9 (d, 
4
JC-P 13 Hz, C
2
), 117.8 (d, 
2
JC-P 9 Hz, C
4
), 62.5 (d, 
2
JC-P 6 Hz, C
7
), 24.9 (s, C
9
), 
16.5 (d, 
3
JC-P 6 Hz, C
8
);F (CDCl3) -42.0; P (CDCl3) + 22.1; m/z (HRMS
+
) 407.0435 
[M + H]
+
 (C15H15N2O4F3PS requires 407.0442); Rf = 0.70 (silica, EtOAc : Hex 2 : 1). 
4-Bromo-6-methylpyridin-2-yl(4-(trifluoromethylthio)phenyl)phosphinic acid, 49a 
 
Ethyl 6-methyl-4-nitropyridin-2-yl(4-(trifluoromethylthio)phenyl)phosphinate, 49 (380 mg, 
0.94 mmol) was dissolved in acetyl bromide (2.1 mL, 28.2 mmol) and the mixture stirred at 
70 °C for 16 h under argon. The brown solution was dropped cautiously into MeOH (30 mL) 
stirred at 0 °C. The solvent was removed under reduced pressure to yield a pale brown solid. 
The resulting material, containing unidentified contaminants, was used without further 
purification, assuming quantitative conversion to the bromo-phosphinic acid; H (CDCl3) 8.21 
(2H, dd, 
3
JH-P 12 Hz,
 3
JH-H 8.5 Hz, H
11
), 8.06-7.91 (2H, m, H
4-2
), 7.80 (2H, s, H
12
), 3.07 (3H, 
s, H
9
); C (CDCl3) 157.8 (s, C
1
), 149.8 (d, 
1
JC-P 106 Hz, C
5
), 144.2 (s, C
3
), 135. 7 (d, 
3
JC-P 14 
Hz, C
12
), 133.8 (d, 
2
JC-P 12 Hz, C
11
), 133.5 (s, C
2
), 131.9 (s, C
13
), 131.8 (s, C
4
), 131.1 (q, 
1
JC-F 
308 Hz, CF3), 131.0 (d, 
1
JC-P 140 Hz, C
10
), 21.2 (s, C
9
);F (CDCl3) -41.5; P (CDCl3) + 12.5; 
m/z (HRMS
+
) 411.9383 [M + H]
+
 (C13H11NO2F3PS
79
Br requires 411.9384). 
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Ethyl 4-bromo-6-methylpyridin-2-yl(4-(trifluoromethylthio)phenyl)phosphinate, 50 
 
4-Bromo-6-methylpyridin-2-yl(4-(trifluoromethylthio)phenyl)phosphinic acid, 49a (670 mg, 
1.62 mmol) was added to HC(OCH2CH3)3 (25 mL) and the mixture stirred at 140 °C for 72 h 
under argon. The solvent was removed under reduced pressure and the resulting residue was 
purified by column chromatography (silica, DCM : 1 % MeOH) to yield a clear oil (475 mg, 
68 % over two steps); H (CDCl3) 8.09 (1H, dd, 
3
JH-P 6 Hz, 
4
JH-H 1.5 Hz, H
4
), 8.03 (2H, dd, 
3
JH-P 12 Hz,
 3
JH-H 8 Hz, H
11
), 7.72 (2H, dd, 
3
JH-H 8, 
4
JH-P 3 Hz, H
12
), 7.43 (1H, s, H
2
), 4.40 – 
3.87 (2H, m, H
7
), 2.55 (3H, s, H
9
), 1.37 (3H, t, 
3
JH-H 7 Hz, H
8
); C (CDCl3) 161.2 (d, 
5
JC-P 22 
Hz, C
1
), 154.5 (d, 
1
JC-P 168 Hz, C
5
), 135.2 (d, 
3
JC-P 13.5 Hz, C
12
), 133.5 (d, 
3
JC-P 15.5 Hz, C
3
), 
133.3 (d, 
2
JC-P 10 Hz, C
11
), 132.7 (d, 
1
JC-P 138 Hz, C
10
), 129.6 (s, C
13
), 129.3 (q, 
1
JC-F 314 Hz, 
CF3), 128.9 (d, 
4
JC-P 2 Hz, C
2
), 129.7 (d, 
2
JC-P 6 Hz, C
4
), 62.3 (d, 
2
JC-P 6 Hz, C
7
), 24.3 (s, C
9
), 
16.5 (d, 
3
JC-P 6 Hz, C
8
);F (CDCl3) -41.9; P (CDCl3) + 22.6; m/z (HRMS
+
) 439.9697 
[M + H]
+
 (C15H15O2N
79
BrF3PS requires 439.9691); Rf = 0.41 (silica, DCM : MeOH 96 : 4). 
4-Bromo-2-(ethoxy(4-(trifluoromethylsulfonyl)phenyl)phosphoryl)-6-methylpyridine 1-
oxide, 51 
 
Ethyl 4-bromo-6-methylpyridin-2-yl(4-(trifluoromethylthio)phenyl)phosphinate, 50 (475 mg, 
1.08 mmol) was dissolved in CHCl3 (10 mL). 3-Chloroperbenzoic acid (1.10 g, 6.48 mmol) 
was added and the solution stirred at 65 °C for 16 h. The solvent was removed under reduced 
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pressure, with the resulting material being re-dissolved in DCM (10 mL), and washed with 
aqueous NaHCO3 (0.5 M, 10 mL). The aqueous layer was re-extracted with DCM (3 × 10 
mL), the organic extracts combined, dried over MgSO4, and the solvent removed under 
reduced pressure. Purification of the resulting yellow oil was undertaken by column 
chromatography (silica, DCM : MeOH 0 to 2 %) giving a colourless oil (250 mg, 48 %); H 
(CDCl3) 8.30 (2H, dd, 
3
JH-P 13 Hz,
 3
JH-H 8.5 Hz, H
11
), 8.12 (1H, dd, 
3
JH-P 8 Hz, 
4
JH-H 2.5 Hz, 
H
4
), 8.08 (2H, dd, 
3
JH-H 8.5 Hz, 
4
JH-P 3.0 Hz, H
12
), 7.55 (1H, d,
 4
JH-H 3 Hz, H
2
), 4.35 – 4.26 
(2H, m, H
7
), 2.35 (3H, s, H
9
), 1.39 (3H, t, 
3
JH-H 7 Hz, H
8
); C (CDCl3) 151.0 (d, 
5
JC-P 4.5 Hz, 
C
1
), 142.5 (d, 
1
JC-P 154 Hz, C
5
), 138.4 (d, 
1
JC-P 150 Hz, C
10
), 135.0 (s, C
13
), 134.3 (d, 
3
JC-P 
11.5 Hz, C
11
), 133.3 (d, 
2
JC-P 11 Hz, C
4
), 132.9 (d, 
4
JC-P 1.5 Hz, C
2
), 130.1 (d, 
2
JC-P 14.5 Hz, 
C
12
), 119.1 (q, 
1
JC-F 317 Hz, CF3), 118.2 (d, 
3
JC-P 13 Hz, C
3
), 63.1 (d, 
2
JC-P 6 Hz, C
7
), 17.2 (s, 
C
9
), 16.4 (d, 
3
JC-P 6.5 Hz, C
8
);F (CDCl3) -77.9; P (CDCl3) + 16.8; m/z (HRMS
+
) 487.9544 
[M + H]
+
 (C15H15O5N
79
BrF3PS requires 487.9539); Rf = 0.45 (silica, DCM : MeOH 97 : 3). 
Ethyl-4-bromo-6-(hydroxymethyl)pyridin-2-yl(4-
(trifluoromethylsulfonyl)phenyl)phosphinate, 52 
  
Trifluoroacetic anhydride (1.4 mL) was added to a solution of 4-bromo-2-(ethoxy(4-
(trifluoromethylsulfonyl)phenyl)phosphoryl)-6-methylpyridine 1-oxide, 51 (240 mg, 0.49 
mmol),  in dry CHCl3 (10 mL). The reaction mixture was heated to 60 °C for 3 h under argon. 
The solvent was removed under reduced pressure and the resulting oil was dissolved in EtOH 
(10 mL) and H2O (10 mL) and stirred for 1 h. After this time the solution was concentrated 
(ca. 10 mL) and extracted with DCM (3 × 30 mL). The organic extracts were combined, dried 
over MgSO4, and the solvent removed under reduced pressure, giving a clear oil (220 mg, 92 
%); H (CDCl3) 8.25 (2H, dd, 
3
JH-P 11.5 Hz,
 3
JH-H 8.5 Hz, H
11
), 8.15 (1H, d, 
3
JH-P 5.0 Hz, H
4
), 
8.08 (2H, m, H
12
), 7.75 (1H, s, H
2
), 6.47 (1H, br, OH), 4.76 (2H, s, H
9
), 4.18 (2H, m, H
7
), 
1.37 (3H, t, 
3
JH-H 7 Hz, H
8
); C (CDCl3) 163.3 (d, 
5
JC-P 21 Hz, C
1
), 152.6 (d, 
1
JC-P 169.5 Hz, 
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C
5
), 138.5 (d, 
1
JC-P 136.5 Hz, C
10
), 135.3 (s, C
13
), 134.6 (d, 
3
JC-P 15 Hz, C
3
), 133.6 (d, 
3
JC-P 10 
Hz, C
11
), 130.4 (d, 
2
JC-P 13 Hz, C
12
), 130.3 (d, 
2
JC-P 11.5 Hz, C
4
), 126.8 (d, 
4
JC-P 3 Hz, C
2
), 
119.6 (q, 
1
JC-F 327 Hz, CF3), 64.1 (s, C
9
), 63.3 (d, 
2
JC-P 6.5 Hz, C
7
), 16.4 (d, 
3
JC-P 6 Hz, C
8
);F 
(CDCl3) -78.3; P (CDCl3) + 21.6; m/z (HRMS
+
) 487.9558 [M + H]
+
 (C15H15O5N
79
BrF3PS 
requires 487.9544); Rf = 0.31 (silica, DCM : MeOH 97 : 3). 
Ethyl 6-(hydroxymethyl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-yl(4-
(trifluoromethylsulfonyl)phenyl)phosphinate, 53 
 
Ethyl 4-bromo-6-(hydroxymethyl)pyridin-2-yl(4-
(trifluoromethylsulfonyl)phenyl)phosphinate, 52 (100 mg, 0.20 mmol), was dissolved in dry 
THF (2 mL) and the solution was degassed (freeze-thaw cycle) three times. 4-Ethynylanisole 
(45 mg, 0.30 mmol) and NEt3 (0.65 mL) were added and the solution degassed once more. 
[1,1’-Bis(diphenylphosphino)ferrocene]palladium(II) chloride (27 mg, 0.02 mmol) and CuI (4 
mg, 0.02 mmol) were added and the solution was degassed a further three times. The solution 
was stirred at 65 °C under argon for 16 h, solvent was removed under reduced pressure and 
the crude material purified by column chromatography (silica, DCM : MeOH 0 to 2 %) to 
give a dark yellow oil (80 mg, 68 %); H (CDCl3) 8.27 (2H, dd, 
3
JH-P 11.1 Hz,
 3
JH-H 8.5 Hz, 
H
11
), 8.12 (3H, m, H
4-12
), 7.50 (1H, s, H
2
), 7.47 (2H, d, 
3
JH-H 8.4 Hz, H
17
), 6.90 (2H, d, 
3
JH-H 
8.5 Hz, H
18
), 4.78 (2H, s, H
9
), 4.40-4.00 (2H, m, H
7
), 3.83 (3H, s, OMe), 3.49 (1H, br, OH), 
1.40 (3H, t, 
3
JH-H 7 Hz, H
8
); C (CDCl3) 161.2 (d, 
5
JC-P = 19 Hz, C
1
), 160.8 (s, C
19
), 151.6 (d, 
1
JC-P 169 Hz, C
5
), 139.5 (d, 
1
JC-P 135 Hz, C
10
), 135.0 (s, C
13
), 133.7 (d, 
3
JC-P 18 Hz, C
17
), 
133.5 (d, 
3
JC-P 15 Hz, C
11
), 133.4 (s, C
3
), 130.4 (s, C
12
), 129.1 (d, 
2
JC-P 26 Hz, C
4
), 126.8 (d, 
4
JC-P 13 Hz, C
2
), 118.4 (q, 
1
JC-F 329 Hz, CF3), 114.3 (d, 
2
JC-P 3 Hz, C
18
), 113.4 (s, C
16
), 96.8 
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(s, C
15
), 85.0 (s, C
14
), 64.1 (s, C
9
), 62.7 (d, 
2
JC-P 6.5 Hz, C
7
), 55.4 (d, 
11
JC-P 15 Hz, OMe), 16.5 
(d, 
3
JC-P 4.5 Hz, C
8
);F (CDCl3) -77.9; P (CDCl3) + 22.1; m/z (HRMS
+
) 540.0856 [M + H]
+
 
(C24H22NO6F3PS requires 540.0858); Rf = 0.46 (silica, DCM : MeOH 95 : 5). 
(6-(Ethoxy(4-(trifluoromethylsulfonyl)phenyl)phosphoryl)-4-((4-
methoxyphenyl)ethynyl)pyridin-2-yl)methyl methanesulfonate, 54 
 
Ethyl 6-(hydroxymethyl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-yl(4-
(trifluoromethylsulfonyl)phenyl)phosphinate, 53 (130 mg, 0.24 mmol), was dissolved in 
anhydrous THF (5 mL) and NEt3 (0.10 mL, 0.72 mmol) was added. The mixture was stirred at 
5 °C and methanesulfonyl chloride (28 μL, 0.36 mmol) was added. The reaction was 
monitored by TLC (silica; DCM : 3 % MeOH, Rf(product) = 0.50, Rf(reactant) = 0.31) and 
stopped after 15 min. The solvent was removed under reduced pressure and the residue 
dissolved in DCM (15 mL) and washed with saturated brine (10 mL). The aqueous layer was 
re-extracted with DCM (3 × 10 mL) and the organic layers combined, dried over MgSO4 and 
the solvent removed under reduced pressure to leave a colourless oil (140 mg, 95 %); H 
(CDCl3) 8.30 (2H, dd, 
3
JH-P 11.5 Hz,
 3
JH-H 8.4 Hz, H
11
), 8.18 (1H, d, 
3
JH-H 6.5 Hz, H
4
), 8.13 
(2H, m, H
12
), 7.62 (1H, s, H
2
), 7.49 (2H, d, 
3
JH-H 9 Hz, H
17
), 6.91 (2H, d, 
3
JH-H 9 Hz, H
18
), 
5.25 (2H, m, H
9
), 4.18 (2H, m, H
7
), 3.84 (3H, s, OMe), 3.08 (3H, s, Ms), 1.39 (3H, t, 
3
JH-H 7 
Hz, H
8
); F (CDCl3) -78.3; P (CDCl3) + 22.4; m/z (HRMS
+
) 618.0649 [M + H]
+
 
(C25H24NO8F3PS2 requires 618.0633); Rf = 0.31 (silica, DCM : MeOH 97 : 3). 
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tert-Butyl 4-((S)-1,4,7-tris((6-(ethoxy(4-(trifluoromethylsulfonyl)phenyl)phosphoryl)-4-
((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-triazacyclononan-2-
yl)butylcarbamate, 55 
 
(S)-tert-Butyl 4-(1,4,7-triazacyclononan-2-yl)butylcarbamate, 17 (23 mg, 0.078 mmol) and 
(6-(ethoxy(4-(trifluoromethylsulfonyl)phenyl)phosphoryl)-4-((4-
methoxyphenyl)ethynyl)pyridin-2-yl)methyl methanesulfonate, 54 (140 mg, 0.22 mmol), 
were dissolved in anhydrous CH3CN (4 mL) and K2CO3 (32 mg, 0.23 mmol) was added. The 
mixture was stirred under argon at 60 °C for 2 h. The reaction was cooled and the solution 
decanted from excess potassium salts. The solvent was removed under reduced pressure to 
give an orange oil (58 mg, 40 %); H (CDCl3) 8.28 (6H, m, H
4
), 8.11 (3H, m, H
3
), 8.06 (6H, 
m, H
5
), 7.57 (3H, m, H
2
), 7.45 (6H, m, H
6
), 6.88 (6H, m, H
7
), 5.04 (1H, br, CONH), 4.16 (6H, 
m, P-OCH2), 3.82 (15H, m, H
1
 and OMe), 3.00-2.61 (13H, m, 9N3 and H
11
), 1.37 (9H, s, 
Boc), 1.45-1.23 (6H, m, H
10-9-8
), 1.35 (9H, m, CH3(Et)); F (CDCl3) -78.3, -78.4, -78.5; P 
(CDCl3) + 22.1; m/z (ESI) 1864.5 [M + H]
+
.
h
  
 
 
 
 
                                                          
h
 HRMS could not be obtained due the mass out of the calibration range. 
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Triethyl 6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(4-
(trifluoromethylsulfonyl)phenylphosphinate), 56 
 
tert-Butyl 4-((S)-1,4,7-tris((6-(ethoxy(4-(trifluoromethylsulfonyl)phenyl)phosphoryl)-4-((4-
methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-triazacyclononan-2-yl)butylcarbamate, 55 
(57 mg, 30 mol) was dissolved in dry DCM (1.8 mL). Argon was bubbled for 10 min after 
which time TFA (0.2 mL) was added. The solution was stirred for 15 min and the solvent was 
removed under reduced pressure to give the trifluoroacetate salt as a yellow oil (60 mg, 
quantitative yield); H (CD3OD) 8.26 (6H, m, H
4
), 8.09 (3H, m, H
4
), 8.04 (6H, m, H
5
), 7.62 
(3H, m, H
2
), 7.55 (6H, m, H
6
), 6.98 (6H, m, H
7
), 4.12 (6H, m, P-OCH2), 3.82 (15H, m, H
1
 and 
OMe), 3.10-2.75 (13H, m, 9N3 and H
11
), 1.45-1.23 (7H, H
10-9-8
), 1.41 (9H, m, CH3(Et)); F 
(CD3OD) -80.2, -80.3, -80.4; P (CD3OD) + 22.5; m/z (ESI) 1764.4 [M + H]
+
.
 i
 
 
 
 
 
 
 
                                                          
i
 HRMS could not be obtained due the mass out of the calibration range. 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(4-
(trifluoromethylsulfonyl)phenylphosphinate), [EuL
21
]
+
 
 
Triethyl 6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(4-
(trifluoromethylsulfonyl)phenylphosphinate) (3.0 mg, 1.7 mol) was dissolved in dry MeOH 
(2 mL) and Na (2 mg, excess) was added. The reaction was stirred under argon at -20 °C and 
monitored by 
19
F-NMR [F(reactant) = - 80.3, (F(product) = - 80.7] and 
31
P-NMR 
[P(reactant) = + 25.5, (P(product) = + 11.7]. After 16 h, the ethylphosphinate esters were 
completely hydrolysed. The reaction was allowed to warm to RT, water (1 mL) was added to 
the reaction and the pH was adjusted to 7 with HCl. Eu(AcO)3H2O (0.6 mg, 1.7mol) was 
added and the mixture heated to 65 °C overnight under argon. The solvent was removed under 
reduced pressure giving a white solid (1.4 mg, 45 %); m/z (HRMS+) 915.6102 [M + H]
2+
 
(C76H68
153
EuF9N7O15P3S3 requires 915.6113);  MeOH = 1.10 ms; max (MeOH) = 342 nm;  = 58 
mM
-1
 cm
-1
. 
 
Method I, tR = 15.0 min 
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2,2,2-Trifluoroethyl 4-(ethoxyhydrophosphoryl)benzenesulfonate, 57 
 
 
To a suspension of anilinium hypophosphite (1.00 g, 6.29 mmol) in dry toluene was added 
2,2,2-trifluoroethyl 4-bromobenzenesulfonate, 43 (1.60 g, 5.02 mmol).  Argon was bubbled 
through the solution for 30 min, then aminopropyltriethoxysilane (1.48 mL, 6.30 mmol) was 
added, and argon was bubbled through the solution for an additional 30 min. 
PdCl2(dppf)·DCM (220 mg, 0.27 mmol) was added, and the mixture stirred at 100 °C for 45 
min under argon. The reaction was monitored by 
31
P-NMR [P(reactant) = 7.4, P(product) = 
20.8, P(diaryl phosphinate) = 25.5]. The solvent was removed under reduced pressure, dilute 
HCl (1 M, 10 mL) was added and the mixture extracted with EtOAc (3 x 20 mL). The organic 
fractions were combined, dried over MgSO4 and concentrated to give a pale orange oil. The 
crude product was used in the next step without further purification; H (CDCl3) 8.03 (4H, m, 
H
2-3
), 7.76 (1H, d, 
1
JP-H 576 Hz, PH), 4.43 (2H, q, 
3
JF-H 10 Hz, H
7
), 4.21 (2H, m, H
5
), 1.40 
(3H, t, 
3
JH-H 7.0 Hz, H
6
); F (CDCl3) -74.2 (t, 
3
JF-H 8 Hz); P (CDCl3)  +20.8; m/z (HRMS+) 
333.0167 [M + H]
+
 (C10H13O5SF3P requires 333.0173). 
2,2,2-Trifluoroethyl 3-bromobenzenesulfonate, 60 
 
 
3-Bromobenzenesulfonyl chloride, 59 (5.00 g, 19.5 mmol) was dissolved in DCM (25 mL) 
and trifluoroethanol (1.40 mL, 19.5 mmol) was added. A solution of DABCO (2.60 g, 23.4 
mmol) in DCM (15 mL) was added resulting in precipitate formation. The reaction was stirred 
for 1 h at RT, after which time a solution of 1 M NaOH (8 mL) was added. The reaction was 
diluted in EtOAc (100 mL) and washed successively with 0.5 M aq. NaHCO3, 0.1 M HCl, 
water and brine. The organic layer was dried over MgSO4 and the solvent removed under 
reduced pressure to give a clear oil (5.50 g, 88 %); H (CDCl3) 8.06 (1H, d, 
4
JH-H 2 Hz, H
2
), 
7.86 (1H, dd,
 3
JH-H 8 Hz, 
4
JH-H 1.5 Hz, H
4
), 7.84 (1H, d,
 3
JH-H 8 Hz, 
4
JH-H 1.5, H
6
), 7.48 (1H, t, 
3
JH-H 8 Hz, H
5
), 4.41 (2H, q, 
3
JH-F 8 Hz, H
7
); C (CDCl3) 137.7 (C
6
), 136.7 (C
3
), 131.0 (C
5
), 
130.8 (C
2
), 126.5 (C
4
), 123.4 (C
1
), 121.7 (q, J 278 Hz, C
5
), 64.8 (q, J 38 Hz, CF3);F (CDCl3) 
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-73.8 (t, 
3
JF-H 7.0 Hz); m/z (HRMS+) 340.9078 [M + Na]
+
 (C8H6O3S
79
BrF3Na requires 
340.9071); Rf = 0.58 (silica, EtOAc : Hex 2 : 8). 
2,2,2-Trifluoroethyl 4-(ethoxyhydrophosphoryl)benzenesulfonate, 61 
 
 
To a suspension of anilinium hypophosphite (1.20 g, 7.54 mmol) in dry toluene was added 
2,2,2-trifluoroethyl 3-bromobenzenesulfonate, 60 (2.00 g, 6.27 mmol).  Argon was bubbled 
through the solution for 30 min, then aminopropyltriethoxysilane (1.80 mL, 7.65 mmol) was 
added, and argon was bubbled through the solution for an additional 30 min. 
PdCl2(dppf)·DCM (270 mg, 0.33 mmol) was added, and the mixture stirred at 100 °C for 30 
min under argon. The reaction was monitored by 
31
P-NMR [P(reactant) = 7.4, P(product) = 
20.2, P(diaryl phosphinate) = 24.9]. The solvent was removed under reduced pressure, dilute 
HCl (1 M, 12 mL) was added and the mixture extracted with EtOAc (3 x 30 mL). The organic 
fractions were combined, dried over MgSO4 and concentrated to give a pale orange oil. The 
crude product was used for the next step without further purification; H (CDCl3) 8.32 (1H, m, 
H
2
), 8.12 (2H, m, H
4 
and H
6
), 7.48 (1H, t, 
3
JH-H = 8 Hz, H
5
),  7.67 (1H, d, 
1
JP-H 576 Hz, PH), 
4.45 (2H, q, 
3
JF-H 9 Hz, H
7
), 4.23 (2H, m, H
5
), 1.42 (3H, t, 
3
JH-H 7.0 Hz, H
6
); F (CDCl3) -74.2 
(t, 
3
JF-H 8 Hz); P (CDCl3)  +20.2; m/z (HRMS+) 333.0170 [M + H]
+
 (C10H13O5SF3P requires 
333.0173). 
2,2,2-Trifluoroethyl 4-(ethoxy(6-methyl-4-nitropyridin-2-
yl)phosphoryl)benzenesulfonate, 62 
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2,2,2-Trifluoroethyl 4-(ethoxyhydrophosphoryl)benzenesulfonate, 57 (1.60 g, 4.82 mmol) was 
added to degassed toluene (40 mL), followed by 2-bromo-6-methyl-4-nitropyridine, 10 (1.00 
g, 4.61 mmol) and freshly distilled triethylamine (2.30 mL, 16.8 mmol). Argon was bubbled 
through the yellow solution for 30 min, then PdCl2(dppf)·DCM (110 mg, 0.13 mmol) was 
added, and the mixture stirred at 120 °C for 2 h under argon, during which time the mixture 
turned brown. The solvent was removed under reduced pressure, with purification of the 
resulting black oil by column chromatography (silica, EtOAc : Hex 1:3 to 1:1) giving a 
colourless oil (902 mg, 40 %); H (CDCl3) 8.63 (1H, dd, 
3
JH-P  6.5 
4
JH-H  1.5 Hz, H
4
), 8.24 
(2H, dd, 
3
JH-P  11.5 Hz,
 3
JH-H 8.5 Hz, H
11
), 8.02 (2H, dd, 
3
JH-H 8.5 Hz, 
4
JH-P 3 Hz, H
12
), 7.79 
(1H, s, H
2
), 4.42 (2H, q, 
3
JF-H 8 Hz, H
6
), 4.27 – 4.09 (2H, m, H7), 2.74 (3H, s, H9), 1.40 (3H, t, 
3
JH-H 7.0 Hz, H
8
); C (CDCl3) 163.5 (d, 
5
JC-P 21.5 Hz, C
1
), 156.5 (d, 
1
JC-P 171 Hz, C
5
), 154.2 
(d, 
3
JC-P 13.5 Hz, C
3
), 138.9 (d, 
5
JC-P 3.5 Hz, C
13
), 136.5 (d, 
1
JC-P 138 Hz, C
10
), 133.7 (d, 
2
JC-P 
10 Hz, C
11
), 127.7 (d, 
3
JC-P 13.5 Hz, C
12
), 122.1 (q, 
1
JC-F 281 Hz, CF3), 118.2 (s, C
2
), 118.0 (d, 
2
JC-P 9 Hz, C
4
), 64.8 (q, 
2
JC-F 38.5 Hz, C
6
), 62.9 (d, 
2
JC-P 6.5 Hz, C
7
), 24.8 (s, C
9
), 16.5 (d, 
3
JC-
P 6 Hz, C
8
);F (CDCl3) -74.2 (t, 
3
JF-H 7 Hz); P (CDCl3) + 20.7; m/z (HRMS
+
) 469.0444 
[M + H]
+
 (C16H17N2O7SF3P requires 469.0446); Rf = 0.70 (silica, EtOAc : Hex 2 : 1). 
2,2,2-Trifluoroethyl 3-(ethoxy(6-methyl-4-nitropyridin-2-
yl)phosphoryl)benzenesulfonate, 63 
 
2,2,2-Trifluoroethyl-3-(ethoxyhydrophosphoryl)benzenesulfonate, 61 (1.60 g, 4.82 mmol) 
was added to degassed toluene (40 mL), followed by 2-bromo-6-methyl-4-nitropyridine, 10 
(1.00 g, 4.61 mmol) and freshly distilled triethylamine (2.30 mL, 16.8 mmol). Argon was 
bubbled through the yellow solution for 30 min, then PdCl2(dppf)·DCM (110 mg, 0.13 mmol) 
was added, and the mixture stirred at 120 °C overnight under argon, during which time the 
mixture turned brown. The solvent was removed under reduced pressure, with purification of 
the resulting black oil by column chromatography (silica, EtOAc : Hex 1:3 to 1:1) giving a 
clear oil (850 mg, 38 %); H (CDCl3) 8.61 (1H, dd, 
3
JH-P  6.5 
4
JH-H  2 Hz, H
4
), 8.57 (1H, d, 
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3
JH-P  12 Hz,
 
H
11
), 8.33 (1H, dd, 
3
JH-P  12 Hz,
 3
JH-H  7.5 Hz,
 
H
15
), 8.09 (1H, d, 
3
JH-H  7 Hz,
 
H
13
), 
7.94 (1H, s, H
2
), 7.72 (1H, m,
 
H
14
),  4.41 (2H, q, 
3
JF-H 8 Hz, H
6
), 4.24 – 4.11 (2H, m, H7), 2.71 
(3H, s, H
9
), 1.38 (3H, t, 
3
JH-H 7.0 Hz, H
8
); C (CDCl3) 163.5 (d, 
5
JC-P 21.5 Hz, C
1
), 156.5 (d, 
1
JC-P 171.5 Hz, C
5
), 154.2 (d, 
3
JC-P 14 Hz, C
3
), 138.4 (d, 
2
JC-P 9.5 Hz, C
15
), 135.7 (d, 
3
JC-P 14 
Hz, C
12
), 132.1 (d, 
2
JC-P 10.5 Hz, C
11
), 132.0 (d, 
1
JC-P 142 Hz, C
10
), 131.7 (d, 
4
JC-P 2.5 Hz, 
C
13
), 129.8 (d, 
3
JC-P 13 Hz, C
14
), 121.7 (q, 
1
JC-F 278 Hz, CF3), 118.1 (d, 
4
JC-P 3 Hz, C
2
), 118.0 
(d, 
2
JC-P 24.5 Hz, C
4
), 64.8 (q, 
2
JC-F 38.5 Hz, C
6
), 62.8 (d, 
2
JC-P 6 Hz, C
7
), 24.7 (s, C
9
), 16.4 (d, 
3
JC-P 6 Hz, C
8
);F (CDCl3) -74.2 (t, 
3
JF-H 7 Hz); P (CDCl3) + 20.4; m/z (HRMS
+
) 469.0443 
[M + H]
+
 (C16H17N2O7SF3P requires 469.0446); Rf = 0.70 (silica, EtOAc : Hex 2 : 1). 
4-Bromo-6-methylpyridin-2-yl(4-(2,2,2-trifluoroethoxysulfonyl)phenyl)phosphinic acid, 
62a 
 
2,2,2-Trifluoroethyl 4-(ethoxy(6-methyl-4-nitropyridin-2-yl)phosphoryl)benzenesulfonate, 62  
(600 mg, 1.28 mmol) was dissolved in acetyl bromide (3.0 mL, 39 mmol) and the mixture 
stirred at 70 °C for 16 h under argon. The brown solution was dropped cautiously into MeOH 
(30 mL) stirred at 0 °C. The solvent was removed under reduced pressure to yield a pale 
brown solid. The resulting material, containing unidentified contaminants, was used without 
further purification, assuming quantitative conversion to the bromophosphinic acid; H 
(CDCl3) 8.42 (1H, d, 
3
JH-P  7, H
4
), 8.31 (1H, s, H
2
), 8.24 (2H, dd, 
3
JH-P  12.5 Hz,
 3
JH-H 8.5 Hz, 
H
11
), 8.09 (2H, dd, 
3
JH-H 8.5 Hz, 
4
JH-P 2 Hz, H
12
), 4.66 (2H, q, 
3
JF-H 8 Hz, H
6
), 2.81 (3H, s, 
H
9
); C (CDCl3) 158.0 (d, 
5
JC-P 8 Hz, C
1
), 151.0 (d, 
1
JC-P 134 Hz, C
5
), 143.5 (d, 
3
JC-P 10.5 Hz, 
C
3
), 138.9 (s, C
13
), 138.8 (d, 
1
JC-P 155 Hz, C
10
), 133.4 (s, C
2
), 133.3 (d, 
2
JC-P 11 Hz, C
11
), 
131.5 (d, 
2
JC-P 12 Hz, C
4
), 128.0 (d, 
3
JC-P 14 Hz, C
12
), 122.2 (q, 
1
JC-F 277 Hz, CF3), 65.1 (q, 
2
JC-F 37.5 Hz, C
6
), 19.0 (s, C
9
);F (CDCl3) -76.0 (t, 
3
JF-H 7 Hz); P (CDCl3) + 8.1; m/z 
(HRMS
+
) 473.9390 [M + H]
+
 (C14H13NO5F3PS
79
Br requires 473.9388). 
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4-Bromo-6-methylpyridin-2-yl(3-(2,2,2-trifluoroethoxysulfonyl)phenyl)phosphinic acid, 
63a 
 
2,2,2-Trifluoroethyl-3-(ethoxy(6-methyl-4-nitropyridin-2-yl)phosphoryl)benzenesulfonate, 63 
(300 mg, 0.64 mmol) was dissolved in acetyl bromide (2 mL) and the mixture stirred at 70 °C 
for 16 h under argon. The brown solution was dropped cautiously into MeOH (20 mL) stirred 
at 0 °C. The solvent was removed under reduced pressure to yield a pale brown solid. The 
resulting material, containing unidentified contaminants, was used without further 
purification, assuming quantitative conversion to the bromo-phosphinic acid; H (CD3OD) 
8.53 (1H, d, 
3
JH-P  13, H
11
), 8.46 (1H, d, 
3
JH-P  6.5 Hz,
 
H
4
), 8.40 (1H, m, H
15
), 8.38 (1H, s,
 
H
2
), 
8.18 (1H, d, 
3
JH-H  7.5 Hz,
 
H
13
), 7.91 (1H, td, 
3
JH-H  8 Hz,
 4
JH-P  3 Hz,
  
H
14
), 4.70 (2H, q, 
3
JF-H 8 
Hz, H
6
), 2.88 (3H, s, H
9
); C (CD3OD) 158.1 (d, 
5
JC-P 7.5 Hz, C
1
), 149.9 (d, 
1
JC-P 131 Hz, C
5
), 
144.2 (d, 
3
JC-P 11 Hz, C
3
), 138.3 (d, 
2
JC-P 11 Hz, C
15
), 135.8 (d, 
3
JC-P 15 Hz, C
12
), 134.7 (C
2
), 
133.6 (d, 
1
JC-P 148 Hz, C
10
), 132.1 (d, 
4
JC-P 2.5 Hz, C
13
), 131.8 (d, 
2
JC-P 11.5 Hz, C
4
), 131.3 (d, 
2
JC-P 12 Hz, C
11
), 130.9 (d, 
3
JC-P 13.5 Hz, C
14
), 122.3 (q, 
1
JC-F 277 Hz, CF3), 65.4 (q, 
2
JC-F 37.5 
Hz, C
6
), 19.4 (s, C
9
);F (CD3OD) -76.0 (t, 
3
JF-H 7 Hz); P (CD3OD) + 8.0; m/z (HRMS
+
) 
473.9388 [M + H]
+
 (C14H13NO5F3PS
79
Br requires 473.9388). 
2,2,2-Trifluoroethyl 4-((4-bromo-6-methylpyridin-2-
yl)(ethoxy)phosphoryl)benzenesulfonate, 64 
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4-Bromo-6-methylpyridin-2-yl(4-(2,2,2-trifluoroethoxysulfonyl)phenyl)phosphinic acid, 62a 
(606 mg, 1.28 mmol) was added to HC(OCH2CH3)3 (25 mL) and the mixture stirred at 140 °C 
for 16 h under argon. The solvent was removed under reduced pressure and the resulting 
residue was purified by column chromatography (silica, DCM : 1 % MeOH) to yield a yellow 
oil (530 mg, 81 % over two steps); H (CDCl3) 8.22 (2H, dd, 
3
JH-P  11.5 Hz,
 3
JH-H 8.5 Hz, H
11
), 
8.11 (1H, dd, 
3
JH-P  6.5, 
4
JH-H  1.5 Hz, H
4
), 8.00 (2H, dd, 
3
JH-H 8.5 Hz, 
4
JH-P 3 Hz, H
12
), 7.45 
(1H, s, H
2
), 4.40 (2H, q, 
3
JF-H 8 Hz, H
6
), 4.23 – 4.08 (2H, m, H7), 2.54 (3H, s, H9), 1.37 (3H, t, 
3
JH-H 7 Hz, H
8
); C (CDCl3) 161.3 (d, 
5
JC-P 22 Hz, C
1
), 153.8 (d, 
1
JC-P 169 Hz, C
5
), 138.5 (d, 
5
JC-P 3 Hz, C
13
), 137.3 (d, 
1
JC-P 136 Hz, C
10
), 133.7 (s,  C
3
), 133.6 (d, 
2
JC-P 10 Hz, C
11
), 129.2 
(s, 
4
JC-P 3 Hz, C
2
), 129.0 (d, 
2
JC-P 24 Hz, C
4
), 127.5 (d, 
3
JC-P 13 Hz, C
12
), 121.7 (q, 
1
JC-F 278 
Hz, CF3), 64.8 (q, 
2
JC-F 38.5 Hz, C
6
), 62.6 (d, 
2
JC-P 6.5 Hz, C
7
), 24.3 (s, C
9
), 16.4 (d, 
3
JC-P 6.5 
Hz, C
8
);F (CDCl3) -74.2 (t, 
3
JF-H 7 Hz); P (CDCl3) + 21.5; m/z (HRMS
+
) 501.9690 
[M + H]
+
 (C16H17NO5F3PS
79
Br requires 501.9701); Rf = 0.50 (silica, DCM : MeOH 96 : 4).      
2,2,2-Trifluoroethyl 3-((4-bromo-6-methylpyridin-2-
yl)(ethoxy)phosphoryl)benzenesulfonate, 65 
 
4-Bromo-6-methylpyridin-2-yl(3-(2,2,2-trifluoroethoxysulfonyl)phenyl)phosphinic acid, 63a 
(300 mg, 0.64 mmol) was added to HC(OCH2CH3)3 (13 mL) and the mixture stirred at 140 °C 
for 16 h under argon. The solvent was removed under reduced pressure and the resulting 
residue was purified by column chromatography (silica, DCM : 1 % MeOH) to yield a yellow 
oil (256 mg, 77 % over two steps); H (CDCl3) 8.58 (1H, dt, 
3
JH-P  11.5, 
4
JH-H  1.5, H
11
), 8.32 
(1H, m, H
15
), 8.11 (1H, d, 
3
JH-P  6.5 Hz,
 
H
4
), 8.07 (1H, dd, 
3
JH-H  8 Hz,
 4
JH-H  2 Hz,
 
H
13
), 7.69 
(1H, td, 
3
JH-H  8 Hz,
 4
JH-P  3 Hz,
  
H
14
), 7.43 (1H, s,
 
H
2
), 4.40 (2H, qd, 
3
JF-H 8 Hz, 
2
JH-H 3.5 Hz, 
H
6
), 4.12 (2H, m, H
7
), 2.52 (3H, s, H
9
), 1.36 (3H, t, 
3
JH-H 7 Hz, H
6
); C (CDCl3) 161.3 (d, 
5
JC-P 
22 Hz, C
1
), 153.8 (d, 
1
JC-P 169.5 Hz, C
5
), 138.3 (d, 
2
JC-P 9.5 Hz, C
15
), 135.4 (d, 
3
JC-P 14 Hz, 
C
12
), 133.6 (d, 
3
JC-P 15.5 Hz, C
3
), 132.6 (d, 
1
JC-P 139 Hz, C
10
), 132.1 (d, 
2
JC-P 10.5 Hz, C
11
), 
131.4 (d, 
4
JC-P 2.5 Hz, C
13
), 129.6 (d, 
3
JC-P 12.5 Hz, C
14
), 129.1 (d, 
4
JC-P 3 Hz, C
2
), 128.9 (d, 
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2
JC-P 24 Hz, C
4
), 121.7 (q, 
1
JC-F 278 Hz, CF3), 64.8 (q, 
2
JC-F 38 Hz, C
6
), 62.5 (d, 
2
JC-P 6 Hz, 
C
7
), 24.2 (C
9
), 16.4 (d, 
3
JC-P 6 Hz, C
8
);F (CDCl3) -74.2 (t, 
3
JF-H 7 Hz); P (CDCl3) + 21.1; m/z 
(HRMS
+
) 501.9693 [M + H]
+
 (C16H17NO5F3PS
79
Br requires 501.9701); Rf = 0.50 (silica, 
DCM : MeOH 96 : 4). 
4-Bromo-2-(ethoxy(4-(2,2,2-trifluoroethoxysulfonyl)phenyl)phosphoryl)-6-
methylpyridine 1-oxide, 66 
 
2,2,2-Trifluoroethyl 4-((4-bromo-6-methylpyridin-2-yl)(ethoxy)phosphoryl)benzenesulfonate, 
64 (530 mg, 1.06 mmol) was dissolved in CHCl3 (15 mL). 3-Chloroperbenzoic acid (345 mg, 
2.01 mmol) was added and the solution stirred at 65 °C for 16 h. The solvent was then 
removed under reduced pressure, with the resulting material being re-dissolved in DCM (15 
mL), and washed with aqueous NaHCO3 (0.5 M, 10 mL). The aqueous layer was re-extracted 
with DCM (3 × 10 mL), the organic extracts combined, dried over MgSO4, and the solvent 
removed under reduced pressure to afford a yellow oil (475 mg, 91 %); H (CDCl3) 8.25 (2H, 
dd, 
3
JH-P 13 Hz,
 3
JH-H 8.5 Hz, H
11
), 8.12 (1H, dd, 
3
JH-P  8, 
4
JH-H  3 Hz, H
4
), 7.99 (2H, dd, 
3
JH-H 
8.5 Hz, 
4
JH-P 3 Hz, H
12
), 7.55 (1H, d, 
5
JH-P  2.5 Hz, H
2
), 4.40 (2H, q, 
3
JF-H 8 Hz, H
6
), 4.26 – 
4.16 (2H, m, H
7
), 2.37 (3H, s, H
9
), 1.40 (3H, t, 
3
JH-H 7.0 Hz, H
8
); C (CDCl3) 150.9 (s, C
1
), 
142.8 (d, 
1
JC-P 153 Hz, C
5
), 138.7 (s, C
13
), 136.3 (d, 
1
JC-P 151 Hz, C
10
), 134.2 (d, 
2
JC-P 11.5 
Hz, C
11
), 133.2 (d, 
2
JC-P 11 Hz, C
4
), 132.7 (s, C
2
), 127.4 (d, 
3
JC-P 14.5 Hz, C
12
), 124.1 (s, C
3
), 
121.6 (q, 
1
JC-F 274 Hz, CF3), 64.8 (q, 
2
JC-F 38.5 Hz, C
6
), 63.0 (d, 
2
JC-P 6 Hz, C
7
), 17.2 (s, C
9
), 
16.5 (d, 
3
JC-P 6 Hz, C
8
);F (CDCl3) -74.2 (t, 
3
JF-H 8 Hz); P (CDCl3) + 17.2; m/z (HRMS
+
) 
517.9650 [M + H]
+
 (C16H17NO6PS
79
BrF3 requires 517.9650); Rf = 0.49 (silica, DCM : MeOH 
96 : 4).      
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4-Bromo-2-(ethoxy(3-(2,2,2-trifluoroethoxysulfonyl)phenyl)phosphoryl)-6-
methylpyridine 1-oxide, 67 
 
2,2,2-Trifluoroethyl 3-((4-bromo-6-methylpyridin-2-yl)(ethoxy)phosphoryl)benzenesulfonate, 
65 (350 mg, 0.70 mmol) was dissolved in CHCl3 (10 mL). 3-Chloroperbenzoic acid (240 mg, 
1.39 mmol) was added and the solution stirred at 65 °C for 16 h. The solvent was removed 
under reduced pressure, with the resulting material being re-dissolved in DCM (15 mL), and 
washed with aqueous NaHCO3 (0.5 M, 10 mL). The aqueous layer was re-extracted with 
DCM (3 × 10 mL), the organic extracts combined, dried over MgSO4, and the solvent 
removed under reduced pressure giving a yellow oil (320 mg, 85 %); H (CDCl3) 8.53 (1H, dt, 
3
JH-P  13.5, 
4
JH-H  1.5, H
11
), 8.36 (1H, m, H
15
), 8.09 (1H, dd, 
3
JH-P  8 Hz,
 4
JH-H 3 Hz,
 
H
4
), 8.05 
(1H, d, 
3
JH-H  8 Hz,
 
H
13
), 7.68 (1H, td, 
3
JH-H  8 Hz,
 4
JH-P  3.5 Hz,
  
H
14
), 7.52 (1H, d,
 4
JH-H  3 Hz,
 
H
2
), 4.41 (2H, m, H
6
), 4.18 (2H, m, H
7
), 2.30 (3H, s, H
9
), 1.38 (3H, t, 
3
JH-H 7 Hz, H
6
); C 
(CDCl3) 150.8 (d, 
5
JC-P 4.5 Hz, C
1
), 142.7 (d, 
1
JC-P 154 Hz, C
5
), 139.2 (d, 
2
JC-P 10.5 Hz, C
15
), 
134.8 (d, 
3
JC-P 15.5 Hz, C
12
), 133.1 (d, 
2
JC-P 11 Hz, C
4
), 132.8 (d, 
2
JC-P 12.5 Hz, C
11
), 132.7 (d, 
4
JC-P 2 Hz, C
2
), 131.8 (d, 
4
JC-P 2.5 Hz, C
13
), 131.4 (d, 
1
JC-P 129 Hz, C
10
), 129.5 (d, 
3
JC-P 14 Hz, 
C
14
), 121.8 (q, 
1
JC-F 278 Hz, CF3), 117.9 (d, 
3
JC-P 13 Hz, C
3
), 65.0 (q, 
2
JC-F 38 Hz, C
6
), 62.9 (d, 
2
JC-P 6 Hz, C
7
), 17.0 (C
9
), 16.4 (d, 
3
JC-P 6 Hz, C
8
); F (CDCl3) -74.2 (t, 
3
JF-H 7 Hz); P (CDCl3) 
+ 17.0; m/z (HRMS
+
) 517.9653 [M + H]
+
 (C16H17NO6PS
79
BrF3 requires 517.9650); Rf = 0.49 
(silica, DCM : MeOH 96 : 4).    
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2,2,2-Trifluoroethyl-4-((4-bromo-6-(hydroxymethyl)pyridin-2-
yl)(ethoxy)phosphoryl)benzenesulfonate, 68 
  
Trifluoroacetic anhydride (2.5 mL) was added to a solution of 4-bromo-2-(ethoxy(4-(2,2,2-
trifluoroethoxysulfonyl)phenyl)phosphoryl)-6-methylpyridine 1-oxide, 66 (475 mg, 0.91 
mmol)  in anhydrous CHCl3 (20 mL). The reaction mixture was heated to 60 °C for 3 h under 
argon. The solvent was removed under reduced pressure and the resulting oil was dissolved in 
EtOH (15 mL) and H2O (15 mL) and stirred for 1 h. After this time, the solution was 
concentrated (ca. 15 mL) and extracted with DCM (3 × 30 mL). The organic extracts were 
combined, dried over MgSO4, and the solvent removed under reduced pressure, giving a clear 
oil (430 mg, 91 %); H (CDCl3) 8.19-8.13 (3H, m, H
4-11
), 8.00 (2H, dd, 
3
JH-H 8.5 Hz, 
4
JH-P 2.5 
Hz,
 
 H
12
), 7.72 (1H, s, H
2
), 6.83 (1H, br, OH), 4.76 (2H, s, H
9
), 4.41 (2H, q, 
3
JF-H 8 Hz, H
6
), 
4.29-4.04 (2H, m, H
7
), 1.37 (3H, t, 
3
JH-H 7 Hz, H
8
); C (CDCl3) 163.1 (s, 
5
JC-P 20.5 Hz, C
1
), 
152.8 (d, 
1
JC-P 169 Hz, C
5
), 139.0 (d, 
4
JC-P 3 Hz C
13
), 136.2 (d, 
1
JC-P 138.5 Hz, C
10
), 134.6 (d, 
3
JC-P 15 Hz, C
3
), 133.5 (d, 
2
JC-P 10.5 Hz, C
11
), 130.3 (d, 
2
JC-P 23.5 Hz, C
4
), 127.8 (d, 
3
JC-P 13.5 
Hz, C
12
), 126.8 (d, 
4
JC-P 3 Hz, C
2
), 122.8 (q, 
1
JC-F 274 Hz, CF3), 64.9 (q, 
2
JC-F 38.5 Hz, C
6
), 
64.0 (s, C
9
), 63.2 (d, 
2
JC-P 6.5 Hz, C
7
), 16.4 (d, 
3
JC-P 6 Hz, C
8
);F (CDCl3) -74.2 (t, 
3
JF-H 8 
Hz); P (CDCl3) + 22.1; m/z (HRMS
+
) 517.9647 [M + H]
+
 (C16H17NO6PS
79
BrF3 requires 
517.9650); Rf = 0.56 (silica, DCM : MeOH 96 : 4).      
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2,2,2-Trifluoroethyl-3-((4-bromo-6-(hydroxymethyl)pyridin-2 
yl)(ethoxy)phosphoryl)benzenesulfonate, 69 
  
Trifluoroacetic anhydride (1.70 mL) was added to a solution of 4-bromo-2-(ethoxy(3-(2,2,2-
trifluoroethoxysulfonyl)phenyl)phosphoryl)-6-methylpyridine 1-oxide, 67 (310 mg, 0.60 
mmol)  in dry CHCl3 (15 mL). The reaction mixture was heated to 60 °C for 3 h under argon. 
The solvent was removed under reduced pressure and the resulting oil was dissolved in EtOH 
(12 mL) and H2O (12 mL) and stirred for 1 h. After this time, the solution was concentrated 
(ca. 15 mL) and extracted with DCM (3 × 30 mL). The organic extracts were combined, dried 
over MgSO4, the solvent removed under reduced pressure and the resulting residue was 
purified by column chromatography (silica, DCM : MeOH  100 : 0 to 97 : 3) to yield a clear 
oil (220 mg, 70 %); H (CDCl3) 8.55 (1H, dt, 
3
JH-P  12, 
4
JH-H  1.5, H
11
), 8.29 (1H, m, H
15
), 
8.19 (1H, dd, 
3
JH-P  6.5 Hz,
 4
JH-H 2 Hz,
 
H
4
), 8.08 (1H, d, 
3
JH-H  8 Hz,
 
H
13
), 7.71 (1H, td, 
3
JH-H  8 
Hz,
 4
JH-P  3 Hz,
  
H
14
), 7.66 (1H, s,
 
H
2
), 6.72 (1H, br, OH), 4.75 (2H, s, H
9
), 4.43 (2H, m, H
6
), 
4.16 (2H, m, H
7
), 1.37 (3H, t, 
3
JH-H 7 Hz, H
6
); C (CDCl3) 162.7 (d, 
5
JC-P 20.5 Hz, C
1
), 153.3 
(d, 
1
JC-P 168.5 Hz, C
5
), 138.2 (d, 
2
JC-P 10 Hz, C
15
), 135.7 (d, 
3
JC-P 14 Hz, C
12
), 134.5 (d, 
3
JC-P 
14.5 Hz, C
3
), 132.0 (d, 
1
JC-P 128.5 Hz, C
10
), 131.9 (d, 
2
JC-P 11 Hz, C
11
), 131.7 (d, 
4
JC-P 2.5 Hz, 
C
13
), 130.3 (d, 
2
JC-P 23.5 Hz, C
4
), 129.8 (d, 
3
JC-P 12.5 Hz, C
14
), 126.5 (d, 
4
JC-P 3 Hz, C
2
), 121.8 
(q, 
1
JC-F 278 Hz, CF3), 64.8 (q, 
2
JC-F 38 Hz, C
6
), 64.0 (C
9
), 62.8 (d, 
2
JC-P 6 Hz, C
7
), 16.4 (d, 
3
JC-P 6 Hz, C
8
); F (CDCl3) -74.3 (t, 
3
JF-H 7 Hz); P (CDCl3) + 21.9; m/z (HRMS
+
) 517.9646 
[M + H]
+
 (C16H17NO6PS
79
BrF3 requires 517.9650); Rf = 0.56 (silica, DCM : MeOH 96 : 4).      
1-Ethynyl-4-methoxy-2-methylbenzene  
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3-Methyl-4-bromoanisole (700 mg, 3.48 mmol) was dissolved in anhydrous THF (12 mL) and 
the solution was degassed (freeze-thaw cycle) three times. Ethynyltrimethylsilane (0.74 mL, 
5.24 mmol) and triethylamine (2.40 mL, 17.4 mmol) were added and the solution was 
degassed (freeze-thaw cycle) once more. [1,1-
Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (400 mg, 0.49 mmol) and CuI (66 
mg, 0.35 mmol) were added and the resulting brown solution was stirred at 65 °C under argon 
for 16 h. The solvent was removed under reduced pressure and the resulting brown oil was 
purified by column chromatography (silica, Hex : DCM 10:0 to 10:1) to give (4-methoxy-2-
methylphenylethynyl)trimethylsilane as a yellow oil (440 mg, 58 %); Rf = 0.49 (silica, Hex : 
DCM 3:1). This compound (440 mg, 2.0 mmol) was immediately dissolved in anhydrous 
THF (5 mL) and triethylammonium dihydrofluoride (3.3 mL, 20 mmol) was added. The 
mixture was stirred at 35 °C under argon for 48 h. The solvent was removed under reduced 
pressure to give a yellow oil which was subjected to column chromatography (silica, Hex : 
DCM 3:1), to afford 1-ethynyl-4-methoxy-2-methylbenzene as a colourless oil (200 mg, 
68%); δH (CDCl3) 7.39 (1H, d, 
3
JH-H 8.6 Hz, H
8
), 6.74 (1H, d, 
4
JH-H 2.6 Hz, H
5
), 6.68 (1H, dd, 
3
JH-H 8.6 Hz, 
4
JH-H 2.6 Hz, H
7
), 3.80 (3H, s, H
10
), 3.19 (1H, s, H
1
), 2.43 (3H, s, H
9); δC (151 
MHz, CDCl3) δ 160.0 (C
6
), 142.7 (C
4
), 134.0 (C
8
), 115.2 (C
5
), 114.3 (C
3
), 111.3 (C
7
), 82.7 
(C
2
), 79.6 (C
1
), 55.4 (C
9
), 21.0 (C
10
); (HRMS
-
) m/z 145.0667 [M - H]
-
 (C10H9O requires 
145.0653); Rf = 0.46 (silica; Hex : DCM 2 : 1). 
2,2,2-Trifluoroethyl-4-(ethoxy(6-(hydroxymethyl)-4-((4-methoxyphenyl)ethynyl)pyridin-
2-yl)phosphoryl)benzenesulfonate, 70 
 
2,2,2-Trifluoroethyl 4-((4-bromo-6-(hydroxymethyl)pyridin-2-
yl)(ethoxy)phosphoryl)benzenesulfonate, 68 (200 mg, 0.39 mmol) was dissolved in dry THF 
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(2.5 mL) and the solution was degassed (freeze-thaw cycle) three times. 4-Ethynylanisole (76 
mg, 0.57 mmol) and NEt3 (1.0 mL) were added and the solution degassed once more. [1,1’-
Bis(diphenylphosphino)ferrocene]palladium(II) chloride (45 mg, 55 mol) and CuI (7 mg, 37 
mol) were added and the solution was degassed a further three times. The solution was 
stirred at 65 °C under argon for 16 h, solvent was removed under reduced pressure and the 
crude material purified by column chromatography (silica, DCM : MeOH 0 to 2 %) to give a 
pale orange oil (153 mg, 69 %); H (CDCl3) 8.19 (2H, d, 
3
JH-H 8.5 Hz, H
11
), 8.10 (1H, s, H
4
), 
8.01 (2H, d, 
3
JH-H 7 Hz, H
12
), 7.47 (3H, m, H
17 
and
 
H
2
), 6.90 (2H, d, 
3
JH-H 8.5 Hz, H
18
), 4.78 
(2H, s, H
9
), 4.40 (2H, q, 
3
JF-H 7.5 Hz, H
6
), 4.17 (2H, m, H
7
), 3.84 (3H, s, OMe), 3.52 (1H, br, 
OH), 1.39 (3H, t, 
3
JH-H 6.5 Hz, H
8
); C (CDCl3) 161.2 (s, C
1
), 160.7 (s, C
19
), 151.0 (d, 
1
JC-P 
183 Hz, C
5
), 138.6 (s, C
13
), 137.4 (d, 
1
JC-P 136 Hz, C
10
), 133.7 (s, C
17
), 133.5 (s, C
3
), 133.4 (d, 
2
JC-P 9 Hz, C
11
), 128.9 (s, C
4
), 127.7 (d, 
4
JC-P 12.5 Hz, C
12
), 124.4 (s, C
2
), 121.7 (q, 
1
JC-F 327 
Hz, CF3), 114.3 (s, C
18
), 113.5 (s, C
16
), 96.7 (s, C
15
), 85.0 (s, C
14
), 64.9 (q, 
2
JC-F 38 Hz, C
6
), 
64.1 (s, C
9
), 62.6 (s, C
7
), 55.4 (s, OMe), 16.5 (s, C
8
);F (CDCl3) -74.2 (t, 
3
JF-H 8 Hz); P 
(CDCl3) + 22.5; m/z (HRMS
+
) 570.0973 [M + H]
+
 (C25H24F3NO7PS requires 570.0963); Rf = 
0.61 (silica, DCM : MeOH 95 : 5). 
2,2,2-trifluoroethyl 3-(ethoxy(6-(hydroxymethyl)-4-((4-methoxyphenyl)ethynyl)pyridin-
2-yl)phosphoryl)benzenesulfonate, 71 
 
2,2,2-Trifluoroethyl 3-((4-bromo-6-(hydroxymethyl)pyridin-2-
yl)(ethoxy)phosphoryl)benzenesulfonate, 69 (260 mg, 0.50 mmol) was dissolved in dry THF 
(1.5 mL) and the solution was degassed (freeze-thaw cycle) three times. 4-Ethynylanisole 
(100 mg, 0.75 mmol) and NEt3 (1.3 mL) were added and the solution degassed once more. 
[1,1’-Bis(diphenylphosphino)ferrocene]palladium(II) chloride (53 mg, 0.05 mmol) and CuI (9 
mg, 0.05 mmol) were added and the solution was degassed a further three times. The solution 
was stirred at 65 °C under argon for 16 h, solvent was removed under reduced pressure and 
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the crude material purified by column chromatography (silica, DCM : MeOH 0 to 2 %) to 
give an orange oil (140 mg, 49 %); H (CDCl3) 8.57 (1H, d, 
3
JH-P  10, H
11
), 8.31 (1H, m, H
15
), 
8.11 (1H, s,
 
H
4
), 8.08 (1H, d, 
3
JH-H  7.5 Hz,
 
H
13
), 7.71 (1H, t, 
3
JH-H  8 Hz,
 
H
14
), 7.47 (3H, m, 
H
17-2 
), 6.89 (2H, d, 
3
JH-H 8.5 Hz, H
18
), 4.75 (2H, s, H
9
), 4.42 (2H, m, H
6
), 4.16 (2H, m, H
7
), 
3.83 (3H, s, OMe), 3.34 (1H, br, OH), 1.39 (3H, t, 
3
JH-H 6.5 Hz, H
8
); C (CDCl3) 160.8 (s, C
1
), 
160.7 (s, C
19
), 151.9 (d, 
1
JC-P 169 Hz, C
5
), 138.1 (s, C
12
), 135.6 (d, 
2
JC-P 14 Hz, C
15
), 133.7 (s, 
C
17
), 132.7 (d, 
1
JC-P 140 Hz, C
10
), 131.9 (d, 
2
JC-P 11 Hz, C
11
), 131.6 (s, C
3
), 131.5 (s, C
13
), 
129.8 (d, 
3
JC-P 13 Hz, C
14
), 128.7 (d, 
2
JC-P 23 Hz, C
4
), 124.5 (s, C
2
), 121.7 (q, 
1
JC-F 278 Hz, 
CF3), 114.3 (s, C
18
), 113.5 (s, C
16
), 96.7 (s, C
24
), 85.0 (s, C
23
), 64.9 (q, 
2
JC-F 39 Hz, C
6
), 64.0 
(s, C
9
), 62.6 (d, 
2
JC-P 6 Hz, C
7
), 55.4 (s, OMe), 16.5 (s, C
8
);F (CDCl3) -74.2 (t, 
3
JF-H 8 Hz); P 
(CDCl3) + 22.1; m/z (HRMS
+
) 570.0968 [M + H]
+
 (C25H24F3NO7PS requires 570.0963); Rf = 
0.61 (silica, DCM : MeOH 95 : 5). 
2,2,2-Trifluoroethyl-4-(ethoxy(6-(hydroxymethyl)-4-((4-methoxy-2-
methylphenyl)ethynyl)pyridin-2-yl)phosphoryl)benzenesulfonate, 72 
 
2,2,2-Trifluoroethyl 4-((4-bromo-6-(hydroxymethyl)pyridin-2-
yl)(ethoxy)phosphoryl)benzenesulfonate, 68 (230 mg, 0.44 mmol) was dissolved in dry THF 
(2 mL) and the solution was degassed (freeze-thaw cycle) three times. 1-Ethynyl-4-methoxy-
2-methylbenzene (100 mg, 0.66 mmol) and NEt3 (1.2 mL) were added and the solution 
degassed once more. [1,1’-Bis(diphenylphosphino)ferrocene]palladium(II) chloride (51 mg, 
63 mol) and CuI (8 mg, 42 mol) were added and the solution was degassed a further three 
times. The solution was stirred at 65 °C under argon for 16 h, the solvent was removed under 
reduced pressure and the crude material purified by column chromatography (silica, DCM : 
MeOH 0 to 2 %) to give a pale orange oil (185 mg, 72 %); H (CDCl3) 8.19 (2H, dd, 
3
JH-P 11 
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Hz, 
3
JH-H 8 Hz, H
11
), 8.08 (1H, s, H
4
), 7.98 (2H, d, 
3
JH-H 8 Hz, H
12
), 7.48 (1H, s, H
2
), 7.41 
(1H, d, 
3
JH-H 8.5 Hz, H
17 
), 6.76 (1H, d, 
4
JH-H 2.5 Hz, H
20
), 6.72 (1H, dd, 
3
JH-H 8.5 Hz, 
4
JH-H 
2.5 Hz, H
18
), 4.76 (2H, s, H
9
), 4.39 (2H, q, 
3
JF-H 8 Hz, H
6
), 4.16 (2H, m, H
7
), 3.80 (3H, s, 
OMe), 3.57 (1H, br, OH), 2.46 (3H, s, H
22
), 1.38 (3H, t, 
3
JH-H 7 Hz, H
8
); C (CDCl3) 161.1 (s, 
C
1
), 160.7 (s, C
19
), 151.8 (d, 
1
JC-P 168 Hz, C
5
), 142.9 (s, C
21
), 138.6 (s, C
13
), 137.3 (d, 
1
JC-P 
137 Hz, C
10
), 134.0 (s, C
17
), 133.4 (d,
 2
JC-P 9 Hz, C
11
), 133.3 (s, C
3
), 128.9 (s, C
4
), 127.6 (d, 
4
JC-P 13 Hz, C
12
), 124.3 (s, C
2
), 121.7 (q, 
1
JC-F 279 Hz, CF3), 115.3 (s, C
20
), 113.4 (s, 
C
16
),111.6 (s, C
18
), 95.8 (s, C
15
), 88.7 (s, C
14
), 64.8 (q, 
2
JC-F 38.5 Hz, C
6
), 64.1 (s, C
9
), 62.6 (d, 
2
JC-P 6 Hz, C
7
), 55.3 (s, OMe), 21.0 (s, C
22
), 16.5 (s, C
8
);F (CDCl3) -74.2 (t, 
3
JF-H 8 Hz); P 
(CDCl3) + 22.6; m/z (HRMS
+
) 584.1111 [M + H]
+
 (C26H26F3NO7PS requires 584.1120); Rf = 
0.52 (silica, DCM : MeOH 97 : 3). 
2,2,2-Trifluoroethyl 3-(ethoxy(6-(hydroxymethyl)-4-((4-methoxy-2-
methylphenyl)ethynyl)pyridin-2-yl)phosphoryl)benzenesulfonate, 73 
 
2,2,2-Trifluoroethyl 3-((4-bromo-6-(hydroxymethyl)pyridin-2-
yl)(ethoxy)phosphoryl)benzenesulfonate, 69 (160 mg, 0.31 mmol) was dissolved in dry THF 
(1.5 mL) and the solution was degassed (freeze-thaw cycle) three times. 1-Ethynyl-4-
methoxy-2-methylbenzene (68 mg, 0.47 mmol) and NEt3 (0.90 mL) were added and the 
solution degassed once more. [1,1’-Bis(diphenylphosphino)ferrocene]palladium(II) chloride 
(36 mg, 58 mol) and CuI (6 mg, 31 mol) were added and the solution was degassed a 
further three times. The solution was stirred at 65 °C under argon for 16 h, the solvent was 
removed under reduced pressure and the crude material purified by column chromatography 
(silica, DCM : MeOH 0 – 2 %) to give an orange oil (90 mg, 50 %); H (CDCl3) 8.57 (1H, d, 
3
JH-P  11.5, H
11
), 8.31 (1H, m, H
15
), 8.10 (1H, d, 
3
JH-P  6 Hz,
 
H
4
), 8.07 (1H, d, 
3
JH-H  8 Hz,
 
H
13
), 
7.70 (1H, td, 
3
JH-H  8 Hz,
 4
JH-P  3 Hz,
  
H
14
), 7.46 (1H, s,
 
H
2
) 7.42 (1H, d, 
3
JH-H 8.5 Hz, H
17 
), 
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6.77 (1H, d, 
4
JH-H 2.5 Hz, H
20
), 6.72 (1H, dd, 
3
JH-H 8.5 Hz, 
4
JH-H 2.5 Hz, H
18
), 4.75 (2H, s, H
9
), 
4.35 (2H, m, H
6
), 4.16 (2H, m, H
7
), 3.80 (3H, s, OMe), 3.44 (1H, br, OH), 2.47 (3H, s, H
22
), 
1.38 (3H, t, 
3
JH-H 7 Hz, H
8
); C (CDCl3) 161.0 (d, 
4
JC-P 19 Hz, C
1
), 160.7 (s, C
19
), 151.9 (d, 
1
JC-P 169 Hz, C
5
), 142.9 (s, C
21
), 138.1 (d, 
2
JC-P 10 Hz, C
15
), 135.6 (d, 
3
JC-P 14 Hz, C
12
), 134.0 
(s, C
17
), 132.7 (d, 
1
JC-P 140 Hz, C
10
), 131.9 (d, 
2
JC-P 11 Hz, C
11
), 131.6 (s, C
3
), 131.5 (s, C
13
), 
129.7 (d, 
3
JC-P 13 Hz, C
14
), 128.8 (d, 
2
JC-P 23 Hz, C
4
), 124.3 (s, C
2
), 121.7 (q, 
1
JC-F 278 Hz, 
CF3), 115.3 (s, C
20
), 113.5 (s, C
16
), 111.6 (s, C
18
), 95.8 (s, C
24
), 88.8 (s, C
23
), 64.8 (q, 
2
JC-F 
38.5 Hz, C
6
), 64.0 (s, C
9
), 62.6 (d, 
2
JC-P 6 Hz, C
7
), 55.3 (s, OMe), 21.0 (s, C
22
), 16.5 (s, 
3
JC-P 6 
Hz, C
8
);F (CDCl3) -74.2 (t, 
3
JF-H 8 Hz); P (CDCl3) + 22.2; m/z (HRMS
+
) 584.1111 [M + H]
+
 
(C26H26F3NO7PS requires 584.1120); Rf = 0.52 (silica, DCM : MeOH 97 : 3). 
2,2,2-Trifluoroethyl-4-(ethoxy(4-((4-methoxyphenyl)ethynyl)-6-
((methylsulfonyloxy)methyl)pyridin-2-yl)phosphoryl)benzenesulfonate, 74 
 
2,2,2-Trifluoroethyl-4-(ethoxy(6-(hydroxymethyl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-
yl)phosphoryl)benzenesulfonate, 70 (93 mg, 0.16 mmol) was dissolved in anhydrous THF (4 
mL) and NEt3 (0.07 mL, 0.50 mmol) was added. The mixture was stirred at 5 °C and 
methanesulfonyl chloride (19 μL, 0.24 mmol) was added. The reaction was monitored by 
TLC (silica; DCM : 5 % MeOH, Rf(product) = 0.75, Rf(reactant) = 0.61) and stopped after 30 
min. The solvent was removed under reduced pressure and the residue dissolved in DCM (15 
mL) and washed with NaCl solution (saturated, 10 mL). The aqueous layer was re-extracted 
with DCM (3 × 10 mL) and the organic layers combined, dried over MgSO4 and the solvent 
removed under reduced pressure to afford a colourless oil (95 mg, 92 %); H (CDCl3) 8.22 
(2H, dd, 
3
JH-P 11.5 Hz,
 3
JH-H 8.5 Hz, H
11
), 8.17 (1H, d, 
3
JH-H 6.5 Hz, H
4
), 8.02 (2H, dd, 
3
JH-H 
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8.5 Hz, 
4
JH-P 2.5 Hz, H
12
), 7.62 (1H, s, H
2
), 7.50 (2H, d, 
3
JH-H 9 Hz, H
17
), 6.91 (2H, d, 
3
JH-H 9 
Hz, H
18
), 5.32 (2H, m, H
9
), 4.42 (2H, q, 
3
JF-H 8 Hz, H
6
), 4.18 (2H, m, H
7
), 3.85 (3H, s, OMe), 
3.08 (3H, s, Ms), 1.40 (3H, t, 
3
JH-H 7 Hz, H
8
); F (CDCl3) -74.1 (t, 
3
JF-H 8 Hz); P (CDCl3) 
+ 21.9; m/z (HRMS
+
) 648.0728 [M + H]
+
 (C26H26F3NO9PS2 requires 648.0739); Rf = 0.75 
(silica, DCM : MeOH 95 : 5). 
2,2,2-Trifluoroethyl 3-(ethoxy(4-((4-methoxyphenyl)ethynyl)-6-
((methylsulfonyloxy)methyl)pyridin-2-yl)phosphoryl)benzenesulfonate, 75 
 
2,2,2-trifluoroethyl 3-(ethoxy(6-(hydroxymethyl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-
yl)phosphoryl)benzenesulfonate, 71 (120 mg, 0.21 mmol) was dissolved in anhydrous THF (3 
mL) and NEt3 (87 mL, 0.63 mmol) was added. The mixture was stirred at 5 °C and 
methanesulfonyl chloride (24 μL, 0.32 mmol) was added. The reaction was monitored by 
TLC (silica; DCM : 5 % MeOH, Rf(product) = 0.75, Rf(reactant) = 0.61) and stopped after 30 
min. The solvent was removed under reduced pressure and the residue dissolved in DCM (10 
mL) and washed with NaCl solution (saturated, 10 mL). The aqueous layer was re-extracted 
with DCM (3 × 10 mL) and the organic layers combined, dried over MgSO4 and the solvent 
removed under reduced pressure to leave a colourless oil (130 mg, 96 %); H (CDCl3) 8.57 
(1H, dd, 
3
JH-P  11.5,
 4
JH-H  1.5, H
11
), 8.31 (1H, m, H
15
), 8.17 (1H, d,
 3
JH-P  6.5,
 
H
4
), 8.08 (1H, d, 
3
JH-H  8 Hz,
 
H
13
), 7.71 (1H, td, 
3
JH-H  8 Hz,
 4
JH-H  1.5 Hz,
 
H
14
), 7.60 (1H, s, H
17-2 
), 6.49 (2H, d, 
3
JH-H 9 Hz, H
18
), 6.90 (2H, d, 
3
JH-H 9 Hz, H
18
), 5.30 (2H, s, H
9
), 4.43 (2H, q, 
3
JH-F 9 Hz, H
6
), 
4.16 (2H, m, H
7
), 3.83 (3H, s, OMe), 3.08 (3H, s, Ms), 1.38 (3H, t, 
3
JH-H 7 Hz, H
8
); F 
(CDCl3) -74.1 (t, 
3
JF-H 8 Hz); P (CDCl3) + 21.5; m/z (HRMS
+
) 648.0732 [M + H]
+
 
(C26H26F3NO9PS2 requires 648.0739); Rf = 0.75 (silica, DCM : MeOH 95 : 5). 
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2,2,2-Trifluoroethyl-4-(ethoxy(4-((4-methoxy-2-methylphenyl)ethynyl)-6-
((methylsulfonyloxy)methyl)pyridin-2-yl)phosphoryl)benzenesulfonate, 76 
 
2,2,2-Trifluoroethyl-4-(ethoxy(6-(hydroxymethyl)-4-((4-methoxy-2 -
methylphenyl)ethynyl)pyridin-2-yl)phosphoryl)benzenesulfonate, 72 (185 mg, 0.32 mmol) 
was dissolved in anhydrous THF (5 mL) and NEt3 (0.14 mL, 0.96 mmol) was added. The 
mixture was stirred at 5 °C and methanesulfonyl chloride (37 μL, 0.48 mmol) was added. The 
reaction was monitored by TLC (silica; DCM : 5 % MeOH, Rf(product) = 0.75, Rf(reactant) = 
0.61) and stopped after 30 min. The solvent was removed under reduced pressure and the 
residue dissolved in DCM (15 mL) and washed with NaCl solution (saturated, 10 mL). The 
aqueous layer was re-extracted with DCM (3 × 10 mL) and the organic layers combined, 
dried over MgSO4 and the solvent removed under reduced pressure to leave a colourless oil 
(160 mg, 76 %); H (CDCl3) 8.23 (2H, dd, 
3
JH-P 11 Hz, 
3
JH-H 8 Hz, H
11
), 8.08 (1H, d, 
4
JH-H 2.5 
Hz, H
4
), 8.03 (2H, d, dd, 
3
JH-H 8 Hz, 
4
JH-P 2 Hz, H
12
), 7.59 (1H, s, H
2
), 7.44 (1H, d, 
3
JH-H 8.5 
Hz, H
17 
), 6.78 (1H, s, H
20
), 6.74 (1H, dd, 
3
JH-H 8.5 Hz, 
4
JH-H 2.5 Hz, H
18
), 5.29 (2H, m, H
9
), 
4.42 (2H, q, 
3
JF-H 8 Hz, H
6
), 4.18 (2H, m, H
7
), 3.82 (3H, s, OMe), 3.07 (3H, s, Ms), 2.48 (2H, 
s, H
22
), 1.39 (3H, t, 
3
JH-H 7 Hz, H
8
); F (CDCl3) -74.1 (t, 
3
JF-H 8 Hz); P (CDCl3) + 21.9; m/z 
(HRMS
+
) 662.0900 [M + H]
+
 (C27H28NO9F3PS2 requires 662.0895); Rf = 0.75 (silica, DCM : 
MeOH 95 : 5). 
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2,2,2-Trifluoroethyl 3-(ethoxy(4-((4-methoxy-2-methylphenyl)ethynyl)-6-
((methylsulfonyloxy)methyl)pyridin-2-yl)phosphoryl)benzenesulfonate, 77 
 
2,2,2-Trifluoroethyl 3-(ethoxy(6-(hydroxymethyl)-4-((4-methoxy-2-
methylphenyl)ethynyl)pyridin-2-yl)phosphoryl)benzenesulfonate, 73 (45 mg, 78 mol) was 
dissolved in anhydrous THF (2.5 mL) and NEt3 (32 mL, 0.23 mmol) was added. The mixture 
was stirred at 5 °C and methanesulfonyl chloride (9 μL, 0.12 mmol) was added. The reaction 
was monitored by TLC (silica; DCM : 5 % MeOH, Rf(product) = 0.75, Rf(reactant) = 0.61) 
and stopped after 30 min. The solvent was removed under reduced pressure and the residue 
dissolved in DCM (10 mL) and washed with NaCl solution (saturated, 10 mL). The aqueous 
layer was re-extracted with DCM (3 × 10 mL) and the organic layers combined, dried over 
MgSO4 and the solvent removed under reduced pressure to leave a colourless oil (40 mg, 76 
%); H (CDCl3) 8.59 (1H, d, 
3
JH-P  11.5, H
11
), 8.36 (1H, m, H
15
), 8.18 (1H, d, 
3
JH-P  6.5 Hz,
 
H
4
), 8.10 (1H, d, 
3
JH-H  8 Hz,
 
H
13
), 7.73 (1H, td, 
3
JH-H  8 Hz,
 4
JH-P  3 Hz,
  
H
14
), 7.60 (1H, s,
 
H
2
), 
7.45 (1H, d, 
3
JH-H 8.5 Hz, H
17
), 6.83 (1H, s, H
20
), 6.73 (1H, d, 
3
JH-H 8.5 Hz, H
18
), 5.29 (2H, m, 
H
9
), 4.44 (2H, q, 
3
JF-H 8 Hz, H
6
), 4.16 (2H, m, H
7
), 3.82 (3H, s, OMe), 3.09 (2H, s, Ms), 2.49 
(3H, s, H
22
), 1.42 (3H, t, 
3
JH-H 7 Hz, H
8
); F (CDCl3) -74.1 (t, 
3
JF-H 8 Hz); P (CDCl3) + 21.5; 
m/z (HRMS
+
) 662.0902 [M + H]
+
 (C27H28NO9F3PS2 requires 662.0895); Rf = 0.75 (silica, 
DCM : MeOH 95 : 5). 
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2,2,2-Trifluoroethyl 6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(4-(ethoxyphosphoryl benzenesulfonate), 
78 
 
1,4,7-Triazacyclononane trihydrochloride (2.5 mg, 10 mol) and 2,2,2-trifluoroethyl 4-
(ethoxy(4-((4-methoxyphenyl)ethynyl)-6-((methylsulfonyloxy)methyl)pyridin-2-
yl)phosphoryl)benzenesulfonate, 74 (20 mg, 29 mol) were dissolved in anhydrous CH3CN 
(1 mL) and K2CO3 (8.0 mg, 58 mol) was added. The mixture was stirred under argon at 60 
°C for 16 h. The reaction was cooled and the solution decanted from excess potassium salts. 
The solvent was removed under reduced pressure and the crude product purified by HPLC 
(Method J, tR = 12.6 min) to give a pale yellow oil (7.5 mg, 42 %); H (CDCl3) 8.18 (6H, dd, 
3
JH-P 11.5 Hz,
 3
JH-H 8.5 Hz, H
11
), 8.05 (3H, d, 
3
JH-H 6 Hz, H
4
), 7.97 (6H, dd, 
3
JH-H 8.5 Hz, 
4
JH-P 
2 Hz, H
12
), 7.62 (3H, s, H
2
), 7.45 (6H, d, 
3
JH-H 9 Hz, H
17
), 6.88 (6H, d, 
3
JH-H 9 Hz, H
18
), 4.40 
(6H, q, 
3
JF-H 8 Hz, H
6
), 4.20 - 4.06 (6H, m, H
7
), 3.87 (6H, s, H
9
), 3.82 (9H, s, OMe), 2.81 
(12H, br, 9N3), 1.34 (9H, t, 
3
JH-H 7 Hz, H
8
); C (CDCl3) 160.9 (s, C
1
), 160.7 (s, C
19
), 153.0 (d, 
1
JC-P 184 Hz, C
5
), 138.4 (s, C
13
), 137.4 (d, 
1
JC-P 138 Hz, C
10
), 133.6 (s, C
17
), 133.5 (d, 
2
JC-P 9.5 
Hz, C
11
), 128.1 (d, 
2
JC-P 12 Hz, C
4
), 128.2 (s, C
3
), 127.5 (d, 
4
JC-P 13.5 Hz, C
12
), 127.0 (s, C
2
), 
121.7 (q, 
1
JC-F 329 Hz, CF3), 114.3 (s, C
18
), 113.5 (s, C
16
), 96.3 (s, C
15
), 85.0 (s, C
14
), 64.8 (q, 
2
JC-F 37 Hz, C
6
), 62.9 (s, C
9
), 62.3 (d,
 2
JC-P 14 Hz, C
7
), 55.5 (OMe), 55.2-54.5 (br, 9N3), 16.5 
(s, C
8
);F (CDCl3) -74.1 (t, 
3
JF-H 8 Hz); P (CDCl3) + 22.5; m/z (HRMS
+
) 1783.362 [M + H]
+
 
(C81H79F9N6O18P3S3 requires 1783.368).  
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2,2,2-Trifluoroethyl-6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-
((4-methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(3-(ethoxyphosphoryl 
benzenesulfonate), 79 
 
1,4,7-Triazacyclononane trihydrochloride (1.4 mg, 5.9 mol) and 2,2,2-trifluoroethyl 3-
(ethoxy(4-((4-methoxyphenyl)ethynyl)-6-((methylsulfonyloxy)methyl)pyridin-2-
yl)phosphoryl)benzenesulfonate, 75 (11 mg, 17 mol) were dissolved in anhydrous CH3CN 
(1 mL) and K2CO3 (4.9 mg, 35.4 mol) was added. KI (0.1 mg) was added to the reaction and 
the mixture was stirred under argon at 60 °C for 3 h. The reaction was cooled and the solution 
decanted from excess potassium salts. The solvent was removed under reduced pressure to 
give a yellow oil (5.6 mg, 53 %); H (CDCl3) 8.62 (3H, d, 
3
JH-P  11.5, H
11
), 8.37 (3H, m, H
15
), 
8.10 (6H, m,
 
H
4-13
), 7.71 (6H, m,
  
H
14-2
), 7.41 (6H, d, 
3
JH-H 8.5 Hz, H
17
), 6.75 (6H, d, 
3
JH-H 8.5 
Hz, H
18
), 4.40 (6H, q, 
3
JF-H 8 Hz, H
6
), 4.20 - 4.03 (6H, m, H
7
), 3.82 (6H, s, H
9
), 3.78 (9H, s, 
OMe), 2.81 (12H, br, 9N3), 1.38 (9H, t, 
3
JH-H 7 Hz, H
8
); C (CDCl3) 161.0 (d, 
4
JC-P 20 Hz, C
1
), 
160.3 (s, C
19
), 151.3 (d, 
1
JC-P 169 Hz, C
5
), 138.0 (d, 
2
JC-P 10 Hz, C
15
), 135.7 (d, 
3
JC-P 12 Hz, 
C
12
), 134.5 (s, C
17
), 132.7 (d, 
1
JC-P 139 Hz, C
10
), 131.7 (d, 
2
JC-P 11 Hz, C
11
), 131.4 (s, C
3
), 
131.2 (s, C
13
), 129.6 (d, 
3
JC-P 14 Hz, C
14
), 128.6 (d, 
2
JC-P 22.5 Hz, C
4
), 124.1 (s, C
2
), 121.7 (q, 
1
JC-F 278 Hz, CF3), 113.3 (s, C
16
), 111.2 (s, C
18
), 95.7 (s, C
24
), 88.2 (s, C
23
), 64.8 (q, 
2
JC-F 38.5 
Hz, C
6
), 62.9 (s, C
9
), 62.7 (d,
 2
JC-P 7 Hz, C
7
), 55.3 (s, OMe), 55.2-54.5 (br, 9N3), 16.5 (s, 
C
8
);F (CDCl3) -74.1 (t, 
3
JF-H 8 Hz); P (CDCl3) + 22.3; m/z (HRMS
+
) 1783.360 [M + H]
+
 
(C81H79F9N6O18P3S3 requires 1783.368). 
 
Chapter 7: Experimental 
 
208 
 
2,2,2-Trifluoroethyl 6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
methoxy-2-methylphenyl)ethynyl)pyridine-6,2-diyl)tris(4-(ethoxy phosphoryl 
benzenesulfonate), 80 
 
1,4,7-Triazacyclononane trihydrochloride (3.0 mg, 12 mol) and 2,2,2-trifluoroethyl 4-
(ethoxy(4-((4-methoxy-2-methylphenyl)ethynyl)-6-((methylsulfonyloxy)methyl)pyridin-2-
yl)phosphoryl)benzenesulfonate, 76 (24 mg, 36 mol) were dissolved in anhydrous CH3CN 
(1 mL) and K2CO3 (10 mg, 72 mol) was added. The mixture was stirred under argon at 60 
°C for 16 h. KI (0.1 mg) was added to the reaction and the mixture was heated for further 1 h. 
The reaction was cooled and the solution decanted from excess potassium salts. The solvent 
was removed under reduced pressure to give a yellow oil (15 mg, 69 %); H (CDCl3) 8.21 
(6H, dd, 
3
JH-P 11 Hz, 
3
JH-H 8 Hz, H
11
), 8.03 (3H, s, H
4
), 7.98 (6H, d, 
3
JH-H 8 Hz, H
12
), 7.53 
(3H, s, H
2
), 7.41 (3H, d, 
3
JH-H 8.5 Hz, H
17 
), 6.80 (3H, d, 
4
JH-H 2.5 Hz, H
20
), 6.74 (3H, dd, 
3
JH-
H 8.5 Hz, 
4
JH-H 2.5 Hz, H
18
), 4.40 (6H, q, 
3
JF-H 8 Hz, H
6
), 4.20 - 4.06 (6H, m, H
7
), 3.85 (6H, s, 
H
9
), 3.80 (9H, s, OMe), 2.46 (9H, s, H
22
), 2.81 (12H, br, 9N3), 1.38 (9H, t, 
3
JH-H 7 Hz, H
8
); C 
(CDCl3) 161.2 (s, C
1
), 160.5 (s, C
19
), 151.8 (d, 
1
JC-P 168 Hz, C
5
), 142.7 (s, C
21
), 138.6 (s, C
13
), 
137.4 (d, 
1
JC-P 137 Hz, C
10
), 134.1 (s, C
17
), 133.4 (d, 
2
JC-P 11 Hz, C
11
), 133.2 (s, C
3
), 128.9 (s, 
C
4
), 127.6 (d, 
4
JC-P 13 Hz, C
12
), 124.2 (s, C
2
), 121.7 (q, 
1
JC-F 279 Hz, CF3), 115.1 (s, C
20
), 
113.4 (s, C
16
),111.6 (s, C
18
), 95.8 (s, C
15
), 88.8 (s, C
14
), 64.8 (q, 
2
JC-F 38.5 Hz, C
6
), 62.9 (s, 
C
9
), 62.7 (d,
 2
JC-P 14 Hz, C
7
), 55.3 (s, OMe), 55.2-54.5 (br, 9N3), 21.0 (s, C
22
), 16.5 (s, C
8
);F 
(CDCl3) -74.2 (t, 
3
JF-H 8 Hz); P (CDCl3) + 22.6; m/z (HRMS
+
) 1825.410 [M + H]
+
 
(C84H85N6O18F9P3S3 requires 1825.415).  
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2,2,2-Trifluoroethyl-6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-
((4-methoxy-2-methylphenyl)ethynyl)pyridine-6,2-diyl)tris(3-(ethoxyphosphoryl 
benzenesulfonate), 81 
 
1,4,7-Triazacyclononane trihydrochloride (5.0 mg, 20 mol) and 2,2,2-trifluoroethyl 3-
(ethoxy(4-((4-methoxy-2-methylphenyl)ethynyl)-6-((methylsulfonyloxy)methyl)pyridin-2-
yl)phosphoryl)benzenesulfonate, 77 (40 mg, 60 mol) were dissolved in anhydrous CH3CN 
(1.5 mL) and K2CO3 (17 mg, 0.12 mmol) was added. KI (catalytical) was added to the 
reaction and the mixture was stirred under argon at 60 °C for 1 h. The reaction was cooled 
and the solution decanted from excess potassium salts. The solvent was removed under 
reduced pressure to give a yellow oil (18 mg, 51 %); H (CDCl3) 8.61 (3H, d, 
3
JH-P  11.5, H
11
), 
8.37 (3H, m, H
15
), 8.12 (6H, m,
 
H
4-13
), 7.72 (6H, m,
  
H
14-2
), 7.41 (3H, d, 
3
JH-H 8.5 Hz, H
17
), 
6.83 (3H, s, H
20
), 6.78 (3H, d, 
3
JH-H 8.5 Hz, H
18
), 4.40 (6H, q, 
3
JF-H 8 Hz, H
6
), 4.20 - 4.06 (6H, 
m, H
7
), 3.83 (6H, s, H
9
), 3.80 (9H, s, OMe), 2.48 (9H, s, H
22
), 2.81 (12H, br, 9N3), 1.38 (9H, 
t, 
3
JH-H 7 Hz, H
8
); C (CDCl3) 161.0 (d, 
4
JC-P 20 Hz, C
1
), 160.3 (s, C
19
), 151.4 (d, 
1
JC-P 169 Hz, 
C
5
), 142.4 (s, C
21
), 138.1 (d, 
2
JC-P 10 Hz, C
15
), 135.7 (d, 
3
JC-P 12 Hz, C
12
), 134.0 (s, C
17
), 
132.7 (d, 
1
JC-P 140 Hz, C
10
), 131.9 (d, 
2
JC-P 11 Hz, C
11
), 131.6 (s, C
3
), 131.4 (s, C
13
), 129.7 (d, 
3
JC-P 13 Hz, C
14
), 128.6 (d, 
2
JC-P 23 Hz, C
4
), 124.2 (s, C
2
), 121.7 (q, 
1
JC-F 278 Hz, CF3), 115.1 
(s, C
20
), 113.6 (s, C
16
), 111.6 (s, C
18
), 95.8 (s, C
24
), 88.2 (s, C
23
), 64.8 (q, 
2
JC-F 38.5 Hz, C
6
), 
62.9 (s, C
9
), 62.7 (d,
 2
JC-P 7 Hz, C
7
), 55.3 (s, OMe), 55.2-54.5 (br, 9N3), 21.0 (s, C
22
), 16.5 (s, 
C
8
);F (CDCl3) -74.1 (t, 
3
JF-H 8 Hz); P (CDCl3) + 22.3; m/z (HRMS
+
) 1825.417 [M + H]
+
 
(C84H85N6O18F9P3S3 requires 1825.415). 
Chapter 7: Experimental 
 
210 
 
Eu(III) complex of 6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(4-(hydroxyphosphoryl benzenesulfonate), 
[EuL
20a
]
3-
 
 
2,2,2-Trifluoroethyl 6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(4-(ethoxyphosphoryl benzenesulfonate), 78 
(3.0 mg, 1.7 mol) was dissolved in CD3OD (1 mL) and a solution of NaOH in D2O (0.1 M, 
0.5 mL) was added. The mixture was heated to 60 °C under argon and monitored with 
19
F-
NMR [F(reactant) = - 76.0, F(product, trifluoroethanol) = - 78.0] and 
31
P-NMR [P(reactant) 
= + 23.1, P(product) = + 14.9]. After 3 h the solution was cooled to RT and the pH was 
adjusted to 7 with HCl. Eu(Cl)36H2O (0.7 mg, 1.7mol) was added and the mixture heated to 
65 °C overnight under argon. The solvent was removed under reduced pressure and the 
product purified by HPLC (Method K, tR = 17.7 min) giving the triethylammonium salt as a 
white solid (2.0 mg, 75 %); (HRMS
-
) 1599.146 [MH2]
-
 (C69H59
151
EuN6O18P3S3 requires 
1599.146);  H2O = 1.11 ms; max (H2O) = 332 nm;  = 58 mM
-1
 cm
-1
. 
 
Method L, tR = 17.7 min 
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Eu(III) complex of 6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(3-(hydroxyphosphoryl benzenesulfonate), 
[EuL
23a
]
3-
 
 
2,2,2-Trifluoroethyl-6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(3-(ethoxyphosphoryl benzenesulfonate), 79 (9 
mg, 5.0 mol) was dissolved in CD3OD (1.5 mL) and a solution of NaOH in D2O (0.1 M, 0.8 
mL) was added. The mixture was heated to 60 °C under argon and monitored with 
19
F-NMR 
[F(reactant) = - 75.3, F(product, trifluoroethanol) = - 78.0] and 
31
P-NMR [P(reactant) = + 
22.3, P(product) = + 13.3]. After 3 h the solution was cooled to RT and the pH was adjusted 
to 7 with HCl. Eu(Ac)3H2O (1.8 mg, 5.5mol) was added and the mixture heated to 65 °C 
overnight under argon. The solvent was removed under reduced pressure and the product 
purified by HPLC (Method K, tR = 18.2 min) giving the triethylammonium salt as a white 
solid (4.8 mg, 59 %); (HRMS
-
) 1599.148 [MH2]
-
 (C69H59
151
EuN6O18P3S3 requires 1599.146); 
 H2O = 1.10 ms; max (H2O) = 332 nm;  = 58 mM
-1
 cm
-1
. 
 
Method M, tR = 4.8 min 
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Eu(III) complex of 6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
methoxy-2-methylphenyl)ethynyl)pyridine-6,2-diyl)tris(4-(hydroxyphosphoryl 
benzenesulfonate), [EuL
24a
]
3-
 
 
2,2,2-Trifluoroethyl 6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
methoxy-2-methylphenyl)ethynyl)pyridine-6,2-diyl)tris(4-(ethoxyphosphoryl 
benzenesulfonate), 80 (5.0 mg, 2.7 mol) was dissolved in CD3OD (1.5 mL) and a solution of 
NaOH in D2O (0.1 M, 0.8 mL) was added. The mixture was heated to 60 °C under argon and 
monitored with 
19
F-NMR [F(reactant) = - 76.2, F(product, trifluoroethanol) = - 78.0] and 
31
P-NMR [P(reactant) = + 22.3, P(product) = + 13.1]. After 3 h the solution was cooled to 
RT and the pH was adjusted to 7 with HCl. Eu(Cl)36H2O (1.0 mg, 2.9mol) was added and 
the mixture heated to 65 °C overnight under argon. The solvent was removed under reduced 
pressure and the product purified by HPLC (Method K, tR = 19.8 min) giving the 
triethylammonium salt as a white solid (2.6 mg, 60 %); (HRMS
-
) 1644.205 [MH2]
-
 
(C72H65
153
EuN6O18P3S3 requires 1644.202);  H2O = 1.09 ms; max (H2O) = 340 nm;  = 58 mM
-1
 
cm
-1
. 
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Method L, tR = 18.3 min 
Eu(III) complex of 6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
methoxy-2-methylphenyl)ethynyl)pyridine-6,2-diyl)tris(3-(hydroxyphosphoryl 
benzenesulfonate), [EuL
25a
]
3-
 
 
2,2,2-Trifluoroethyl-6,6',6''-(1,4,7-triazacyclononane-1,4,7-triyl)tris(methylene)tris(4-((4-
methoxy-2-methylphenyl)ethynyl)pyridine-6,2-diyl)tris(3-(ethoxyphosphoryl 
benzenesulfonate), 81 (5.0 mg, 2.7 mol) was dissolved in CD3OD (1.5 mL) and a solution of 
NaOH in D2O (0.1 M, 0.8 mL) was added. The mixture was heated to 60 °C under argon and 
monitored with 
19
F-NMR [F(reactant) = - 76.1, F(product, trifluoroethanol) = - 78.0] and 
31
P-NMR [P(reactant) = + 22.3, P(product) = + 12.9]. After 3 h the solution was cooled to 
RT and the pH was adjusted to 7 with HCl. Eu(Cl)36H2O (1.0 mg, 2.9mol) was added and 
the mixture heated to 65 °C overnight under argon. The solvent was removed under reduced 
pressure and the product purified by HPLC (Method K, tR = 19.2 min) giving the 
triethylammonium salt as a white solid (2.5 mg, 58 %); (HRMS
-
) 1644.200 [MH2]
-
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(C72H65
153
EuN6O18P3S3 requires 1644.202);  H2O = 1.12 ms; max (H2O) = 340 nm;  = 58 mM
-1
 
cm
-1
. 
 
Method L, tR = 19.0 min 
tert-Butyl-4-((S)-1,4,7-tris((6-(ethoxy(4-(2,2,2-trifluoroethyl)phosphoryl 
benzenesulfonate)-4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-
triazacyclononane-2-yl)butylcarbamate, 82 
 
(S)-tert-Butyl 4-(1,4,7-triazacyclononane-2-yl)butylcarbamate, 17 (15 mg, 0.05 mmol) and 
2,2,2-trifluoroethyl-4-(ethoxy(4-((4-methoxyphenyl)ethynyl)-6-
((methylsulfonyloxy)methyl)pyridin-2-yl)phosphoryl)benzenesulfonate, 74 (95 mg, 0.15 
mmol), were dissolved in anhydrous CH3CN (2 mL) and K2CO3 (21 mg, 0.15 mmol) was 
added. The mixture was stirred under argon at 60 °C for 16 h. The reaction was cooled and 
the solution decanted from excess potassium salts. The solvent was removed under reduced 
pressure and the crude product purified by HPLC (Method J, tR = 14.1 min) to give a pale 
 
Chapter 7: Experimental 
 
215 
 
yellow oil (32 mg, 33 %); H (CDCl3) 8.18 (6H, m, H
4
), 8.04 (3H, m, H
3
), 7.96 (6H, m, H
5
), 
7.48 (3H, m, H
2
), 7.44 (6H, m, H
6
), 6.88 (6H, m, H
7
), 5.08 (1H, br, CONH), 4.40 (6H, q, 
3
JF-H 
7.5 Hz, H
12
), 4.14 (6H, m, P-OCH2), 3.83 (15H, m, H
1
 and OMe), 3.00-2.56 (13H, m, 9N3 
ring protons and H
11
), 1.38 (9H, s, Boc), 1.45-1.30 (6H, m, H
10-9-8
), 1.35 (9H, m, CH3(Et)); F 
(CDCl3) -74.2 (t, 
3
JF-H 8 Hz); P (CDCl3) + 22.6; m/z (HRMS
+
) 977.7515 [M + 2H]
2+
 
(C90H97F9N7O20P3S3 requires 977.7510). 
tert-Butyl-4-((S)-1,4,7-tris((6-(ethoxy(3-(2,2,2-trifluoroethyl)phosphoryl 
benzenesulfonate)-4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-
triazacyclononane-2-yl)butylcarbamate, 83 
 
(S)-tert-Butyl 4-(1,4,7-triazacyclononan-2-yl)butylcarbamate, 17 (17.5 mg, 58 mol) and 
2,2,2-Trifluoroethyl 3-(ethoxy(4-((4-methoxyphenyl)ethynyl)-6-
((methylsulfonyloxy)methyl)pyridin-2-yl)phosphoryl)benzenesulfonate, 75 (110 mg, 174 
mol), were dissolved in anhydrous CH3CN (4 mL) and K2CO3 (23 mg, 174 mol) was 
added. The mixture was stirred under argon at 60 °C for 16 h. The reaction was cooled and 
the solution decanted from excess potassium salts. The solvent was removed to give a yellow 
oil (34 mg, 30 %); H (CDCl3) 8.53 (3H, m, H
4
), 8.33 (3H, m, H
13
), 8.05 (6H, m,
 
H
5-3
), 7.74 
(3H, m, H
12
), 7.48 (3H, m, H
2
), 7.42 (6H, m, H
6
), 6.86 (6H, m, H
7
), 5.00 (1H, br, CONH), 
4.40 (6H, q, 
3
JF-H 7.5 Hz, H
14
), 4.12 (6H, m, P-OCH2), 3.81 (15H, m, H
1
 and OMe), 3.05-2.59 
(13H, m, 9N3 ring protons and H
11
), 1.39 (9H, s, Boc), 1.42-1.29 (6H, m, H
10-9-8
), 1.34 (9H, 
m, CH3(Et)); F (CDCl3) -74.2 (t, 
3
JF-H 8 Hz); P (CDCl3) + 22.3; m/z (HRMS
+
) 977.7517 
[M + 2H]
2+
 (C90H97F9N7O20P3S3 requires 977.7510). 
Chapter 7: Experimental 
 
216 
 
2,2,2-Trifluoroethyl-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(4-(ethoxy 
phosphoryl benzenesulfonate), 82a 
 
tert-Butyl 4-((S)-1,4,7-tris((6-(ethoxy(4-(2,2,2-trifluoroethyl)phosphoryl benzenesulfonate)-4-
((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-triazacyclononane-2-
yl)butylcarbamate, 82 (30 mg, 15 mol) was dissolved in dry DCM (1.8 mL). Argon was 
bubbled for 10 min after which time TFA (0.2 mL) was added. The solution was stirred for 20 
min and the solvent was removed under reduced pressure to give the trifluoroacetate salt as a 
yellow oil (16 mg, 60 %); H (CD3OD) 8.11 (6H, m, H
4
), 8.04 (3H, m, H
3
), 8.01 (6H, m, H
5
), 
7.61 (3H, m, H
2
), 7.57 (6H, m, H
6
), 6.93 (6H, m, H
7
), 4.65 (6H, m, H
12
), 4.17 (6H, m, P-
OCH2), 3.96 (15H, m, H
1
 and OMe), 3.82-3.60 (13H, m, 9N3 and H
11
), 1.61-1.47 (6H, m, H
10-
9-8
), 1.46 (9H, m, CH3(Et)); F (CD3OD) -76.0 (br); P (CD3OD) + 23.6; m/z (HRMS
+
) 
1854.437 [M + H]
+
 (C85H88N7O18F9P3S3 requires 1854.442). 
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2,2,2-Trifluoroethyl 6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(3-( ethoxy 
phosphoryl benzenesulfonate), 83a 
 
tert-Butyl 4-((S)-1,4,7-tris((6-(ethoxy(3-(2,2,2-Trifluoroethyl)phosphoryl benzenesulfonate)-
4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7-triazacyclononan-2-
yl)butylcarbamate, 83 (20.0 mg, 10 mol) was dissolved in dry DCM (1.8 mL). Argon was 
bubbled for 10 min after which time TFA (0.2 mL) was added. The solution was stirred for 20 
min and the solvent was removed under reduced pressure to give the trifluoroacetate salt as a 
yellow oil (5.7 mg, 30 %); H (CDCl3) 8.43 (3H, m, H
4
), 8.30 (3H, m, H
13
), 7.88 (6H, m,
 
H
5-
3
), 7.61 (3H, m, H
12
), 7.52 (3H, m, H
2
), 7.43 (6H, m, H
6
), 6.93 (6H, m, H
7
), 4.65 (6H, q, 
3
JF-H 
7.5 Hz, H
14
), 4.15 (6H, m, P-OCH2), 3.95 (15H, m, H
1
 and OMe), 3.78-3.34 (13H, m, 9N3 
ring protons and H
11
), 1.62-1.49 (6H, m, H
10-9-8
), 1.43 (9H, m, CH3(Et)); F (CD3OD) -76.2 
(br); P (CD3OD) + 22.0; m/z (HRMS
+
) 1854.439 [M + H]
+
 (C85H88N7O18F9P3S3 requires 
1854.442). 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(4-
(hydroxyphosphoryl benzenesulfonate), [EuL
20
]
2-
 
 
2,2,2-Trifluoroethyl 6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(4-(ethoxy 
phosphoryl benzenesulfonate), 82a (5.0 mg, 2.7 mol) was dissolved in CD3OD (1 mL) and a 
solution of NaOH in D2O (0.1 M, 0.5 mL) was added. The mixture was heated to 60 °C under 
argon and monitored with 
19
F-NMR [F(reactant) = - 76.0, F(product, trifluoroethanol) = - 
78.0] and 
31
P-NMR [P(reactant) = + 23.6, P(product) = + 15.1]. After 3 h the solution was 
cooled to RT and the pH was adjusted to 7 with HCl. Eu(Cl)36H2O (1.0 mg, 2.7mol) was 
added and the mixture heated to 65 °C overnight under argon. The solvent was removed under 
reduced pressure and the product purified by HPLC (Method K, tR = 16.1 min) giving the 
triethylammonium salt as a white solid (2.8 mg, 63 %); (HRMS
-
) 1671.237 [MH2]
-
 
(C73H68
151
EuN7O18P3S3 requires 1671.238);  H2O = 1.13 ms; max (H2O) = 332 nm;  = 58 mM
-1
 
cm
-1
. 
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Method L, tR = 15.7 min 
Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(3-
(hydroxyphosphoryl benzenesulfonate), [EuL
23
]
2-
 
 
2,2,2-Trifluoroethyl 6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(3-( ethoxy 
phosphoryl benzenesulfonate), 83a (7 mg, 4.2 mol) was dissolved in CD3OD (1 mL) and a 
solution of NaOH in D2O (0.1 M, 0.5 mL) was added. The mixture was heated to 60 °C under 
argon and monitored with 
19
F-NMR [F(reactant) = - 76.2, F(product, trifluoroethanol) = - 
78.0] and 
31
P-NMR [P(reactant) = + 22.0, P(product) = + 13.7]. After 3 h the solution was 
cooled to RT and the pH was adjusted to 7 with HCl. Eu(Ac)3H2O (1.4 mg, 4.2mol) was 
added and the mixture heated to 65 °C overnight under argon. The solvent was removed under 
reduced pressure and the product purified by HPLC (Method K, tR = 16.6 min) giving the 
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triethylammonium salt as a white solid (3.0 mg, 42 %); (HRMS
-
) 1671.239 [MH]
-
 
(C73H68
151
EuN7O18P3S3 requires 1671.238);  H2O = 1.10 ms; max (H2O) = 332 nm;  = 58 mM
-1
 
cm
-1
. 
 
Method M, tR = 4.8 min 
Eu(III) complex of (R,R,R)-6,6',6''-((S)- 2-(4-(4-carboxybutanamido) butyl))-1,4,7-
triazacyclonane-1,4,7-triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-
6,2-diyl)tris(4-(hydroxyphosphoryl benzenesulfonate), [EuL
20
]-glu
4-
 
 
The Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclonane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(4-
(hydroxyphosphoryl benzenesulfonate), [EuL
20
]
2-
 (0.4 mg, 0.24 mol), was dissolved in dry 
DMF (300 L). Glutaric anhydride (0.03 mg, 0.24 mol) and DIPEA (2 L) were added and 
the reaction was stirred at RT for 1 h. The product was purified by HPLC (Method K, tR = 
18.4 min) giving the triethylammonium salt as a white solid (0.4 mg, 93 %); (HRMS
-
) 
1786.255 [MH3]
-
 (C78H74
153
EuN7O21P3S3 requires 1786.254). 
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Eu(III) complex of (R,R,R)-6,6',6''-((S)- 2-(4-(4-carboxybutanamido) butyl))-1,4,7-
triazacyclonane-1,4,7-triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-
6,2-diyl)tris(3-(hydroxyphosphoryl benzenesulfonate), [EuL
23
]-glu
4-
 
 
The Eu(III) complex of (R,R,R)-6,6',6''-((S)-2-(4-aminobutyl)-1,4,7-triazacyclonane-1,4,7-
triyl)tris(methylene)tris(4-((4-methoxyphenyl)ethynyl)pyridine-6,2-diyl)tris(3-
(hydroxyphosphoryl benzenesulfonate), [EuL
23
]
2-
 (0.3 mg, 0.18 mol), was dissolved in dry 
DMF (400 L). Glutaric anhydride (0.03 mg, 0.18 mol) and DIPEA (2 L) were added and 
the reaction was stirred at RT for 1 h. The product was purified by HPLC (Method K, tR = 
16.1 min) giving the triethylammonium salt as a white solid (0.3 mg, 93 %); (HRMS
-
) 
1786.258 [MH3]
-
 (C78H74
153
EuN7O21P3S3 requires 1786.254). 
2-(2-Bromoethyl)-1-iodo-4-methoxybenzene, 86 
 
3-Methoxyphenethyl bromide (1.9 g, 8.7 mmol), was dissolved in MeOH (30 mL) and ICl 
(2.8 g, 17.4 mmol) was added to the solution. The mixture was stirred at RT for 3 h, after 
which time 10 % solution of Na2S2O3 (90 mL) was added causing the formation of a white 
solid. The solvent was removed under reduced pressure, the crude product re-dissolved in 
DMC (50 mL) and washed with 10 % solution of Na2S2O3. The organic layer was dried over 
MgSO4 and the solvent removed under reduced pressure. The crude material was purified by 
column chromatography (silica, Hex : DCM 10 : 0 to 10 : 1) to give a clear oil (1.5 mg, 51 
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%); H (CDCl3) 7.78 (1H, d, 
3
JH-H 9 Hz, H
5
), 6.83 (1H, d,
 4
JH-H 3 Hz, H
2
), 6.56 (1H, dd,
 3
JH-H 9 
Hz, 
4
JH-H 3, H
6
) 3.78 (3H, s, OMe), 3.55 (2H, t,
 3
JH-H 8 Hz,  H
8
), 3.23 (2H, t,
 3
JH-H 7.5 Hz, H
7
), 
NMR data are in good agreement with those previously reported
138
, Rf = 0.41 (silica, Hex : 
DMC 3 : 1). 
2-(2-Iodo-5-methoxyphenethyl)isothiouronium bromide, 87 
 
2-(2-Bromoethyl)-1-iodo-4-methoxybenzene, 86 (1.50 g, 4.40 mmol) was added to EtOH (25 
mL), followed by thiourea (335 mg, 4.70 mmol). The mixture was refluxed for 16 h, after 
which time the solvent was removed under reduced pressure. The crude compound was 
washed with Et2O (2 x 5 mL) giving a white solid (1.63 g, 89 %); m.p. = 183 - 186 °C; H 
(CD3OD) 7.69 (1H, d, 
3
JH-H 8.5 Hz, H
5
), 6.96 (1H, d, 
4
JH-H 3 Hz, H
2
), 6.63 (1H, dd, 
3
JH-H 8.5 
Hz, 
4
JH-H 3 Hz, H
6
), 3.78 (3H, s, OMe), 3.42 (2H, t, 
3
JH-H 7.5 Hz, H
8
), 3.10 (2H, t, 
3
JH-H 7.5 
Hz, H
7
); C (CD3OD) 171.2 (s, C
9
), 160.4 (s, C
1
), 141.8 (s, C
3
), 140.0 (s, C
5
), 115.9 (s, C
2
), 
114.7 (s, C
6
), 87.8 (s, C
4
), 54.6 (s, OMe), 38.9 (s, C
7
), 30.9 (s, C
8
); m/z (HRMS+) 336.9878 
[M]
+
 (C10H14N2OSI requires 336.9872). 
2,2,2-Trifluoroethyl 2-(2-iodo-5-methoxyphenyl)ethanesulfonate, 88 
 
6 M H2SO4 (0.8 mL) and Et2O (9 mL) were added to 2-(2-iodo-5-
methoxyphenethyl)isothiouronium bromide, 87 (750 mg, 1.80 mmol) at 0 °C. A solution of 
bleach (5 %, 10.5 mL) was added dropwise to the resultant suspension under vigorous stirring 
keeping the temperature below 20 °C. After the addition, the mixture was stirred for 30 min at 
RT after which time the reaction was transferred into a separating funnel and the two layers 
partitioned. The organic layer was washed with brine (2 x 10 mL) and 10 % solution of 
Na2S2O3 (2 x 20 mL), dried over MgSO4 and the solvent removed under reduced pressure 
giving the sulfonyl chloride compound as a yellow oil. Without further purification the 
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compound was dissolved in DCM (12 mL). Trifluoroethanol (130 L, 1.8 mmol) was added 
to the solution, followed by Et3N (300 mg, 2.1 mmol). The mixture was stirred at RT for 1 h 
after which time the solvent was removed under reduced pressure. The crude compound was 
purified by column chromatography (silica, Hex : DCM 4 : 1 to 1 : 1) to yield a clear oil 
(297 mg, 39 %); H (CDCl3) 7.68 (1H, d, 
3
JH-H 8.5 Hz, H
5
), 6.83 (1H, d, 
4
JH-H 3 Hz,  H
2
), 6.57 
(1H, dd, 
3
JH-H 8.5 Hz,
 4
JH-H 3 Hz,  H
6
), 4.52 (2H, q, 
3
JH-F 8 Hz, H
9
), 3.77 (3H, s, OMe), 3.45 
(2H, m, H
8
), 3.24 (2H, m, H
7
); C (CDCl3) 160.3 (s, C
1
), 140.4 (s, C
5
), 140.3 (s, C
3
),  122.0 (q, 
1
JC-F 278 Hz, CF3), 116.1 (s, C
2
), 115.2 (s, C
6
), 87.8 (s, C
4
), 63.9 (q, 
2
JC-F 38 Hz, C
9
), 55.4 (s, 
OMe), 51.0 (s, C
8
), 34.8 (s, C
7
);F (CDCl3) -74.2 (t, 
3
JF-H 7.0 Hz); m/z (HRMS+) 423.9463 
[M + H]
+
 (C11H12O4F3SI requires 423.9453), Rf = 0.16 (silica, Hex : DCM 3 : 1). 
2,2,2-Trifluoroethyl 2-(5-methoxy-2-((trimethylsilyl)ethynyl)phenyl)ethanesulfonate, 88a 
 
2,2,2-Trifluoroethyl 2-(2-iodo-5-methoxyphenyl)ethanesulfonate, 88 (110 mg, 0.26 mmol), 
was dissolved in dry THF (1.5 mL) and the solution was degassed (freeze-thaw cycle) three 
times. Ethynyltrimethylsilane (55 L, 0.39 mmol) and NEt3 (0.35 mL) were added and the 
solution degassed once more. [1,1’-bis(diphenylphosphino)ferrocene]palladium(II) chloride 
(30 mg, 0.03 mmol) and CuI (5 mg, 0.03 mmol) were added and the solution was degassed a 
further three times. The solution was stirred at 65 °C under argon for 16 h, solvent was 
removed under reduced pressure and the crude material purified by column chromatography 
(silica, DCM : Hex 1 : 4 to 1 : 2) to give a clear oil (76 mg, 75 %); H (CDCl3) 7.40 (1H, d, 
3
JH-H 9 Hz, H
5
), 6.75 (2H, m, H
2-6
), 4.48 (2H, q, 
3
JH-F 8 Hz, H
9
), 3.80 (3H, s, OMe), 3.52 (2H, 
m, H
8
), 3.27 (2H, m, H
7
), 0.25 (9H, s, SiMe3); C (CDCl3) 160.0 (s, C
1
), 140.6 (s, C
3
), 134.3 
(s, C
5
),  122.2 (q, 
1
JC-F 278 Hz, CF3), 115.1 (s, C
2
), 114.8 (s, C
4
), 112.8 (s, C
6
), 102.3 (s, C
10
), 
98.2 (s, C
11
), 63.6 (q, 
2
JC-F 38 Hz, C
9
), 55.3 (s, OMe), 51.1 (s, C
8
), 29.2 (s, C
7
), -0.2 (s, 
SiMe3);F (CDCl3) -74.3 (t, 
3
JF-H 7.0 Hz); m/z (HRMS+) 417.0781 [M + H]
+
 
(C16H21O4F3NaSSi requires 417.0774), Rf = 0.66 (silica, EtOAc : Hex 2 : 8). 
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2,2,2-Trifluoroethyl 2-(2-ethynyl-5-methoxyphenyl)ethanesulfonate, 89 
 
2,2,2-Trifluoroethyl 2-(5-methoxy-2-((trimethylsilyl)ethynyl)phenyl)ethanesulfonate, 88a (45 
mg, 0.11 mmol) was dissolved in anhydrous THF (0.8 mL) and triethylammonium 
dihydrofluoride (190 L, 1.1 mmol) was added. The mixture was stirred at 35 °C under argon 
for 48 h. The solvent was removed under reduced pressure to give a yellow oil which was 
subjected to column chromatography (silica, Hex : DCM 3 : 1 to 1: 1) to give a clear oil (35 
mg, 98 %); H (CDCl3) 7.42 (1H, d, 
3
JH-H 9 Hz, H
5
), 6.77 (2H, m, H
2-6
), 4.49 (2H, q, 
3
JH-F 8 
Hz, H
9
), 3.80 (3H, s, OMe), 3.50 (2H, m, H
8
), 3.30 (2H, m, H
7
), 3.26 (1H, s, CH); C (CDCl3) 
160.3 (s, C
1
), 140.8 (s, C
3
), 134.7 (s, C
5
),  122.4 (q, 
1
JC-F 278 Hz, CF3), 115.1 (s, C
2
), 113.7 (s, 
C
4
), 112.9 (s, C
6
), 81.0 (s, C
11
), 80.8 (s, C
10
), 63.7 (q, 
2
JC-F 38.5 Hz, C
9
), 55.4 (s, OMe), 51.2 
(s, C
8
), 29.2 (s, C
7
);F (CDCl3) -74.3 (t, 
3
JF-H 7.0 Hz); m/z (HRMS+) 323.0559 [M + H]
+
 
(C13H14O4F3S requires 323.0565); Rf = 0.33 (silica, EtOAc : Hex 1 : 9). 
2,2,2-Trifluoroethyl 2-(2-((2-(ethoxy(phenyl)phosphoryl)-6-(hydroxymethyl)pyridin-4-
yl)ethynyl)-5-methoxyphenyl)ethanesulfonate, 90 
 
Ethyl (4-bromo-6-hydroxymethylpyridin-2-yl)(phenyl)phosphinate, 31 (29 mg, 80 mol), was 
dissolved in anhydrous THF (1 mL) and the solution was degassed (freeze-thaw cycle) three 
times. 2,2,2-Trifluoroethyl 2-(2-ethynyl-5-methoxyphenyl)ethanesulfonate, 89 (40 mg, 120 
mol) and NEt3 (0.22 mL) were added and the solution degassed once more. [1,1’-
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bis(diphenylphosphino)ferrocene]palladium(II) chloride (9 mg, 8 mol) and CuI (1.5 mg, 8 
mol) were added and the solution was degassed a further three times. The solution was 
stirred at 65 °C under argon for 16 h, solvent was removed under reduced pressure and the 
crude material purified by column chromatography (silica, DCM : MeOH 0 to 2 %) to give a 
clear oil (25 mg, 52 %); H (CDCl3) 8.12 (1H, d 
3
JH-P 6 Hz, H
4
), 7.95 (2H, m, H
11
), 7.47 (5H, 
m, H
2-12-13-17
), 6.84 (2H, m, H
18-20
), 4.77 (2H, s, H
9
), 4.57 (2H, q, 
3
JH-F 8 Hz, H
9
), 4.15 (2H, m, 
H
7
), 4.05 (1H, br, OH), 3.85 (3H, s, OMe), 3.56 (2H, m, H
23
), 3.34 (2H, m, H
22
), 1.39 (3H, d, 
3
JH-H 7 Hz, H
10
);C (CDCl3) 161.7 (s, C
19
), 160.1 (s, C
1
), 154.5 (d, 
1
JC-P 153 Hz, C
5
), 140.9 (s, 
C
21
), 134.9 (s, C
17
), 132.7 (s, C
3
), 132.5 (s, C
13
), 132.4 (s, C
11
), 128.7 (s, C
4
), 128.8 (s, C
12
), 
128.5 (s, C
2
), 123.8 (s, C
16
), 122.4 (q, 
1
JC-F 278 Hz, CF3), 115.4 (s, C
20
), 113.2 (s, C
18
), 93.8 
(s, C
15
), 90.2 (s, C
14
), 63.7 (s, C
9
), 63.6 (q, 
2
JC-F 38.5 Hz, C
6
), 62.1 (s, C
7
), 55.5 (s, OMe), 51.7 
(s, C
23
), 29.1 (s, C
22
), 16.6 (s, C
8
);F (CDCl3) -74.2 (t, 
3
JF-H 7.0 Hz);P (CDCl3) +24.7; m/z 
(HRMS+) 598.1277 [M + H]
+
 (C27H28NO7F3PS requires 598.1276); Rf = 0.37 (silica; DCM : 
3 % MeOH).  
2,2,2-Trifluoroethyl 2-(2-((2-(ethoxy(phenyl)phosphoryl)-6-
((methylsulfonyloxy)methyl)pyridin-4-yl)ethynyl)-5-methoxyphenyl)ethanesulfonate, 91 
 
2,2,2-Trifluoroethyl 2-(2-((2-(ethoxy(phenyl)phosphoryl)-6-(hydroxymethyl)pyridin-4-
yl)ethynyl)-5-methoxyphenyl)ethanesulfonate, 90 (25 mg, 42 mol) was dissolved in 
anhydrous THF (1 mL) and NEt3 (17 L, 0.12 mmol) was added. The mixture was stirred at 5 
°C and methanesulfonyl chloride (5 μL, 65 mol) was added. The reaction was monitored by 
TLC (silica; DCM : 5 % MeOH, Rf(product) = 0.44, Rf(reactant) = 0.33) and stopped after 15 
min. The solvent was removed under reduced pressure and the residue dissolved in DCM (10 
mL) and washed with NaCl solution (saturated, 10 mL). The aqueous layer was re-extracted 
with DCM (3 × 10 mL) and the organic layers combined, dried over MgSO4 and the solvent 
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removed under reduced pressure to leave a colourless oil (19 mg, 67 %); H (CDCl3) 8.15 
(1H, dd, 
3
JH-P 6 Hz,
 4
JH-H 1.5 Hz, H
4
), 7.96 (2H, ddd, 
3
JH-P 12.5 Hz,
 3
JH-H 8.5 Hz, 
4
JH-H 1.5 Hz, 
H
11
), 8.15 (1H, s, H
2
),7.49 (4H, m, H
12-13-17
), 6.85 (2H, m, H
18-20
), 5.33 (2H, s, H
9
), 4.59 (2H, 
q, 
3
JH-F 8 Hz, H
9
), 4.15 (2H, m, H
7
), 3.85 (3H, s, OMe), 3.56 (2H, m, H
23
), 3.35 (2H, m, H
22
), 
3.03 (3H, s, Ms), 1.39 (3H, d, 
3
JH-H 7 Hz, H
10
);F (CDCl3) -74.2 (t, 
3
JF-H 7.0 Hz);P (CDCl3) 
+24.7; m/z (HRMS+) 676.1036 [M + H]
+
 (C28H30NO9F3PS2 requires 676.1052); Rf = 0.44 
(silica; DCM : 3 % MeOH).  
Tris(2,2,2-trifluoroethyl) 2,2',2''-(6,6',6''-(6,6',6''-(1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(2-(ethoxy(phenyl)phosphoryl)pyridine-6,4-diyl))tris(ethyne-2,1-
diyl)tris(3-methoxybenzene-6,1-diyl))triethanesulfonate, 92 
 
1,4,7-Triazacyclononane trihydrochloride (1.0 mg, 4.0 mol) and (S)-2,2,2-trifluoroethyl 2-
(2-((2-(ethoxy(phenyl)phosphoryl)-6-((methylsulfonyloxy)methyl)pyridin-4-yl)ethynyl)-5-
methoxyphenyl)ethanesulfonate, 91 (8.8 mg, 13.0 mol), were dissolved in anhydrous 
CH3CN (1 mL) and K2CO3 (3.5 mg, 26.0 mol) was added. KI (catalytical) was added to the 
reaction and the mixture was stirred under argon at 60 °C for 16 h. The reaction was cooled 
and the solution decanted from excess potassium salts. The solvent was removed under 
reduced pressure to give a yellow oil (4.0 mg, 57 %); H (CDCl3) 8.08 (3H, d, 
3
JH-P 6 Hz, H
4
), 
7.91 (6H, m, H
11
), 7.42 (15H, m, H
2-12-13-17
), 6.83 (6H, m, H
18-20
), 4.57 (6H, q, 
3
JH-F 8 Hz, H
6
), 
4.15 (6H, m, H
7
), 3.90 (6H, s, H
9
), 3.85 (9H, s, OMe), 3.59 (6H, m, H
23
), 3.37 (6H, m, H
22
), 
2.94 (12H, br, 9N3),  1.41 (9H, d, 
3
JH-H 7 Hz, H
10
);C (CDCl3) 161.8 (s, C
19
), 160.2 (s, C
1
), 
154.6 (d, 
1
JC-P 153 Hz, C
5
), 140.9 (s, C
21
), 134.9 (s, C
17
),  132.7 (s, C
3
), 132.3 (s, C
13
), 132.4 
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(s, C
11
), 128.7 (s, C
4
), 128.9 (s, C
12
), 128.5 (s, C
2
), 123.8 (s, C
16
), 122.4 (q, 
1
JC-F 278 Hz, CF3), 
115.2 (s, C
20
), 113.1 (s, C
18
), 93.8 (s, C
15
), 90.2 (s, C
14
), 63.9 (s, C
9
), 63.6 (q, 
2
JC-F 38 Hz, C
6
), 
62.1 (s, C
7
), 56.0 (br, ring C), 55.5 (s, OMe), 51.7 (s, C
23
), 29.1 (s, C
22
), 16.6 (s, C
8
);F 
(CDCl3) -74.2 (t, 
3
JF-H 8 Hz); P (CDCl3) + 25.2; m/z (HRMS
+
) 1867.453 [M + H]
+
 
(C87H91N6O18F9S3P3 requires 1867.462).  
Eu(III) complex of 2,2',2''-(6,6',6''-(6,6',6''-(1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(2-(hydroxy(phenyl)phosphoryl)pyridine-6,4-diyl))tris(ethyne-
2,1-diyl)tris(3-methoxybenzene-6,1-diyl))triethanesulfonate, [EuL
26a
]
3-
 
 
Tris(2,2,2-trifluoroethyl) 2,2',2''-(6,6',6''-(6,6',6''-(1,4,7-triazacyclononane-1,4,7-
triyl)tris(methylene)tris(2-(ethoxy(phenyl)phosphoryl)pyridine-6,4-diyl))tris(ethyne-2,1-
diyl)tris(3-methoxybenzene-6,1-diyl))triethanesulfonate, 92 (5.0 mg, 2.6 mol) was dissolved 
in MeOH (1.5 mL) and a solution of KOH in H2O was added (pH = 12). The mixture was 
heated to 60 °C under argon and monitored with 
31
P-NMR [P(reactant) = + 25.2, P(product) 
= + 14.6]. After 3 h the solution was cooled to RT and the pH was adjusted to 7 with HCl. 
Eu(AcO)3H2O (1.0 mg, 3.0mol) was added and the mixture heated to 65 °C overnight under 
argon to give the sulfonate protected complex (m/z (HRMS
+
) 1931.262 [M + H]
+
 
(C81H76N6O18S3P3
151
EuF9 requires 1931.265)). A solution of KOH in H2O was added (pH = 
14) and the mixture heated to 60 °C overnight. The solution was cooled to RT and the pH was 
adjusted to 7 with HCl. Further Eu(AcO)3H2O (1.0 mg, 3.0mol) was added and the mixture 
heated to 65 °C overnight. The solvent was removed under reduced pressure and the product 
purified by HPLC (Method K, tR = 21.1 min) giving the triethylammonium salt as a white 
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solid (1.0 mg, 25 %); m/z (HRMS
-
) 841.1129 [MH]
2-
 (C75H72
151
EuN6O18P3S3 requires 
841.1160);  H2O = 1.15 ms; max (H2O) = 336 nm;  = 58 mM
-1
 cm
-1
.  
 
Method M, tR = 5.5 min 
tert-Butyl 4,7-bis((6-(ethoxy(methyl)phosphoryl)-4-((4-methoxyphenyl)ethynyl)pyridin-
2-yl)methyl)-1,4,7-triazacyclononane-1-carboxylate, 94 
 
tert-Butyl-1,4,7-triazacyclononane-1-carboxylate, 93 (14 mg, 47 mol) and ethyl(6-(ethyl-
methanesulfonate)-4-[2-(4-methoxyphenyl)ethynyl]pyridin-2-yl)(methyl)phosphinate, 19 (40 
mg, 94 mol) were dissolved in anhydrous CH3CN (3 mL) and K2CO3 (13 mg, 94 mol) was 
added. The mixture was stirred under argon at 60 °C overnight. The reaction was cooled and 
the solution decanted from excess potassium salts. The solvent was removed under reduced 
pressure to give a yellow oil (37 mg, 89 %): δH (CDCl3) 7.96 (2H, m, H
3
), 7.65 (2H, bs, H
5
), 
7.44 (4H, d, 
3
JH-H 8.5 Hz, H
13
), 6.87 (4H, d, 
3
JH-H 8.5 Hz, H
14
), 4.11 – 4.05 (2H, m, H7), 3.93, 
(2H, s, H
1
), 3.92 (2H, s, H
1
), 3.86 – 3.82 (2H, m, H7), 3.81 (6H, s, H16), 3.35 (4H, br m, ring 
Hs), 3.08 (4H, br m, ring Hs), 2.68 (4H, br m, ring Hs), 1.75 (3H, d, 
2
JH-P 15 Hz, H
9
), 1.74 
(3H, d, 
2
JH-P 15 Hz, H
9
), 1.46 (9H, s, H
19
), 1.23 (3H, t, 
3
JH-H 7 Hz, H
8
), 1.22 (3H, t, 
3
JH-H 7 Hz, 
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H
8); δC (CDCl3) 161.6, 161.4 (d,
 3
JC-P 20 Hz, C
6
), 160.5, 160.4 (s, C
17
), 155.6 (s, C
15
), 153.8, 
153.6 (d, 
1
JC-P 165 Hz, C
2
), 133.6, 133.5 (s, C
15
), 132.5 (br m, C
4
), 127.6 (br m, C
3
), 126.4, 
126.1 (d, 
4
JC-P 3 Hz, C
5
), 114.2, 114.1 (s, C
14
), 113.9, 113.8 (s, C
12
), 95.6, 95.3 (s, C
11
), 85.6, 
85.4 (br m, C
10
),79.4 (s, C
18
) 62.8, 62.5 (s, C
1
), 60.9, 60.8 (d, 
2
JC-P 3 Hz, C
7
), 55.3 (s, C
16
), 
55.0 – 49.7 (br m, ring Cs), 28.6 (s, C19), 16.4 (d, 3JC-P 6 Hz, C
8
), 13.3, 13.2 (d, 
1
JC-P 109 Hz, 
C
9); δP (CDCl3) +40.0, +39.9; m/z (HRMS
+
) 884.3937 [M + H]
+
 (C47H60O8N5P2 requires 
884.3917). 
Diethyl-6,6'-(1,4,7-triazacyclononane-1,4-diyl)bis(methylene)bis(4-((4-
methoxyphenyl)ethynyl)pyridine-6,2-diyl)bis(methylphosphinate), 95 
 
tert-Butyl 4,7-bis((6-(ethoxy(methyl)phosphoryl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-
yl)methyl)-1,4,7-triazacyclononane-1-carboxylate, 94 (37 mg, 60 mol) was dissolved in 
anhydrous DCM (3 mL) and TFA (0.7 mL) was added. The solution was stirred under argon 
at 23 °C for 45 min. The solvent was removed using a high vacuum line (without heating) and 
the residue re-dissolved in DCM (1 mL), which was again removed using the same method. 
This process was repeated 5 times to ensure complete removal of excess trifluoroacetic acid. 
The crude material was purified by HPLC (Method A, tR = 11.8 min) to give a yellow oil (15 
mg, 45 %); δH (CDCl3) 7.95 (2H, d,
 3
JH-P 6 Hz, H
3
), 7.46 (4H, d, 
3
JH-H 9 Hz, H
13
), 7.41 (2H, 
bs, H
5
), 6.88 (4H, d, 
3
JH-H 9 Hz, H
14
), 4.15 – 4.10 (2H, m, H7), 3.99 (4H, s, H1), 3.92 – 3.87 
(2H, m, H
7
), 3.81 (6H, s, H
16
), 3.19 (4H, br s, ring Hs), 3.07 (4H, br s, ring Hs), 2.69 (4H, br 
s, ring Hs), 1.76 (6H, d, 
2
JH-P 15.0 Hz, H
9
), 1.27 (6H, t, 
3
JH-H 7 Hz, H
8); δC (CDCl3) 160.7 (s, 
C
15
), 159.3 (d,
 3
JC-P 20 Hz, C
6
), 154.4 (d, 
1
JC-P 157 Hz, C
2
), 133.7 (s, C
13
), 133.1 (d,
 3
JC-P 11 
Hz,  C
4
), 127.7 (d,
 2
JC-P 20 Hz,  C
3
), 126.3 (d,
 4
JC-P 3 Hz,  C
5
), 114.2 (s, C
14
), 113.5 (s, C
12
), 
96.4 (s, C
11
), 85.0 (s, C
10
), 61.1 (d, 
2
JC-P 6.3 Hz, C
7
), 60.1 (s, C
1
), 55.3 (s, C
16
), 51.1 – 43.9 (br 
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m, ring Cs), 16.5 (d, 
3
JC-P 6 Hz, C
8
), 13.6 (d, 
1
JC-P 103 Hz, C
9); δP (CDCl3) +39.3; m/z 
(HRMS
+
) 784.3387 [M + H]
+
 (C42H52O6N5P2 requires 784.3393). 
Methyl 6-(hydroxymethyl)-4-((4-methoxyphenyl)ethynyl)picolinate 
 
6-(Hydroxymethyl)-4-iodopicolinate (100 mg, 0.34 mmol) was dissolved in dry THF (1.5 
mL) and the solution was degassed (freeze-thaw cycle) three times. 4-Ethynylanisole (67 mg, 
0.51 mmol) and NEt3 (0.95 mL) were added and the solution degassed once more. [1,1’-
bis(diphenylphosphino)ferrocene]palladium(II) chloride (40 mg, 0.034 mmol) and CuI (6 mg, 
0.034 mmol) were added and the solution was degassed a further three times. The solution 
was stirred at 65 °C under argon for 12 h, solvent was removed under reduced pressure and 
the crude material purified by column chromatography (silica, DCM : MeOH 0 to 2 %) to 
give a dark yellow oil (98 mg, 95 %); H (CDCl3) 8.07 (1H, bs, H
3
), 7.59 (1H, bs, H
5
), 7.49 
(2H, d, 
3
JH-H 9 Hz, H
12
), 6.90 (2H, d, 
3
JH-H 9 Hz, H
13
), 4.85 (2H, s, H
7
),  4.00 (3H, s, H
8
), 3.84 
(3H, s, H
15
); C (CDCl3) 165.4 (s, CO), 160.7 (s, C
6
), 160.6 (s, C
14
), 147.3 (s, C
2
), 134.0 (s, 
C
4
), 133.8 (s, C
12
), 125.8 (s, C
5
), 125.4 (s, C
3
), 114.4 (s, C
13
), 113.8 (s, C
11
), 96.0 (s, C
10
), 85.3 
(s, C
9
), 64.7 (s, C
7
), 55.5 (s, C
15
), 53.1 (s, C
8
); (HRMS
+
) 298.1075 [M + H]
+
 (C17H16NO4 
requires 298.1079); Rf = 0.6 (silica, DCM: MeOH 9 : 1). 
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Methyl 4-((4-methoxyphenyl)ethynyl)-6-(((methylsulfonyl)oxy)methyl)picolinate, 96 
 
Methyl 6-(hydroxymethyl)-4-((4-methoxyphenyl)ethynyl)picolinate (28 mg, 0.09 mmol) was 
dissolved in anhydrous THF (2 mL) and NEt3 (40 L, 0.27 mmol) was added. The mixture 
was stirred at 5 °C and methanesulfonyl chloride (11 L, 0.13 mmol) was added. The reaction 
was monitored by TLC (silica, DCM : 5 % MeOH, Rf(product) = 0.70, Rf(reactant) = 0.35) 
and stopped after 15 min. The solvent was removed under reduced pressure and the residue 
dissolved in DCM (10 mL) and washed with NaCl solution (saturated, 8 mL). The aqueous 
layer was re-extracted with DCM (3 × 10 mL) and the organic layers combined, dried over 
MgSO4 and the solvent removed under reduced pressure to leave a colourless oil (27 mg, 77 
%); H (CDCl3) 8.14 (1H, bs, H
3
), 7.70 (1H, bs, H
5
), 7.50 (2H, d, 
3
JH-H 9 Hz, H
12
), 6.91 (2H, 
d, 
3
JH-H 9 Hz, H
13
), 5.40 (2H, s, H
7
),  4.00 (3H, s, H
8
), 3.84 (3H, s, H
15
), 3.16 (3H, s, Ms); m/z 
(ESI) 376.1 [M + H]
+
 . 
Methyl 6-((4,7-bis((6-(ethoxy(methyl)phosphoryl)-4-((4-methoxyphenyl)ethynyl)pyridin-
2-yl)methyl)-1,4,7-triazacyclononan-1-yl)methyl)-4-((4-
methoxyphenyl)ethynyl)picolinate, 97 
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Methyl 4-((4-methoxyphenyl)ethynyl)-6-(((methylsulfonyl)oxy)methyl)picolinate, 96 (7.0 
mg. 19mol)  and diethyl 6,6'-(1,4,7-triazacyclononane-1,4-diyl)bis(methylene)bis(4-((4-
methoxyphenyl)ethynyl)pyridine-6,2-diyl)bis(methylphosphinate), 95 (15.0 mg, 19 mol) 
were dissolved in anhydrous CH3CN (1.5 mL) and K2CO3 (6.0 mg, 40mol) was added. The 
mixture was stirred under argon at 60 °C for 24 h, after which time, the reaction was cooled 
and the solution decanted from excess potassium salts. The solvent was removed under 
reduced pressure to give an orange oil. The crude material was purified by HPLC (Method A, 
tR = 10.6 min) to give a yellow oil (7.0 mg, 35 %); δH (CDCl3) 8.06 (1H, s,
 
H
17
), 7.99 (2H, d, 
3
JH-P 6 Hz, H
12
), 7.73 (1H, s,
 
H
16
), 7.67 (2H, d, H
11
), 7.50 (2H, d, 
3
JH-H 8 Hz, H
19
), 7.46 (4H, 
d, 
3
JH-H 8.0 Hz, H
13
), 6.91 (2H, d, 
3
JH-H 8.0 Hz, H
20
), 6.89 (4H, d, 
3
JH-H 8 Hz, H
14
), 4.37 (2H, 
s, H
21
), 4.23 (4H, s, H
10
),   4.10 – 3.85 (4H, m, POCH2), 3.97 (3H, s, H
16
), 3.85 (3H, s, H
22
), 
3.83 (6H, s, H
15
), 3.35 – 3.20 (12H, br, ring H), 1.73 (6H, d, 2JH-P 15 Hz, P-Me), 1.26 (6H, t, 
3
JH-H 7 Hz, CH3 (Et)); δP (CDCl3) +40.0; m/z (HRMS
+
) 1063.429 [M + H]
+
 (C59H65N6O9P2 
requires 1063.429). 
Eu(III) complex of (R,R)-6-((4,7-bis((4-((4-methoxyphenyl)ethynyl)-6-
(methyloxidophosphoryl)pyridin-2-yl)methyl)-1,4,7-triazacyclononan-1-yl)methyl)-4-((4-
methoxyphenyl)ethynyl)picolinate, [EuL
8
] 
 
Methyl 6-((4,7-bis((6-(ethoxy(methyl)phosphoryl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-
yl)methyl)-1,4,7-triazacyclononan-1-yl)methyl)-4-((4-methoxyphenyl)ethynyl)picolinate, 97 
(7.0 mg, 6.6 mol) was dissolved in CD3OD (1 mL) and a solution of NaOH in D2O (0.1 M, 
0.5 mL) was added. The mixture was heated to 60 °C under argon and monitored with 
31
P-
NMR [P(reactant) = + 40.0, (P(product) = + 25.6]. After 5 h the solution was cooled to RT 
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and the pH was adjusted to 7 with HCl. Eu(AcO)3H2O (2.4 mg, 6.6mol) was added and the 
mixture heated to 65 °C overnight under argon. The solvent was removed under reduced 
pressure giving a white solid (7.5 mg, quantitative yield); P (CD3OD) 50.2, 31.9; m/z 
(HRMS+) 1141.247 [M + H]
+
 (C54H51
151
EuN6O9P2 requires 1141.247); H2O = 0.89 ms; max 
(H2O) = 328 nm;  = 58 mM
-1
 cm
-1
.  
 
Method C, tR = 11.0 min 
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8 Appendix 
 
Very bright europium complexes that stain cellular mitochondria 
J.W. Walton, A. Bourdolle, S.J. Butler, M. Soulie, M. Delbianco, B.K. McMahon, R. Pal, H. 
Puschmann, J.M. Zwier, L. Lamarque, O. Maury, C. Andraudb, D. Parker 
Chem. Commun., 2013, 49, 1600  
Complete stereocontrol in the synthesis of macrocyclic lanthanide complexes: direct 
formation of enantiopure systems for circularly polarised luminescence applications  
N.H. Evans, R. Carr, M. Delbianco, R. Pal, D. S. Yufit, D. Parker 
Dalton Trans., 2013, 42, 15610 
Utility of tris(4-bromopyridyl) europium complexes as versatile intermediates in the 
divergent synthesis of emissive chiral probes  
S.J. Butler, M. Delbianco, N.H. Evans, A.T. Frawley, R. Pal, D. Parker, R.S. Puckrin, D.S. 
Yufit 
Dalton Trans., 2014, 43, 5721 
 
Nouveaux agents complexants hydrosolubles et complexes de lanthanide 
correspondants,  
L. Lamarque, M. Delbianco, S.J. Butler, D. Parker 
World patent application, WO 2014/111661; PCT/FR20 14/0500085, published July 24, 2014 
 
Synthesis of meta and para-substituted aromatic sulfonate groups in polydentate 
phenylazaphosphinate ligands: enhancement of the water solubility of emissive 
europium (III) EuroTracker dyes 
M. Delbianco, L. Lamarque, D. Parker 
Org. Biomol. Chem., 2014, 12, 8061 
Bright, highly water soluble triazacyclononane europium complexes to detect ligand 
binding with time resolved-FRET microscopy  
M. Delbianco, V. Sadovnikova, E. Bourrier, L. Lamarque, J.M. Zwier, D. Parker 
Angew. Chem. Int. Ed., 2014, 53, 10718 
EuroTracker Dyes: design, synthesis, structure and photophysical properties of very 
bright europium complexes and their use in bioassays and cellular optical imaging 
S.J. Butler, M. Delbianco, L. Lamarque, B.K. McMahon, E.R. Neil, R. Pal, D. Parker, J.W. 
Walton, J.M. Zwier 
Dalton Trans. 2015, (accepted for the DD15 issue as a Perspective article). 
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